4673.full.pdf - Anticancer Research

ANTICANCER RESEARCHInternational Journal of Cancer Research and Treatment

ISSN (print): 0250-7005; ISSN (online): 1791-7530

VOLUME 312011

Editorial Board

B. B. Aggarwal Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. AndersonCancer Center, Houston, TX, USA

J. P. Armand Institut Claudius Regaud, Toulouse, FranceV. I. Avramis Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USAR. C. Bast Department of Translational Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, USAG. Bauer Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, GermanyE. E. Baulieu INSERM U488 and College de France, Le Kremlin-Bicetre, FranceY. Becker Department of Biochemistry, Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, IsraelE. J. Benz, Jr. Dana-Farber Cancer Institute, Boston, MA, USAJ. Bergh Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, SwedenD. D. Bigner Department of Pathology, Duke University Medical Center, Durham, NC, USA A. Böcking Institute for Cytopathology, University of Düsseldorf, GermanyG. Bonadonna Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, ItalyF. T. Bosman Institute of Pathology, University of Lausanne, SwitzerlandG. Broich Gruppo Policlinico di Monza, Monza, ItalyJ. M. Brown Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USAØ. S. Bruland Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, NorwayM. M. Burger Novartis, Basel, SwitzerlandM. Carbone Cancer Research Center of Hawaii, Honolulu, HI, USAJ. Carlsson Department of Biomedical Radiation Sciences, Uppsala University, SwedenA. F. Chambers Department of Oncology, London Regional Cancer Center, London, Ontario, CanadaP. Chandra Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, GermanyL. Cheng Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USAJ.-G. Chung Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROCE. De Clercq Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium W. De Loecker Department of Biochemistry, Katholieke Universiteit Leuven, BelgiumW. Den Otter VUMC, Department of Urology, Amsterdam, The NetherlandsE. P. Diamandis Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, CanadaG. Th. Diamandopoulos Department of Pathology, Harvard Medical School, Boston, MA, USAW. Ebert Thoraxclinic HD-Rohrbach, Heidelberg, GermanyJ. A. Fernandez-Pol Metalloproteomics, LLC, Chesterfield, MO, USAI. J. Fidler Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USAG. Gabbiani Department of Pathology, University of Geneva, SwitzerlandR. Ganapathi Department of Clinical Pharmacology, Taussing Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USAA. F. Gazdar Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas,

TX, USAA. Giordano Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USAG. Gitsch Department of Gynecology and Obstetrics, University of Freiburg, GermanyR. H. Goldfarb Sopherion Therapeutics, Inc., Princeton, NJ, USAJ. W. Gorrod Toxicology Unit, John Tabor Laboratories, University of Essex, Colchester, Essex, UKS. Hammarstrom Department of Immunology, University of Umea, SwedenI. Hart Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart’s and The London, Queen

Mary’s School of Medicine and Dentistry, London, UKI. Hellstrom Harborview Medical Center, Seattle, WA, USAL. Helson Sign Path Pharma, Inc., Quakertown, PA, USAR. B. Herberman Intrexon Corporation, Germantown, MD, USAR. M. Hoffman Department of Surgery, University of California, San Diego, CA, USA

ANTICANCER RESEARCH 31: Index (2011)

4675


4676

C. G. Ioannides Department of Gynecology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USAS. C. Jhanwar Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New

York, NY, USAJ. V. Johannessen Department of Pathology, The Norwegian Radium Hospital, Oslo, NorwayB. Kaina Institute of Toxicology, University of Mainz, GermanyB. K. Keppler School of Medicine, University of Vienna, AustriaD. G. Kieback Department of Obstetrics and Gynecology, Elblandklinikum Riesa, Riesa (Dresden), GermanyR. Klapdor Medical Clinic, University of Hamburg, GermanyU. R. Kleeberg Hämatologisch - Onkologisch - Praxis Altona, Hamburg, GermanyP. Kleihues Department of Pathology, University Hospital Zürich, SwitzerlandE. Klein Department of Tumor Biology, Karolinska Institute, Stockholm, SwedenS. von Kleist Institut für Immunologie der Universität der Freiburg, GermanyS. D. Kottaridis Department of Virology, Hellenic Anticancer Institute, Athens, GreeceG. R. F. Krueger Center of Anatomy II, University of Cologne Medical School, Cologne, GermanyD. W. Kufe Division of Medicine, Dana-Farber Cancer Institute, Boston, MA, USAPat M. Kumar Department of Biological Sciences, Manchester Metropolitan University, Manchester, UKShant Kumar Department Pathology, University of Manchester Medical School, Manchester, UKM. Kuroki Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka, JapanO. D. Laerum Department of Pathology, The Gade Institute, University of Bergen, NorwayF. J. Lejeune Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, SwitzerlandL. F. Liu Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USAD. M. Lopez Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USAE. Lundgren Unit of Applied Cell and Molecular Biology, University of Umea, SwedenH. T. Lynch Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USAJ. Marescaux IRCAD, University of Strasbourg, FranceJ. Mark Department of Pathology, Kärnsjukhuset, Skövde, SwedenJ. F. Marshall Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart’s and The London, Queen

Mary’s School of Medicine and Dentistry, London, UKD. Medina Department of Cell Biology, Baylor College of Medicine, Houston, TX, USAS. Mitra Sealy Center for Molecular Science, University of Texas Medical Branch, Galveston, TX, USAM. Mueller Research Group of Tumor and Microenvironment (A101), German Cancer Research Center (DKFZ),

Heidelberg, GermanyF. M. Muggia New York University Cancer Institute, School of Medicine, NY, USAM. J. Murphy, Jr. Hipple Cancer Research Center, Dayton, OH, USAR. Narayanan Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USAK. Nilsson Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, SwedenJ. F. Novak Department of Biology, Bucknell University, Lewisburg, PA, USAS. Pathak Department of Cell Biology, University of Texas, Houston, TX, USAS. Pestka Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey,

Piscataway, NJ, USAG. J. Pilkington Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences,

University of Portsmouth, UKC. D. Platsoucas College of Sciences, Old Dominion University, Norfolk, VA, USAF. Podo Laboratory of Cell Biology, Istituto Superione di Sanita, Rome, Italy A. Polliack Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, IsraelM. F. Rajewsky Institute of Cell Biology, University of Essen Medical School, Essen, GermanyG. Rebel IRCAD, Hopitaux Universitaires, Strasbourg, FranceM. Rigaud Laboratory Biochimie et Génétique Molecules, Faculté de Médecine de Limoges, FranceU. Ringborg Department of General Oncology, Karolinska Hospital, Stockholm, Sweden


4677

M. Roselli Department of Medical Oncology, University of Rome “Tor Vergata”, ItalyA. Schauer Zentrum Pathologie, Georg-August Universität, Göttingen, GermanyM. Schneider Department of Organic Chemistry, Bergische University, Wuppertal, GermanyA. Seth Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada G. V. Sherbet Cancer Research Unit, University of Newcastle-upon-Tyne, UKG.-I. Soma Institute for Health Sciences, Tokushima Bunri University, Tokushima, JapanG. S. Stein Department of Cell Biology, University of Massachusetts Medical Center, Worcester, MA, USAT. Stigbrand Department of Immunology, Umea University, Umea, SwedenD. Tarin University of California at San Diego, Cancer Center, La Jolla, CA, USAT. M. Theophanides Department of Chemistry, Technical University of Athens, GreeceB. Toth The Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE, USAP. M. Ueland Clinical Pharmacolocy Unit, Department of Pharmacology, University of Bergen, NorwayP. T. Vihko Department of Clinical Chemistry, University of Oulu, FinlandM. Volm German Cancer Research Center, Heidelberg, GermanyG. Weber Laboratory of Experimental Oncology, Indiana University, Indianapolis, IN, USAB. Westermark Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, SwedenB. Zumoff Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA

Aaltonen foundation, Helsinki, FinlandAcademia Sinica, Taipei, Taiwan, R.O.C.Academy of Finland, FinlandAichi Cancer Research Foundation, Nagoya, JapanAlbert Einstein College of Medicine, Bronx, NY, U.S.A.

Albert Hung Foundation, U.K.Alberta Cancer Board, Alberta , CanadaAlberta Heritage Foundation for Medical Research, CanadaAlbertinen-Stiftung, Hamburg, GermanyAlfred und Ursula Kulemann Stiftung, Philipps University,

Marburg, GermanyAlma Toorock Memorial for Cancer Research, Brooklyn,

NY, U.S.A.American Cancer Society, Atlanta, GA, U.S.A.American Heart Association, Dallas, TX, U.S.A.AmpliMed Corporation, Tucson, AZ, U.S.A.Animal Care Resource Centre, BC Cancer Agency’s

Vancouver Research Centre, Vancouver, CanadaAr.Ger.on onlus, ItalyARIAD Pharmaceuticals Inc., Cambridge, MA, U.S.A.Artemisia BioMedical Inc (AB), Newcastle, WA, U.S.A.Asan Institute for Life Science, Seoul, Republic of KoreaAssociation for International Cancer Research, UKAssociation for the Promotion of Research in

Arteriosclerosis, Thrombosis and Vascular Biology,U.S.A.

Associazione gli Amici di Marco, La Spezia, Italy Associazione Italiana Contro le Leucemie/Linfoma e

Mieloma, AIL, Sezione Francesca Lanzone, La Spezia,Italy

AstraZeneca, Wilmington, NC, U.S.A.Australian Catholic University, Brisbane, AustraliaAustralian Department of Education, Employment and

Workplace Relations (DEEWR), AustraliaAustralian Nuclear Science and Technology Organisation,

AustraliaAustralian Orthopaedic Association, AustraliaAvanti Polar Lipids, Alabaster, AL, U.S.A.Avon Foundation, New York, NY, U.S.A.

Bernard O’Brien Institute of Medical Research, Fitzroy,Australia

Biomedical Laboratory Research and Development,Washington, DC, U.S.A.

Biomedical Research Laboratory, Kureha Chemical Industry,Japan

Biomedicum Helsinki Foundation, Helsinki, Finland BioMolecular Products, Newburyport, MA, U.S.A.Björnsson Foundation, SwedenBoehringer-Ingelheim, Ingelheim am Rhein, GermanyBristol-Myers Squibb, New York, U.S.A. Bruce Meyers Associates LP, New York, NY, U.S.A. Bruker Daltonics, GermanyBundesministerium für Bildung und Forschung, Germany

Canadian Breast Cancer Foundation-Prairies/NWT, CanadaCanadian Breast Cancer Research Alliance, CanadaCanadian Cancer Society Research Institute, Canada Canadian Institutes of Health Research (CIHR), CanadaCancer Association of South Africa, Johannesburg, South

AfricaCancer Assosciation North Rhine

Westphalia(Krebsgesellschaft Nordrhein-Westfalen e.V.),Germany

Cancer Center Research, National Cancer Institute (NCI),NIH, Bethesda, MD, U.S.A.

Cancer Coordinating Committee, University of California,San Fransisco, CA, U.S.A.

Cancer Institute, University of Mississippi Medical Center,Jackson, MS, U.S.A.

Cancer Research Wales, Wales, U.K.Cancer Vaccine Institute, Selborne, U.K.Cardiovascular Institute, University of Pittsburg, Pittsburg,

PA, U.S.A.Celgene Corporation, Summit, NJ, U.S.A.CellTrend, GmbH, Luckenwalde, Germany Center for Development and Commercialization of Anti-

Cancer Therapeutics, Ministry of Health and Welfare,Republic of Korea.

Centre for Medical Research (ZMF), Medical University ofGraz, Graz, Austria

Centro de Terapia Celular/Fundação Hemocentro de RibeirãoPreto (CTC/FUNDHERP), Sao Paolo, Brazil

Chang Gung Medical Research Council, P.R. ChinaChang Gung Memorial Hospital, Kaohsiung, Taiwan,

R.O.C.Chang-Hua Hospital, Taiwan, R.O.C.Charles River Laboratories, Ann Arbor, MI, U.S.A.Childrens Hospital Los Angeles, Los Angeles, CA, U.S.A.


4679

AcknowledgementsThe following Organisations supported many of the works published in Anticancer Research, Volume 31, 2011.

China Medical University and Hospital, Taichung City,Taiwan, R.O.C.

China Postdoctoral Science Foundation, P.R. ChinaChina Scholarship Council, Beijing, P.R. China Chinese Ministry of Education, P.R. ChinaChinese National Natural Science Foundation, P.R. ChinaChulabhorn Research Institute, Bangkok, ThailandCIRRO, The Lundbeck Foundation Center for Interventional

Research in Radiation Oncology, DenmarkCNRS, Paris, FranceCollege of Medicine, Chang Gung University, Taiwan,

R.O.C.Commission of Higher Education, Thailand Company and Cutting Image Histology, Ann Arbor, MI,

U.S.A.Conselho Nacional de Desenvolvimento Científico e

Tecnológico (CNPq), BrazilCore Genomics Facility, Gothenburg, SwedenCotton Inc., Cary, NC, U.S.A.Cure Foundation, Montreal, CanadaCVMNAH Center of Excellence Tuskegee, U.S.A.

Daiichi Sankyo Co. Ltd., Tokyo, JapanDental Society Apollonia, Helsinki, FinlandDepartment of Biotechnology, Ministry of Science, IndiaDepartment of Dermatology, Hamamatsu University School

of Medicine, Shizuoka, JapanDepartment of Environmental and Occupational Health,

Graduate School of Public Health, University ofPittsburgh, Pittsburgh, PA, U.S.A.

Department of Environmental Medicine, School ofMedicine, New York University, Tuxedo, NY, U.S.A.

Department of Health, China Medical University HospitalCancer Research of Excellence, Taichung, Taiwan, R.O.C.

Department of International Medical Communications ofTokyo Medical University, Tokyo, Japan

Department of Medicine, University of California, LosAngeles, CA, U.S.A.

Department of Obstetrics and Gynecology, Ashiya MunicipalHospital, Ashiya, Japan

Department of Obstetrics and Gynecology, InaminoHospital, Kakogawa, Japan

Department of Obstetrics and Gynecology, Izumi MunicipalHospital, Osaka, Japan

Department of Otorhinolaryngology, Head and NeckSurgery, University of Heidelberg, Heidelberg, Germany

Department of Otorhinolaryngology, Head and NeckSurgery, University Hospital Giessen and Marburg,Marburg, Germany

Department of Pathology and Cell Biology, University ofSouth Florida College of Medicine, Tampa, FL, U.S.A.

Department of Pathology, Shizuoka Cancer Center,Shizuoka, Japan

Department of Pharmaceutical Biology, Institute ofPharmacy and Biochemistry, University of Mainz, Mainz,Germany

Department of Radiology, Breast Imaging Center, UllevaalUniversity Hospital, Oslo, Norway

Department of Radiotherapy, Charité University Medicine ofBerlin, Berlin, Germany

Department of Stem Cell Biology, Institute for FrontierMedical Sciences, Kyoto University, Kyoto, Japan

Department of Surgical Pathology, University of Foggia,Foggia, Italy

Department of Surgical Sciences, Medical Faculty UppsalaUniversity, Uppsala, Sweden

Department of Urology, Albertinen-Krankenhaus, Hamburg,Germany

Department of Veterans Affairs, Washington, DC, U.S.A.

Desirée and Niels Yde Foundation, DenmarkDeutsche Forschungsgemeinschaft (DFG), Bonn, GermanyDeutsche Krebshilfe, Bonn, GermanyDivision of Cancer Epidemiology and Prevention, National

Cancer Institute, NIH, Bethesda, MD, U.S.A.Division of Cancer Treatment and Diagnosis, National

Cancer Institute, NIH, Bethesda, MD, U.S.A.Dr. Mildred Scheel Stiftung für Krebsforschung, GermanyDuke University GI Oncology, Durham, NC, U.S.A.Duodecim Foundation, Helsinki, FinlandDutch Cancer Foundation, the Netherlands

Eli Lilly, Indianapolis, IN, U.S.A.Epidemiological & Clinical Research Information Network

(ECRIN)Erik, Karin and Gösta Selenders Foundation, Sweden

F. Hoffmann-La Roche Ltd., Basel, Switzerland Faculty Research and Publications Board, UNC, Greeley,

CO, U.S.A.Far Eastern Memorial Hospital, Taiwan, R.O.C.Feinberg School of Medicine, Northwestern University,

Chicago, IL, U.S.A. Felix Mindus Foundation, Stockholm, SwedenFinnish Cancer Organizations, Helsinki, FinlandFinnish Cancer Society, FinlandFinnish Cultural Foundation, Helsinki, FinlandFinnish Medical Society Duodecim, Helsinki, Finland


4680

Finnish Society for Therapeutic Radiology and Oncology,Finland

Flow Cytometry Laboratory, Medical School, University ofIllinois, Chicago, U.S.A.

Fondation Andreas P. Naef pour la Chirurgie Thoracique,Lausanne, Switzerland

Fondation pour la Recherche et l’Enseignement enPharmacologie Clinique, Lausanne, Switzerland

Fondazione CARIPUGLIA, Bari, Italy Fondazione Ente Cassa di Risparmio di Firenze, Florence,

ItalyFondazione per il Diabete, Endocrinologia e Metabolismo

(DEM), Rome, ItalyFondazione per la Ricerca Oncologica (FO.R.O.-onlus),

Italy Fonds der Chemischen Industrie (FCI), Frankfurt, GermanyFonds voor Wetenschappelijk Onderzoek Vlaanderen,

Brussel, BelgiumFong Family Foundation, San Francisco, CA, U.S.A.Foundation for Promotion of Cancer Research, JapanFrench Ministry of Health, FranceFriedrich-Baur-Stiftung, Munich, GermanyFukuoka OBGYN Researcher’s Charity Foundation,

Fukuoka, JapanFundação de Amparo à Pesquisa do Estado de Minas Gerais,

Sao Paolo, BrazilFundação de Amparo à Pesquisa do Estado de São Paulo

(FAPESP), Sao Paolo, BrazilFundação para a Ciência e Tecnologia, Ministério da Ciência

e Ensino Superior, PortugalFundación Mutua Madrileña, Madrid, SpainFundamental Research Department, Fujirebio Inc., Yoshiwa,

Japan

Genesis Pharma SA, Athens, GreeceGenzyme, Japan German Cancer Research Center (DKFZ), Heidelberg,

GermanyGerman Jose Carreras Leukemia Foundation, GermanyGesellschaft zur Förderung Kynologischer Forschung e.V.,

Bonn, Germany GmbH, Berlin, Germany.Gothenburg Medical Association, Gothenburg, SwedenGothenburg University, Gothenburg, Sweden Graduate Institute of Biomedical Sciences, Chang Gung

University, Taoyuan, Taiwan, R.O.C.Grand Forks Human Nutrition Research Center, Grand

Forks, ND, U.S.A.Greek Ministry of Education, Athens, Greece

Guangxi Ministry of Science and Technology, P.R. China

Guangxi Provincial Science Foundation for YoungScientists, P.R. China

Harbin Institute of Technology, Heilongjiang, P.R. ChinaHarry S. Truman Memorial Veterans’ Hospital, Columbia,

MO, U.S.A. Harvard Catalyst, The Harvard Clinical and Translational

Science Center, Boston, MA, U.S.A.Health Service Center, University of Tokushima,

Tokushima, JapanHelsinki University Central Hospital Research Foundation,

Helsinki, FinlandHelsinki University Central Hospital, Helsinki, FinlandHighTech.NRW (ForSaTum), GermanyHilleroed Hospital Research Foundation, DenmarkHistology Section of the Tissue Core and the Analytic

Microscopy Core at the Moffitt Cancer Center andResearch Institute, Tampa, FL, U.S.A.

Huazhong University of Science and TechnologyFoundation, P.R. China

Hungarian Science and Technology Foundation, Budapest,Hungary

Hunter New England Pathology, Tamworth Base Hospital,Australia

Imperial College, London, U.K.Independent Innovation Foundation of Shandong University

(IIFSDU), P.R. ChinainScience Communications, Yardley, PA, U.S.A.INSERM, Paris-Diderot University, Paris, FranceInstitut National du Cancer (INCa), Boulogne Billancourt,

FranceInstitute for Medical Informatics, Statistics and

Epidemiology, Leipzig, GermanyInstitute for Molecular Biology and Tumor Research,

Philipps University, Marburg, GermanyInstitute of Biology, Demokritos, Athens, GreeceInstitute of Biomedical Informatics, Medical Faculty,

Ljubljana, SloveniaInstitute of Biomedical Science of Academia Sinica, Taiwan,

R.O.C.Institute Paoli-Calmettes, Marseille, FranceInstituto de Ciencia y Tecnología del D.F., MexicoInstituto Nacional de Ciencias Médicas y Nutrición, MexicoInternational Myeloma Foundation, Japan Irish Cancer Society, Dublin, IrelandIstanbul University, Istanbul, Turkey


4681

Jan M & Eugenia Krol Charitable Foundation Inc,Barnegat,NJ, U.S.A.

Japan Society for the Promotion of Science (JSPS), Tokyo,Japan

Japan Society for the Promotion of Science, JapanJapanese Ministry of Health, Welfare and Labor, JapanJapanese Society for the Promotion of Science (JSPS),

Tokyo, JapanJarislowsky Foundation, CanadaJennifer Hunter Yates Sarcoma Foundation, Hudson, MA,

U.S.A.Juvenile Diabetes Research Foundation, New York, NY, U.S.A.

Kakihara Science and Technology Foundation, Fukuoka,Japan

Kansas State University, Manhattan, KS, U.S.A. Kaohsiung Chang Gung Memorial Hospital, College of

Medicine, Chang Gung University, Taiwan, R.O.C.Kaohsiung Medical University Hospital, P.R. ChinaKarolinska Institute, Huddinge, SwedenKarolinska Institutet, Stockholm, SwedenKentucky Lung Cancer Foundation, U.S.A.Khulna University, BangladeshKing Abdulaziz City for Science and Technology (KACST ),

Riyadh, Saudi ArabiaKing Gustaf the Vths Jubilee Foundation, SweedenKinki University, Osaka, JapanKnut and Alice Wallenberg Foundation, SwedenKorea Healthcare Technology R&D Project, Ministry for

Health & Welfare Affairs, Republic of KoreaKrebs- und Scharlachforschung Foundation, University of

Heidelberg, Heidelberg, GermanyKreitz-Stiftung, GermanyKuopio University Hospital, Kuopio, FinlandKureha Corporation, Tokyo, JapanKyowa Hakko Kirin Co. Ltd., Tokyo, JapanKyung Hee University, Seoul, Republic of Korea

Laboratory of Clinical Chemistry, Centre HospitalierUniversitaire Vaudois (CHUV), Lausanne, Switzerland

Laboratory of Experiment Pathology, Vrije UniversiteitBrussel, Brussels, Belgium

Laboratory of Genomic Studies, São Paulo State University,Sao Paulo, Brazil

Laboratory of Molecular Oncology, Vrije UniversiteitBrussel, Brussels, Belgium

Laboratory of Tumor Biology, Department of Obstetrics andGynaecology, Ludwig Maximilians University of Munich,Munich, Germany

Les Amis de l’Institut Bordet, Brussels, BelgiumLigue Contre le Cancer, FranceLimoges Teaching Hospital, Limoges, FranceLithuanian State Science and Studies Foundation, LithuaniaLloyd-Carr Harris Foundation, CanadaLudwig Boltzmann Cluster for Cardiovascular Research,

Vienna, AustriaLundberg Foundation, Sweden

M.D. Anderson Cancer Center, Houston, TX, U.S.A.Mackay Memorial Hospital, Taiwan, R.O.C.Manitoba Health Research Council, Winnipeg, CanadaMaryland Technology Corporation, Ellicott City, MD, U.S.A.Mass Spectrometry Unit, Department of Chemistry,

University of Florida, Gainesville, FL, U.S.A.Maud Kuistila Memorial Foundation (EK), FinlandMaud Kuistila Memorial Foundation, Helsinki, FinlandMax Eder Stiftung, Deutsche Krebshilfe, Bonn, Germany Max-Planck Institute für experimentelle Medizin, Göttingen,

GermanyMedical Faculty, University of Heidelberg, Heidelberg,

GermanyMedical University of Lublin, PolandMerck GesmbH, Vienna, AustriaMerkel Technologies Ltd., IsraelMetastasis and Angiogenesis Research Group, Cardiff, U.K.Methodist Research Institute, Indiana University Health,

U.S.A.Michael J. Fox Foundation for Parkinson’s Disease

Research, New York, NY, U.S.A.Microbiology Department, UCC, Cork, Ireland Ministero dell’Università e della Ricerca Scientifica e

Tecnologica (MIUR), Rome, ItalyMinistry for Health, Welfare & Family Affairs, Republic of

KoreaMinistry of Education, Culture, Sports, Science and

Technology, JapanMinistry of Education, Youth and Sports, Czech Republic Ministry of Health and Welfare, Republic of KoreaMinistry of Health, Czech RepublicMinistry of Health, Labor and Welfare of Japan, JapanMinistry of Science and Technology, IsraelMiUR, Diagnostica molecolare in Oncologia and Banco di

Sardegna, ItalyMonika Kutzner Stiftung, Germany

Nagono Medical Foundation, Nagoya, JapanNagoya City University, Nagoya, JapanNational Cancer Institute of Canada, Toronto, Canada


4682

National Cancer Institute Tumor Repository, National CancerInstitute, Frederick, MD, U.S.A.

National Cerebral & Cardiovascular Center ResearchInstitute, Osaka, Japan

National Hospital Organization Policy Based MedicalServices.

National Institute of Health, Bethesda, MD, U.S.A.National Institute of Radiological Sciences, Chiba, JapanNational Natural Science Foundation, Guangdong, P.R.

ChinaNational Research Council of Thailand (NRCT), Bangkok,

ThailandNational Research Foundation of Korea (NRF), Republic of

KoreaNational Research Foundation of Korea, Republic of KoreaNational Science Council, Taipei, Taiwan, R.O.C. National Science Foundation of China, P.R. China National Yang-Ming University, P.R. China Natural Science Foundation of Guangdong Province, P.R.

China Necropsy Unit, Southwest National Primate Research

Center, San Antonio, TX, U.S.A.New Energy and Industrial Technology Development

Organization, JapanNippon Kayaku Co., Ltd., Tokyo, JapanNord Chemicals Ltd., Ningbo, P.R. ChinaNorthern Norway Regional Health Authority, NorwayNorwegian Cancer Society, Norway Norwegian Research Council, Oslo, NorwayNovartis Pharma AG, Basel, SwitzerlandNovartis Pharma, Vilvoorde, BelgiumNovartis, Spain

Office of Research Affairs (ORA), King Faisal SpecialistHospital & Research Centre, Riyadh, Saudi Arabia

Oklahoma Center for the Advancement of Science andTechnology, Oklahoma City, OK, U.S.A.

ORTON, Helsinki, FinlandOsaka Medical College, Osaka, JapanOslo Breast Cancer Micrometastasis Project, Oslo, Norway

Paavo Koistinen Foundation, FinlandPancreatic Cancer Action Network-AACR, Manhattan

Beach, CA, U.S.A.Pathology Department, Mercy University Hospital, Cork,

IrelandPathology Service, Hospital de Base de São José do Rio

Preto, Sao Paulo, BrazilPaul Blümel Stiftung, Hannover, Germany

Pfizer, Inc, New York, U.S.A.Pfizer, Inc., FrancePfizer, Inc., Vienna, Austria Pharmacia & Upjohn, Dübendorf, SwitzerlandPierre Fabre Pharma, New Jersey, U.S.A.Polish State Committee for Scientific Research, PolandPort Macquarie Private Hospital, AustraliaPresbyterian Health Foundation, Oklahoma City, OK, U.S.A. Provincial Research Project Funding of Guangxi, P.R. China

Rappaport Research Institute, Haifa, IsraelREHAU AG & Co., GermanyResearch Center Administration, King Faisal Specialist

Hospital & Research Centre, Riyadh, Saudi ArabiaResearch Council of Lithuania, LithuaniaResearch Network for Tissue Engineering and Rapid

Prototyping (Forschungsverbund FORTEPRO), BavarianResearch Foundation (Bayerische Forschungsstiftung),Germany

Research Reactor Institute, Kyoto University, Kyoto, JapanRHL Comprehensive Cancer Center, Northwestern

University, Chicago, IL, U.S.A.Riley Children’s Foundation, Indiana, U.S.A.Roche Hellas SA, Athens, GreeceRomanian Ministry of Education and Research, RomaniaRowett Institute for Nutrition, Aberdeen, ScotlandRudolf Bartling Stiftung, GermanyRural and Environmental Research and Analysis Directorate,

ScotlandRural Development Administration, Republic of Korea

SAIC-Frederick, Inc, Maryland, U.S.A.Sanofi S.A., Paris, FranceSarcoma Foundation of America, Damascus, MD, U.S.A.Science and Technology Commission Foundation of

Guangxi Province, P.R. ChinaScientific Research Foundation, Heilongjiang, P.R. ChinaSeidel Family Trust, California, U.S.A.Seta Clinic Group, JapanShimane University, Shimane, JapanSigrid Juselius Foundation, Helsinki, FinlandSNFK, Amsterdam, the NetherlandsSociety of Nuclear Medicine, Reston, VA, U.S.A. Soochow University Medical Development Foundation, P.R.

ChinaSouthwest Finland Cancer Society, Turku, FinlandSterix Ltd, London, U.K.Stockholm Cancer Society, Stockholm, SwedenStockholm City Council, Stockholm, Sweden


4683

Sukuseura Lindgren, Helsinki, FinlandSurgical Department, South Infirmary Victoria University

Hospital, Cork, IrelandSwedish Cancer Foundation, Stockholm, SwedenSwedish Cancer Society, SwedenSwedish Children’s Cancer Foundation, Stockholm , SwedenSwedish Larynx Foundation, Stockholm, Sweden Swedish Match AB, Stockholm, SwedenSwedish Research Council, Stockholm, SwedenSwiss Cancer League, SwitzerlandSwiss National Science FoundationSydney Medical School, University of Sydney, Sydney,

AustraliaSzeged Foundation for Cancer Research, Szeged, Hungary

Taiwan Department of Health Clinical Trial and ResearchCenter of Excellence, Taiwan, R.O.C.

Tampere University Hospital, Tampere, FinlandTerry Fox Cancer Research Foundation, National Science

Council, CanadaTexas AgriLife, College Station, TX, U.S.A.Texas Health Harris Methodist Foundation, Fort Worth, TX,

U.S.A.The Cancer Society in Stockholm, Stockholm, SwedenThe Chinese Scholarship Council, P.R. China The Delta State University Foundation, Cleveland, MS, U.S.A. The Institute of Medical Science, Tokyo, JapanThe King Gustav V Jubilee Fund, Stockholm, Sweden The Sallie Astor Burdine Breast Foundation, Baton Rouge,

LA, U.S.A. The Swedish Cancer Society, Stockholm, Sweden The Third Affiliated Hospital, Soochow University,

Changzhou, P.R. China The University of Tokyo, Tokyo, Japan Third Faculty of Medicine, Charles University, Prague,

Czech RepublicTissue Bank and Lung Cancer Registry, Thoraxklinik,

University of Heidelberg, Heidelberg, Germany

Tissue Bank, China Medical University, Taichung City,Taiwan, R.O.C.

Tissue Bank, National Center for Tumor Diseases,University of Heidelberg, Heidelberg, Germany

Tohoku University, Sendai, JapanTranslational Research Informatics Center, Kobe, JapanTurku University, Turku, Finland

Università degli Studi di Milano, Milan, ItalyUniversity Hospitals Trust, Bristol, U.K.University of Bristol, Bristol, U.K.University of Maryland School of Medicine, Baltimore, MD,

U.S.A. University of Melbourne, Melbourne, AustraliaUniversity of Nebraska Medical Center, Omaha, NE,

U.S.A.University of the Basque Country (UPV/EHU), Bilbao,

SpainUniversity Research Council and the College of Liberal Arts

and Sciences, DePaul University, Chigago, U.S.A.Uppsala University Hospital, Uppsala, Sweden.USC Norris Comprehensive Cancer Center, Los Angeles,

CA, U.S.A.

Vanderes Foundation, Breda, the Netherlands Verein für Tumorforschung Innsbruck, Innsbruck, AustriaVGH & UBC Hospital Foundation, Vancouver, CanadaVrije Universiteit Brussel (VUB), Brussels, Belgium

Weill Cornell Medical College, New York, U.S.A.Wetenschappelijk Fonds Willy Gepts, UZ Brussel, Brussels,

BelgiumWroclaw Research Centre, EIT+, Wrocław, Poland

Yokohama City University, Yokohama, Japan

Zentrum für Medizinische Forschung, UniversitätsklinikumTübingen, Germany


4684

Contents, Volume 31, 2011

Number 1

Experimental Studies

Inhibition of Tumor Cellular Proteasome Activity by Triptolide Extracted from the Chinese Medicinal Plant‘Thunder God Vine’. L. LU, J. KANWAR, S. SCHMITT, Q.C. CUI, C. ZHANG, C. ZHAO, Q. PINGDOU (Guangdong, China; Detroit, MI, USA) ....................................................................................

Frequent Absence of Tumor Suppressor FUS1 Protein Expression in Human Bone and Soft Tissue Sarcomas.G. LI, H. KAWASHIMA, L. JI, A. OGOSE, T. ARIIZUMI, H. UMEZU, Y. XU, T. HOTTA, N. ENDO(Niigata, Japan; Heilongjiang, PR China; Houston, TX, USA) ............................................................

Measuring IGF-1, ER-α and EGFR Expression Can Predict Tamoxifen-resistance in ER-positive BreastCancer. K. CHONG, A. SUBRAMANIAN, A. SHARMA, K. MOKBEL (London, UK) .........................

Human Lymphoma Cells Develop Resistance to Radiation in the Presence of Astrocytes In Vitro. M. KOTO,H. CHO, O. RIESTERER, U. GIRI, M.D. STORY, C.S. HA, U. RAJU (Sendai, Japan; Pusan, SouthKorea; Zurich, Switzerland; Houston; Dallas; San Antonio, TX, USA) .................................................

Apoptosis of SAS Cells Induced by Sonodynamic Therapy Using 5-Aminolevulinic Acid Sonosensitizer. W.SONG, H. CUI, R. ZHANG, J. ZHENG, W. CAO (Heilongjiang, PR China; University Park, PA, USA) ........

Procathepsin D and Cytokines Influence the Proliferation of Lung Cancer Cells. V. VETVICKA, J.VETVICKOVA (Louisville, KY, USA) ...............................................................................................

Feulgen Staining Remains the Gold Standard for Precise DNA Image Cytometry. S. BIESTERFELD, S.BECKERS, M. DEL CARMEN VILLA CADENAS, M. SCHRAMM (Düsseldorf, Germany) .................

EGFR Codon 497 Polymorphism – Implications for Receptor Sensitivity to Inhibitors in HNSCC CellLines. V. KROHN, S. WIEGAND, J.A. WERNER, R. MANDIC (Marburg, Germany) ...........................

Overexpression of Interleukin-6 Suppresses Cisplatin-induced Cytotoxicity in Esophageal Squamous CellCarcinoma Cells. K. SUCHI, H. FUJIWARA, S. OKAMURA, H. OKAMURA, S. UMEHARA, M. TODO,A. FURUTANI, M. YONEDA, A. SHIOZAKI, T. KUBOTA, D. ICHIKAWA, K. OKAMOTO, E. OTSUJI(Kyoto, Japan) ...............................................................................................................................

TIP60 as a Potential Marker for the Malignancy of Gastric Cancer. K. SAKURABA, K. YOKOMIZO, A.SHIRAHATA, T. GOTO, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, K. HIBI (Yokohama,Japan) ...........................................................................................................................................

Cytotoxicity of Thymus vulgaris Essential Oil Towards Human Oral Cavity Squamous Cell Carcinoma. S.SERTEL, T. EICHHORN, P.K. PLINKERT, T. EFFERTH (Heidelberg; Mainz, Germany) ......................

Thyroid Hormones (T3 and T4): Dual Effect on Human Cancer Cell Proliferation. G. MORIGGI, C.VERGA FALZACAPPA, C. MANGIALARDO, S. MICHIENZI, A. STIGLIANO, E. BRUNETTI, V.TOSCANO, S. MISITI (Rome, Italy) ................................................................................................

Prognostic Value of Mitotic Counts in Breast Cancer of Saudi Arabian Patients. A. BUHMEIDA, J. AL-MAGHRABI, A. MERDAD, F. AL-THUBAITY, A. CHAUDHARY, M. GARI, A. ABUZENADAH, Y.COLLAN, K. SYRJÄNEN, M. AL-QAHTANI (Jeddah, Saudi Arabia; Turku, Finland) ..........................


4685

1

11

23

33

39

47

53

59

67

77

81

89

97

NK4 Gene Therapy Combined with Cisplatin Inhibits Tumour Growth and Metastasis of Squamous CellCarcinoma. G. MATSUMOTO, Y. OMI, U. LEE, E. KUBOTA, Y. TABATA (Kanagawa; Kyoto, Japan) .........

Constitutively Active FGFR3 with Lys650Glu Mutation Enhances Bortezomib Sensitivity in Plasma CellMalignancy. M. OTSUKA, M. MIZUKI, J. FUJITA, S. KANG, Y. KANAKURA (Osaka, Japan; Atlanta,GA, USA) ......................................................................................................................................

The Tumor Suppressive Effect of Angiotensin II Type 1 Receptor Antagonist in a Murine Osteosarcoma Model.J. WASA, H. SUGIURA, E. KOZAWA, K. KOHYAMA, K. YAMADA, O. TAGUCHI (Nagoya, Japan) .......

New Sarcomatoid Cancer Cell Line SAR-HCV Established from a Hepatitis C Virus-related Liver TumourLesion. D.-I. TAI, Y.-J. SHEN, W.-H. WENG, H.-W. CHEN, C.-C. KANG, T.-C. CHEN, S.-K. LIAO(Taoyuan; Taipei, Taiwan, ROC) ......................................................................................................

Oncogramme, A New Promising Method for Individualized Breast Tumour Response Testing for CancerTreatment. S. GIRAUD, E. LOUM, B. BESSETTE, V. FERMEAUX, C. LAUTRETTE (Limoges Cedex,France) .........................................................................................................................................

Hepatic Arterial Infusion in the Treatment of Liver Metastases with PEG Liposomes in Combination withDegradable Starch Microspheres (DSM) Increases Tumor 5-FU Concentration. An Animal Study in CC-531Liver Tumor-bearing Rats. U. POHLEN, R. RESZKA, H.J. BUHR, G. BERGER (Berlin, Germany) ..........

Improvement of Biodistribution with PEGylated Liposomes Containing Docetaxel with Degradable StarchMicrospheres for Hepatic Arterial Infusion in the Treatment of Liver Metastases: A Study in CC-531 LiverTumor-bearing WAG RIJ Rats. U. POHLEN, H.J. BUHR, G. BERGER (Berlin, Germany) ....................

Neem Leaf Extract Induces Radiosensitization in Human Neuroblastoma Xenograft Through Modulation ofApoptotic Pathway. J. VEERARAGHAVAN, S. ARAVINDAN, M. NATARAJAN, V. AWASTHI, T.S.HERMAN, N. ARAVINDAN (Oklahoma City, OK; San Antonio, TX, USA) ..........................................

MAGE Expressions Mediated by Demethylation of MAGE Promoters Induce Progression of Non-small CellLung Cancer. N. YANAGAWA, G. TAMURA, H. OIZUMI, M. ENDOH, T. MOTOYAMA (Yamagata,Japan) ...........................................................................................................................................

Oleic Acid Is the Active Component in the Mushroom Daedalea gibbosa Inhibiting Bcr-Abl KinaseAutophosphorylation Activity. H. KHAMAISIE, S. SUSSAN, M. TAL, Y. NAJAJREH, M. RUTHARDT, J.MAHAJNA (Kiryat Shmona; Ness-Ziona, Israel; Jerusalem-Abu Dies, Palestine; Frankfurt, Germany) ........

Chemical Composition and Antiproliferative Activity of Essential Oil from the Leaves of a Medicinal Herb,Levisticum officinale, against UMSCC1 Head and Neck Squamous Carcinoma Cells. S. SERTEL, T.EICHHORN, P.K. PLINKERT, T. EFFERTH (Heidelberg; Mainz, Germany) .........................................

Anticancer and Antimetastatic Activities of Renieramycin M, a Marine Tetrahydroisoquinoline Alkaloid, inHuman Non-small Cell Lung Cancer Cells. H. HALIM, P. CHUNHACHA, K. SUWANBORIRUX, P.CHANVORACHOTE (Bangkok, Thailand) ........................................................................................

ATM/ATR and SMAD3 Pathways Contribute to 3-Indole-induced G1 Arrest in Cancer Cells and XenograftModels. S.-M. HUANG, K.-T. LU, Y.-C. WANG (Taipei; Tainan, Taiwan, ROC) .................................

Effect of Genistein on p90RSK Phosphorylation and Cell Proliferation in T47D Breast Cancer Cells. J.GWIN, N. DREWS, S. ALI, J. STAMSCHROR, M. SORENSON, T.T. RAJAH (Chicago, IL, USA) ......

Increased Efficacy and Reduced Cardiotoxicity of Metronomic Treatment with Cyclophosphamide in RatBreast Cancer. V.K. TODOROVA, Y. KAUFMANN, V.S. KLIMBERG (Little Rock, AR, USA) ................


4686

105

113

123

129

139

147

153

161

171

177

185

193

203

209

215

Association of Cyclooxygenase 2 Polymorphic Genotypes with Prostate Cancer in Taiwan. H.-C. WU, C.-H. CHANG, H.-L. KE, W.-S. CHANG, H.-N. CHENG, H.-H. LIN, C.-Y. WU, C.-W. TSAI, R.-Y. TSAI,W.-C. LO, D.-T. BAU (Taichung; Kaohsiung; Chang-Hua, Taiwan, ROC) ...........................................

Significant Association of Cyclin D1 Single Nucleotide Polymorphisms with Oral Cancer in Taiwan. M.-H. TSAI,C.-W. TSAI, Y.-A. TSOU, C.-H. HUA, C.-F. HSU, D.-T. BAU (Taichung; Chang-Hua, Taiwan, ROC) .........

Ruta graveolens Extract Induces DNA Damage Pathways and Blocks Akt Activation to Inhibit Cancer CellProliferation and Survival. K. FADLALLA, A. WATSON, T. YEHUALAESHET, T. TURNER, T. SAMUEL(Tuskegee, AL, USA) .......................................................................................................................

Clinical Studies

Detection and Significance of Parametrial Micrometastases in Early-stage Cervical Cancer. P.C. BRADY, X.CHEN, W.M. BURKE, I. DEUTSCH, X. SUN, T.J. HERZOG, J.D. WRIGHT (New York, NY, USA) ..........

Phase II Study of Saracatinib (AZD0530) for Patients with Recurrent or Metastatic Head and NeckSquamous Cell Carcinoma (HNSCC). M.G. FURY, S. BAXI, R. SHEN, K.W. KELLY, B.L. LIPSON, D.CARLSON, H. STAMBUK, S. HAQUE, D.G. PFISTER (New York, NY, USA) ....................................

A Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of MetastaticColorectal Cancer. N.S. WONG, N.H. FERNANDO, A.B. NIXON, S. CUSHMAN, M. AKLILU, J.C.BENDELL, M.A. MORSE, G.C. BLOBE, J. ASHTON, H. PANG, H.I. HURWITZ (Durham; Winston-Salem, NC, USA) ...........................................................................................................................

Expression of LGR5, an Intestinal Stem Cell Marker, During Each Stage of Colorectal Tumorigenesis. K. TAKEDA,I. KINOSHITA, Y. SHIMIZU, Y. MATSUNO, T. SHICHINOHE, H. DOSAKA-AKITA (Sapporo, Japan) ..........

Short Review: The Role of Pelvic Lymph Node Dissection During Radical Cystectomy for Bladder Cancer.E. BRUNOCILLA, R. PERNETTI, G. MARTORANA (Bologna, Italy) ................................................

Two Cases with a Long-term Survival Following Multidisciplinary Treatment for Recurrent Breast CancerAfter Surgery. H. URAMOTO, T. HANAGIRI (Kitakyushu, Japan) .......................................................

C-erbB-3 Expression in Non-small Cell Lung Cancer (NSCLC) Patients Treated by Erlotinib. I. CsTOTH,G. ANTHOINE, T. BERGHMANS, C. MASCAUX, M. PAESMANS, J.-P. SCULIER, A.-P. MEERT(Brussels, Belgium) ........................................................................................................................

A Phase II Study of Weekly Paclitaxel and Doxifluridine Combination Chemotherapy for Advanced/RecurrentGastric Cancer. I. TAKEYOSHI, F. MAKITA, Y. TANAHASHI, S. IWAZAKI, T. OGAWA, N. TOMIZAWA,S. NAKAMURA, H. ISHIKAWA, T. OHYA, S. KAKINUMA, K. NAKAGAMI, Y. SATO, T. KOYANO, T.ROPPONGI, M. IZUMI, J. KOBAYASHI, S. KAWATE, Y. SUNOSE, M. KOBAYASHI, T. YAMADA, I.SAKAMOTO (Maebashi; Shibukawa; Tatebayashi; Takasaki; Ota; Numata; Annaka, Gunma; Yamanashi,Yamanashi; Ojiya, Niigata; Shimada, Shizuoka; Saitama, Saitama, Japan) ...........................................

Cortactin in Breast Cancer: Analysis with Tissue Microarray. S.-M. SHEEN-CHEN, C.-Y. HUANG, Y.-Y.LIU, C.-C. HUANG, R.-P. TANG (Kaohsiung, Taiwan, ROC; Xiamen, PR China) ...............................

Successful S-1 Monotherapy for Chemorefractory Thymic Carcinoma. T. KOIZUMI, T. AGATSUMA, Y.KOMATSU, K. KUBO (Matsumoto, Nagano, Japan) .........................................................................

Prognostic Value of the Human Antigen R (HuR) in Human Breast Cancer: High Level Predicts a FavourablePrognosis. Z. YUAN, A.J. SANDERS, LI. YE, Y. WANG, W.G. JIANG (Cardiff, UK; Beijing, PR China).....


4687

221

227

233

243

249

255

263

271

277

281

287

293

299

303

*

Pronounced Tumour Regression after Radiotherapy is Associated with Negative/Weak Glucose Transporter-1 Expression in Rectal Cancer. E. KORKEILA, P.M. JAAKKOLA, K. SYRJÄNEN, S. PYRHÖNEN, J.SUNDSTRÖM (Turku, Finland) ......................................................................................................

Randomized Phase II Study of Paclitaxel and Carboplatin or Vinorelbine in Advanced Non-small Cell LungCancer. K. JAHNKE, U. KEILHOLZ, D. LÜFTNER, E. THIEL, A. SCHMITTEL (Berlin, Germany) ......

Clinical Significance of STC1 Gene Expression in Patients with Colorectal Cancer. S. TAMURA, T. OSHIMA, K.YOSHIHARA, A. KANAZAWA, T. YAMADA, D. INAGAKI, T. SATO, N. YAMAMOTO, M. SHIOZAWA, S.MORINAGA, M. AKAIKE, C. KUNISAKI, K. TANAKA, M. MASUDA, T. IMADA (Kanagawa-ken, Japan) ....

Temsirolimus in Metastatic Chromophobe Renal Cell Carcinoma after Interferon and Sorafenib Therapy. B.PAULE, N. BRION (Creteil; Le Chesnay; Guyancourt, France) ...........................................................

5-FU-induced Hyperammonemic Encephalopathy in a Case of Metastatic Rectal Adenocarcinoid SuccessfullyRechallenged with the Fluoropyrimidine Analog, Capecitabine. P.P. ADVANI, M.G. FAKIH (Buffalo, NY, USA) ...

Predictive Value of Serum Biomarkers in Patients After Portal Vein Embolization (PVE): A Pilot Study. V.TRESKA, O. TOPOLCAN, J. VRZALOVA, T. SKALICKY, A. SUTNAR, V. LISKA, J. FICHTL, A.NARSANSKA, J. FERDA, I. TRESKOVA, H. MIRKA, B. KREUZBERG (Pilsen, Czech Republic) .......

The Dynamics of Serum Tumor Markers in Predicting Metastatic Uveal Melanoma (Part 1). V. BARAK, I.KAISERMAN, S. FRENKEL, K. HENDLER, I. KALICKMAN, J. PE’ER (Ashkelon; Jerusalem, Israel)......

Trends in Liver Function Tests: A Comparison with Serum Tumor Markers in Metastatic Uveal Melanoma(Part 2). K. HENDLER, J. PE’ER, I. KAISERMAN, R. BARUCH, I. KALICKMAN, V. BARAK, S.FRENKEL (Jerusalem; Ashkelon, Israel) ...........................................................................................

Pharmacogenetic Tailoring of Irinotecan-based First-line Chemotherapy in Metastatic Colorectal Cancer:Results of a Pilot Study. G. FREYER, A. DURET, G. MILANO, E. CHATELUT, C. REBISCHUNG, J.-P. DELORD, Y. MERROUCHE, G. LLEDO, M.-C. ETIENNE, C. FALANDRY (Pierre-Bénite; Nice;Grenoble; Saint-Priest-en-Jarez; Lyon, France) ..................................................................................

Risk of Ipsilateral Breast Tumor Recurrence in Patients Treated with Tamoxifen or Anastrozole FollowingBreast-conserving Surgery with or without Radiotherapy. M. ISHITOBI, S. NAKAHARA, Y. KOMOIKE,K. MOTOMURA, H. KOYAMA, H. INAJI (Osaka, Japan) .................................................................

Parameters of Biological Activity in Colorectal Cancer. S. SVOBODOVA, O. TOPOLCAN, L. HOLUBECJr., M. LEVY, L. PECEN, S. SVACINA (Prague, Czech Republic) ......................................................

Review (page 271)

Number 2


Apurinic/Apyrimidinic Endonuclease 1 Regulates Inflammatory Response in Macrophages. A. JEDINAK, S.DUDHGAONKAR, M.R. KELLEY, D. SLIVA (Indianapolis, IN, USA) .....................................................

Magnetic Resonance and Fluorescence–Protein Imaging of the Anti-angiogenic and Anti-tumor Efficacy ofSelenium in an Orthotopic Model of Human Colon Cancer. A. BHATTACHARYA, S.G TUROWSKI, I.D.SAN MARTIN, A. RAJPUT, Y.M. RUSTUM, R.M. HOFFMAN, M. SESHADRI (Buffalo, NY; Albuquerque,NM; San Diego, CA, USA) .....................................................................................................................


4688

311

317

325

331

335

339

345

351

359

367

373

379

387

*

Four Cardiac Hormones Cause Death of Human Cancer Cells but Not of Healthy Cells. W.P. SKELTON IV,G.E. PI, D.L. VESELY (Durham, NC; Notre Dame, IN; Tampa, FL, USA) ................................................

miR-221 Is Down-regulated in TMPRSS2:ERG Fusion-positive Prostate Cancer. A. GORDANPOUR, A.STANIMIROVIC, R.K. NAM, C.S. MORENO, C. SHERMAN, L. SUGAR, A. SETH (Atlanta, GA, USA,Toronto, ON, Canada) ...........................................................................................................................

Increased Tumor Uptake of Chemotherapeutics and Improved Chemoresponse by Novel Non-anticoagulantLow Molecular Weight Heparin. P.G. PHILLIPS, M. YALCIN, H. CUI, H. ABDEL-NABI, M. SAJJAD,R. BERNACKI, J. VEITH, S.A. MOUSA (Rensselaer; Buffalo, NY, USA; Bursa, Turkey; Riyadh, SaudiArabia) ..................................................................................................................................

Addition of 2-Deoxyglucose Enhances Growth Inhibition But Reverses Acidification in Colon Cancer CellsTreated with Phenformin. M.A. LEA, J. CHACKO, S. BOLIKAL, J.Y. HONG, R. CHUNG, A. ORTEGA, C.desBORDES (Newark, NJ; Brooklyn, NY, USA) .......................................................................................

A New Device for Rapid Isolation by Size and Characterization of Rare Circulating Tumor Cells. I. DESITTER,B.S. GUERROUAHEN, N. BENALI-FURET, J. WECHSLER, P.A. JÄNNE, Y. KUANG, M. YANAGITA, L.WANG, J.A. BERKOWITZ, R.J. DISTEL, Y.E. CAYRE (Paris, France; Boston, MA, USA) ........................

The Prognostic Value of the Orphan Nuclear Receptor DAX-1 (NROB1) in Node-negative Breast Cancer. H.ZHANG, A. SLEWA, E. JANSSEN, I. SKALAND, Y. YU, E. GUDLAUGSSON, W. FENG, K.KJELLEVOLD, H. SØILAND, J.P.A. BAAK (Stavanger; Bergen, Norway; Houston, TX, USA; Shanghai, PRChina) ..................................................................................................................................................

Expression of Mucin-1, Galectin-1 and Galectin-3 in Human Leiomyosarcoma in Comparison to Leiomyomaand Myometrium. T. WEISSENBACHER, C. KUHN, D. MAYR, R. PAVLIK, K. FRIESE, C. SCHOLZ, U.JESCHKE, N. DITSCH, D. DIAN (Munich, Germany) .............................................................................

Oxidative Stress Reduces Na+/H+ Exchange (NHE) Activity in a Biliary Epithelial Cancer Cell Line (Mz-Cha-1). C. ELSING, A. VOSS, T. HERRMANN, I. KAISER, C.A. HUEBNER, T. SCHLENKER (Dorsten;Heidelberg; Idar-Oberstein; Jena, Germany) .............................................................................................

HAVcR-1 Reduces the Integrity of Human Endothelial Tight Junctions. T.A. MARTIN, G.M. HARRISON,M.D. MASON, W.G. JIANG (Cardiff, UK) .............................................................................................

Natural Killer Cell Line YT Exerts Cytotoxicity Against CD86+ Myeloma Cells. U. HARNACK, H. JOHNEN,G. PECHER (Berlin, Germany) ..............................................................................................................

Serum Derived from Zeranol-implanted ACI Rats Promotes the Growth of Human Breast Cancer Cells In Vitro.S. ZHONG, W.-P. YE, E. FENG, S.-H. LIN, J.-Y. LIU, J. LEONG, C. MA, Y.C. LIN (Beijing, PR China;Columbus, OH, USA) .............................................................................................................................

The Effect of Normoxia and Hypoxia on a Prostate (PC-3) CD44/CD41 Cell Side Fraction. K.M. ANDERSON,P. GUINAN, M. RUBENSTEIN (Chicago, IL, USA) ................................................................................

Expression of Cancer Stem Cell Markers CD133 and CD44 in Locoregional Recurrence of Rectal Cancer. T.NAGATA, C. SAKAKURA, S. KOMIYAMA, A. MIYASHITA, M. NISHIO, Y. MURAYAMA, S. KOMATSU,A. SHIOZAKI, Y. KURIU, H. IKOMA, M. NAKANISHI, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, T.OCHIAI, Y. KOKUBA, T. SONOYAMA, E. OTSUJI (Kyoto, Japan) .........................................................

Sonodynamically-induced Antitumor Effect of Mono-l-aspartyl Chlorin e6 (NPe6). N. YUMITA, Y. IWASE, K.NISHI, T. IKEDA, H. KOMATSU, T. FUKAI, K. ONODERA, H. NISHI, K. TAKEDA, S.-I. UMEMURA, K.OKUDAIRA, Y. MOMOSE (Yokohama, Kanagawa; Sendai; Funabashi, Chiba, Japan) ...............................


4689

395

403

411

421

427

443

451

459

467

475

481

487

495

501

Hypoxia-inducible Adrenomedullin in Colorectal Cancer. M. UEMURA, H. YAMAMOTO, I. TAKEMASA,K. MIMORI, T. MIZUSHIMA, M. IKEDA, M. SEKIMOTO, Y. DOKI, M. MORI (Osaka; Beppu, Japan) ....

Quantitative Structure–Cytotoxicity Relationship of Newly Synthesised Trihaloacetylazulenes Determined by aSemi-Empirical Molecular-Orbital Method (PM5). M. ISHIHARA, H. WAKABAYASHI, N. MOTOHASHI, H.SAKAGAMI (Saitama; Tokyo, Japan) ......................................................................................................

Reassessment of Estrogen Receptor Expression in Human Breast Cancer Cell Lines. C.H.J. FORD, M. AL-BADER, B. AL-AYADHI, I. FRANCIS (Safat, Kuwait) ...........................................................................

Binding of Lactoferrin to IGBP1 Triggers Apoptosis in a Lung Adenocarcinoma Cell Line. D. LI, S. SAKASHITA,Y. MORISHITA, J. KANO, A. SHIBA, T. SATO, M. NOGUCHI (Tsukuba, Ibaraki, Japan) ...........................

Sustained Aberrant Localization of KL-6 Mucin and β-Catenin at the Invasion Front of Human Gastric CancerCells. Y. INAGAKI, W. TANG, H. XU, M. NAKATA, K.-I. MAFUNE, T. KONISHI, Y. SETO, N. KOKUDO(Tokyo; Kanagawa, Japan) .....................................................................................................................

Mutations and Aberrant Transcriptions of Stk11 (Lkb1) Gene in Rat Liver Tumors. N. WAKABAYASHI, K.OKABE, M. HAYASHI, K. HONOKI, T. TSUJIUCHI (Higashiosaka, Osaka; Kashihara, Nara, Japan) .......

The Role of MAPK Pathway in Bone and Soft Tissue Tumors. K. SASAKI, T. HITORA, O. NAKAMURA,R. KONO, T. YAMAMOTO (Kagawa, Japan) ..........................................................................................

Tissue Expression of Glycated Apolipoprotein B in Colorectal Adenoma and Cancer. R. REDDAVIDE, G.MISCIAGNA, M.G. CARUSO, M. NOTARNICOLA, R. ARMENTANO, M.L. CARUSO, M. PIRRELLI,A.M. VALENTINI (Castellana Grotte, Italy) ............................................................................................

Late Residual γ-H2AX Foci in Murine Spinal Cord Might Facilitate Development of Response-modifyingStrategies: A Research Hypothesis. N. ANDRATSCHKE, T. BLAU, S. SCHILL, C. NIEDER (Munich;Cologne, Germany; Bodø; Tromsø, Norway) .............................................................................................

Glutamate Receptors in Laryngeal Cancer Cells. A. STEPULAK, H. LUKSCH, O. UCKERMANN, M.SIFRINGER, W. RZESKI, K. POLBERG, K. KUPISZ, J. KLATKA, M. KIEŁBUS, A. GRABARSKA, J.MARZAHN, L. TURSKI, C. IKONOMIDOU (Lublin, Poland; Dresden; Berlin, Germany; Weesp, Netherlands;Madison, WI, USA) ................................................................................................................................

Associations between Single Nucleotide Polymorphisms of MMP2, VEGF, and HIF1A Genes and the Risk ofDeveloping Colorectal Cancer. M.-J. KANG, S.-A. JUNG, J.M. JUNG, S.-E. KIM, H.-K. JUNG, T.-H. KIM,K.-N. SHIM, S.Y. YI, K. YOO, I.H. MOON (Seoul, South Korea) ............................................................

Clinical Studies

Implementation of Molecular Intra-operative Assessment of Sentinel Lymph Node in Breast Cancer. A.KHADDAGE, S.-A. BERREMILA, F. FOREST, A. CLEMENSON, C. BOUTEILLE, P. SEFFERT, M.PEOC’H (St. Etienne, France) ................................................................................................................

Osseous Changes in Meningioma En Plaque. J. MATSCHKE, J. ADDO, C. BERNREUTHER, J. ZUSTIN(Hamburg, Germany) .............................................................................................................................

Clinical Significance and Predictive Value of Prostaglandin E2 Receptors (EPR) 1 – 4 in Patients with RenalCell Carcinoma. K. OHBA, Y. MIYATA, S.-I. WATANABE, T. HAYASHI, H. KANETAKE, S. KANDA, H.SAKAI (Nagasaki, Japan) ......................................................................................................................

Vitamin D Supplement Doses and Serum 25-Hydroxyvitamin D in the Range Associated with Cancer Prevention.C.F. GARLAND, C.B. FRENCH, L.L. BAGGERLY, R.P. HEANEY (La Jolla, CA; Omaha, NE, USA) .........


4690

507

515

521

529

535

543

549

555

561

565

575

585

591

597

607

Low Number of Detectable Circulating Tumor Cells in Non-metastatic Colon Cancer. M. THORSTEINSSON,G. SÖLETORMOS, P. JESS (Roskilde; Hilleroed, Denmark) ....................................................................

The Development of Bronchopleural Fistula in Lung Cancer Patients after Major Surgery: 31 Years of Experiencewith 19 Cases. H. URAMOTO, T. HANAGIRI (Kitakyushu, Japan) ...........................................................

A Phase I Study Evaluating the Effect of CDHP as a Component of S-1 on the Pharmacokinetics of 5-Fluorouracil. M.W. SAIF, L.S. ROSEN, K. SAITO, C. ZERGEBEL, L. RAVAGE-MASS, D.S.MENDELSON (New York, NY; Santa Monica, CA; Princeton, NJ; Scottsdale, AZ, USA) .............................

Phase II Study of Combined Chemotherapy with Docetaxel, CDDP and 5-FU for Highly Advanced EsophagealCancer. Y. OSAKA, M. SHINOHARA, S. HOSHINO, T. OGATA, Y. TAKAGI, A. TSUCHIDA, T. AOKI(Tokyo, Japan) ....................................................................................................................................

Review: Prediction of Response in Cancer Immunotherapy. D. CHARACIEJUS, J.J.L. JACOBS, V.PAŠUKONIENĖ, N. KAZLAUSKAITĖ, V. DANILEVIČIŪTĖ, M. MAURICAS, W. DEN OTTER (Vilnius,Lithuania; Amsterdam, Netherlands) ........................................................................................................

Review: The Need for Third-line Treatment in Non-small Cell Lung Cancer: An Overview of New Options.K.N. SYRIGOS, M.W. SAIF, E.M. KARAPANAGIOTOU, G. OIKONOMOPOULOS, F. DE MARINIS(Athens, Greece; New Haven, CT; New York, NY, USA; Rome, Italy) ...........................................................

Pediatric Neuro-oncology in Small Centers – Quality Control of Network Support: The HIT-GBM Experience.J.E.A. WOLFF, P.H. DRIEVER, B. WOLFF, C.M. KRAMM, R.-D. KORTMANN, T. PIETSCH, S.RUTKOWSKI, A. GNEKOW (Houston, TX, USA; Berlin; Halle; Leipzig; Bonn; Hamburg; Augsburg,Germany) ..............................................................................................................................................

Heterogeneity of Primary Site Biopsies in Head and Neck Squamous Cell Carcinoma. S. MOERTEL, H.ACKERMANN, M. BAGHI, A. ECKARDT, J. WAGENBLAST, T. STÖVER, M. HAMBEK (Frankfurt amMain, Germany) .....................................................................................................................................

Premenopausal Hormone-responsive Breast Cancer with Extensive Axillary Nodes Involvement: Total EstrogenBlockade and Chemotherapy. F. RECCHIA, G. CANDELORO, S. NECOZIONE, G. DESIDERI, C.O.C.RECCHIA, J. PIAZZE, S. REA (Avezzano; Rome; L’Aquila, Italy) ............................................................

Alcohol-dehydrogenase (ADH1B) Arg48His Polymorphism in Basque Country Patients with Oral and LaryngealCancer: Preliminary Study. X. MARICHALAR-MENDIA, A. ACHA-SAGREDO, M.J. RODRIGUEZ-TOJO,N. REY-BARJA, M. HERNANDO-RODRIGUEZ, J.I. AGUIRREGAVIRIA, J.M. AGUIRRE-URIZAR (Leioa;San Sebastian, Spain) ............................................................................................................................

Gastric Cancer in a Pregnant Woman Presenting with Low Back Pain and Bilateral Erythematous BreastHypertrophy Mimicking Primary Inflammatory Breast Carcinoma. V.D. MANDATO, D. PIRILLO, M.C.GELLI, M. CAVINA, G.B LA SALA (Reggio Emilia, Italy) .....................................................................

Clinical Application of Determining Serum AFP-IgM Complexes for Diagnosis of Small HepatocellularCarcinoma. J. JIANG, C. WU, Y. SHEN, B. XU, X. ZHENG, X. LI, N. XU (Changzhou; Suzhou, PR China;Lund, Sweden) .......................................................................................................................................

Axillary Node Sampling in Conjunction with Sentinel Node Biopsy in Patients with Breast Cancer. AProspective Preliminary Study. F. LUMACHI, L. NORBERTO, S. ZANELLA, F. MARINO, S.M.M. BASSO,U. BASSO, A. BRUNELLO, A. FASSINA (Padova; Pordenone, Italy) .......................................................

Prognostic Significance of Peripheral Blood CD8highCD57+ Lymphocytes in Bladder Carcinoma Patients AfterIntravesical IL-2. D. CHARACIEJUS, V. PAŠUKONIENĖ, J.J.L. JACOBS, R. EIDUKEVIČIUS, F.JANKEVIČIUS, N. DOBROVOLSKIENĖ, M. MAURICAS, R.J. VAN MOORSELAAR, W. DEN OTTER(Vilnius, Lithuania; Amsterdam, Netherlands) ..........................................................................................


4691

613

619

625

633

639

649

661

665

671

677

681

687

693

699

*

*

Effect of Genetic Polymorphisms Related to DNA Repair and the Xenobiotic Pathway on the Prognosis andSurvival of Gastric Cancer Patients. T. TAHARA, T. SHIBATA, M. NAKAMURA, H. YAMASHITA, D.YOSHIOKA, M. OKUBO, J. YONEMURA, T. ISHIZUKA, N. MARUYAMA, T. KAMANO, Y. KAMIYA, H.FUJITA, Y. NAKAGAWA, M. NAGASAKA, M. IWATA, H. YAMADA, I. HIRATA, T. ARISAWA (Toyoake;Ishikawa, Japan) ....................................................................................................................................

Loss of Estrogen Receptor Beta Expression Correlates with Shorter Overall Survival and Lack of ClinicalResponse to Chemotherapy in Ovarian Cancer Patients. A. HALON, E. NOWAK-MARKWITZ, A.MACIEJCZYK, M. PUDELKO, T. GANSUKH, B. GYÖRFFY, P. DONIZY, D. MURAWA, R.MATKOWSKI, M. SPACZYNSKI, H. LAGE, P. SUROWIAK (Wroclaw; Poznan, Poland; Ulan Bator,Mongolia; Budapest, Hungary; Berlin, Germany) ......................................................................................

Hemangiopericytoma/Solitary Fibrous Tumor of the Oral Cavity. F. ANGIERO, A. SIGNORE, S.BENEDICENTI (Milan; Genoa, Italy) .....................................................................................................

Review: Influencing the Wnt Signaling Pathway in Multiple Myeloma. Y. KIM, G. REIFENBERGER, D. LU,T. ENDO, D.A. CARSON, S.-M. GAST, K. MESCHENMOSER, M. NOWAK, I.G.H. SCHMIDT-WOLF(Bonn; Duesseldorf, Germany; La Jolla, CA, USA; Sapporo, Hokkaido, Japan) ...........................................

Expression of the Vascular Endothelial Growth Factor (VEGF) Gene in Epithelial Ovarian Cancer: An Approachto Anti-VEGF Therapy. K. HATA, Y. WATANABE, H. NAKAI, T. HATA, H. HOSHIAI (Takamastu; Osaka-Sayama; Kagawa, Japan) .......................................................................................................................

Forsen Psychological Risk Inventory for Breast Cancer Patients: A Prospective Case–Control Study with SpecialReference to the Use of Psychiatric Medications. M. ESKELINEN, P. OLLONEN (Kuopio, Finland) ............

Significant Association of Caveolin-1 (CAV1) Genotypes with Prostate Cancer Susceptibility in Taiwan. H.-C.WU, C.-H. CHANG, Y.-A. TSOU, C.-W. TSAI, C.-C. LIN, D.-T. BAU (Taichung, Taiwan, ROC) .............

Reviews (pages 639, 649, 725)

Number 3


HMGA2 and p14Arf: Major Roles in Cellular Senescence of Fibroids and Therapeutic Implications. D.N.MARKOWSKI, B.M. HELMKE, G. BELGE, R. NIMZYK, S. BARTNITZKE, U. DEICHERT, J.BULLERDIEK (Bremen; Heidelberg; Cuxhaven, Hannover, Germany) .......................................................

Anticancer Effects of Novel Photodynamic Therapy with Glycoconjugated Chlorin for Gastric and ColonCancer. M. TANAKA, H. KATAOKA, M. MABUCHI, S. SAKUMA, S. TAKAHASHI, R. TUJII, H.AKASHI, H. OHI, S. YANO, A. MORITA, T. JOH (Nagoya; Okayama; Kyoto; Nara, Japan) ....................

Microfluidic Assembly of Lipid-based Oligonucleotide Nanoparticles. B. YU, J. ZHU, W. XUE, Y. WU, X.HUANG, L.J. LEE, R.J. LEE (Columbus, OH, USA; Xian, PR China) ....................................................

MACC 1 as a Marker for Vascular Invasive Hepatocellular Carcinoma. A. SHIRAHATA, W. FAN, K.SAKURABA, K. YOKOMIZO, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H.NEMOTO, Y. SANADA, K. HIBI (Yokohama, Japan) .............................................................................

Promotion of the Self-renewal Capacity of Human Leukemia Cells by Sonic Hedgehog Protein. N. KAWAGUCHI-IHARA, Y. OKUHASHI, M. ITOH, I. MUROHASHI, N. NARA, S. TOHDA (Tokyo; Saitama, Japan) ............


4692

705

711

719

725

731

739

745

753

763

771

777

781

*

*

The Min Mouse on FVB Background: Susceptibility to Spontaneous and Carcinogen-induced IntestinalTumourigenesis. C. SVENDSEN, J. ALEXANDER, H.K. KNUTSEN, T. HUSØY (Oslo, Norway) ............

Inhibition of c-ABL Sensitizes Breast Cancer Cells to the Dual ErbB Receptor Tyrosine Kinase InhibitorLapatinib (GW572016). Y.-H. LO, P.-C. HO, H. ZHAO, S.-C. WANG (Cincinnati, OH, USA)..................

Citrate Induces Apoptotic Cell Death: A Promising Way to Treat Gastric Carcinoma? Y. LU, X. ZHANG, H.ZHANG, J. LAN, G. HUANG, E. VARIN, H. LINCET, L. POULAIN, P. ICARD (Guangxi, PRC; Caen,France) ..............................................................................................................................................

Identification of the M541L Sequence Variation of the Transmembrane KIT domain in Merkel Cell Carcinoma.K. KRASAGAKIS, M. METAXARI, M. ZERVOU, E.N. STATHOPOULOS, J. EBERLE, J. KANITAKIS,V. GEORGOULIAS, S. KRÜGER-KRASAGAKIS, N. TAVERNARAKIS, A.D. TOSCA (Heraklion, Greece;Berlin, Germany; Lyon, France) ............................................................................................................

The PPARγ Antagonist T0070907 Suppresses Breast Cancer Cell Proliferation and Motility via Both PPARγ-dependent and -independent Mechanisms. Y.Y. ZAYTSEVA, N.K. WALLIS, R.C. SOUTHARD, M.W.KILGORE (Lexington, KY, USA) ..........................................................................................................

Cytotoxicity of Ferrocenyl–Ethynyl Phosphine Metal Complexes of Gold and Platinum. E. FOURIE, E.ERASMUS, J.C. SWARTS, A. JAKOB, H. LANG, G. K. JOONE, C.E.J. VAN RENSBURG (Bloemfontein;Pretoria, Republic of South Africa; Chemnitz, Germany) .........................................................................

In Silico/In Vitro Study of Hybrid D-modified Steroidal Alkylator Anticancer Activity Using UridinePhosphorylase as Target Protein. G.D. GEROMICHALOS, E. GEROMICHALOU, C. CAMOUTSIS, M.KONTOS, P. DALEZIS, A. PAPAGEORGIOU, A.A. GRIVAS, C. TSIGRIS, D.T. TRAFALIS (Thessaloniki;Ioannina; Patras; Piraeus, Greece) ........................................................................................................

Co-localization of Prothrombin Fragment F1+2 and VEGF-R2-Bound VEGF in Human Colon Cancer. E.SIERKO, M.Z. WOJTUKIEWICZ, L. ZIMNOCH, P.E. THORPE, R.A. BREKKEN, W. KISIEL (Bialystok,Poland; Dallas, TX; Seattle, WA; Albuquerque, NM, USA) .......................................................................

The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer Cell Lines. V. ARRIAS-HERRERA, E.ZEINDL-EBERHART, A. JUNG, R.M. HUBER, A. BERGNER (Munich, Germany) ................................

Lack of Direct Association between EGFR Mutations and ER Beta Expression in Lung Cancer. T. ONITSUKA,H. URAMOTO, F. TANAKA (Kitakyushu, Japan) ..................................................................................

The Endothelin Axis in the Metastatic Process of Colon Carcinoma. L.A. SØRBY, C.R. KLEIVELAND, S.N.ANDERSEN, I.R. BUKHOLM, M.B. JACOBSEN (Fredrikstad; Ås; Lørenskog; Oslo, Norway) ................

Novel Quinuclidinone Derivative 8a Induced Apoptosis in Human MCF-7 Breast Cancer Cell Lines. A.MALKI, S.C. BERGMEIER (Athens, OH, USA; Alexandria, Egypt) ........................................................

Insoluble Fraction of Tumor Cell Homogenate Is a Useful Material for Eliciting Cytotoxic T Lymphocytes: AUnique Method for Protein Solubilization. E. KUWADA, K. KAMBARA, T. TADAKI, K. NOGUCHI (Tokyo,Japan) ................................................................................................................................................

Effects of Combination of Notch Inhibitor plus Hedgehog Inhibitor or Wnt Inhibitor on Growth of LeukemiaCells. Y. OKUHASHI, M. ITOH, N. NARA, S. TOHDA (Tokyo, Japan) ..................................................

Biotinylated PAMAM Dendrimers for Intracellular Delivery of Cisplatin to Ovarian Cancer: Role of SMVT.V.K. YELLEPEDDI, A. KUMAR, D.M. MAHER, S.C. CHAUHAN, K.K. VANGARA, S. PALAKURTHI(Kingsville, TX; Sioux Falls, SD, USA) .................................................................................................


4693

785

789

797

807

813

825

831

843

849

855

861

871

881

893

897

Differential Distribution of Intravenous Curcumin Formulations in the Rat Brain. S.S. CHIU, E. LUI, M.MAJEED, J.K. VISHWANATHA, A.P. RANJAN, A. MAITRA, D. PRAMANIK, J.A. SMITH, L. HELSON(London, ON, Canada; Princeton, NJ; Baltimore, MD; Houston; Fort Worth, TX; Quakertown, PA, USA;Bangalore, India) ................................................................................................................................

Measles Virus Antigens in Breast Cancer. S. ARIAD, N. MILK, A. BOLOTIN, J. GOPAS, N. SION-VARDY,D. BENHAROCH (Beer Sheva, Israel) ..................................................................................................

Overcoming Multidrug Resistance in Human Lung Cancer with Novel Benzo[a]quinolizin-4-ones. Y. KANINTRONKUL, R. WORAYUTHAKARN, N. THASANA, P. WINAYANUWATTIKUN, K. PATTANAPANYASAT, R. SURARIT, S. RUCHIRAWAT, J. SVASTI (Bangkok, Thailand) ...................

Instillation of Mitomycin C after Transurethral Resection of Bladder Cancer Impairs Wound Healing: An AnimalModel. J.C.-T. HOU, S. LANDAS, C.Y. WANG, O. SHAPIRO (Syracuse, NY, USA) ...............................

Host Genetic Factors, Related to Inflammatory Response, Influence the CpG Island Methylation Status inColonic Mucosa in Ulcerative Colitis. T. TAHARA, T. SHIBATA, M. NAKAMURA, M. OKUBO, H.YAMASHITA, D. YOSHIOKA, J. YONEMURA, Y. KMIYA, T. ISHIZUKA, H. FUJITA, M. NAGASAKA,H. YAMADA, I. HIRATA, T. ARISAWA (Toyoake; Ishikawa, Japan) ........................................................

Clinical Studies

Review: Full Myeloablative Conditioning and an Unrelated HLA Mismatched Donor Increase the Risk for BKVirus-positive Hemorrhagic Cystitis in Allogeneic Hematopoetic Stem Cell Transplanted Patients. T.DALIANIS, P. LJUNGMAN (Stockholm, Sweden) ..................................................................................

Fascin and CK4 as Biomarkers for Esophageal Squamous Cell Carcinoma. M. TAKIKITA, N. HU, J.-Z.SHOU, C. GIFFEN, Q.-H. WANG, C. WANG, S.M. HEWITT, P.R. TAYLOR (Bethesda; Silver Spring, MD,USA; Beijing; Shanxi; PR China) ..........................................................................................................

Immunohistochemical Analyses of α1 and α3 Na+/K+-ATPase Subunit Expression in Medulloblastomas. M.SUÑOL, V. CUSI, O. CRUZ, R. KISS, F. LEFRANC (Barcelona, Spain; Brussels, Belgium) ...................

No Circulating Cytomegalovirus in Five Patients with Glioblastoma Multiforme. S. LEHRER, V.LABOMBARDI, S. GREEN, M.S. PESSIN-MINSLEY, I.M. GERMANO, K.E. ROSENZWEIG (New York,NY, USA) ...........................................................................................................................................

Phase I Trial of Fenretinide Lym-X-Sorb Oral Powder in Adults with Solid Tumors and Lymphomas. S.KUMMAR, M.E. GUTIERREZ, B.J. MAURER, C.P. REYNOLDS, M. KANG, H. SINGH, S. CRANDON,A.J. MURGO, J.H. DOROSHOW (Bethesda, MD; Lubbock, TX, USA) ....................................................

High-fidelity of Five Quasimonomorphic Mononucleotide Repeats to High-frequency Microsatellite InstabilityDistribution in Early-stage Adenocarcinoma of the Colon. K. SØREIDE (Stavanger; Bergen, Norway) .........

Prolonged Response to Early Docetaxel in a Patient with Biochemical Relapse after Primary Therapy forProstate Cancer and Incomplete Response to Androgen Suppression Therapy. C.M. BARNETT, J.F.FLAMIATOS, T.M. BEER (Portland, OR, USA) ...................................................................................

First-line Cisplatin Plus Etoposide in High-grade Metastatic Neuroendocrine Tumors of Colon and Rectum(MCRC NET): Review of 8 Cases. A. PATTA, M. FAKIH (Buffalo, NY, USA) ........................................

Changing Levels of Circulating Tumor Cells in Monitoring Chemotherapy Response in Patients withMetastatic Breast Cancer. A.D. HARTKOPF, P. WAGNER, D. WALLWIENER, T. FEHM, R. ROTHMUND(Tuebingen, Germany) ..........................................................................................................................


4694

907

913

921

929

933

939

945

953

959

961

967

973

975

979

*

15-Year Survival Rates after Transurethral Resection and Radiochemotherapy or Radiation in Bladder CancerTreatment. F.S. KRAUSE, B. WALTER, O.J. OTT, L. HÄBERLE, C. WEISS, C. RÖDEL, B. WULLICH,R. SAUER (Erlangen; Frankfurt, Germany; Linz, Austria) ......................................................................

Clinical Significance of Wnt-induced Secreted Protein-1 (WISP-1/CCN4) in Esophageal Squamous CellCarcinoma. Y. NAGAI, M. WATANABE, S. ISHIKAWA, R. KARASHIMA, J. KURASHIGE, S. IWAGAMI,M. IWATSUKI, Y. BABA, Y. IMAMURA, N. HAYASHI, H. BABA (Kumamoto, Japan) ...........................

Is Class III β-Tubulin a True Predictive Marker of Sensitivity to Vinorelbine in Non-small Cell Lung Cancer?Chemosensitivity Data Evidence. Y. HIRAI, T. YOSHIMASU, S. OURA, F. OTA, K. NAITO, H.NISHIGUCHI, S. HASHIMOTO, Y. OKAMURA (Wakayama, Japan) ......................................................

Interphase FISH Does Not Improve the Detection of DEL(5q) and DEL(20q) in Myelodysplastic Syndromes.N. DOUET-GUILBERT, A. HERRY, M.-J. LE BRIS, N. GUÉGANIC, C. BOVO, F. MOREL, M. DEBRAEKELEER (Brest, France) ............................................................................................................

The Evaluation of MSX2 mRNA Expression Level in Biliary Brush Cytological Specimens. H. ITO, K.SATOH, S. HAMADA, M. HIROTA, A. KANNO, K. ISHIDA, J. UNNO, A. MASAMUNE, Y. KATAYOSE,M. UNNO, T. SHIMOSEGAWA (Sendai, Miyagi, Japan) ........................................................................

A Case of Complete Response to S-1 plus CDDP in Early-Stage Mucosal Esophageal Cancer. Y. TAKAYAMA,M. KOCHI, M. FUJII, N. KANAMORI, T. KAIGA, Y. MIHARA, T. MIYAZAKI, H. TAMEGAI, M.WATANABE, T. TAKAYAMA (Tokyo, Japan) ........................................................................................

Response to Temozolomide in Supratentorial Multifocal Recurrence of Malignant Ependymoma. C.F.FREYSCHLAG, J. TUETTENBERG, F. LOHR, C. THOMÉ, K. SCHMIEDER, M. SEIZ (Heidelberg; Idar-Oberstein, Germany; Innsbruck, Austria) ................................................................................................

A New Indicator of Favorable Prognosis in Locally Advanced Renal Cell Carcinomas: γδ T-Cells in PeripheralBlood. H. KOBAYASHI, Y. TANAKA, H. NAKAZAWA, J. YAGI, N. MINATO, K. TANABE (Tokyo-to;Kyoto, Japan) .....................................................................................................................................

Effective Panitumumab Treatment in Patients with Heavily Pre-treated Metastatic Colorectal Cancer: A CaseSeries. A.A. TZOVARAS, A. KARAGIANNIS, C. MARGARI, G. BARLA, A. ARDAVANIS (Athens,Greece) ...............................................................................................................................................

Does Erlotinib Restore Chemosensitivity to Chemotherapy in Pancreatic Cancer? A Case Series. M.W. SAIF(New York, NY, USA) ..........................................................................................................................

CCND1 1722 Polymorphism and Potential Relevance to Upper Tract Urothelial Cancer. H.-H. LIN, H.-L.KE, K.-H. HSIAO, C.-W. TSAI, W.-J. WU, D.-T. BAU, L.-L. CHANG (Kaohsiung; Taichung, Taiwan,ROC) ................................................................................................................................................

Efficacy of Surgery for Lung Metastases from Colorectal Cancer Synchronous to or Following that for LiverMetastases. K. NOJIRI, K. TANAKA, Y. NAGANO, M. UEDA, K. MATSUO, M. OTA, Y. ICHIKAWA, H.SHIMADA, I. ENDO (Yokohama, Japan) ..............................................................................................

The Influence of Viral Hepatitis Status on Long-term HCC Outcome in Patients with Non-cirrhotic Livers.K. NOJIRI, Y. NAGANO, K. TANAKA, M. UEDA, K. TAKEDA, T. KUMAMOTO, S. FUJII, C.KUNISAKI, I. ENDO (Yokohama, Japan) ..............................................................................................

Human Mammaglobin Transcript Amplification for Differential Diagnosis in a Breast Cancer Metastatic toDura Mater. M. DONO, P. FERRO, M.C. FRANCESCHINI, P. DESSANTI, B. BACIGALUPO, E. CIBEI,C. CAPELLINI, D. AMOROSO, A. CAMERINI, F. FEDELI, S. RONCELLA (Genova; La Spezia; Lido diCamaiore, Italy) ..................................................................................................................................


4695

985

991

999

1007

1011

1019

1023

1027

1033

1039

1043

1049

1055

1061

Montgomery-Asberg Depression Rating Scale (MADRS) in Healthy Study Subjects, in Patients with BreastDisease and Breast Cancer: A Prospective Case−Control Study. M. ESKELINEN, P. OLLONEN (Kuopio,Finland) .............................................................................................................................................

Investigative Clinical Study on Prostate Cancer Part V: Luteinizing Hormone and the Pituitary-Testicular-Prostate Axis at the Time of Initial Diagnosis and Subsequent Cluster Selection of the Patient Population.A.B. PORCARO, A. PETROZZIELLO, F. MIGLIORINI, B. CARUSO, C. COCCO, T. SAVA, C.GHIMENTON, M. ROMANO, C. MONACO, L. COMUNALE (Verona, Italy) .........................................

Capecitabine after Anthracycline and Taxane Exposure in HER2-negative Metastatic Breast Cancer Patients:Response, Survival and Prognostic Factors. M. GILABERT, F. BERTUCCI, B. ESTERNI, A.MADROSZYK, C. TARPIN, J. JACQUEMIER, J.-M. EXTRA, P. VIENS, A. GONÇALVES (Marseille,France) ..............................................................................................................................................

Book Reviews .....................................................................................................................................

Announcements ...................................................................................................................................

Review (page 939)

Number 4


Synergistic Activity of Histone Deacetylase and Proteasome Inhibition Against Pancreatic and HepatocellularCancer Cell Lines. J.L. SPRATLIN, T.M. PITTS, G.N. KULIKOWSKI, M.P. MORELLI, J.J. TENTLER,N.J. SERKOVA, S.G. ECKHARDT (Aurora, CO, USA; Edmonton, AB, Canada) .................................

Review: Targeting Notch to Eradicate Pancreatic Cancer Stem Cells for Cancer Therapy. Z. WANG, A.AHMAD, Y. LI, A.S. AZMI, L. MIELE, F.H. SARKAR (Detroit, MI; Jackson, MS, USA) .....................

Histone Deacetylase Inhibitor PCI-24781 Enhances Chemotherapy-induced Apoptosis in Multidrug-resistantSarcoma Cell Lines. C. YANG, E. CHOY, F.J. HORNICEK, K.B. WOOD, J.H. SCHWAB, X. LIU, H.MANKIN, Z. DUAN (Wuhan, China; Boston, MA, USA) ....................................................................

Fractionated Irradiation of Five Human Lung Cancer Cell Lines and Prediction of Survival According to aRadiobiology Model. M. HEDMAN, M. BERGQVIST, D. BRATTSTRÖM, O. BRODIN (Stockholm;Uppsala, Sweden) ...........................................................................................................................

Synergism from Sequenced Combinations of Curcumin and Epigallocatechin-3-gallate with Cisplatin in theKilling of Human Ovarian Cancer Cells. N.M. YUNOS, P. BEALE, J.Q. YU, F. HUQ (Lidcombe; Sydney,NSW, Australia; Kepong, Malaysia) ..................................................................................................

Molecular Diagnosis of MACC1 Status in Lung Adenocarcinoma by Immunohistochemical Analysis. G.CHUNDONG, H. URAMOTO, T. ONITSUKA, H. SHIMOKAWA, T. IWANAMI, M. NAKAGAWA, T.OYAMA, F. TANAKA (Dalian, China; Kitakyushu, Japan).................................................................

Ras/Raf/MEK/ERK Pathway Is Associated with Lung Metastasis of Osteosarcoma in an Orthotopic MouseModel. Y. YU, F. LUK, J.-L. YANG, W.R. WALSH (Sydney, NSW, Australia) ......................................

The Effect of PTEN on Serotonin Synthesis and Secretion from the Carcinoid Cell Line BON. S.R. SILVA,Y.Y. ZAYTSEVA, L.N. JACKSON, E.Y. LEE, H.L. WEISS, K.A. BOWEN, C.M. TOWNSEND JR., B.M.EVERS (Lexington, KY; Galveston, TX, USA) ...................................................................................


4696

1065

1071

1079

1087

1091

1093

1105

1115

1125

1131

1141

1147

1153

*

*

Review: Body Fluid Biomarkers for Early Detection of Head and Neck Squamous Cell Carcinomas. K.-D.LEE, H.-S. LEE, C.-H. JEON (Busan; Daegu, South Korea) ..............................................................

Beta-(1-3),(1-6)-D-glucan Enhances the Effect of Low-dose Cyclophosphamide Treatment on A20Lymphoma in Mice. U. HARNACK, K. ECKERT, G. PECHER (Berlin, Germany) ...............................

Pigment Epithelial-derived Factor Inhibits c-FLIP Expression and Assists Ciglitazone-induced Apoptosisin Hepatocellular Carcinoma. L.-J. LAI, T.-C. HO (Chia-Yi; Tao-Yuan; Taipei, Taiwan, ROC) ...............

MT477 Acts in Tumor Cells as an AURKA Inhibitor and Strongly Induces NRF-2 Signaling. P. JASINSKI,P. ZWOLAK, K. TERAI, R.I. VOGEL, D. BORJA-CACHO, A.Z. DUDEK (Minneapolis, MN, USA;Vienna, Austria) .............................................................................................................................

Quantitative Comparison of Erythropoietin Receptor Levels in the Epithelial versus Endothelial Fractions ofPrimary Breast Tumors. C.P. MILLER, N. URBAN, C.A. BLAU (Seattle, WA, USA) ............................

Antitumor Effect of Novel HSP90 Inhibitor NVP-AUY922 against Oral Squamous Cell Carcinoma. T.OKUI, T. SHIMO, N.M. HASSAN, T. FUKAZAWA, N. KURIO, M. TAKAOKA, Y. NAOMOTO, A.SASAKI (Okayama, Japan) .............................................................................................................

EMMPRIN Expression in Oral SCC Is Regulated by FYN Kinase. D.M. RAMOS, D. DANG (SanFrancisco, CA, USA) ......................................................................................................................

Inverse Correlation between EGFR Mutation and FHIT, RASSF1A and RUNX3 Methylation in LungAdenocarcinoma: Relation with Smoking Status. N. YANAGAWA, G. TAMURA, H. OIZUMI, M. ENDOH,M. SADAHIRO, T. MOTOYAMA (Yamagata, Japan) .........................................................................

Increased Apoptosis of Host Cells and Tumor Cells in the Invasion Front of Colorectal Liver Metastases.O.R. BANDAPALLI, N. HARIRI, S. MACHER-GÖPPINGER, C. KAHLERT, P. SCHIRMACHER, K.BRAND (Heidelberg, Germany) .......................................................................................................

Sunitinib Suppresses Tumor Growth and Metastases in a Highly Metastatic Mouse Mammary Cancer Model.Y. TANAKA, M.-A. SHIBATA, J. MORIMOTO, Y. OTSUKI (Osaka, Japan) .......................................

Revitalization of Human Bone after Extracorporeal High Hydrostatic Pressure Treatment. J.SCHAUWECKER, R. VON EISENHART-ROTHE, R. BURGKART, J. TUEBEL, M. SCHMITT, W.MITTELMEIER, P. DIEHL (Munich; Rostock, Germany) ....................................................................

Enhancement of Dectin-2 Gene Expression by Lignin–Carbohydrate Complex from Lentinus edodes MyceliaExtract (LEM) in a Mouse Macrophage-like Cell Line. T. KUSHIDA, T. MAKINO, M. TOMOMURA, A.TOMOMURA, H. SAKAGAMI (Tokyo; Saitama, Japan) ....................................................................

Review: Potential Tumor-tropic Effect of Genetically Engineered Stem Cells Expressing Suicide Enzymes toSelectively Target Invasive Cancer in Animal Models. S.U. KIM, E.-B. JEUNG, Y.-B. KIM, M.-H. CHO,K.-C. CHOI (Vancouver, BC, Canada; Chungbuk; Seoul, South Korea) ................................................

Two-dimensional Gel Electrophoresis Using Immobilized pH Gradient Strips and Flamingo™ FluorescentGel Stain Identified Non-nuclear Proteins Possibly Related to Malignant Tumour Progression. Y.KURAMITSU, E. HAYASHI, F. OKADA, X. ZHANG, Y. UEYAMA, K. NAKAMURA (Ube; Yonago,Japan) ...........................................................................................................................................

Human EAG1 Potassium Channels in the Epithelial-to-Mesenchymal Transition in Lung Cancer Cells. I.RESTREPO-ANGULO, C. SÁNCHEZ-TORRES, J. CAMACHO (Mexico City, Mexico) ........................


4697

1161

1169

1173

1181

1189

1197

1205

1211

1215

1225

1235

1241

1249

1259

1265

*

*

Claudin-4: A Potential Therapeutic Target in Chemotherapy-resistant Ovarian Cancer. H. YOSHIDA, T.SUMI, X. ZHI, T. YASUI, K.-I. HONDA, O. ISHIKO (Osaka, Japan) .................................................

Adenoviral Therapy Is More Effective in Gemcitabine-resistant Pancreatic Cancer than in Gemcitabine-sensitive Cells. T. YASUI, K. OHUCHIDA, M. ZHAO, L. CUI, M. ONIMARU, T. EGAMI, H. FUJITA,T. OHTSUKA, K. MIZUMOTO, K. MATSUMOTO, M. TANAKA (Fukuoka; Kanazawa, Japan) ............

Aberrant Methylation of the Vimentin Gene in Hepatocellular Carcinoma. Y. KITAMURA, A. SHIRAHATA,K. SAKURABA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y.SANADA, K. HIBI (Yokohama, Japan) .............................................................................................

Methylation of OSMR Gene Is Frequently Observed in Non-invasive Colorectal Cancer. K. HIBI, T. GOTO,K. SAKURABA, A. SHIRAHATA, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA(Yokohama, Japan) .........................................................................................................................

Involvement of Cancer Biomarker C7orf24 in the Growth of Human Osteosarcoma. D. UEJIMA, K.NISHIJO, Y. KAJITA, T. ISHIBE, T. AOYAMA, S. KAGEYAMA, H. IWAKI, T. NAKAMURA, H. IIDA,T. YOSHIKI, J. TOGUCHIDA (Kyoto; Osaka; Shiga, Japan) ...............................................................

Induction of MMP-13 Expression in Bone-metastasizing Cancer Cells by Type I Collagen through Integrinα1β1 and α2β1-p38 MAPK Signaling. S. IBARAGI, T. SHIMO, N.M. HASSAN, S. ISOWA, N. KURIO,H. MANDAI, S. KODAMA, A. SASAKI (Okayama, Japan) ...............................................................

Prognostic Impact of CD133 Immunoexpression in Node-negative Invasive Breast Carcinomas. A. IENI, G.GIUFFRÈ, V. ADAMO, G. TUCCARI (Messina, Italy) ......................................................................

Chitosan Derivatives Inhibit Cell Proliferation and Induce Apoptosis in Breast Cancer Cells. M. JIANG, H.OUYANG, P. RUAN, H. ZHAO, Z. PI, S. HUANG, P. YI, M. CREPIN (Wuhan; Guangzhou; Shiyan, PRChina; Bobigny, France) .................................................................................................................

Tumour-derived Microvesicles Contain Interleukin-8 and Modulate Production of Chemokines by HumanMonocytes. M. BAJ-KRZYWORZEKA, K. WĘGLARCZYK, B. MYTAR, R. SZATANEK, J. BARAN,M. ZEMBALA (Cracow, Poland) ....................................................................................................

Abnormal Methylation of Histone Deacetylase Genes: Implications on Etiology and Epigenetic Therapy ofAstrocytomas. M.V. GOMES, K.S. BORGES, D.A. MORENO, R.G. QUEIROZ, H.R. MACHADO, C.G.CARLOTTI JR., C.A. SCRIDELI, L.G. TONE (Londrina, PR; Ribeirão Preto, SP, Brazil) ...................

Differential Apoptotic Effects of Novel Quinuclidinone Analogs 8a and 8b in Normal and Lung Cancer CellLines. A. MALKI, S. BERGMEIER (Athens, OH, USA; Alexandria, Egypt) .........................................

Polymorphisms of the CYP1A1, CYP2E1 and XRCC1 Genes and Cancer Risk in a Southern ItalianPopulation: A Case–Control Study. G. BIANCHINO, A. CITTADINI, V. GRIECO, A. TRAFICANTE, A.ZUPA, G. IMPROTA, M. AIETA, A. SGAMBATO (Potenza; Rome, Italy) ............................................

Clinical Studies

Effect of Tamoxifen or Anastrozole on Steroid Sulfatase Activity and Serum Androgen Concentrations inPostmenopausal Women with Breast Cancer. S.J. STANWAY, C. PALMIERI, F.Z. STANCZYK, E.J.FOLKERD, M. DOWSETT, R. WARD, R.C. COOMBES, M.J. REED, A. PUROHIT (London, UK; LosAngeles, CA, USA) .........................................................................................................................

Single Nucleotide Polymorphisms of Integrin Alpha-2 and Beta-3 Genes Are not Associated with Relapse-free and Overall Survival in Colorectal Cancer Patients. G. HOFMANN, U. LANGSENLEHNER, T.LANGSENLEHNER, M. GLEHR, A. GERGER, G. ABSENGER, J. SZKANDERA, F. FUERST, H.SAMONIGG, P. KRIPPL, W. RENNER (Graz; Fuerstenfeld, Austria) .................................................


4698

1271

1279

1289

1293

1297

1307

1315

1321

1329

1337

1345

1359

1367

1373

Combined KRAS and TP53 Mutation Status Is not Predictive in CAPOX-treated Metastatic ColorectalCancer. M.T. DE BRUIJN, D.A.E. RAATS, J. TOL, J. HINRICHS, S. TEERENSTRA, C.J.A. PUNT,I.H.M. BOREL RINKES, O. KRANENBURG (Utrecht; Nijmegen, Netherlands) ...................................

Review: The Involvement of Retroperitoneal Lymph Nodes in Primary Serous-papillary Peritoneal Carcinoma.A Systematic Review of the Literature. P.R. STEINHAGEN, J. SEHOULI (Berlin, Germany) .....................

The Expression of Sialic Fibronectin Correlates with Lymph Node Metastasis of Thyroid MalignantNeoplasmas. H. TAKEYAMA, S. KYODA, T. OKAMOTO, Y. MANOME, M. WATANABE, S.KINOSHITA, K. UCHIDA, A. SAKAMOTO, T. MORIKAWA (Tokyo, Japan) .......................................

PCA3 Urinary Test Versus 1H-MRSI and DCEMR in the Detection of Prostate Cancer Foci in Patients withBiochemical Alterations. V. PANEBIANCO, A. SCIARRA, E. DE BERARDINIS, G.M. BUSETTO, D.LISI, V. BUONOCORE, V. GENTILE, F. DI SILVERIO, R. PASSARIELLO (Rome, Italy) ....................

Nonadherence to Imatinib Treatment in Patients with Gastrointestinal Stromal Tumors: The ADAGIO Study. F.MAZZEO, L. DUCK, E. JOOSENS, L. DIRIX, C. FOCAN, F. FORGET, S. DE GEEST, K. MUERMANS,M.-A. VAN LIERDE, K. MACDONALD, I. ABRAHAM, J. DE GRÈVE (Brussels; Ottignies; Antwerp; Liège;Libramont; Vilvoorde, Belgium; Basel; Switzerland; Earlysville, VA; Tucson, AZ, USA) ................................

Elevated Serum 8-OHdG Is Associated with Poor Prognosis in Epithelial Ovarian Cancer. M. PYLVÄS, U.PUISTOLA, L. LAATIO, S. KAUPPILA, P. KARIHTALA (Oulu, Finland) ..........................................

Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer. D.R.FOGELMAN, R.A. WOLFF, S. KOPETZ, M. JAVLE, C. BRADLEY, I. MOK, F. CABANILLAS, J.L.ABBRUZZESE (Houston, TX; Francisco, CA, USA; San Juan, Puerto Rico) ........................................

The Value and Limitations of Contrast-enhanced Ultrasound in Detection of Prostate Cancer. A.STRAZDIŅA, G. KRŪMIŅA, M. SPERGA (Riga, Latvia) ................................................................

Impact of Renal Failure on the Tumor Markers of Mesothelioma, N-ERC/Mesothelin and Osteopontin. K.SHIOMI, S. SHIOMI, Y. ISHINAGA, M. SAKURABA, Y. HAGIWARA, K. MIYASHITA, M. MAEDA, K.SUZUKI, K. TAKAHASHI, O. HINO (Tokyo; Gunma, Japan) .............................................................

Roles of BCL-2 and MDR1 Expression in the Efficacy of Paclitaxel-based Lung Cancer Chemoradiation. A.MARÁZ, J. FURÁK, R. PÁLFÖLDI, J. ELLER, E. SZÁNTÓ, Z. KAHÁN, L. THURZÓ, J. MOLNÁR,L. TISZLAVICZ, K. HIDEGHÉTY (Szeged, Hungary) ........................................................................

High-risk Group for Locoregional Recurrence in Patients with Stage IB-IIB Squamous Cell Carcinoma ofthe Cervix Treated with Concurrent Chemoradiotherapy. M. HIRAKAWA, Y. NAGAI, T. TOITA, W.KUDAKA, M. INAMINE, K. OGAWA, S. MURAYAMA, Y. AOKI (Okinawa, Japan)............................

Sentinel Lymph Node Biopsy for Squamous Cell Carcinoma of the Extremities: Case Report and Review ofthe Literature. Y.Y. LIU, W.M. ROZEN, R. RAHDON (Geelong, VIC, Australia) ..................................

Evaluation of Tumour Markers as Differential Diagnostic Tool in Patients with Suspicion of Liver Metastasesfrom Breast Cancer. V. LISKA, L. HOLUBEC JR., V. TRESKA, J. VRZALOVA, T. SKALICKY, A.SUTNAR, S. KORMUNDA, J. BRUHA, O. VYCITAL, J. FINEK, M. PESTA, L. PECEN, O.TOPOLCAN (Prague, Czech Republic) .............................................................................................

Prognostic Value of Persistent Peripheral Blood and Bone Marrow Lymphoblasts on Day 15 of Therapy inChildhood Acute Lymphoblastic Leukemia as Detected by Flow Cytometry. A. JAWORSKA-POSADZY,J. STYCZYNSKI, M. KUBICKA, R. DEBSKI, B. RAFINSKA-KURYLO, B. KOLODZIEJ, M.POGORZALA, M. WYSOCKI (Bydgoszcz, Poland) ...........................................................................


4699

1379

1387

1395

1399

1407

1411

1417

1421

1427

1431

1437

1443

1447

1453

*

Association between Genetic Polymorphisms Related to DNA Repair or Xenobiotic Pathways and GastricPremalignant Conditions. T. TAHARA, T. SHIBATA, M. NAKAMURA, H. YAMASHITA, D. YOSHIOKA,M. OKUBO, J. YONEMURA, Y. KAMIYA, T. ISHIZUKA, Y. NAKAGAWA, M. NAGASAKA, M. IWATA,I. HIRATA, T. ARISAWA (Toyoake; Ishikawa, Japan) .........................................................................

Concomitant Diagnosis of Myeloproliferative Neoplasm and Non-Hodgkin’s Lymphoma in a Patient withPortal Vein Thrombosis. M.-V. PAPAGEORGIOU, A. ALEXOPOULOU, F. KONTOPIDOU, A. FILIOTOU,J. KOSKINAS, D. PECTASIDES (Athens, Greece).............................................................................

Continuous Saline Bladder Irrigation after Transurethral Resection Is a Prophylactic Treatment Choice for Non-muscle Invasive Bladder Tumor. T. ONISHI, T. SASAKI, A. HOSHINA, T. YABANA (Ise; Mie, Japan) ........

Time to Castration Resistance Is an Independent Predictor of Castration-resistant Prostate Cancer Survival.E. BOURNAKIS, E. EFSTATHIOU, A. VARKARIS, S. WEN, M. CHRISOFOS, C. DELIVELIOTIS, C.ALAMANIS, I. ANASTASIOU, C. CONSTANTINIDES, A. BAMIAS, M.A. DIMOPOULOS (Athens,Greece; Houston, TX, USA) .............................................................................................................

Phase II Trial of Preoperative Chemotherapy for Breast Cancer: Japan Breast Cancer Research Network(JBCRN)-02 Trial. S. IWASE, D. YAMAMOTO, Y. KURODA1, T. KAWAGUCHI, K. KITAMURA, H.ODAGIRI, S. TERAMOTO, K. AKAZAWA, Y. NAGUMO (Tokyo; Hirakata, Osaka; Fukuoka; Hirosaki;Niigata, Japan) ..............................................................................................................................

ABSTRACTS OF THE 4TH INTERNATIONAL SYMPOSIUM ON VITAMIN D AND ANALOGS INCANCER PREVENTION AND THERAPY, Homburg/Saar, Germany, 20-21 May, 2011 .........................

Erratum .........................................................................................................................................

Review (page 1105, 1161, 1249, 1387)

Number 5


Review: An Epidemic of Oropharyngeal Squamous Cell Carcinoma (OSCC) Due to Human Papillomavirus(HPV) Infection and Aspects of Treatment and Prevention. T. RAMQVIST, T. DALIANIS (Stockholm,Sweden) .........................................................................................................................................

Synthesis and Evaluation of a Novel Lipophilic Folate Receptor Targeting Ligand. Y. LIU, S. XU, L. TENG,B. YUNG, J. ZHU, H. DING, R.J. LEE (Wuhan; Changchun, China; Columbus, OH, USA) ..................

Direct Effects of Pure Nicotine, Cigarette Smoke Extract, Swedish-type Smokeless Tobacco (Snus) Extractand Ethanol on Human Normal Endothelial Cells and Fibroblasts. N. LAYTRAGOON-LEWIN, F.BAHRAM, L.E. RUTQVIST, I. TURESSON, F. LEWIN (Jönköping; Uppsala; Stockholm, Sweden) ........

Circulating Human Prostate Cancer Cells from an Orthotopic Mouse Model Rapidly Captured byImmunomagnetic Beads and Imaged by GFP Expression. K. KOLOSTOVA, D. PINTEROVA, R.M.HOFFMAN, V. BOBEK (Prague, Czech Republic; San Diego, CA, USA) .............................................

Quantitative PCR and Immunohistochemical Analyses of HMGB1 and RAGE Expression in CanineDisseminated Histiocytic Sarcoma (Malignant Histiocytosis). K.A. STERENCZAK, S. KLEINSCHMIDT,P. WEFSTAEDT, N. EBERLE, M. HEWICKER-TRAUTWEIN, J. BULLERDIEK, I. NOLTE, H.M.ESCOBAR (Hannover; Bremen, Germany) ........................................................................................


4700

1459

1467

1471

1475

1483

1489

1513

1515

1521

1527

1535

1541

*

*

Anticancer Effect of Dihydroartemisinin (DHA) in a Pancreatic Tumor Model Evaluated by ConventionalMethods and Optical Imaging. W. AUNG, C. SOGAWA, T. FURUKAWA, T. SAGA (Chiba, Japan) .......

Pretreatment HIF-1α and GLUT-1 Expressions Do Not Correlate with Outcome after PreoperativeChemoradiotherapy in Rectal Cancer. B.M. HAVELUND, F.B. SØRENSEN, J. LINDEBJERG, K.-L.G.SPINDLER, A. JAKOBSEN (Vejle, Denmark) ...................................................................................

Heterogeneity of Metalloproteinase Expression in Colorectal Cancer – Relation of Molecular Findings toBasic Morphology. Y. KAJIWARA, H. UENO, Y. HASHIGUCHI, E. SHINTO, H. SHIMAZAKI, H.MOCHIZUKI, K. HASE (Saitama, Japan) ........................................................................................

Overexpression of the TXNDC5 Protein in Non-small Cell Lung Carcinoma. E.E. VINCENT, D.J.E.ELDER, L. PHILLIPS, K.J. HEESOM, J. PAWADE, M. LUCKETT, M. SOHAIL, M.T. MAY, M.R.HETZEL, J.M. TAVARÉ (Bristol, UK) .............................................................................................

Effect of Hyperthermia on Liver Cell Lines: Important Findings for Thermal Therapy in HepatocellularCarcinoma. U. MAYRHAUSER, P. STIEGLER, V. STADLBAUER, S. KOESTENBAUER, B. LEBER,K. KONRAD, F. IBERER, R.H. PORTUGALLER, K. TSCHELIESSNIGG (Graz, Austria) ...................

Lectin Histochemistry of Metastasizing and Non-metastasizing Breast and Colon Cancer Cells. B.SCHNEGELSBERG, U. SCHUMACHER, U. VALENTINER (Hamburg, Germany) ...............................

Structural Rearrangements of Trisomies Are a Risk Marker of Clinical Progression in Hyperdiploid MultipleMyeloma. R. ALFARO, J. ROSELL, M.A. DURÁN, G. PUGET, J. BESALDUCH, P. GALÁN, A.VALLÉS, M. BERNUÉS (Mallorca; Menorca, Spain) ........................................................................

Correlation and Coexpression of HIFs and NOTCH Markers in NSCLC. S. ANDERSEN, T. DONNEM, S. AL-SAAD, K. AL-SHIBLI, H. STENVOLD, L.-T. BUSUND, R.M. BREMNES (Tromsø; Bodo, Norway) .........

NF-κB Activation by Peroxynitrite through IκBα-dependent Phosphorylation versus Nitration in ColonCancer Cells. E. GOCHMAN, J. MAHAJNA, A.Z. REZNICK (Haifa; Kiryat Shmona, Israel) ................

Efficient Down-regulation of CDK4 by Novel Lipid Nanoparticle mediated siRNA Delivery. X. WANG, B.YU, Y. WU, R.J. LEE, L.J. LEE (Beijing, PR China; Columbus, OH, USA) ........................................

Targeting of Breast Metastases Using a Viral Gene Vector with Tumour-selective Transcription. S.RAJENDRAN, S. COLLINS, J.P. VAN PIJKEREN, D. O’HANLON, G.C. O’SULLIVAN, M. TANGNEY(Cork, Ireland) ...............................................................................................................................

Experimental Study of the Anticancer Effect of Gemcitabine Combined with Sirolimus on ChemicallyInduced Urothelial Lesions. C. VASCONCELOS-NÓBREGA, A. COLAÇO, L. SANTOS, H. VALA, L.F.PALOMINO, C. LOPES, P.A. OLIVEIRA (Viseu; Vila Real; Porto, Portugal; Lugo, Spain) ...................

p16INK4a Methylation in Serum as a Follow-up Marker for Recurrence of Colorectal Cancer. G. NAKAYAMA,Y. KODERA, N. OHASHI, M. KOIKE, M. FUJIWARA, A. NAKAO (Nagoya; Aichi, Japan) ......................

Barley Low Molecular Weight β-Glucan Potently Induces Maturation of Mouse Dendritic Cells. A.TANIOKA, W.-W. AN, T. KUGE, K. TSUBAKI, K. NAKAYA (Tokyo; Niigata, Japan) .........................

The Effect of PTEN on Proliferation and Drug-, and Radio-sensitivity in Malignant Glioma Cells. N.INABA, M. KIMURA, K. FUJIOKA, K. IKEDA, H. SOMURA, K. AKIYOSHI, Y. INOUE, M.NOMURA, Y. SAITO, H. SAITO, Y. MANOME (Tokyo, Japan) .........................................................

Zeranol Induces Cell Proliferation and Protein Disulfide Isomerase Expression in Mammary Gland of ACIRat. S. ZHONG, W. YE, S.-H. LIN, J.-Y. LIU, J. LEONG, C. MA, Y.C. LIN (Beijing, PR China;Columbus, OH, USA) ......................................................................................................................


4701

1549

1559

1567

1577

1583

1589

1599

1603

1607

1619

1627

1637

1643

1647

1653

1659

Zanthoxylum ailanthoides Sieb and Zucc. Extract Inhibits Growth and Induces Cell Death through G2/M-phase Arrest and Activation of Apoptotic Signals in Colo 205 Human Colon Adenocarcinoma Cells. S.-T.CHOU, H.-Y. PENG, C.-T. CHANG, J.-S. YANG, H.-K. CHUNG, S.-T. YANG, W. GIBSON WOOD, J.-G. CHUNG (Taichung, Taiwan, ROC; Minneapolis, MN, USA) ...........................................................

Association of FOXP3 Expression with Non-small Cell Lung Cancer. F.-I.D. DIMITRAKOPOULOS, H.PAPADAKI, A.G. ANTONACOPOULOU, A. KOTTOROU, A.D. GOTSIS, C. SCOPA, H.P.KALOFONOS, A. MOUZAKI (Patras, Greece) .................................................................................

Gene Mutations and Polymorphisms of TP53 and FHIT in Chronic Esophagitis and Esophageal Carcinoma.A.P.F. SILVEIRA, F. MANOEL-CAETANO, S. AOKI, L.H.T. YAMASAKI, P. RAHAL, A.E. SILVA (SãoJosé do Rio Preto, SP, Brazil) ..........................................................................................................

Phenethyl Isothiocyanate (PEITC) Promotes G2/M Phase Arrest via p53 Expression and Induces Apoptosisthrough Caspase- and Mitochondria-dependent Signaling Pathways in Human Prostate Cancer DU 145 Cells.N.-Y. TANG, Y.-T. HUANG, C.-S. YU, Y.-C. KO, S.-H. WU, B.-C. JI, J.-S. YANG, J.-L. YANG, T.-C.HSIA, Y.-Y. CHEN, J.-G. CHUNG (Taichung; Chiayi; Changhua, Taiwan, ROC) .................................

Potential Prognostic Value of Repulsive Guidance Molecules in Breast Cancer. J. LI, L. YE, R.E. MANSEL,W.G. JIANG (Cardiff, UK) .............................................................................................................

Prognostic Effects and Regulation of Activin A, Maspin, and the Androgen Receptor in Upper Urinary TractUrothelial Carcinoma. K.-M. RAU, Y.-J. CHEN, M.-T. SUN, H.-Y. KANG (Kaohsiung, Taiwan, ROC) ......

Response of Medulloblastoma Cells to Vincristine and Lomustine: Role of TRKC, CTNNB1 and STK15.Z. SHINWARI, H. AL-HINDI, E. AL-SHAIL, Y. KHAFAGA, A. AL-KOFIDE, N. EL-KUM, A.ABOUSSEKHRA (Riyadh, Saudi Arabia) .........................................................................................

Clinical Studies

Impact of Common Medications on Serum Total Prostate-specific Antigen Levels and Risk GroupAssignment in Patients with Prostate Cancer. C. NIEDER, J. NORUM, H. GEINITZ (Bodo; Tromsø,Norway; Munich, Germany) .............................................................................................................

Iron Chelation Therapy with Deferasirox Induced Complete Remission in a Patient with Chemotherapy-resistant Acute Monocytic Leukemia. T. FUKUSHIMA, H. KAWABATA, T. NAKAMURA, H. IWAO, A.NAKAJIMA, M. MIKI, T. SAKAI, T. SAWAKI, Y. FUJITA, M. TANAKA, Y. MASAKI, Y. HIROSE, H.UMEHARA (Ishikawa; Kyoto, Japan) ...............................................................................................

Treatment of Low-risk Prostate Cancer with Radical Hypofractionated Accelerated Radiotherapy withCytoprotection (HypoARC): An Interim Analysis of Toxicity and Efficacy. M.I. KOUKOURAKIS, G.KYRGIAS, A. PAPADOPOULOU, M. PANTELIADOU, A. GIATROMANOLAKI, E. SIVRIDIS, S.MAVROPOULOU, K. KALOGERIS, P. NASSOS, N. MILIOUDIS, S. TOULOUPIDIS (Alexandroupolis;Larissa; Xanthi, Greece) .................................................................................................................

Pemetrexed-induced Hyperpigmentation of the Skin. D. SCHALLIER, L. DECOSTER, J. DE GREVE(Brussels, Belgium) ........................................................................................................................

Lymphatic Microvessel Density, VEGF-C, and VEGFR-3 Expression in Different Molecular Types of BreastCancer. M. RAICA, A.M. CIMPEAN, R. CEAUSU, D. RIBATTI (Timisoara, Romania; Bari, Italy) ......

Off-label Use of Oxaliplatin in Patients with Metastatic Breast Cancer. A. DELPEUCH, D. LEVEQUE, L.ROB, J.-P. BERGERAT (Strasbourg, France) ...................................................................................


4702

1667

1677

1685

1691

1703

1713

1721

1735

1741

1745

1753

1757

1765

Correlation between Tumor-associated Proteins and Response to Neoadjuvant Treatment in Patients withAdvanced Squamous-cell Esophageal Cancer. R. FARKAS, E. POZSGAI, S. BELLYEI, L. CSEKE, A.SZIGETI, A. VERECZKEI, S. MARTON, L. MANGEL, O.P. HORVATH, A. PAPP (Pécs, Hungary) .....

Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRIand XELIRI. J. OCVIRK, M. REBERSEK, M. BOC (Ljubljana, Slovenia) ..........................................

Differences in Breast Carcinoma In Situ Between Menopausal and Premenopausal Women. C. PRADIER, M.CORNUAU, J. NORCA, H. MESBAH, P. POREE, G. BODY, J.-M. CLASSE, J. LEVEQUE (Rennes;Tours; Nantes, France) ....................................................................................................................

Fundic Gland Polyps. C.A. RUBIO, G. NESI (Stockholm, Sweden) .....................................................

Short Review: Current Concepts in the Non-operative Management of Rectal Cancer after NeoadjuvantChemoradiation. G. SINGH-RANGER, D. KUMAR (London, UK) .....................................................

Assessment of General Anxiety in Patients with Breast Disease and Breast Cancer Using the SpielbergerSTAI Self Evaluation Test: A Prospective Case-Control Study in Finland. M. ESKELINEN, P. OLLONEN(Kuopio, Finland) ..........................................................................................................................

ABSTRACTS OF THE 21st ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY(SIUrO), Naples, Italy, 22-24 June, 2011 ..........................................................................................

ABSTRACTS OF THE 15th INTERNATIONAL HAMBURG SYMPOSIUM ON TUMOR MARKERS,Hamburg, Germany, 29-31 May, 2011 ...............................................................................................

Reviews (pages 1515, 1795)

Number 6


Cytotoxic Activity of New Acetoxycoumarin Derivatives in Cancer Cell Lines. M.A. MUSA, V.L.D. BADISA,L.M. LATINWO, J. COOPERWOOD, A. SINCLAIR, A. ABDULLAH (Tallahassee, FL, USA) .................

Characterization of the Effect of In Vivo Doxorubicin Treatment on Skeletal Muscle Function in the Rat. D.S.HYDOCK, C.-Y. LIEN, B.T. JENSEN, C.M. SCHNEIDER, R. HAYWARD (Greeley, CO, USA) ..............

LLL12 Inhibits Endogenous and Exogenous Interleukin-6-induced STAT3 Phosphorylation in Human PancreaticCancer Cells. A. LIU, Y. LIU, P.-K. LI, C. LI, J. LIN (Columbus, OH, USA; Wuhan, PR China) .................

Overexpression of κ-Actin Alters Growth Properties of Hepatoma Cells and Predicts Poor PostoperativePrognosis. K.-W. CHANG, A. CHOU, C.-C. LEE, C. YEH, M.-W. LAI, T.-S. YEH, T.-C. CHEN, K.-H.LIANG, C.-T. YEH (Taoyuan; Taipei, Taiwan, ROC; Palo Alto; Los Angeles, CA; Milwaukee, WI, USA) ......

Predicting Response to Benzamide Riboside Chemotherapy in Hepatocellular Carcinoma Using ApparentDiffusion Coefficient of Water. A.M. BABSKY, S. JU, B. GEORGE, S. BENNETT, M. HUANG, H.N.JAYARAM, G. MCLENNAN, N. BANSAL (Indianapolis, IN, USA) .........................................................

Review: Disseminated and Circulating Tumor Cells for Monitoring Chemotherapy in Urological Tumors. S.KRUCK, G. GAKIS, A. STENZL (Tuebingen, Germany) ....................................................................


4703

1769

1777

1783

1789

1795

1801

1807

1957

2017

2023

2029

2037

2045

2053

*

*

*

Identification of Differentially Expressed Proteins in Tumour Necrosis Factor-alpha-resistant and -sensitiveRat Hepatoma Cells. Y. KURAMITSU, X. ZHANG, Y. WANG, K. NAKAMURA (Ube, Japan) ..............

The Therapeutic Effects of R8-Liposome-BCG-CWS on BBN-Induced Rat Urinary Bladder Carcinoma. J.MIYAZAKI, H. NISHIYAMA, I. YANO, A. NAKAYA, H. KOHAMA, K. KAWAI, A. JORAKU, T.NAKAMURA, H. HARASHIMA, H. AKAZA (Tsukuba, Ibaraki; Kiyose; Tokyo, Tokyo; Sapporo, Hokkaido,Japan) ...........................................................................................................................................

Ischemic Time Impacts Biological Integrity of Phospho-proteins in PI3K/Akt, Erk/MAPK, and p38 MAPKSignaling Networks. T.R. HOLZER, A.D. FULFORD, A.M. ARKINS, J.M. GRONDIN, C.W. MUNDY, A.NASIR, A.E. SCHADE (Indianapolis, IN, USA)................................................................................

Bioactivity of Synthetic 2-Halo-3-aryl-4(3H)-quinazoliniminium Halides in L1210 Leukemia and SK-BR-3 Mammary Tumor Cells In Vitro. J.-P. H. PERCHELLET, A. M. WATERS, E.M. PERCHELLET, V.K.NAGANABOINA, K.L. CHANDRA, J. DESPER, S. RAYAT (Manhattan, KS, USA) ............................

Associations of HSP90 Client Proteins in Human Breast Cancer. C. SHIPP, K. WATSON, G.L. JONES(Armidale, NSW, Australia) .............................................................................................................

Proteomic Differential Display Analysis for TS-1-resistant and -sensitive Pancreatic Cancer Cells UsingTwo-dimensional Gel Electrophoresis and Mass Spectrometry. K. YOSHIDA, Y. KURAMITSU, K.MURAKAMI, S. RYOZAWA, K. TABA, S. KAINO, X. ZHANG, I. SAKAIDA, K. NAKAMURA (Ube,Yamaguchi, Japan)..........................................................................................................................

Response of Thyroglobulin to Radioiodine Therapy in Thyroglobulin-elevated Negative Iodine Scintigraphy(TENIS) Syndrome. P. SINHA, G.R. CONRAD, H.C. WEST (Lexington, KY, USA) .............................

Dosimetry of a238Pu-based α-Particle Irradiator and Its Biological Application in a Study of the BystanderEffect. J. DAHLE, E. KALANXHI, N. TISNEK (Oslo, Norway) ..........................................................

P-Glycoprotein Modulation by Valspodar and Cyclosporin Does Not Increase Tumor Uptake of DoxorubicinAdministered via Isolated Lung Perfusion to Rats Bearing Sarcoma Lung Metastases. A. KUEMMERLE, H.YAN, T. KRUEGER, T. BUCLIN, O. BRAISSANT, H. HENRY, H.-B. RIS, L.A. DECOSTERD(Lausanne, Switzerland)..................................................................................................................

Cyclosporine A Induces Apoptosis of Human Lung Adenocarcinoma Cells via Caspase-dependent Pathway.M. SATO, I. TSUJINO, M. FUKUNAGA, K. MIZUMURA, Y. GON, N. TAKAHASHI, S. HASHIMOTO(Tokyo, Japan) ...............................................................................................................................

Quantitative Analysis of Thymidine Kinase 1 and 5’(3’)-Deoxyribonucleotidase mRNA Expression: TheRole of Fluorothymidine Uptake. S.J. LEE, H.J. LEE, D.H. MOON (Seoul, South Korea) .....................

Huachansu, Containing Cardiac Glycosides, Enhances Radiosensitivity of Human Lung Cancer Cells. L.WANG, U. RAJU, L. MILAS, D. MOLKENTINE, Z. ZHANG, P. YANG, L. COHEN, Z. MENG, Z. LIAO(Houston, TX, USA; Shanghai, PR China) ........................................................................................

Estimating Preclinical Efficacy Targets Utilizing Cetuximab Efficacy in KRAS Mutant and Wild-typeColorectal Cancer Models. M. PREWETT, R. BASSI, K. PAZ, M. AMATULLI, D. DEEVI, H. LI, S.WANG, L. WITTE, S. SAMAKOGLU, J.R. TONRA (New York, NY, USA) ..........................................

Development of Glioblastoma Cell Lines Expressing Red Fluorescence for Non-invasive Live Imaging ofIntracranial Tumors. M. VERREAULT, D. STRUTT, D. MASIN, D. FINK, R. GILL, M.B. BALLY(Vancouver, BC, Canada; Vienna, Austria) ........................................................................................


4704

2059

2065

2073

2083

2095

2103

2109

2113

2121

2129

2135

2141

2149

2161

Inhibition of Expression of HTLV-1 Structural Genes Mediated by Short Hairpin RNA In Vitro. R.HADDAD, S. KASHIMA, E.S. RODRIGUES, P.V.B. PALMA, M.A. ZAGO, D.T. COVAS (RibeirãoPreto, São Paulo, Brazil) ................................................................................................................

3-Oxoolean-12-en-27-oic Acid Inhibits the Proliferation of Non-small Cell Lung Carcinoma Cells byInducing Cell-cycle Arrest at G0/G1 Phase. N. TAE, J. SEO, B.-S. MIN, S. RYOO, J.-H. LEE (Chuncheon;Gyeongsan, Republic of Korea) ........................................................................................................

Mucous Gland Metaplasia in the Esophagus and Gastric Mucosa in Baboons. C.A. RUBIO, M. OWSTON,A. ORREGO, R. NILSSON, H. LÖFDAHL, G. NESI, E.J. DICK Jr. (San Antonio, TX, USA) ...............

Correlation between COX-2 and APC Expression in Left Versus Right-sided Human Colon Cancer. A.NASIR, A. LOPEZ, D. BOULWARE, M. MALAFA, D. COPPOLA (Tampa, FL, USA) ........................

Circulating 20S Proteasome in Patients with Non-metastasized Breast Cancer. O. HOFFMANN, M.HEUBNER, T. ANLASIK, M. WINTERHALTER, B. DAHLMANN, S. KASIMIR-BAUER, R. KIMMIG,J. WOHLSCHLAEGER, S.U. SIXT (Essen; Duesseldorf; Berlin, Germany) ..........................................

Etomidate Induces Cytotoxic Effects and Gene Expression in a Murine Leukemia Macrophage Cell Line(RAW264.7). R.S.-C. WU, K.-C. WU, J.-S. YANG, S.-M. CHIOU, C.-S. YU, S.-J. CHANG, F.-S.CHUEH, J.-G. CHUNG (Taichung; Kaohsiung, Taiwan, ROC) ...........................................................

18β-Glycyrrhetinic Acid and Glabridin Prevent Oxidative DNA Fragmentation in UVB-irradiated HumanKeratinocyte Cultures. E. VERATTI, T. ROSSI, S. GIUDICE, L. BENASSI, G. BERTAZZONI, D.MORINI, P. AZZONI, E. BRUNI, A. GIANNETTI, C. MAGNONI (Modena, Italy) ...............................

NK4 Gene Expression Enhances 5-Fluorouracil-induced Apoptosis of Murine Colon Cancer Cells. H.TAIYOH, T. KUBOTA, H. FUJIWARA, A. MATSUMURA, Y. MURAYAMA, K. OKAMOTO, D.ICHIKAWA, T. OCHIAI, T. NAKAMURA, K. MATSUMOTO, T. NAKAMURA, E. OTSUJI (Kyoto;Kanazawa, Ishikawa; Osaka, Japan) .................................................................................................

Paraoxonase-1 192/55 Polymorphisms and the Risk of Lung Cancer in a Turkish Population. P. AKSOY-SAGIRLI, B. CAKMAKOGLU, T. ISBIR, E. KAYTAN-SAGLAM, A. KIZIR, E. TOPUZ, H. BERKKAN(Istanbul, Turkey) ...........................................................................................................................

Combined Valproic Acid and Celecoxib Treatment Induced Synergistic Cytotoxicity and Apoptosis inNeuroblastoma Cells. Y. CHEN, Y.-H. TSAI, S.-H. TSENG (New Taipei; Taoyuan; Taipei, Taiwan, ROC) .....

Selective Inhibition of HTLV-1-infected Cell Proliferation by a Novel Tetramethylnaphthalene Derivative.T. HAMASAKI, M. TOYAMA, H. AOYAMA, Y. WHITE, M. OKAMOTO, N. ARIMA, Y. HASHIMOTO,M. BABA (Kagoshima; Tokyo, Japan) ..............................................................................................

Down-regulation of EGFL8: A Novel Prognostic Biomarker for Patients with Colorectal Cancer. F. WU, A.SHIRAHATA, K. SAKURABA, Y. KITAMURA, T. GOTO, M. SAITO, K. ISHIBASHI, G. KIGAWA, H.NEMOTO, Y. SANADA, K. HIBI (Guangzhou, PR China; Yokohama, Japan) .......................................

Phosphorylation of p53 Modifies Sensitivity to Ionizing Radiation. K. OKAICHI, K. NOSE, T. KOTAKE,N. IZUMI, T. KUDO (Nagasaki, Japan) ...........................................................................................

Association of C-Reactive Protein (CRP) Gene Polymorphisms, Serum CRP Levels and Cervical CancerPrognosis. S. POLTERAUER, C. GRIMM, R. ZEILLINGER, G. HEINZE, C. TEMPFER, A.REINTHALLER, L. HEFLER (Vienna, Austria; Bochum, Germany) .....................................................


4705

2173

2179

2187

2191

2197

2203

2209

2217

2225

2231

2241

2249

2255

2259

Clinical Studies

Induction Treatment for Diffuse Intrinsic Pontine Glioma, Experience of M.D. Anderson Cancer Center. J.E.WOLFF, M. RYTTING, T. VATS, J. ATER, A. MAHAJAN, S. WOO, L. KETONEN, J. KUTTESCH, D.LIU, P. THALL, E.L. CHANG (Houston, TX; Boston, MA; Nashivlle, TN, USA) ..................................

Phase II Trial of Weekly Alternating Sequential BIBF 1120 and Afatinib for Advanced Colorectal Cancer. O.BOUCHE, F. MAINDRAULT-GOEBEL, M. DUCREUX, G. LLEDO, T. ANDRE, P. STOPFER, N.AMELLAL, M. MERGER, A. DE GRAMONT (Paris; Lyon, France; Biberach, Germany) .....................

Review: Endoglin (CD105): A Review of its Role in Angiogenesis and Tumor Diagnosis, Progression andTherapy. F. NASSIRI, M.D. CUSIMANO, B.W. SCHEITHAUER, F. ROTONDO, A. FAZIO, G.M.YOUSEF, L.V. SYRO, K. KOVACS, R.V. LLOYD (Toronto, ON, Canada; Rochester, MN; Madison, WI,USA; Medellin, Colombia) ...............................................................................................................

Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma Compared to Percutaneous EthanolInjection in Treatment of Cirrhotic Patients: An Italian Randomized Controlled Trial. A. GIORGIO, A. DISARNO, G. DE STEFANO, U. SCOGNAMIGLIO, N. FARELLA, A. MARINIELLO, V. ESPOSITO, C.COPPOLA, V. GIORGIO (Naples, Italy) ...........................................................................................

Efficacy and Safety of Bortezomib plus Dexamethasone Therapy for Refractory or Relapsed Multiple Myeloma:Once-weekly Administration of Bortezomib May Reduce the Incidence of Gastrointestinal Adverse Events. T.FUKUSHIMA, T. NAKAMURA, H. IWAO, A. NAKAJIMA, M. MIKI, T. SATO, T. SAKAI, T. SAWAKI, Y.FUJITA, M. TANAKA, Y. MASAKI, H. NAKAJIMA, Y. MOTOO, H. UMEHARA (Ishikawa, Japan) .............

Identification of Polymorphisms Associated with Hypertriglyceridemia and Prolonged Survival Induced byBexarotene in Treating Non-small Cell Lung Cancer. W. LUO, N.J. SCHORK, K.B. MARSCHKE, S.-C.NG, T.W. HERMANN, J. ZHANG, J.M. SANDERS, P. TOOKER, N. MALO, M.A. ZAPALA, Z.E.DZIEWANOWSKA, A. NEGRO-VILAR, M.D. MEGLASSON (San Diego; La Jolla, CA, USA) .............

Surgical Management of Bisphosphonate-related Osteonecrosis of the Jaw in Oncologic Patients: AChallenging Problem. A.M. ECKARDT, J. LEMOUND, D. LINDHORST, M. RANA, N.-C. GELLRICH(Hannover, Germany) ......................................................................................................................

Expression of iNOS - A Favourable Prognostic Marker for Early-stage Carcinoma of the Uterine Cervix. T.EGGEN, G. SAGER, M. ARNES, I. PETTERSEN, A. ØRBO (Tromsø, Norway) .................................

Mammographic Features Are Associated with Clinicopathological Characteristics in Invasive Breast Cancer.L. JIANG, T. MA, M.S. MORAN, X. KONG, X. LI, B.G. HAFFTY, Q. YANG (Ji’nan, Shandong, PRChina; New Haven, CT; Brunswick, NJ, USA) ...................................................................................

Response of Recurrent Urachal Cancer to Gemcitabine and Cisplatin Therapy: A Case Report and LiteratureReview. Y. MIYATA, Y. SAGARA, T. MATSUO, K. OHBA, H. TAKAHASHI, H. SAKAI, H. KANETAKE(Nagasaki, Japan) ..........................................................................................................................

Complete Response to Chemoradiotherapy in a Patient with Synchronous Double Gastric and EsophagealCancer. N. YOSHIDA, M. KOCHI, M. FUJII, N. KANAMORI, T. KAIGA, Y. MIHARA, T. FUNADA, H.TAMEGAI, M. WATANABE, T. TAKAYAMA (Tokyo, Japan) ..............................................................

Spreading of Acute Myeloid Leukemia Cells by Trafficking along the Peripheral Outflow Pathway ofCerebrospinal Fluid. M. SCHMITT, A. NEUBAUER, J. GREINER, X. XU, T.F.E. BARTH, K. BECHTER(Rostock; Marburg; Ulm; Günzburg, Germany) ...................................................................................

Variations in Demography and Prognosis by Colon Cancer Location. K. DERWINGER, B. GUSTAVSSON(Gothenburg, Sweden) .....................................................................................................................


4706

2265

2271

2283

2291

2297

2303

2313

2319

2327

2335

2339

2343

2347

*

Clinical Significance of HIF-1α Expression in Patients with Esophageal Cancer Treated with ConcurrentChemoradiotherapy. K. OGAWA, I. CHIBA, T. MORIOKA, H. SHIMOJI, W. TAMAKI, R. TAKAMATSU,T. NISHIMAKI, N. YOSHIMI, S. MURAYAMA (Okinawa, Japan) .....................................................

Comparison of Staging between the Old (6th Edition) and New (7th Edition) TNM Classifications inAdvanced Gastric Cancer. S. KIKUCHI, N. FUTAWATARI, S. SAKURAMOTO, N. KATADA, K.YAMASHITA, T. SHIBATA, M. NEMOTO, M. WATANABE (Kanagawa, Japan) .................................

Case Report of a Poorly Differentiated Uterine Tumour with t(10;17) Translocation and NeuroectodermalPhenotype. F. AMANT, T. TOUSSEYN, L. COENEGRACHTS, J. DECLOEDT, P. MOERMAN, M.DEBIEC-RYCHTER (Leuven; Dendermonde, Belgium) .......................................................................

Cutaneous Metastasis of Signet-ring Gastric Adenocarcinoma to the Breast with Unusual ClinicopathologicalFeatures. G. AVGERINOU, I. FLESSAS, E. HATZIOLOU, G. ZOGRAFOS, I. NITSIOS, F. ZAGOURI, A.KATSAMBAS, J. KANITAKIS (Athens, Greece; Lyon, France) ...........................................................

Docetaxel, Cisplatin and 5-Fluorouracil plus Granulocyte Colony-stimulating Factor Prophylaxis in Patientswith Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction: Experience at the MedicalUniversity of Vienna. M. BOJIC, U. PLUSCHNIG, J. ZACHERL, C.M.R. THALLINGER, A. BA-SSALAMAH, J. MARESCH, P. DATLER, S.F. SCHOPPMANN, M. HEJNA (Vienna, Austria) ............

Incidence of Venous Thromboembolism during Chemotherapy for Breast Cancer: Impact on Cancer Outcome.C.C. KIRWAN, G. MCDOWELL, C.N. MCCOLLUM, G.J. BYRNE (Manchester, UK) ........................

Expression of p53, Ki-67, E-Cadherin, N-Cadherin and TOP2A in Triple-negative Breast Cancer. M.NAKAGAWA, Y. BANDO, T. NAGAO, M. MORIMOTO, C. TAKAI, T. OHNISHI, J. HONDA, T.MORIYA, K. IZUMI, M. TAKAHASHI, M. SASA, A. TANGOKU (Tokushima; Itano, Fukushima;Kakogawa, Hyogo; Kurashiki, Okayama, Japan).................................................................................

Methylenetetrahydrofolate Reductase (MTHFR) Genotype, Smoking Habit, Metastasis and Oral Cancer inTaiwan. C.-W. TSAI, C.-F. HSU, M.-H. TSAI, Y.-A. TSOU, C.-H. HUA, W.-S. CHANG, C.-C. LIN, D.-T. BAU (Taichung; Chang-Hua, Taiwan, ROC) .................................................................................

Book Reviews .....................................................................................................................................

Announcements ...................................................................................................................................


Number 7

Proceedings of the 14th Annual Meeting of the Society of Biotherapeutic ApproachesDecember 11, 2010, Fukuoka, Japan.Special Issue Edited by M. Kuroki, S. Oshiro, G.-I. Soma

Preface...........................................................................................................................................

Review: KRAS-induced Actin-interacting Protein: A Potent Target for Obesity, Diabetes and Cancer. T.FUJIMOTO, S. SHIRASAWA (Fukuoka, Japan) ................................................................................

Induction of Cytotoxic T Lymphocytes by CEA Peptide-pulsed γδ T-Cells Isolated from Patients withAdvanced Cancer. A. YAMASAKI, H. ONISHI, T. MORISAKI, M. KATANO (Fukuoka, Japan) ..............


4707

2351

2361

2367

2373

2379

2383

2389

2395

2401

2407

2409

2413

2419

*

Review: Sonodynamic Cancer Therapy: A Non-invasive and Repeatable Approach Using Low-intensityUltrasound with a Sonosensitizer. H. SHIBAGUCHI, H. TSURU, MOTOMU KUROKI, MASAHIDEKUROKI (Fukuoka, Japan) ..............................................................................................................

Short Review: Oral Administration of Lipopolysaccharides for the Prevention of Various Diseases: Benefit andUsefulness. H. INAGAWA, C. KOHCHI, G.-I. SOMA (Kagawa-ken; Chiba-ken; Tokushima-ken, Japan) ......

Short Review: Lipopolysaccharide IP-PA1 from Pantoea agglomerans Prevents Suppression of Macrophage Functionin Stress-induced Diseases. K. NAKATA, H. INAGAWA, G.-I. SOMA (Okayama; Kagawa; Tokushima, Japan) ..

WT1 Peptide Vaccine Stabilized Intractable Ovarian Cancer Patient for One Year: A Case Report. S. DOHI, S.OHNO, Y. OHNO, M. TAKAKURA, S. KYO, G.-I. SOMA, H. SUGIYAMA, M. INOUE (Ishikawa; Tokyo;Tokushima; Chiba; Osaka, Japan) .........................................................................................................

Frequency of Myeloid Dendritic Cells Can Predict the Efficacy of Wilms' Tumor 1 Peptide Vaccination. S.OHNO, F. TAKANO, Y. OHTA, S. KYO, S. MYOJO, S. DOHI, H. SUGIYAMA, T. OHTA, M. INOUE(Tokyo; Ishikawa; Osaka, Japan) ......................................................................................................

Oncogenic KRAS Regulates miR-200c and miR-221/222 in a 3D-Specific Manner in Colorectal Cancer Cells.T. TSUNODA, Y. TAKASHIMA, Y. YOSHIDA, K. DOI, Y. TANAKA, T. FUJIMOTO, T. MACHIDA, T.OTA, M. KOYANAGI, M. KUROKI, T. SASAZUKI, S. SHIRASAWA (Fukuoka, Japan) ..........................

A Possible Clinical Adaptation of CRM197 in Combination with Conventional Chemotherapeutic Agents forOvarian Cancer. H. TSUJIOKA, T. FUKAMI, F. YOTSUMOTO, T. UEDA, S. HIKITA, Y. TAKAHASHI,H. KONDO, M. KUROKI, S. MIYAMOTO (Fukuoka, Japan) .............................................................

Functional Characterization of Lipopolysaccharide derived from Symbiotic Bacteria in Rice as a Macrophage-activating Substance. T. KADOWAKI, H. INAGAWA, C. KOHCHI, M. HIRASHIMA, G.-I. SOMA(Kagawa-ken, Yamaguchi-ken; Chiba-ken; Tokushima-ken, Japan) ........................................................

Design, Synthesis and Destructive Dynamic Effects of BODIPY-containing and Curcuminoid BoronTracedrugs for Neutron Dynamic Therapy. E. NAKATA, M. KOIZUMI, Y. YAMASHITA, K. ONAKA, Y.SAKURAI, N. KONDO, K. ONO, Y. UTO, H. HORI (Tokushima; Osaka, Japan) .................................

Antitumor Effects of CRM197, A Specific Inhibitor of HB-EGF, in T-Cell Acute Lymphoblastic Leukemia.N. KUNAMI, F. YOTSUMOTO, K. ISHITSUKA, T. FUKAMI, T. ODAWARA, S. MANABE, T.ISHIKAWA, K. TAMURA, M. KUROKI, S. MIYAMOTO (Fukuoka; Osaka, Japan) ..............................

Effect of the Gc-derived Macrophage-activating Factor Precursor (preGcMAF) on Phagocytic Activation ofMouse Peritoneal Macrophages. Y. UTO, S. YAMAMOTO, R. TAKEUCHI, Y. NAKAGAWA, K. HIROTA, H.TERADA, S. ONIZUKA, E. NAKATA, H. HORI (Tokushima; Tokyo; Chiba; Nagasaki; Kyoto, Japan) .......

Differential Expression of mRNA in Human Monocytes following Interaction with Human Colon CancerCells. T. HONDA, H. INAGAWA, I. YAMAMOTO (Kanagawa; Kagawa, Japan) ..................................

Clinical Course of Colorectal Cancer in Patients with Ulcerative Colitis. D. HIGASHI, K. FUTAMI, Y.ISHIBASHI, Y. EGAWA, T. MAEKAWA, T. MATSUI, A. IWASHITA, M. KUROKI (Chikushino-shi;Fukuoka, Japan) .............................................................................................................................

Combinatorial Cytotoxicity of Gemcitabine and Cytokine-activated Killer Cells in Hepatocellular Carcinomavia the NKG2D-MICA/B System. T. MORISAKI, H. ONISHI, N. KOYA, A. KIYOTA, H. TANAKA, M.UMEBAYASHI, T. OGINO, I. NAGAMATSU, M. KATANO (Fukuoka, Japan) .....................................

Novel Complementary Peptides to Target Molecules. H. OKADA, M. IMAI, F. ONO, A. OKADA, T.TADA, Y. MIZUE, K. TERAO, N. OKADA (Nagoya; Tsukuba; Sapporo, Japan) ..................................


4708

2425

2431

2437

2441

2447

2453

2461

2467

2477

2483

2489

2493

2499

2505

2511

*

*

*

Decreased Expression of Claudin-1 in Rectal Cancer: A Factor for Recurrence and Poor Prognosis. T.YOSHIDA, T. KINUGASA, Y. AKAGI, A. KAWAHARA, K. ROMEO, I. SHIRATSUCHI, Y. RYU, Y.GOTANDA, K. SHIROUZU (Fukuoka, Japan) ...................................................................................

Sonodynamic Therapy with 5-Aminolevulinic Acid and Focused Ultrasound for Deep-seated IntracranialGlioma in Rat. T. OHMURA, T. FUKUSHIMA, H. SHIBAGUCHI, S. YOSHIZAWA, T. INOUE, M.KUROKI, K. SASAKI, S.-I. UMEMURA (Fukuoka; Miyagi, Saitama, Japan) ......................................

KRAS-mediated Up-regulation of RRM2 Expression Is Essential for the Proliferation of Colorectal CancerCell Lines. Y. YOSHIDA, T. TSUNODA, K. DOI, Y. TANAKA, T. FUJIMOTO, T. MACHIDA, T. OTA, M.KOYANAGI, Y. TAKASHIMA, T. SASAZUKI, M. KUROKI, A. IWASAKI, S. SHIRASAWA (Fukuoka,Japan) ...........................................................................................................................................

Expression of IGF-1 and IGF-1R and Their Relation to Clinicopathological Factors in Colorectal Cancer. I.SHIRATSUCHI, Y. AKAGI, A. KAWAHARA, T. KINUGASA, K. ROMEO, T. YOSHIDA, Y. RYU, Y.GOTANDA, M. KAGE, K. SHIROUZU (Fukuoka, Japan) ...................................................................

Relationship between Ulcerative Colitis Patients Treated with Leukocytapheresis and Ulcerative Colitis-associated Colorectal Cancer. T. KINUGASA, Y. AKAGI, K. MUROTANI, K. ROMEO, T. YOSHIDA, Y.RYU, I. SHIRATUCHI, K. SHIROUZU (Fukuoka; Kobe, Japan) .........................................................

Assessment of HB-EGF Levels in Peritoneal Fluid and Serum of Ovarian Cancer Patients using ELISA. S.HIKITA, F. YOTSUMOTO, T. FUMAKI, S. HORIUCHI, A. SANUI, K. MIYATA, S.O. NAM, H.TSUJIOKA, T. UEDA, K. SHIROTA, T. YOSHIZATO, K. MAEDA, T. ISHIKAWA, Y. OKUNO, M.KUROKI, E. MEKADA, S. MIYAMOTO (Fukuoka; Osaka, Japan) .....................................................

Efficiency of Antimicrobial Defense: Molecular Flexibility of Natural Defensin and Artificial Bis-quaternaryAmmonium Compound. K. OHKURA, Y. SHINOHARA, H. HORI (Suzuka, Mie; Tokushima, Japan) .....

Reviews (pages 2413, 2425, 2431, 2437)

Number 8

Current Aspects and Future Direction in Gynaecological OncologySpecial Issue Edited by J. Sehouli, W. Lichtenegger

Preface...........................................................................................................................................

First Evaluation of the Diagnostic Accuracy of an Automated 3D Ultrasound System in a Breast ScreeningSetting. F. STÖBLEN, S. LANDT, R. STELKENS-GEBHARDT, J. SEHOULI, M. REZAI, S. KÜMMEL(Essen; Düsseldorf; Berlin, Germany) ...............................................................................................

High-frequency Breast Ultrasound for the Detection of Microcalcifications and Associated Masses in BI-RADS 4a Patients. F. STÖBLEN, S. LANDT, R. ISHAQ, R. STELKENS-GEBHARDT, M. REZAI,P. SKAANE, J.-U. BLOHMER, J. SEHOULI, S. KÜMMEL (Essen; Düsseldorf; Berlin, Germany; Oslo,Norway) ......................................................................................................................................

Predictive Factors in Relapsed Ovarian Cancer for Complete Tumor Resection. B. GIL-IBÁÑEZ, G. OSKAY-ÖZCELIK, R. RICHTER, C. FOTOPOULOU, E.I. BRAICU, P. NEUHAUS, W. LICHTENEGGER, J. SEHOULI; On behalf of the Tumor Bank Ovarian Cancer Network (TOC) and European Competence Centrefor Ovarian Cancer (EKZE Berlin) (Berlin, Germany) ...........................................................................


4709

2517

2527

2535

2541

2547

2553

2561

2565

2569

2575

2583

*

Prognostic Significance of Angiogenic Factors in Uterine Cervical Cancer. S. LANDT, M. WEHLING,H. HEIDECKE, S. JESCHKE, S. KORLACH, F. STÖBLEN, P. SCHMID, J.-U. BLOHMER, W. LICHTENEGGER, J. SEHOULI, S. KÜMMEL (Düsseldorf; Essen; Luckenwalde; Berlin, Germany;Brighton, UK) ...........................................................................................................................

CT-Guided High-Dose-Rate Brachytherapy of Metachronous Ovarian Cancer Metastasis to the Liver: InitialExperience. F. COLLETTINI, A. POELLINGER, D. SCHNAPAUFF, T. DENECKE, P. WUST, I.E.BRAICU, J. SEHOULI, B. HAMM, B. GEBAUER (Berlin, Germany) ................................................

First Surgical Experience of Intraperitoneal Treatment with the Trifunctional Antibody Catumaxomab (Anti-EpCam × Anti-CD3) for Epithelial Ovarian Cancer. G. PAPANIKOLAOU, C. FOTOPOULOU, I. BRAICU,R. CHEKEROV, S.C. SCHMIDT, K. PIETZNER, J. SEHOULI (Berlin, Germany) ...............................

In Vitro Vascular Tube Formation Testing as a Tool for Treatment Individualisation in Patients with CervicalCancer. S. LANDT, H. HEIDECKE, S. KORLACH, C. REUTER, I. SCHWIDDE, J. BARINOFF, M.THILL, J. SEHOULI, S. KÜMMEL (Düsseldorf; Luckenwalde; Berlin; Essen; Lübeck, Germany) ...........

Influence of a Dose-dense Adjuvant Chemotherapy on sVCAM-1/sICAM-1 Serum Levels in Breast CancerPatients with 1-3 Positive Lymph Nodes. H. EGGEMAN, F. STÖBLEN, M. THILL, S. KORLACH, P.SCHMID, D. LÜFTNER, D. ELLING, F.-A. TARAN, S. KÜMMEL, S. LANDT (Magdeburg; Essen;Lübeck; Berlin; Düsseldorf, Germany; Brighton, UK) .........................................................................

Review: Cell-free DNA in the Circulation as a Potential Cancer Biomarker. C. KOHLER, Z. BAREKATI,R. RADPOUR, X.Y. ZHONG (Basel, Switzerland) ............................................................................

Systemic Changes of Tryptophan Catabolites via the Indoleamine-2,3-dioxygenase Pathway in Primary CervicalCancer. C. FOTOPOULOU, J. SEHOULI, R. PSCHOWSKI, S. VON HAEHLING, G. DOMANSKA, E.-I.BRAICU, G. FUSCH, P. REINKE, J.C. SCHEFOLD (Berlin; Greifswald, Germany) .................................

Effect of Melatonin on Intra-abdominal Fat in Correlation with Endometrial Proliferation in OvariectomizedRats. R. CIORTEA, N. COSTIN, I. BRAICU, D. HARAGÂŞ, A. HUDACSKO, C. BONDOR, D. MIHU,C.M. MIHU (Cluj-Napoca, Romania; Berlin, Germany) .....................................................................

The Utility of an In Vitro Angiogenesis Score for Prognosis Assessment in Patients with Cervical Cancer. S. LANDT, H. HEIDECKE, C. REUTER, S. KORLACH, J.-U. BLOHMER, W. LICHTENEGGER, T.HEUSNER, F. STÖBLEN, M. THILL, J. BARINOFF, J. SEHOULI, S. KÜMMEL (Düsseldorf; Luckenwalde;Berlin; Essen; Lübeck, Germany) ................................................................................................................

Prognostic Significance of the Angiogenic Factors Angiogenin, Endoglin and Endostatin in Cervical Cancer.S. LANDT, K. MORDELT, I. SCHWIDDE, J. BARINOFF, S. KORLACH, F. STÖBLEN, W.LICHTENEGGER, J. SEHOULI, S. KÜMMEL (Düsseldorf; Berlin; Essen, Germany) ...........................

First Evaluation of the Joint Clinical Registry Data of Patients with Primary Ovarian Cancer at the CoordinatingTumor Center of Berlin. R. CHEKEROV, S. BRAUN, A.D. EBERT, C. HERBSTREIT, A. JAGOTA, K.D.JOHANNSMEYER, C. KRONENBERGER, J. POTENBERG, J.P. SCHARF, R. RICHTER, U. ULRICH, J.SEHOULI (Berlin, Germany) ....................................................................................................................

Review: The Mutational Profile of Sporadic Epithelial Ovarian Carcinoma. S. KALAMANATHAN, V.BATES, R. LORD, J.A. GREEN (Liverpool; Wirral, Merseyside, UK) .................................................

Optimizing the Clinical Management of Gynecological and Breast Cancer via Online Tumor Conferences.J.K. SCHROEDER, S. KUEMMEL, K. PIETZNER, J. HECTOR, J. SEHOULI, R. CHEKEROV (Essen;Berlin, Germany) ............................................................................................................................


4710

2589

2597

2603

2609

2617

2623

2629

2637

2645

2651

2657

2661

2669

*

*

Long Term Combination Treatment with Bevacizumab, Pegylated Liposomal Doxorubicin and RegionalAbdominal Hyperthermia in Platinum Refractory Ovarian Cancer: A Case Report and Review of theLiterature. K. PIETZNER, R.B. SCHMUCK, C. FOTOPOULOU, J. GELLERMANN, F. ISMAEEL, C.H.CHO, M. KALDEN, J. SEHOULI (Berlin; Jena; Dortmund, Germany) .................................................

Bevacizumab in Heavily Pre-treated and Platinum Resistant Ovarian Cancer: A Retrospective Study of theNorth-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group. K.PIETZNER, R. RICHTER, R. CHEKEROV, E. EROL, G. OSKAY-ÖZCELIK, W. LICHTENEGGER, J.SEHOULI (Berlin, Germany) .............................................................................................................


Number 9


Gankyrin, A Biomarker for Epithelial Carcinogenesis, Is Overexpressed in Human Oral Cancer. J. LI, T.J.KNOBLOCH, L.A. KRESTY, Z. ZHANG, J.C. LANG, D.E. SCHULLER, C.M. WEGHORST (Columbus,OH; Miami, FL, USA) ....................................................................................................................

Expression of Selenium-containing Proteins in Human Colon Carcinoma Tissue. V. YAGUBLU, J.R.ARTHUR, S.N. BABAYEVA, F. NICOL, S. POST, M. KEESE (Mannheim; Frankfurt Main, Germany;Aberdeen, UK; Baku, Azerbaijan) .....................................................................................................

Pomegranate Extract Induces Cell Cycle Arrest and Alters Cellular Phenotype of Human Pancreatic CancerCells. V. NAIR, Z. DAI, M. KHAN, H.P. CIOLINO (Austin, TX; Rockville, MD, USA) .........................

6-Thioguanine Inhibition of Parathyroid Hormone-related Protein Expression Is Mediated by GLI2. R.W.JOHNSON, A.R. MERKEL, S. DANILIN, M.P. NGUYEN, G.R. MUNDY, J.A. STERLING (Nashville,TN, USA) ......................................................................................................................................

The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to the Cytotoxic Effect of Carboplatin in Breast CancerIn Vitro. H. LIU, C. ZANG, J.-H. SCHEFE, S. SCHWARZLOSE-SCHWARCK, A.-C. REGIERER, E.ELSTNER, C.-O. SCHULZ, C. SCHOLZ, K. POSSINGER, J. EUCKER (Berlin, Germany) ....................

Histone Deacetylase Inhibitors Reverse CpG Methylation by Regulating DNMT1 through ERK Signaling.S. SARKAR, A.L. ABUJAMRA, J.E. LOEW, L.W. FORMAN, S.P. PERRINE, D.V. FALLER (Boston,MA, USA) ......................................................................................................................................

Protein-bound Polysaccharide-K (PSK) Induces Apoptosis and Inhibits Proliferation of PromyelomonocyticLeukemia HL-60 Cells. N. HIRAHARA, M. FUJIOKA, T. EDAMATSU, A. FUJIEDA, F. SEKINE, T.WADA, T. TANAKA (Izumo; Tokyo, Japan) .......................................................................................

Clioquinol Suppresses Cyclin D1 Gene Expression through Transcriptional and Post-transcriptionalMechanisms. J. ZHENG, D.M. BENBROOK, H. YU, W.-Q. DING (Oklahoma City, OK, USA; Wuhan,PR China) .....................................................................................................................................

Prognostic Relevance of Disseminated Tumor Cells in the Bone Marrow of Patients with Primary BreastCancer – Results of a Standardized Follow-Up. C. SCHINDLBECK, G. PFAB, J. JUECKSTOCK, U.ANDERGASSEN, H. SOMMER, W. JANNI, K. FRIESE, B. RACK (Traunstein; Munich; Duesseldorf,Germany) .......................................................................................................................................


4711

2675

2679

2683

2693

2699

2705

2713

2723

2733

2739

2749

*

Modulation of Cisplatin Cytotoxicity due to its Combination with Bortezomib and the Nature of itsAdministration. Z. AL-EISAWI, P. BEALE, C. CHAN, J.Q. YU, F. HUQ (Sydney, NSW, Australia) .......

Prognostic Significance of Thymidylate Synthase Expression in the Adjuvant Chemotherapy after Resectionfor Pulmonary Metastases from Colorectal Cancer. K. KAIRA, T. OKUMURA, Y. OHDE, T. TAKAHASHI,H. MURAKAMI, H. KONDO, T. NAKAJIMA. N. YAMAMOTO (Shizuoka, Japan) ..............................

In Vitro and In Vivo Anticancer Activity of (+)-Spongistatin 1. Q. XU, K.-C. HUANG, K. TENDYKE, J.MARSH, J. LIU, D. QIU, B.A. LITTLEFIELD, K. NOMOTO, O. ATASOYLU, C.A. RISATTI, J.B.SPERRY, A.B. SMITH III (Andover, MA; Philadelphia, PA, USA) .......................................................

Interaction of Dacarbazine and Imexon, In Vitro and In Vivo, in Human A375 Melanoma Cells. B.K.SAMULITIS, R.T. DORR, H.-H.S. CHOW (Tucson, AZ, USA) ..........................................................

Acquired Drug Resistance to Vascular Endothelial Growth Factor Receptor 2 Tyrosine Kinase Inhibitor inHuman Vascular Endothelial Cells. T. ARAO, K. MATSUMOTO, K. FURUTA, K. KUDO, H. KANEDA,T. NAGAI, K. SAKAI, Y. FUJITA, D. TAMURA, K. AOMATSU, F. KOIZUMI, K. NISHIO (Osaka-Sayama; Tokyo, Japan) ....................................................................................................................

SDF1β Expression in Renal Cell Carcinoma Correlates with Grading and Infiltration by CD8+ T-Cells.T.C. WEHLER, C. GRAF, K. ALTHERR, T. ZIMMERMANN, W. BRENNER, J.W. THÜROFF, S.BIESTERFELD, I. GOCKEL, M. THEOBALD, P.R. GALLE, C.C. SCHIMANSKI (Mainz; Duesseldorf,Germany) .......................................................................................................................................

Activation of the Wnt/Beta-catenin Signaling Pathway during Oral Carcinogenesis Process Is Not Influenced bythe Absence of Galectin-3 in Mice. J.M. SANT’ANA, R. CHAMMAS, F.-T. LIU, S. NONOGAKI, S.V.CARDOSO, A.M. LOYOLA, P.R. DE FARIA (Uberlândia; São Paulo, Brazil; Sacramento, CA, USA) ........

Anti-MDR1 siRNA Restores Chemosensitivity in Chemoresistant Breast Carcinoma and Osteosarcoma CellLines. J. PEREZ, C. BARDIN, C. RIGAL, B. ANTHONY, R. ROUSSEAU, A. DUTOUR (Lyon;Villeurbanne, France) ......................................................................................................................

Gallic Acid Induces G0/G1 Phase Arrest and Apoptosis in Human Leukemia HL-60 Cells through InhibitingCyclin D and E, and Activating Mitochondria-dependent Pathway. R.-D. YEH, J.-C. CHEN, T.-Y. LAI,J.-S. YANG, C.-S. YU, J.-H. CHIANG, C.-C. LU, S.-T. YANG, C.-C. YU, S.-J. CHANG, H.-Y. LIN,J.-G. CHUNG (Kaohsiung; Taichung, Taiwan, ROC) .........................................................................

Correlation between Expression of Metallothionein and Expression of Ki-67 and MCM-2 ProliferationMarkers in Non-small Cell Lung Cancer. B. WERYNSKA, B. PULA, B. MUSZCZYNSKA-BERNHARD,A. PIOTROWSKA, A. JETHON, M. PODHORSKA-OKOLOW, P. DZIEGIEL, R. JANKOWSKA(Wroclaw; Poznan, Poland) .............................................................................................................

Evaluation of Anticancer Activities of Benzo[c]phenanthridine Alkaloid Sanguinarine in Oral Squamous CellCarcinoma Cell Line. H. TSUKAMOTO, S. KONDO, Y. MUKUDAI, T. NAGUMO, A. YASUDA, Y.KURIHARA, T. KAMATANI, S. SHINTANI (Tokyo, Japan) ...............................................................

Interaction of Radiation and Pemetrexed on a Human Malignant Mesothelioma Cell Line In Vitro. D.YOSHIDA, T. EBARA, Y. SATO, T. KAMINUMA, T. TAKAHASHI, T. ASAO, T. NAKANO (Maebashi,Gunma, Japan) ...............................................................................................................................

Antitumor Therapeutic Effects of Cytosine Deaminase and Interferon-β Against Endometrial Cancer CellsUsing Genetically Engineered Stem Cells In Vitro. B.-R. YI, N.-H. KANG, K.-A. HWANG, S.U. KIM, E.-B. JEUNG, K.-C. CHOI (Cheongju, Chungbuk, Republic of Korea; Vancouver, BC, Canada) .................

Determination of Clofarabine Triphosphate Concentrations in Leukemia Cells Using Sensitive, IsocraticHigh-performance Liquid Chromatography. T. YAMAUCHI, R. NISHI, T. UEDA (Fukui, Japan) .............


4712

2757

2763

2773

2781

2787

2797

2805

2813

2821

2833

2841

2847

2853

2863

H-ras Up-regulates Expression of BNIP3. W. KALAS, E. SWIDEREK, A. RAPAK, M. KOPIJ, J. RAK,L. STRZADALA (Wroclaw, Poland; Montreal, QC, Canada) ..............................................................

K-ras Mutations in Lung Tumors from NNK-treated Mice with Lipopolysaccharide-elicited Lung Inflammation.P. KEOHAVONG, B. KAHKONEN, E. KINCHINGTON, J. YIN, J. JIN, X. LIU, J.M. SIEGFRIED, Y.P. DI(Pittsburgh, PA, USA) ............................................................................................................................

Prediction of Synergistic Antitumour Effect of Gefitinib and Radiation In Vitro. H.Q. LIN, H. MERIATY,A. KATSIFIS (Lucas Heights, NSW, Australia) .................................................................................

Methylation of the Homeobox Gene, HOPX, Is Frequently Detected in Poorly Differentiated ColorectalCancer. Y. HARADA, K. KIJIMA, K. SHINMURA, M. SAKATA, K. SAKURABA, K. YOKOMIZO, Y.KITAMURA, A. SHIRAHATA, T. GOTO, H. MIZUKAMI, M. SAITO, G. KIGAWA, H. NEMOTO, K.HIBI (Yokohama, Japan) .................................................................................................................

Etodolac Improves 5-FU Sensitivity of Head and Neck Cancer Cells through Inhibition of ThymidylateSynthase. S. MURATA, M. ADACHI, M. KIOI, S. TORIGOE, K. IJICHI, Y. HASEGAWA, T. OGAWA,M.K. BHAYANI, S.Y. LAI, K. MITSUDO, I. TOHNAI (Yokohama; Nagoya; Nagakute, Aichi, Japan;Houston, TX, USA) .........................................................................................................................

Down-regulation of Expression of Interleukin-6 and its Receptor Results in Growth Inhibition of MCF-7Breast Cancer Cells. X.-P. JIANG, D.C. YANG, R.L. ELLIOTT, J.F. HEAD (Baton Rouge, LA, USA) ....

Comparison of μCT, MRI and Optical Reflectance Imaging for Assessing the Growth of GFP/RFP-expressing Tumors. L. ABOU-ELKACEM, F. GREMSE, S. BARTH, R.M. HOFFMAN, F. KIESSLING,W. LEDERLE (Aachen, Germany; San Francisco; San Diego, CA, USA) ...............................................

Panipenem Does Not Alter the Pharmacokinetics of the Active Metabolite of Irinotecan SN-38 and InactiveMetabolite SN-38 Glucuronide (SN-38G) in Rats. A. KATO, J. UEYAMA, F. ABE, K. HOTTA, I.TSUKIYAMA, T. OSHIMA, F. KONDO, H. SAITO, T. HASEGAWA (Aichi-gun; Nagoya, Aichi; Kanazawa,Ishikawa, Japan) ......................................................................................................................................

Clinical Studies

Review: CT and MR Imaging of the Adrenal Glands in Cortisol-secreting Tumors. F. LUMACHI, P.MARCHESI, D. MIOTTO, R. MOTTA (Padova, Italy) .......................................................................

Cryotreatment against Metastatic Renal Cell Bone Tumour Reduced Multiple Lung Metastases. H.NISHIDA, T. SHIRAI, K. HAYASHI, A. TAKEUCHI, Y. TANZAWA, A. MIZOKAMI, M. NAMIKI, H.TSUCHIYA (Kanazawa, Japan) .......................................................................................................

Nonhepatic Cancer in Liver Cirrhosis: A Retrospective Study of Prevalence, Complication Rate after SpecificOncological Treatment, Follow-up and Prognostic Predictors of Outcome in 354 Patients with Cirrhosis. F.GUNDLING, H. SEIDL, F. SCHMIDTLER, N. LÖFFLER, I. STRASSEN, P. WOLF, C. PEHL, T.SCHMIDT, W. SCHEPP (Munich; Vilsbiburg, Germany) ....................................................................

Serum 25-Hydroxyvitamin D and Prevention of Breast Cancer: Pooled Analysis. S.B. MOHR, E.D.GORHAM, J.E. ALCARAZ, C.J. KANE, C.A. MACERA, J. KELLOGG PARSONS, D.L. WINGARD,C.F. GARLAND (La Jolla; San Diego, CA, USA) .............................................................................

Basic Clinical Parameters Predict Gefitinib Efficacy in Non-small Cell Lung Cancer. A. PIRCHER, E.ULSPERGER, R. HACK, H. JAMNIG, G. PALL, B. ZELGER, W. STERLACCI, W. HILBE, M. FIEGL(Innsbruck; Vienna; Tyrol; Feldkirch, Austria) ....................................................................................


4713

2869

2877

2883

2889

2893

2899

2907

2915

2923

2927

2931

2939

2949

*

Palladin is a Marker of Liver Metastasis in Primary Pancreatic Endocrine Carcinomas. E.B. HENDERSON-JACKSON, J. HELM, J. STROSBERG, N.A. NASIR, T.J. YEATMAN, L.K. KVOLS, D. COPPOLA, A.NASIR (Tampa, FL, USA) ..............................................................................................................

Elevated YB-1 Expression is a New Unfavorable Prognostic Factor in Non-Hodgkin’s Lymphomas. K.SZCZURASZEK, A. HALON, V. MATERNA, G. MAZUR, T. WROBEL, K. KULICZKOWSKI, P.DONIZY, P.S. HOLM, H. LAGE, P. SUROWIAK (Wroclaw, Poland; Berlin; Munich, Germany) .............

The Efficacy of Gemcitabine as Salvage Treatment in Patients with Refractory Advanced Colorectal Cancer(CRC): A Single Institution Experience. M.W. SAIF, K. KALEY, R. PENNEY, S. HOTCHKISS, K.N.SYRIGOS, A.S. STRIMPAKOS (New York, NY, USA) .......................................................................

RASSF1A Methylation is Predictive of Poor Prognosis in Female Breast Cancer in a Background of OverallLow Methylation Frequency. A. BUHMEIDA, A. MERDAD, J. EL-MAGHRABI, F. AL-THOBAITI, M.ATA, A. BUGIS, K. SYRJÄNEN, A. ABUZENADAH, A. CHAUDHARY, M. GARI, M. AL-QAHTANI,A. DALLOL (Jeddah, Saudi Arabia; Turku, Finland) .........................................................................

Safety and Short-term Therapeutic Effects of Miriplatin−Lipiodol Suspension in Transarterial Chemoembolization(TACE) for Hepatocellular Carcinoma. K. OKABE, T. BEPPU, K. HARAOKA, Y. OH-UCHIDA, S.YAMAMURA, S. TOMIYASU, T. YAMANAKA, O. SANO, T. MASUDA, A. CHIKAMOTO, S. FUJIYAMA,H. BABA (Kumamoto, Japan) ................................................................................................................

A Low-grade Myofibroblastic Sarcoma in the Abdominal Cavity. M. MIYAZAWA, Y. NARITAKA, A.MIYAKI, S. ASAKA, N. ISOHATA, K. YAMAGUCHI, M. MURAYAMA, T. SHIMAKAWA, T. KATSUBE,K. OGAWA, M. FUJIBAYASHI (Tokyo, Japan)......................................................................................

Preoperative Neutrophil to Lymphocyte Ratio as a Prognostic Predictor after Curative Resection for Non-smallCell Lung Cancer. M. TOMITA, T. SHIMIZU, T. AYABE, A. YONEI, T. ONITSUKA (Miyazaki, Japan) .......

Lapatinib Enhances Herceptin-mediated Antibody-dependent Cellular Cytotoxicity by Up-regulation of Cell SurfaceHER2 Expression. T. MARUYAMA, K. MIMURA, S. IZAWA, A. INOUE, S. SHIBA, M. WATANABE, Y.KAWAGUCHI, M. INOUE, H. NOGATA, S. INOUE, H. FUJII, K. KONO (Chuo; Kofu, Yamanashi, Japan) ...

Paclitaxel and Bevacizumab as First Line Combined Treatment in Patients with Metastatic Breast Cancer: TheHellenic Cooperative Oncology Group Experience with Biological Marker Evaluation. G. FOUNTZILAS, H.P.KOUREA, M. BOBOS, D. TELEVANTOU, V. KOTOULA, C. PAPADIMITRIOU, K.T. PAPAZISIS, E.TIMOTHEADOU, I. EFSTRATIOU, A. KOUTRAS, G. PENTHEROUDAKIS, C. CHRISTODOULOU, G.ARAVANTINOS, D. MILIARAS, K. PETRAKI, C.N. PAPANDREOU, P. PAPAKOSTAS, D. BAFALOUKOS,D. REPANA, E. RAZIS, D. PECTASIDES, A.M. DIMOPOULOS (Thessaloniki; Patras; Athens; Ioannina;Larissa, Greece) .......................................................................................................................................

Differential Activation of MAPK and PI3K/AKT/mTOR Pathways and IGF1R Expression in GastrointestinalStromal Tumors. M.J. RÍOS-MORENO, S. JARAMILLO, M. DÍAZ-DELGADO, M. SÁNCHEZ-LEÓN,I. TRIGO-SÁNCHEZ, J. POLO PADILLO, J. AMÉRIGO, R. GONZÁLEZ-CÁMPORA (Seville; Badajoz;Almeria, Spain) ..............................................................................................................................

Correlation of Intensity of MT-I/II Expression with Ki-67 and MCM-2 Proteins in Invasive Ductal BreastCarcinoma. A. WOJNAR, B. PULA, A. PIOTROWSKA, A. JETHON, K. KUJAWA, C. KOBIERZYCKI,J. RYS, M. PODHORSKA-OKOLOW, P. DZIEGIEL (Wroclaw; Poznan; Krakow, Poland) .....................

Phase I Study of S-1 in Combination with Trastuzumab for HER2-positive Metastatic Breast Cancer. T.NAKAYAMA, S. MORITA, T. TAKASHIMA, S. KAMIGAKI, K. YOSHIDOME, T. ITO, T. TAGUCHI, J.SAKAMOTO, S. NOGUCHI (Osaka; Kanagawa; Nagoya, Aichi, Japan) ..............................................


4714

2957

2963

2971

2975

2983

2989

2995

2999

3007

3019

3027

3035

Pathological Complete Response and Prognosis in Patients Receiving Neoadjuvant Paclitaxel andTrastuzumab with and without Anthracyclines for Stage II and III, HER2-positive Operable Breast Cancer:A Single-institute Experience. J. HORIGUCHI, T. OYAMA, D. TAKATA, N. ROKUTANDA, R.NAGAOKA, H. ODAWARA, H. TOKINIWA, K. TOZUKA, M. KIKUCHI, A. SATO, I. TAKEYOSHI(Maebashi, Gunma, Japan) ..............................................................................................................

Fertility-sparing Management of Grade 2 and 3 Endometrial Adenocarcinomas. M. KOSKAS, C. YAZBECK,F. WALKER, E. CLOUQUEUR, A. AGOSTINI, S. RUAT, J.P. LUCOT, E. LAMBAUDIE, D. LUTON, P.MADELENAT (Paris; Lille; Marselle, France) ..................................................................................

Effect of Glutathione-S-Transferase M1 and T1 Allelic Polymorphisms on HPV-induced Cervical PrecancerFormation. J. CSEH, E. PÁZSIT, Z. ORSÓS, E. MAREK, A. HUSZÁR, S. BALOGH, I. EMBER, I.KISS (Székesfehérvár; Miskolc; Pécs; Budapest, Hungary) ..................................................................

Gene Polymorphisms MTHFR C677T and A2756G as Predictive Factors in Adjuvant Chemotherapy forStage III Colorectal Cancer. H. TAFLIN, Y. WETTERGREN, E. ODIN, G. CARLSSON, K. DERWINGER(Gothenburg, Sweden) .....................................................................................................................

Evaluation of Oral Etoposide in Combination with Cisplatin for Patients with Recurrent Cervical Cancer:Long-term Follow-up Results of a Japanese Multicenter Study. Y. WATANABE, H. HOSHIAI, T.NAKANISHI, N. KAWAMURA, N. TANAKA, K. ISAKA, S. KAMIURA, M. OHMICHI, M. HATAE, K.OCHIAI (Osaka; Nagoya; Chiba; Tokyo; Kagoshima, Japan) ...............................................................

Pleomorphic Ductal Carcinoma of the Male Breast: Report of a Rare Case and Review of Literature. R.CARUSO, R. PALMERI, S. RACCHIUSA, A. BONANNO, R. LUCIANÒ, M. SCARDIGNO, G.BRANCA, F. FEDELE (Messina, Italy) ............................................................................................

Neoadjuvant Chemoradiotherapy for Clinical Stage II-III Esophageal Squamous Cell Carcinoma. H. SAEKI,M. MORITA, Y. NAKASHIMA, H. SONODA, K. HASHIMOTO, A. EGASHIRA, E. OKI, T. OHGA, Y.KAKEJI, Y. MAEHARA (Fukuoka, Japan) ........................................................................................

Phase I Study of Neoadjuvant Chemoradiotherapy Consisting of S-1 and Cisplatin for Patients withResectable Advanced Gastric Cancer (KOGC-01). T. TAKAHASHI, Y. SAIKAWA, H. TAKAISHI, H.TAKEUCHI, N. WADA, T. OYAMA, K. FUKUDA, J. FUKADA, O. KAWAGUCHI, N. SHIGEMATSU, Y.KITAGAWA (Tokyo, Japan) .............................................................................................................

Feasibility Study of Triplet Combination Chemotherapy of Paclitaxel, Cisplatin and S-1 for AdvancedGastric Cancer. K. FUJITANI, H. HASEGAWA, M. HIRAO, Y. KUROKAWA, T. TSUJINAKA (Osaka,Japan) ...........................................................................................................................................

Evaluation of Kallikrein-related Peptidase 5 Expression and its Significance for Breast Cancer Patients:Association with Kallikrein-related Peptidase 7 Expression. M. TALIERI, M. DEVETZI, A. SCORILAS, P.PREZAS, A. ARDAVANIS, A. APOSTOLAKI, A. KARAMERIS (Athens, Greece) ................................

Sifneos Alexithymia Questionnaire in Assessment of General Alexithymia in Patients with Breast Disease andBreast Cancer: A Prospective Case−Control Study in Finland. M. ESKELINEN, P. OLLONEN (Kuopio,Finland) ........................................................................................................................................

The Role of MonoTotal in the Primary Diagnosis, Prognosis and Follow-up of Patients with Non-smallCell Lung Cancer (NSCLC). M. PRAZAKOVA, J. VRZALOVA, J.M. AUGE, J. SAFRANEK, O.TOPOLCAN, R. FUCHSOVA, M. SPISAKOVA, S. SVOBODOVA, L. HOLUBEC JR., M. PESTA(Prague; Pilsen, Czech Republic; Barcelona, Spain) ...........................................................................

Erratum .........................................................................................................................................

Review (page 2923)


4715

3041

3047

3051

3057

3063

3069

3073

3079

3085

3093

3101

3107

3113

*

Number 10


Autologous Stem Cell Transplantation: Leukapheresis Product has Anti-angiogenic Effects In Vivo Correlatingwith Neutrophil-derived VEGFR1. A. LUETHY, F. STENNER, C. LOHRI, C. MULLER, P. SAMARAS, R.STEINER, M. VAN DEN BROEK, A. MISCHO, C. RENNER, A. KNUTH, C. RUEGG, R.H. WENGER, M.ZWEIFEL (Zurich; Fribourg, Switzerland) ..............................................................................................

A Rapid Imageable In Vivo Metastasis Assay for Circulating Tumor Cells. R.S. MENEN, E. PINNEY, K.KOLOSTOVA, V. BOBEK, A. SUETSUGU, N. ZHANG, M. BOUVET, R.M. HOFFMAN (San Diego;Oakland, CA, USA; Prague, Czech Republic) ...........................................................................................

EBP1 Inhibits Translation of Androgen Receptor mRNA in Castration Resistant Prostate Cancer Cells. H.ZHOU, Y. ZHANG, A.W. HAMBURGER (Baltimore, MD, USA) ..............................................................

FISH Scoring on Paraffin Sections Versus Single-cell Suspension for Chromophobe Renal Carcinoma and RenalOncocytoma. M. BRUNELLI, D. SEGALA, B. DELAHUNT, C. PAROLINI, S. BERSANI, L. CHENG, J.NEBLE, M. CHILOSI, S. GOBBO, G. MARTIGNONI (Verona, Italy; Wellington South, New Zealand;Indianapolis, IN, USA) ...........................................................................................................................

In Vitro Evaluation of Targeted Antisense 177Lu Radiotherapy. E.R. BALKIN, F. JIA, W.H. MILLER, M.R.LEWIS (Columbia, MO, USA) ................................................................................................................

Cyclin B1 Expression and p53 Status in Squamous Cell Carcinomas of the Head and Neck. T.K. HOFFMANN,S. TRELLAKIS, K. OKULICZ, P. SCHULER, J. GREVE, J. ARNOLDS, C. BERGMANN, M. BAS, S.LANG, G. LEHNERDT, S. BRANDAU, S. MATTHEIS, K. SCHECKENBACH, O.J. FINN, T.L. WHITESIDE,E. SONKOLY (Essen; Duesseldorf; Munich, Germany; Pittsburgh, PA, USA; Stockholm, Sweden) .....................

TGF-β Regulation of Focal Adhesion Proteins and Motility of Premalignant Oral Lesions via ProteinPhosphatase 1. J.E. WALSH, M.R. YOUNG (Charleston, SC, USA) ..........................................................

Anticancer Activity of Branched-chain Derivatives of Oleic Acid. O.D. DAILEY JR., X. WANG, F. CHEN, G.HUANG (New Orleans, LA; Clemson, SC, USA) ......................................................................................

Enhanced Efficacy of Gemcitabine by Indole-3-carbinol in Pancreatic Cell Lines: The Role of HumanEquilibrative Nucleoside Transporter 1. H. WANG, B.R. WORD, B.D. LYN-COOK (Jefferson, AR, USA) .....

Silencing of Selected Glutamate Receptor Subunits Modulates Cancer Growth. H. LUKSCH, O.UCKERMANN, A. STEPULAK, S. HENDRUSCHK, J. MARZAHN, S. BASTIAN, C. STAUFNER, A.TEMME, C. IKONOMIDOU (Dresden; Heidelberg, Germany; Lublin, Poland; Madison, WI, USA) ..............

Paclitaxel and TRAIL Synergize to Kill Paclitaxel-resistant Small Cell Lung Cancer Cells through a Caspase-independent Mechanism Mediated through AIF. T.B. HUNTER, N.J. MANIMALA, K.A. LUDDY, T. CATLIN,S.J. ANTONIA (Tampa, FL, USA) ..........................................................................................................

Metastasis Suppressor-1, MTSS1, Acts as a Putative Tumour Suppressor in Human Bladder Cancer. P. DU, L.YE, F. RUGE, Y. YANG, W.G. JIANG (Cardiff, UK; Beijing, PR China) ..................................................

Cytotoxicity of Chalcone Derivatives towards Glioblastoma. P. CHAMPELOVIER, M. MININNO, E.DUCHAMP, E. NICOLLE, V. CURRI, A. BOUMENDJEL, J. BOUTONNAT (Grenoble, France) ................

Breast Cancer Cell-derived Cytokines, Macrophages and Cell Adhesion: Implications for Metastasis. C.EICHBAUM, A.-S. MEYER, N. WANG, E. BISCHOFS, A. STEINBORN, T. BRUCKNER, P. BRODT, C.SOHN, M.H.R. EICHBAUM (Heidelberg, Germany; Montreal, QC, Canada) .............................................


4716

3115

3125

3129

3137

3143

3151

3159

3165

3171

3181

3193

3205

3213

3219

Intracellular Metabolism, Subcellular Localization and Phototoxicity of HMME/HB in Ovarian Cancer Cells. K.SONG, J. LI, L. LI, P. ZHANG, F. GENG, R. DONG, Q. YANG, X. QU, B. KONG (Ji’nan, Shandong, PRChina) .......................................................................................................................................................

The Role of the 3D Environment in Hypoxia-induced Drug and Apoptosis Resistance. J.W. KIM, W.J. HO,B.M. WU (Los Angeles, CA, USA) .........................................................................................................

Anticancer SAR Models for MCF-7 and MDA-MB-231 Breast Cell Lines. S. QAMAR, C.A. CARRASQUER,S.L. CUNNINGHAM, A.R. CUNNINGHAM (Louisville, KY, USA) ..........................................................

Down-regulation of EGFR Prolonged Cell Growth of Glioma but Did Not Increase the Sensitivity toTemozolomide. N. INABA, K. FUJIOKA, H. SAITO, M. KIMURA, K. IKEDA, Y. INOUE, S. ISHIZAWA,Y. MANOME (Tokyo, Japan) ..................................................................................................................

Fluvastatin Enhances Sorafenib Cytotoxicity in Melanoma Cells via Modulation of AKT and JNK SignalingPathways. S. ZHANG, N.A. DOUDICAN, E. QUAY, S.J. ORLOW (New York, NY, USA) ...........................

Epigenetic Modifiers Exert Renal Toxicity through Induction of p66shc. I. ARANY, J.S. CLARK, I. EMBER,L.A. JUNCOS (Jackson, MS, USA; Pécs, Hungary) ..................................................................................

Oncostatin M and IL-6 Induce u-PA and VEGF in Prostate Cancer Cells and Correlate In Vivo. T. W. WEISS,R. SIMAK, C. KAUN, G. REGA, H. PFLÜGER, G. MAURER, K. HUBER, J. WOJTA (Vienna, Austria;Ulleval, Norway) ...................................................................................................................................

Prevention of Mouse Lung Tumors by Combinations of Chemopreventive Agents Using Concurrent andSequential Administration. B.C. CASTO, M.A. PEREIRA (Columbus, OH, USA) ......................................

Modulation of Multidrug Efflux Pump Activity by New Hydantoin Derivatives on Colon Adenocarcinoma Cellswithout Inducing Apoptosis. G. SPENGLER, J. HANDZLIK, I. OCSOVSZKI, M. VIVEIROS, K. KIEĆ-KONONOWICZ, J. MOLNAR, L. AMARAL (Szeged, Hungary; Lisboa,, Portugal; Cracow, Poland; Brussels,Belgium) ...............................................................................................................................................

Polo-like Kinase 1 Inhibition as a New Therapeutic Modality in Therapy of Cholangiocarcinoma. S. THRUM,J. LORENZ, J. MÖSSNER, M. WIEDMANN (Leipzig; Berlin, Germany) .................................................

Phytoestrogens Induce Apoptosis via Extrinsic Pathway, Inhibiting Nuclear Factor-κB Signaling in HER2-overexpressing Breast Cancer Cells. H.S. SEO, HAN SEOK CHOI, HYEONG SIM CHOI, Y.K. CHOI, J.-Y.UM, I. CHOI, Y.C. SHIN, S.-G. KO (Seoul, Republic of Korea) ...............................................................

Biodistribution of 131I-labeled Anti-CK8 Monoclonal Antibody in HNSCC in Xenotransplanted SCID Mice. M.ANDRATSCHKE, C.W. LUEBBERS, V. JOHANNSON, B. SCHMITT, B. MACK, R. ZEIDLER, S. LANG,B. WOLLENBERG, F.J. GILDEHAUS (Munich; Luebeck; Essen, Germany) ...............................................

Combination of Resveratrol and Antiandrogen Flutamide Has Synergistic Effect on Androgen Receptor Inhibitionin Prostate Cancer Cells. L. KAI, A.S. LEVENSON (Jackson, MS, USA)....................................................

Up-regulation of 42 kDa Tubulin Alpha-6 Chain Fragment in Well-differentiated Hepatocellular CarcinomaTissues from Patients Infected with Hepatitis C Virus. Y. KURAMITSU, M. TAKASHIMA, Y. YOKOYAMA,N. IIZUKA, T. TAMESA, J.K. AKADA, Y. WANG, T. TODA, I. SAKAIDA, K. OKITA, M. OKA, K.NAKAMURA (Ube; Tokyo, Japan) ..........................................................................................................

Effects of Non-motorized Voluntary Running on Experimental and Spontaneous Metastasis in Mice. L. YAN,L.C. DEMARS (Grand Forks, ND, USA) ................................................................................................


4717

3229

3237

3247

3253

3259

3267

3273

3279

3285

3289

3301

3315

3323

3331

3337

Differential Expression of Apoptosis, Cell Cycle Regulation and Intermediate Filament Genes in Oral SquamousCell Carcinomas Associated with Toombak Use in Sudan. M.M. JALOULI, J. JALOULI, D. SAPKOTA, S.O.IBRAHIM, L. SAND, J.-M. HIRSCH (Uppsala, Sweden; Bergen, Norway) ...............................................

ERas Enhances Resistance to CPT-11 in Gastric Cancer. E. KUBOTA, H. KATAOKA, M. TANAKA, Y.OKAMOTO, M. EBI, Y. HIRATA, K. MURAKAMI, T. MIZOSHITA, T. SHIMURA, Y. MORI, S. TANIDA,T. KAMIYA, M. AOYAMA, K. ASAI, T. JOH (Nagoya, Japan) ................................................................

Antitumor Effect of New HER2 Peptide Vaccination Based on B Cell Epitope. H. MIYAKO, Y. KAMETANI, I.KATANO, R. ITO, B. TSUDA, A. FURUKAWA, Y. SAITO, D. ISHIKAWA, K. OGINO, S. SASAKI, K. IMAI,S. HABU, H. MAKUUCHI, Y. TOKUDA (Kanagawa; Saitama; Tokushima; Hokkaido; Tokyo, Japan) ............

Effects of Acute and Chronic Hypoxia on the Radiosensitivity of Gastric and Esophageal Cancer Cells. Y. KATO,M. YASHIRO, Y. FUYUHIRO, S. KASHIWAGI, J. MATSUOKA,T. HIRAKAWA, S. NODA, N. AOMATSU,T. HASEGAWA, T. MATSUZAKI, T. SAWADA, M. OHIRA, K. HIRAKAWA (Osaka, Japan) ....................

Down-regulation of EGFL8: A Novel Biomarker for Advanced Gastric Cancer. F. WU, A. SHIRAHATA, K.SAKURABA, Y. KITAMURA, T. GOTO, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y.SANADA, K. HIBI (Guangzhou, China; Yokohama, Japan) ......................................................................

Increased Soluble Leptin Receptor Levels Are Associated with Advanced Tumor Stage in Colorectal CancerPatients. V. TUTINO, M. NOTARNICOLA, V. GUERRA, D. LORUSSO, M.G. CARUSO (Castellana Grotte,Bari, Italy) ............................................................................................................................................

Low-Dose Combinations of LBH589 and TRAIL Can Overcome TRAIL-resistance in Colon Cancer Cell Lines.S.-C. LEE, H.-J. CHEONG, S.-J. KIM, J. YOON, HAN JO KIM, K.H. KIM, S.H. KIM, HYUN JUNG KIM,S.B. BAE, C.-K. KIM, N. LEE, K.T. LEE, S.K. PARK, D.S. HONG, H.S. PARK, J.-H. WON (Seoul;Gyeonggi-Do; Chungchungnam-Do, Republic of Korea) ............................................................................

Thiamine Supplementation Attenuated Hepatocellular Carcinoma in the Atp7b Mouse Model of Wilson’s Disease.C.T. SHELINE (New Orleans, LA, USA) .................................................................................................

Effects of Cytokinins, Cytokinin Ribosides and their Analogs on the Viability of Normal and Neoplastic HumanCells. S. CASATI, R. OTTRIA, E. BALDOLI, E. LOPEZ, J.A.M. MAIER, P. CIUFFREDA (Milan, Italy) ....

Antiproliferative Effects of N-Heterocyclic Indolyl Glyoxylamide Derivatives on Human Lung Cancer Cells. T.-H. HUANG, S.-J. CHIU, P.-H. CHIANG, S.-H. CHIOU, W.-T. LI, C.-T. CHEN, C.A. CHANG, J.-C.CHEN, Y.-J. LEE (Taipei; Hualien; Zhunan, Taiwan, ROC) ......................................................................

Tumor Endothelial Marker 8 Expression in Triple-negative Breast Cancer. L.G. GUTWEIN, S.Z. AL-QURAN,S. FERNANDO, B.S. FLETCHER, E.M. COPELAND, S.R. GROBMYER (Gainesville, FL, USA) ............

Clinical Studies

Clinical Value of Combined Detection of Serum Matrix Metalloproteinase-9, Heparanase, and Cathepsin forDetermining Ovarian Cancer Invasion and Metastasis. W. ZHANG, H.-C. YANG, Q. WANG, Z.-J. YANG, H.CHEN, S.-M. WANG, Z.-M. PAN, B.-J. TANG, Q.Q. LI, L. LI (Guangxi, PR China; Bethesda, MD, USA) ...

Case Report of Pneumatosis Intestinalis Secondary to Sunitinib Treatment for Refractory Gastrointestinal StromalTumor. A. JARKOWSKI III, R. HARE, V. FRANCESCUTTI, N. WILKINSON, N. KHUSHALANI (Buffalo,NY, USA) ..............................................................................................................................................

Diagnostic Value of 16 Cellular Tumor Markers for Metastatic Thyroid Cancer: An Immunohistochemical Study.H. LIANG, Y. ZHONG, Z. LUO, Y. HUANG, H. LIN, S. ZHAN, K. XIE, Q.Q. LI (Beihai; Nanning; Pingnal;Guangzhou, China; Bethesda, MD, USA) .................................................................................................


4718

3345

3353

3361

3369

3377

3381

3385

3395

3401

3407

3417

3423

3429

3433

Conventional Cytogenetics and Breakpoint Distribution by Fluorescent In Situ Hybridization in Patients withMalignant Hemopathies Associated with inv(3)(q21;q26) and t(3;3)(q21;q26). E. DE BRAEKELEER, N.DOUET-GUILBERT, A. BASINKO, C. BOVO, N. GUÉGANIC, M.-J. LE BRIS, F. MOREL, M. DEBRAEKELEER (Brest, France) ..............................................................................................................

Phase II Study of Topotecan with Cisplatin in Japanese Patients with Small Cell Lung Cancer. Y. HOSOMI, M.SHIBUYA, S. NIHO, Y. ICHINOSE, K. KIURA, H. SAKAI, K. TAKEDA, S. KUDO, K. EGUCHI, K.MATSUI, N. MASUDA, M. ANDO, K. WATANABE (Tokyo; Chiba; Fukuoka; Okayama; Saitama; Osaka;Kanagawa; Fukushima, Japan) ...............................................................................................................

Erlotinib in First-line Therapy for Non-small Cell Lung Cancer: A Prospective Phase II Study. D.R. CHOI,D.H. LEE, C.-M. CHOI, S.-W. KIM, C. SUH, J.-S. LEE (Seoul, Republic of Korea) ................................

Clinicopathological Study of Poorly Differentiated Colorectal Adenocarcinomas: Comparison between Solid-typeand Non-solid-type Adenocarcinomas. K. KOMORI, Y. KANEMITSU, S. ISHIGURO, Y. SHIMIZU, T. SANO,S. ITO, T. ABE, Y. SENDA, K. MISAWA, Y. ITO, N. UEMURA, T. KATO (Nagoya, Aichi, Japan) ...............

Uterobrush Method in the Detection of Endometrial Pathology. C. IAVAZZO, G. VORGIAS, G.MASTORAKOS, G. STEFANATOU, A. PANOUSSI, A. ALEXIADOU, S. PLYTA, C. LEKKA, N.KALINOGLOU, V. DERTIMAS, T. AKRIVOS, S. FOTIOU (Athens; Piraeus, Greece) ................................

Expression Status of Ribonucleotide Reductase Small Subunits hRRM2/p53R2 as Prognostic Biomarkers inStage I and II Non-small Cell Lung Cancer. N.-Y. HSU, J.-Y. WU, X. LIU, Y. YEN, C.-Y. CHEN, M.-C.CHOU, C.-H. LIN, H. LEE, Y.-W. CHENG (Taichung; Hsinchu, Taiwan, ROC; Duarte, CA, USA) .............

Patterns of Failures in Endometrial Cancer: Clinicopathological Variables Predictive of the Risk of Local, Distantand Retroperitoneal Failure. A. GADDUCCI, S. COSIO, M.G. FABRINI, A. FANUCCHI, C. BARSOTTI,R. CRISTOFANI, C. GRECO, A.R. GENAZZANI (Pisa, Italy) ................................................................

Review: No Detection of BK Virus, JC Virus, KI, WU and Merkel Cell Polyomaviruses in Cerebrospinal Fluidof Patients with Neurological Complications after Hematopoetic Stem Cell Transplantation. J. RUBIN, G.GIRAUD, P. PRIFTAKIS, K. WIDE, B. GUSTAFSSON, T. RAMQVIST, T. DALIANIS (Stockholm;Eskilstuna, Sweden) ...............................................................................................................................

Oxaliplatin Scale and National Cancer Institute-Common Toxicity Criteria in the Assessment of Chemotherapy-induced Peripheral Neuropathy. A.-L. KAUTIO, M. HAANPÄÄ, H. KAUTIAINEN, A. LEMINEN, E. KALSO,T. SAARTO (Helsinki; Jyväskylä; Tampere, Finland) .................................................................................

Bowel Complication during Robotic-assisted Laparoscopic Radical Prostatectomy. C.-F. HUNG, C.-K. YANG,C.-L. CHENG, Y.-C. OU (Taichung, Taiwan, ROC) .................................................................................

Review: The Prognostic Role of Lymphovascular Invasion in Urothelial-cell Carcinoma of Upper and LowerUrinary Tract. E. BRUNOCILLA, R. PERNETTI, G. MARTORANA (Bologna, Italy).................................

Sunitinib Re-challenge in Metastatic Renal Cell Carcinoma Treated Sequentially with Tyrosine Kinase Inhibitorsand Everolimus. B. PAULE, N. BRION (Creteil; Guyancourt, France) .......................................................

Significant Association of Caveolin-1 (CAV1) Genotypes with Breast Cancer in Taiwan. L.-C. LIU, C.-H. SU,H.-C. WANG, C.-W. TSAI, W.-S. CHANG, C.-Y. HO, C.-I WU, F.-J. LI, C.-H. LIN, H.-Y. LANE, D.-T.BAU (Taichung, Taiwan, ROC)...............................................................................................................

Endoscopic Appearance and Clinicopathological Character of Breast Cancer. D. YAMAMOTO, Y. TSUBOTA, H.YOSHIDA, S. KANEMATSU, N. SUEOKA, Y. UEMURA, K. TANAKA, A-H. KWON (Osaka, Japan) ......


4719

3441

3449

3457

3463

3469

3475

3483

3489

3493

3497

3503

3507

3511

3517

*

*

Expression of Thymidylate Synthase and Dihydropyrimidine Dehydrogenase in Primary Oral Squamous CellCarcinoma and Corresponding Metastases in Cervical Lymph Nodes: Association with the Metastasis SuppressorCD82. G. KAWASAKI, I. YOSHITOMI, S. YANAMOTO, S.-I. YAMADA, A. MIZUNO, M. UMEDA(Nagasaki, Japan) ..................................................................................................................................

Severe Late Complications in Patients with Uterine Cancer Treated with Postoperative Radiotherapy. G.KASUYA, K. OGAWA, S. IRAHA, Y. NAGAI, M. SHIRAISHI, M. HIRAKAWA, H. SAMURA, T. TOITA,Y. KAKINOHANA, W. KUDAKA, M. INAMINE, T. ARIGA, T. NISHIMAKI, Y. AOKI, S. MURAYAMA(Okinawa, Japan) ..................................................................................................................................

Docetaxel plus 5-Fluorouracil and Cisplatin (DCF) Induction Chemotherapy for Locally AdvancedBorderline-resectable T4 Esophageal Cancer. T. YOKOTA, S. HATOOKA, T. URA, T. ABE, D. TAKAHARI,K. SHITARA, M. NOMURA, C. KONDO, A. MIZOTA, Y. YATABE, M. SHINODA, K. MURO (Nagoya,Japan) ...........................................................................................................................................

Review: The Role of Chemotherapy in Metastatic Gastric Cancer. F. PASINI, A.P. FRACCON, G. DEMANZONI (Rovigo; Verona, Italy) ..........................................................................................................

Hypofractionated Radiotherapy with or without IGRT in Prostate Cancer: Preliminary Report of Acute Toxicity.M. VALERIANI, F. MONACO, M.F. OSTI, V. DE SANCTIS, G. MINNITI, R.M. ENRICI (Rome, Italy) ....

Changes in Serial Magnetic Resonance Spectroscopy Predict Outcome in High-grade Glioma During and AfterPostoperative Radiotherapy. H. QUON, B. BRUNET, A. ALEXANDER, A. MURTHA, B. ABDULKARIM, D.FULTON, M. SMERDELY, M. JOHNSON, R. URTASUN, S. PATEL, S. GHOSH, W. ROA (Edmonton, AB,Canada) ...............................................................................................................................................

Efficacy of Meloxicam in Combination with Preoperative Chemotherapy for Breast Cancer - Japan Breast CancerResearch Network (JBCRN) 02-1 Trial. D. YAMAMOTO, S. IWASE, H. YOSHIDA, Y. KURODA, C.YAMAMOTO, K. KITAMURA, H. ODAGIRI, Y. NAGUMO (Osaka; Tokyo; Fukuoka; Hirosaki, Japan) .......

Metabolic Activation of Irinotecan during Intra-arterial Chemotherapy of Metastatic Colorectal Cancer. M. CZEJKA,A. KISS, C. KOESSNER, R. TERKOLA, D. ETTLINGER, J. SCHUELLER (Vienna, Austria) ......................

Long-term Disease-free Survival Following Dendritic Cell Therapy and Resection of Small Bowel MelanomaMetastases – A Case Report. K. VANDERLINDEN, S. WILGENHOF, N. VAN DE WINKEL, C. GEERS, K.THIELEMANS, B. NEYNS, K. DE VOGELAERE, G. DELVAUX (Brussels, Belgium) ...............................

Immunohistochemical Expression and Prognostic Significance of CCND3, MCM2 and MCM7 in Hodgkin’sLymhoma. A. MARNERIDES, T.P. VASSILAKOPOULOS, E. BOLTETSOU, G. LEVIDOU, M.K.ANGELOPOULOU, I. THYMARA, M.-C. KYRTSONIS, V. PAPPI, O. TSOPRA, P. PANAYIOTIDIS, G.A.PANGALIS, P. BERIS, E. PATSOURIS, P. KORKOLOPOULOU (Athens, Greece; Stockholm, Sweden) .......

Expression of Zinc Finger 23 Gene in Human Hepatocellular Carcinoma. Y. SHI, L. ZHENG, G. LUO, J. WEI,J. ZHANG, Y. YU, Y. FENG, M. LI, N. XU (Changzhou, PR China; Lund, Sweden) .................................

Interaction of CCND1 Genotype and Smoking Habit in Taiwan Lung Cancer Patients. T.-C. HSIA, C.-J. LIU,C.-H. LIN, W.-S. CHANG, C.-C. CHU, L.-W. HANG, H.-Z. LEE, W.-C. LO, D.-T. BAU (Taichung,Taiwan, ROC) .......................................................................................................................................

Identification of The Distinctive Type i/XhoI+ Strain of Epstein-Barr Virus in Gastric Carcinoma in Peru. P.ORDONEZ, C. KORIYAMA, S. DING, E. YOSHIWARA, A.H. CORVALAN, J. TAKANO, J.L. CHIRINOS,J. WATANABE, J. MIYAGUI, H. HIDALGO, P. CHACON, V. LINARES, Y. EIZURU, S. AKIBA(Kagoshima, Japan; Lima; Huanuco; Chiclayo, Peru; Santiago, Chile) .......................................................


4720

3521

3527

3535

3543

3555

3559

3567

3573

3579

3585

3595

3601

3607

*

Lower Serum Total Testosterone is Associated with Lymph Node Metastases in a Radical Prostatectomy CohortStudy. C. KRATZIK, I. WOMASTEK, C. BIEGLMAYER, G. SCHATZL, J. LACKNER, C. FREIBAUER,G. LUNGLMAYR (Wien; Mistelbach, Austria) .........................................................................................

Vitamin D in Colorectal, Breast, Prostate and Lung Cancer: A Pilot Study. P. PAZDIORA, S. SVOBODOVA,R. FUCHSOVA, R. KUČERA, M. PRAZAKOVA, J. VRZALOVA, A. NARSANSKA, M. STRAKOVA, I.TRESKOVA, L. PECEN, V. TRESKA, L. HOLUBEC JR., M. PESEK, J. FINEK, O. TOPOLCAN (Pilsen;Prague, Czech Republic) .........................................................................................................................

Effect of Ibandronate on Disseminated Tumor Cells in the Bone Marrow of Patients with Primary Breast Cancer:A Pilot Study. O. HOFFMANN, B. AKTAS, C. GOLDNAU, M. HEUBNER, C. OBERHOFF, R. KIMMIG,S. KASIMIR-BAUER (Essen, Germany) .................................................................................................

Association of Caveolin-1 Genotypes with Nasopharyngeal Carcinoma Susceptibility in Taiwan. Y.-A. TSOU,C.-W. TSAI, M.-H. TSAI, W.-S. CHANG, F.-J. LI, Y.-F. LIU, C.-F. CHIU, C.-C. LIN, D.-T. BAU(Taichung, Taiwan, ROC) .......................................................................................................................

An Evaluation of Prognostic Value of Death-associated Protein Kinase 1 in Breast Cancer. S.-E. CHOU, C.-Y.HUANG, S.-M. SHEEN-CHEN, Y.-W. LIU, C.-H. TSAI, Y.-H. LIN, C.-C. HUANG, R.-P. TANG(Kaohsiung; Linkou, Taiwan, ROC; Xiamen, PR China) ...........................................................................

Errata....................................................................................................................................................

Book Reviews .......................................................................................................................................

Announcements......................................................................................................................................

Reviews (pages 3489, 3503, 3543)

Number 11


Review: Rho Kinase Proteins—Pleiotropic Modulators of Cell Survival and Apoptosis. C.A. STREET, B.A.BRYAN (Worcester, MA; El Paso, TX, USA) ..........................................................................................

Selective Gelatinase Inhibitor Peptide Is Effective in Targeting Tongue Carcinoma Cell Tumors In Vivo. J.SUOJANEN, S.-T. VILEN, P. NYBERG, P. HEIKKILÄ, O. PENATE-MEDINA, P.E.J. SARIS, J.HAGSTRÖM, T.-M. RANTA, T. SALO, T. SORSA, J. REUNANEN (Helsinki; Oulu, Finland; NewYork, NY, USA) .........................................................................................................................

Comparison of Cancer-Cell Seeding, Viability and Deformation in the Lung, Muscle and Liver, Visualized bySubcellular Real-time Imaging in the Live Mouse. K. HAYASHI, H. KIMURA, K. YAMAUCHI, N.YAMAMOTO, H. TSUCHIYA, K. TOMITA, H. KISHIMOTO, A. HASEGAWA, M. BOUVET, R.M.HOFFMAN (San Diego, CA, USA; Kanazawa, Ishikawa; Okayama, Japan) ..............................................

Synthetic Oleanane Triterpenoid, CDDO-Me, Induces Apoptosis in Ovarian Cancer Cells by InhibitingProsurvival AKT/NF-κB/mTOR Signaling. X. GAO, Y. LIU, D. DEEB, A.S. ARBAB, A.M. GUO, S.A.DULCHAVSKY, S.C. GAUTAM (Detroit, MI, USA) ..............................................................................

Targeting Cyclin D1 in Non-small Cell Lung Cancer and Mesothelioma Cells by Antisense Oligonucleotides.S.S. SAINI, M.A. KLEIN (Minneapolis, MN, USA) ...............................................................................


4721

3615

3619

3623

3629

3633

3637

3639

3643

3645

3659

3665

3673

3683

*

*

Antitumour Activity of S-1 in Combination with Cetuximab on Human Gastric Cancer Cell Lines In Vivo. T.KOBUNAI, T. WATANABE, T. FUKUSATO (Tokyo, Japan) ...................................................................

Melanocyte-specific Immune Response in a Patient with Multiple Regressing Nevi and a History of Melanoma.R. SPEECKAERT, N. VAN GEEL, R.M. LUITEN, M. VAN GELE, M. SPEECKAERT, J. LAMBERT, K.VERMAELEN, E.P.M. TJIN, L. BROCHEZ (Ghent, Belgium; Amsterdam, Netherlands) ...........................

MSCTRAIL-mediated HepG2 Cell Death in Direct and Indirect Co-cultures. X.-Y. SUN, J. NONG, K. QIN, H.LU, M.R. MONIRI, L.-J. DAI, G.L. WARNOCK (Nanning, PR China; Vancouver, BC, Canada) ..............

Cell to Cell Interactions Influence Sensitivity of Liver Cell Lines during Hyperthermia. U. MAYRHAUSER,P. STIEGLER, V. STADLBAUER, S. KOESTENBAUER, B. LEBER, K. KONRAD, F. IBERER, K.TSCHELIESSNIGG (Graz, Austria) .....................................................................................................

Novel Curcumin Analogs, GO-Y030 and GO-Y078, Are Multitargeted Agents with Enhanced Abilities forMultiple Myeloma. C. KUDO, H. YAMAKOSHI, A. SATO, H. OHORI, C. ISHIOKA, Y. IWABUCHI, H.SHIBATA (Akita; Sendai, Japan) ..........................................................................................................

Cell Death Forms and HSP70 Expression in U87 Cells after Ionizing Radiation and/or Chemotherapy.A. PAOLINI, F. PASI, A. FACOETTI, G. MAZZINI, F. CORBELLA, R. DI LIBERTO, R. NANO(Pavia, Italy) .............................................................................................................................

Indole-3-carbinol Inhibits Telomerase Activity and Gene Expression in Prostate Cancer Cell Lines. S. ADLER,G. RASHID, A. KLEIN (Kfar Saba; Tel Aviv, Israel) ..............................................................................

Differential Cytotoxicity of Triphala and its Phenolic Constituent Gallic acid on Human Prostate Cancer LNCapand Normal Cells. L.H. RUSSELL JR., E. MAZZIO, R.B. BADISA, Z.-P. ZHU, M. AGHARAHIMI, D.J.MILLINGTON, C.B. GOODMAN (Tallahassee; Gainesville, FL, USA) ....................................................

Mechanisms Underlying Gemcitabine Resistance in Pancreatic Cancer and Sensitisation by the iMiD™Lenalidomide. R.A. FRYER, B. BARLETT, C. GALUSTIAN, A.G. DALGLEISH (London, UK; Summit,NJ, USA) .......................................................................................................................................

5-Azacytidine Reverses Drug Resistance in Bladder Cancer Cells. K. RAMACHANDRAN, E. GORDIAN, R.SINGAL (Miami, FL, USA) .................................................................................................................

Silibinin Suppresses EGFR Ligand-induced CD44 Expression through Inhibition of EGFR Activity in BreastCancer Cells. S. KIM, J. HAN, J.S. KIM, J.-H. KIM, J.-H. CHOE, J.-H. YANG, S.J. NAM, J.E. LEE(Seoul, South Korea) ...........................................................................................................................

Relationship between LAT1 Expression and Response to Platinum-based Chemotherapy in Non-small CellLung Cancer Patients with Postoperative Recurrence. K. KAIRA, T. TAKAHASHI, H. MURAKAMI, T.SHUKUYA, H. KENMOTSU, T. NAITO, N. ORIUCHI, Y. KANAI, M. ENDO, H. KONDO, T. NAKAJIMA,N. YAMAMOTO (Shizuoka; Gunma; Osaka, Japan) ...............................................................................

Differential Akt Signalling in Non-seminomatous Testicular Germ Cell Tumors. J. HENNENLOTTER, B.AMEND, U. VOGEL, M. RENNINGER, C. SPRINGER, U. KUEHS, A. STENZL, J. BEDKE (Tuebingen;Karlsruhe, Germany) ...........................................................................................................................

Synergism from Combinations of Cisplatin and Oxaliplatin with Quercetin and Thymoquinone in HumanOvarian Tumour Models. M.U. NESSA, P. BEALE, C. CHAN, J.Q. YU, F. HUQ (Lidcombe; Concord, NSW,Australia) ...........................................................................................................................................

Induction of Apoptosis by Cannabinoids in Prostate and Colon Cancer Cells Is Phosphatase Dependent. S.SREEVALSAN, S. JOSEPH, I. JUTOORU, G. CHADALAPAKA, S.H. SAFE (College Station; Houston,TX, USA) ...........................................................................................................................................


4722

3691

3697

3705

3713

3719

3727

3733

3739

3747

3757

3767

3775

3783

3789

3799

An Active Endocytosis Pathway Is Required for the Cytotoxic Effects of Glycosylated Antitumor Ether Lipids.P. SAMADDER, H.-S. BYUN, R. BITTMAN, G. ARTHUR (Winnipeg, MB, Canada; Flushing, NY, USA)...

Phosphorylation of STAT3 in Head and Neck Cancer Requires p38 MAPKinase, whereas Phosphorylation ofSTAT1 Occurs via a Different Signaling Pathway. C. RIEBE, R. PRIES, K.N. SCHROEDER, B.WOLLENBERG (Lübeck, Germany) ......................................................................................................

The Role of Circulating Dendritic Cells in Patients with Unresectable Pancreatic Cancer. S. HIROOKA, H.YANAGIMOTO, S. SATOI, T. YAMAMOTO, H. TOYOKAWA, S. YAMAKI, R. YUI, K. INOUE, T.MICHIURA, A-H. KWON (Hirakata, Osaka, Japan) ..............................................................................

Detection of TFPI2 Methylation in the Serum of Gastric Cancer Patients. K. HIBI, T. GOTO, A. SHIRAHATA,M. SAITO, G. KIGAWA, H. NEMOTO, Y. SANADA (Yokohama, Japan) ................................................

Inhibition of Tumor Growth by Antibody to ADAMTS1 in Mouse Xenografts of Breast Cancer. T. HIRANO,K. HIROSE, K. SAKURAI, M. MAKISHIMA, K. SASAKI, S. AMANO (Tokyo, Japan) ..........................

Relationship between TYMS and ERCC1 mRNA Expression and In Vitro Chemosensitivity in Colorectal Cancer.Y.B. CHO, H.J. CHUNG, W.Y. LEE, S.H. CHOI, H.C. KIM, S.H. YUN, H.-K. CHUN (Seoul, South Korea) ....

Mode of Cell Death Associated with Adenovirus-mediated Suicide Gene Therapy in HNSCC Tumor Model. D.SRIVASTAVA, G. JOSHI, K. SOMASUNDARAM, R. MULHERKAR (Mumbai; Bangalore, India) ...........

Down-regulation of MiR-206 Promotes Proliferation and Invasion of Laryngeal Cancer by Regulating VEGFExpression. T. ZHANG, M. LIU, C. WANG, C. LIN, Y. SUN, D. JIN (Harbin, PR China) .......................

Clinical Studies

Lymph Node Assessment with 18F-FDG-PET and MRI in Uterine Cervical Cancer. J. MONTEIL, A.MAUBON, S. LEOBON, S. ROUX, B. MARIN, J. RENAUDIE, D. GENET, V. FERMEAUX, Y. AUBARD,N. TUBIANA-MATHIEU (Limoges, France) ..........................................................................................

Prolonged Administration of Temozolomide in Adult Patients with Anaplastic Glioma. C.F. FREYSCHLAG,D.R. SMOLCZYK, E. JANZEN, K. SCHMIEDER, C. THOMÉ, F. LOHR, F. WENZ, C. WEISS, J.TUETTENBERG, M. SEIZ (Innsbruck, Austria; Mannheim; Idar-Oberstein, Germany) ..............................

Serum N-Telopeptide of Type I Collagen and Bone Alkaline Phosphatase and their Relationship in Patientswith Non-small Cell Lung Carcinoma and Bone Metastases. Preliminary Results. F. LUMACHI, F. MARINO,G. FANTI, G.B. CHIARA, S.M.M. BASSO (Padova; Pordenone, Italy) ..................................................

Correlation of Gene Expression of ATP-binding Cassette Protein and Tyrosine Kinase Signaling Pathway inPatients with Hepatocellular Carcinoma. K. HOFFMANN, L. SHIBO, Z. XIAO, T. LONGERICH, M.W.BÜCHLER, P. SCHEMMER (Heidelberg, Germany) ..............................................................................

Cigarette Smoking and the Risk of Dying from Tobacco-related Malignancies by Race. J.N. CURRAN, E.GARRETT-MAYER, M.J. CARPENTER, M.E. FORD, G.A. SILVESTRI, D.T. LACKLAND, A.J.ALBERG (Charleston, SC, USA) .........................................................................................................

Ethnic Differences in Neuroendocrine Expression in Prostate Cancer Tissue. T.B. DORFF, S.V. LIU, S.XIONG, J. CAI, D. HAWES, J. PINSKI (Los Angeles, CA, USA) ...........................................................

Patients’ Satisfaction with Different Modalities of Prostate Cancer Therapy – A Retrospective Survey among634 Patients. W. WAGNER, T. BÖLLING, C. HAMBRUEGGE, J. HARTLAPP, M.G. KRUKEMEYER(Osnabrück; Extertal, Germany) ..............................................................................................................


4723

3809

3819

3827

3835

3839

3843

3851

3859

3865

3873

3879

3883

3891

3897

3903

Intra-arterial Chemoinfusion prior to Chemoradiotherapy with Full-dose Systemic Gemcitabine for Managementof Locally Advanced Pancreatic Cancer. T. TANAKA, H. NISHIOFUKU, T. TAMAMOTO, M. SHO, H. ANAI,S. SUEYOSHI, H. SAKAGUCHI, M. HASEGAWA, Y. NAKAJIMA, K. KICHIKAWA (Nara, Japan) ........

Investigative Clinical Study on Prostate Cancer Part VII: Prolactin and the Pituitary–Testis–Prostate Axis at theTime of Initial Diagnosis and Subsequent Cluster Selection of the Patient Population. A.B. PORCARO, C.GHIMENTON, A. PETROZZIELLO, F. MIGLIORINI, M. ROMANO, T. SAVA, B. CARUSO, C. COCCO,S.Z. ANTONIOLLI, V. LACOLA, E. RUBILOTTA, C. MONACO, L. COMUNALE (Verona, Italy) ..........

ADH-1 in the Treatment of Metastatic Adrenocortical Carcinoma - Case Report. N. YAROM, D. STEWART,L. AVRUCH, R. MALIK, J. WELLS, D.J. JONKER (Ottawa, ON, Canada; Houston, TX, USA) ..............

Hepatic Intra-arterial Cetuximab in Combination with 5-Fluorouracil and Cisplatin as Salvage Treatment forSorafenib-refractory Hepatocellular Carcinoma. G. POGGI, B. MONTAGNA, F. MELCHIORRE, P. QUARETTI,A. DELMONTE, A. RICCARDI, B. TAGLIAFERRI, F. SOTTOTETTI, P. DI CESARE, M.G. STELLA, L.VILLANI, M. ZORZETTO, G. GRECO, G. CORNALBA, G. BERNARDO (Pavia; Milan, Italy)..................

Repeated Localized Treatment for Extranodal Marginal Zone Lymphoma – Case Report and Review ofLiterature. C.E. SCHÖNKNECHT, C. NIEDER, M. MOLLS, S.T. ASTNER (Munich, Germany; Bodø;Tromsø, Norway) ................................................................................................................................

Association of hOGG1 and XPD Polymorphisms with Urothelial Carcinoma in Taiwan. Y.-H. WANG, S.-D.YEH, K.-H. SHEN, C.-H. SHEN, M.-C. TUNG, C.-T. LIU, H.-Y. CHIOU (Taipei; Tainan; Chiayi;Taichung, Taiwan, ROC) ......................................................................................................................

Polymorphisms in DNA Repair Gene XRCC1 and Skin Cancer Risk: A Meta-analysis. H. ZHANG, W. LI,M.J. FRANKLIN, A.Z. DUDEK (New York, NY; Lexington, KY; Minneapolis, MN, USA) .........................

Bevacizumab in Pediatric Patients: How Safe Is It? M.D. DE PASQUALE, A. CASTELLANO, L. DE SIO,C. DE LAURENTIS, A. MASTRONUZZI, A. SERRA, R. COZZA, A. JENKNER, M.A. DE IORIS(Rome, Italy) ..................................................................................................................................

Prevalence of Level V Metastases in Node-positive Head and Neck Squamous Cell Carcinoma. S. WIEGAND,A.P. ZIMMERMANN, A.M. SESTERHENN, J.A. WERNER (Marburg, Germany) ..................................

Tumor Response and Negative Distal Resection Margins of Rectal Cancer after HyperthermochemoradiationTherapy. S. TSUTSUMI, Y. TABE, T. FUJII, S. YAMAGUCHI, T. SUTO, R. YAJIMA, H. MORITA, T.KATO, M. SHIOYA, J.-I. SAITO, T. ASAO, T. NAKANO, H. KUWANO (Maebashi, Gunma, Japan) ........

Arterial Blood Pressure, Serum Calcium and PTH in Elderly Men with Parathyroid Tumors and PrimaryHyperparathyroidism. F. LUMACHI, V. CAMOZZI, G. LUISETTO, S. ZANELLA, S.M.M. BASSO (Padova;Pordenone, Italy) .................................................................................................................................

Beckwith-Wiedemann Syndrome: Potassium Ascorbate with Ribose Therapy in a Syndrome with HighNeoplastic Risk. C. ANICHINI, C. LO RIZZO, M. LONGINI, G. PAOLI, R.M. DI BARTOLO, F.PROIETTI, G. BUONOCORE (Siena; Firenze, Italy) ..............................................................................

Characterization of Dysplastic Nodules, Early Hepatocellular Carcinoma and Progressed HepatocellularCarcinoma in Cirrhosis with Contrast-Enhanced Ultrasound. A. GIORGIO, G. CALISTI, A. DI SARNO, N.FARELLA, G. DE STEFANO, U. SCOGNAMIGLIO, V. GIORGIO (Naples; Rome, Italy) .........................

Clinical Experience with Chemoradiotherapy Comprising S-1 Plus Low-dose Cisplatin in a Patient with StageIV Anal Cancer. N. NITORI, Y. KATO, A. KATO, T. DEGUCHI, A. OKADA, M. KOJIMA, J. KURODA, T.KADOMURA, K. KUBOTA, N. ORIGUCHI, M. FUJISAKI, M. KITAJIMA (Tokyo; Tochigi, Japan) .........


4724

3909

3913

3921

3927

3935

3939

3945

3953

3959

3963

3969

3973

3977

3983

Resection of Solitary Metachronous Lymph Node Metastasis from Hepatocellular Carcinoma FollowingTransarterial Chemotherapy with Cisplatin: A Case Report. T. KUROKAWA, S. YAMAZAKI, M.MORIGUCHI, M. AOKI, Y. WATANABE, T. HIGAKI, T. TAKAYAMA (Tokyo, Japan) .............................

Long-term Vaccine Therapy with Autologous Whole Tumor Cell-pulsed Dendritic Cells for a Patient withRecurrent Rectal Carcinoma. H. ONISHI, T. MORISAKI, E. BABA, M. NAKAMURA, S. INABA, H.KUROKI, K. MATSUMOTO, M. KATANO (Fukuoka; Kumamoto; Kanagawa, Japan) ..............................

Impact of Baseline Hepatitis B Viral DNA Levels on Survival of Patients with Advanced HepatocellularCarcinoma. Y.-Y. SHAO, P.-J. CHEN, Z.-Z. LIN, C.-C. HUANG, Y.-H. DING, Y.-H. LEE, C.-H. HSU, A.-L. CHENG (Taipei; Yunlin, Taiwan, ROC) ............................................................................................

Assessment of ‘Cancer-prone Personality’ Characteristics in Healthy Study Subjects and in Patients with BreastDisease and Breast Cancer Using the Commitment Questionnaire: A Prospective Case–Control Study inFinland. M. ESKELINEN, P. OLLONEN (Kuopio, Finland) ...................................................................

Measurement of Pessimism: Hopelessness Scale in Healthy Study Subjects, and in Patients with Benign BreastDisease and Breast Cancer: A Prospective Case–Control Study in Finland. M. ESKELINEN, P. OLLONEN(Kuopio, Finland) ...............................................................................................................................

Symptomatic Bone Marrow Involvement in Breast Cancer – Clinical Presentation, Treatment, and Prognosis:A Single Institution Review of 22 Cases. H.-G. KOPP, K. KRAUSS, T. FEHM, A. STAEBLER, J. ZAHM,W. VOGEL, L. KANZ, F. MAYER (Tuebingen, Germany) ......................................................................

Prognostic Significance of TIMP-1 in Non-small Cell Lung Cancer. M. PESTA, V. KULDA, R. KUCERA,M. PESEK, J. VRZALOVA, V. LISKA, L. PECEN, V. TRESKA, J. SAFRANEK, M. PRAZAKOVA, O.VYCITAL, J. BRUHA, L. HOLUBEC, O. TOPOLCAN (Prague; Pilsen, Czech Republic) .........................

3D Breast Ultrasound: Α Significant Predictor in Breast Cancer Reduction under Pre-operative Chemotherapy.M. WARM, V. DUDA, C. EICHLER, N. HARBECK, A. GOSSMANN, A. THOMAS, M. HOOPMANN, R.OHLINGER, M. BREIDENBACH, R.E. KATES (Cologne; Marburg; Berlin; Greifswald; Otterfing,Germany)............................................................................................................................................

Nomogram for Suboptimal Cytoreduction at Primary Surgery for Advanced Stage Ovarian Cancer. C.G.GERESTEIN, M.J. EIJKEMANS, J. BAKKER, O.E. ELGERSMA, M.E.L VAN DER BURG, G.S. KOOI,C.W. BURGER (Rotterdam; Utrecht; Dordrecht, Netherlands) .................................................................

Errata .................................................................................................................................................

Review (page 3645)

Number 12


Quantification of Angiogenesis in Breast Cancer by Automated Vessel Identification in CD34Immunohistochemical Sections. L.T.G. MIKALSEN, H.P. DHAKAL, Ø.S. BRULAND, J.M. NESLAND,D.R. OLSEN (Oslo; Bergen, Norway) ..............................................................................................

Establishing Efficient Xenograft Models with Intrinsic Vascularisation for Growing Primary Human Low-grade Sarcomas. D. TILKORN, A. DAIGELER, I. STRICKER, A. SCHAFFRAN, I. SCHMITZ, L.STEINSTRAESSER, J. HAUSER, A. RING, H.-U. STEINAU, S. AL-BENNA (Ludwigshafen; Bochum,Germany) .......................................................................................................................................


4725

3991

3995

4007

4013

4019

4025

4031

4039

4043

4051

4053

4061

*

Inhibition of Human Tumor Xenograft Growth in Nude Mice by a Novel Monoclonal Anti-HSPG Isolatedfrom Human Liver. P. VONGCHAN, S. KOTHAN, Y. WUTTI-IN, R.J. LINHARDT (Ciang Mai, Thailand;Troy, NY, USA) ..............................................................................................................................

L-Type Amino Acid Transporter 1 (LAT1) Expression in Malignant Pleural Mesothelioma. K. KAIRA, N.ORIUCHI, T. TAKAHASHI, K. NAKAGAWA, Y. OHDE, T. OKUMURA, H. MURAKAMI, T. SHUKUYA,H. KENMOTSU, T. NAITO, Y. KANAI, M. ENDO, H. KONDO, T. NAKAJIMA, N. YAMAMOTO(Shizuoka; Maebashi, Gunma; Osaka, Japan).....................................................................................

Review: Electrotransfer of RNAi-based Oligonucleotides for Oncology. S. CHABOT, S. PELOFY, A.PAGANIN-GIOANNI, J. TEISSIE, M. GOLZIO (Toulouse, France) .....................................................

The Novel Vitamin D Analog ZK191784 Inhibits Prostate Cancer Cell Invasion. M. STIO, M. MARTINESI,A. SIMONI, U. ZUEGEL, A. STEINMEYER, R. SANTI, C. TREVES, G. NESI (Florence, Italy; Berlin,Germany) .......................................................................................................................................

Characterization of T-Cell Memory Phenotype after In Vitro Expansion of Tumor-infiltrating Lymphocytes fromMelanoma Patients. J. ZHOU, P. NAGARKATTI, Y. ZHONG, M. NAGARKATTI (Columbia, SC, USA) ......

Effects of Artemisinin Dimers on Rat Breast Cancer Cells In Vitro and In Vivo. N.P. SINGH, H.C. LAI, J.S.PARK, T.E. GERHARDT, B.J. KIM, S. WANG, T. SASAKI (Seattle, WA, USA) .....................................

Histone-modifier Gene Expression Profiles Are Associated with Pathological and Clinical Outcomes in HumanBreast Cancer. N. PATANI, W.G. JIANG, R.F. NEWBOLD, K. MOKBEL (London; Cardiff, Wales, UK) .....

PINCH mRNA Overexpression in Colorectal Carcinomas Correlated with VEGF and FAS mRNA Expression.Z.Y. ZHANG, Y.F. TIAN, Y.Y. WANG, L.J. ZHANG, Z.R. ZHAO, X.F. SUN (Tangshan; Shijiazhuang, PRChina; Linköping, Sweden) ..................................................................................................................

ERCC1 Expression and Outcomes in Head and Neck Cancer Treated with Concurrent Cisplatin and Radiation.M. HAYES, C. LAN, J. YAN, Y. XIE, T. GRAY, R.H. AMIRKHAN, J.E. DOWELL (Miramar Beach, FL;Modesto, CA; Dallas, TX, USA) ...........................................................................................................

Treatment of Bone Metastasis in Prostate Cancer: Efficacy of a Novel Polybisphosphonate. F. DAUBINE, R.LE BOT, M. MÁRQUEZ, S. NILSSON, T. SCHRÖDER, A.R. HOLMBERG (Nantes, France; Stockholm,Sweden)..............................................................................................................................................

REG4, NEIL2, and BIRC5 Gene Expression Correlates with Gamma-radiation Sensitivity in Patients withRectal Cancer Receiving Radiotherapy. T. KOBUNAI, T. WATANABE, T. FUKUSATO (Tokyo, Japan) ........

Overexpressed HER2 in NSCLC Is a Possible Therapeutic Target of EGFR Inhibitors. N. ISE, K. OMI, D.NAMBARA, S. HIGASHIYAMA, K. GOISHI (Tokyo; Ehime, Japan) ......................................................

Acridine Orange Inhibits Pulmonary Metastasis of Mouse Osteosarcoma. H. SATONAKA, K. KUSUZAKI,K. AKEDA, M. TSUJII, T. IINO, T. UEMURA, T. MATSUBARA, T. NAKAMURA, K. ASANUMA, A.MATSUMINE, A. SUDO (Tsu City, Mie; Kyoto City, Kyoto, Japan) .......................................................

Effects of Inorganic and Organic Arsenic Compounds on Growth and Apoptosis of Human T-LymphoblastoidLeukemia Cells. E. HIKITA, M. ARAI, S. TANAKA, K. ONDA, H. UTSUMI, B. YUAN, H. TOYODA, T.HIRANO (Hachioji; Tokyo, Tokyo; Sagamihara, Kanagawa, Japan) .........................................................

Mutational Screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in Medullary ThyroidCarcinoma. H.-J. SCHULTEN, J. AL-MAGHRABI, K. AL-GHAMDI, S. SALAMA, S. AL-MUHAYAWI, A.CHAUDHARY, O. HAMOUR, A. ABUZENADAH, M. GARI, M. AL-QAHTANI (Jeddah, Saudi Arabia) .....


4726

4067

4075

4083

4091

4099

4111

4115

4127

4135

4141

4147

4155

4163

4169

4179

*

Inactivated Orf virus (Parapoxvirus ovis) Induces Antitumoral Activity in Transplantable Tumor Models. H.-H. FIEBIG, A. SIEGLING, H.-D. VOLK, A. FRIEBE, P. KNOLLE, A. LIMMER, O. WEBER (Freiburg;Wuppertal; Bonn, Germany) .................................................................................................................

Expression of the Apoptosis-related Genes Bcl-2 and p53 in Clinical Samples from Endometrial CarcinomaPatients. I. GONZÁLEZ-RODILLA, V. VERNA, A.-B. MUÑOZ, J. ESTÉVEZ, M. BOIX, J. SCHNEIDER(Santander, Spain)...............................................................................................................................

Yeast-derived Beta-(1-3),(1-6)-D-glucan Induces Up-regulation of CD86 on Dectin-1-positive Human B-Lymphoma Cell Lines. U. HARNACK, U. KELLERMANN, G. PECHER (Berlin, Germany).................

Thioridazine Induces Apoptosis of Multidrug-resistant Mouse Lymphoma Cells Transfected with the HumanABCB1 and Inhibits the Expression of P-Glycoprotein. G. SPENGLER, J. MOLNAR, M. VIVEIROS, L.AMARAL (Szeged, Hungary; Lisboa, Portugal; Brussels, Belgium) ........................................................

Reliability of Direct Sequencing of EGFR: Comparison between Cytological and Histological Samples fromthe Same Patient. P. BRUNO, S. MARIOTTA, A. RICCI, E. DURANTI, D. SCOZZI, A. NOTO, R.MANCINI, E. GIARNIERI, M.R. GIOVAGNOLI (Rome, Italy) ...............................................................

Prognostic Significance of N-Cadherin Expression in Oral Squamous Cell Carcinoma. M. DI DOMENICO,G.M. PIERANTONI, A. FEOLA, F. ESPOSITO, L. LAINO, A. DE ROSA, R. RULLO, M. MAZZOTTA,M. MARTANO, F. SANGUEDOLCE, L. PERILLO, L. D’ANGELO, S. PAPAGERAKIS, S.TORTORELLA, P. BUFO, L. LO MUZIO, G. PANNONE, A. SANTORO (Naples; Foggia; Bari, Italy;Ann Arbor, MI, USA) ....................................................................................................................

Circulating Tumor Cells and “Suspicious Objects” Evaluated Through CellSearch® in Metastatic Renal CellCarcinoma. A. GRADILONE, R. IACOVELLI, E. CORTESI, C. RAIMONDI, W. GIANNI, C. NICOLAZZO,A. PETRACCA, A. PALAZZO, F. LONGO, L. FRATI, P. GAZZANIGA (Rome, Italy) .............................

Resveratrol Reduces TNF-α-induced U373MG Human Glioma Cell Invasion through Regulating NF-κBActivation and uPA/uPAR Expression. J. RYU, B.M. KU, Y.K. LEE, J.Y. JEONG, S. KANG, J. CHOI, Y.YANG, D.H. LEE, G.S. ROH, H.J. KIM, G.J. CHO, W.S. CHOI, N. KIM, S.S. KANG (Jinju; Gimhae;Seoul, South Korea).............................................................................................................................

Quantitative Structure-Activity Relationship (QSAR) Analysis of Tumor-specificity of 1,2,3,4-Tetrahydroisoquinoline Derivatives. Y. UESAWA, K. MOHRI, M. KAWASE, M. ISHIHARA, H. SAKAGAMI(Tokyo; Matsuyama; Saitama, Japan) ....................................................................................................

Cytoskeleton Network and Cellular Migration Modulated by Nuclear-localized Receptor Tyrosine Kinase ROR1.H.-C. TSENG, H.-W. KAO, M.-R. HO, Y.-R. CHEN, T.-W. LIN, P.-C. LYU, W.-C. LIN (Hsinchu; Taipei,Taiwan, ROC).....................................................................................................................................

Novel Cytotoxic Isolated from Jamaican Hyptis verticillata jacq Induces Apoptosis and Overcomes MultidrugResistance. Y. WHITE, T. HAMADA, M. YOSHIMITSU, M. NAKASHIMA, M. HACHIMAN, T. KOZAKO,K. MATSUSHITA, K. UOZUMI, S. SUZUKI, H. KOFUNE, T. FURUKAWA, N. ARIMA (Kagoshima;Fukuoka, Japan) ..................................................................................................................................

IGF1Ec Expression in MG-63 Human Osteoblast-like Osteosarcoma Cells. A. PHILIPPOU, A.ARMAKOLAS, Z. PANTELEAKOU, N. PISSIMISSIS, A. NEZOS, A. THEOS, M. KAPARELOU, N.ARMAKOLAS, S.G. PNEUMATICOS, M. KOUTSILIERIS (Athens, Greece) ..........................................

Mutations of Mitochondrial DNA as Potential Biomarkers in Breast Cancer. F.F. CAI, C. KOHLER, B. ZHANG,W.J. CHEN, Z. BAREKATI, H.S.P. GARRITSEN, P. LENNER, P. TONIOLO, J.J. ZHANG, X.Y. ZHONG(Basel; Lausanne, Switzerland; Braunschweig, Germany; Umeä, Sweden; Hefei, Anhui, PR China) .................


4727

4185

4191

4195

4201

4207

4211

4219

4223

4231

4239

4251

4259

4267

Differential CD133 Expression Pattern during Mouse Colon Tumorigenesis. V. ARENA, E. CAREDDA, V.CUFINO, E. STIGLIANO, F. SCALDAFERRI, A. GASBARRINI, A. CITTADINI, A. SGAMBATO(Rome, Italy) ..................................................................................................................................

The Expression of Ki-67, but Not Proliferating Cell Nuclear Antigen, Predicts Poor Disease Free Survival inPatients with Adenocarcinoma of the Lung. S. OKA, H. URAMOTO, H. SHIMOKAWA, T. IWANAMI, F.TANAKA (Kitakyushu, Japan) ..............................................................................................................

Synergism from the Combination of Oxaliplatin with Selected Phytochemicals in Human Ovarian Cancer CellLines. N.M. YUNOS, P. BEALE, J.Q. YU, F. HUQ (Kepong, Malaysia; Sydney, NSW, Australia) ..............

Investigation of Cell Death Induced by N-Methyl-N-Nitrosourea in Cell Lines of Human Origin andImplication of RNA Binding Protein Alterations. A. KORYLLOU, M. PATRINOU-GEORGOULA, A.DIMOZI, S.A. KYRTOPOULOS, V. PLETSA (Athens, Greece)...............................................................

Association of p53 and CDKN1A Genotypes with Endometriosis. T.-H. YING, C.-J. TSENG, S.-J. TSAI, S.-C. HSIEH, H.-Z. LEE, Y.-H. HSIEH, D.-T. BAU (Taichung, Taiwan, ROC) ............................................

Human Brain Endothelial Cell-derived COX-2 Facilitates Extravasation of Breast Cancer Cells Across theBlood-brain Barrier. K.Y. LEE, Y.-J. KIM, H. YOO, S.H. LEE, J.B. PARK, H.J. KIM (Goyang; Daejeon,Republic of Korea) ..............................................................................................................................

Differential Cytotoxic Effects of Sodium Meta-arsenite on Human Cancer Cells, Dental Papilla Stem Cellsand Somatic Cells Correlate with Telomeric Properties and Gene Expression. B.-G. JEON, B.M KUMAR,E-J. KANG, G.-H. MAENG, Y.-M. LEE, Y.-S. HAH, S.-A OCK, D.-O. KWACK, B.-W. PARK, G.-J. RHO(Jinju, Republic of Korea) ....................................................................................................................

Genome-wide Identification of Chemosensitive Single Nucleotide Polymorphism Markers in Gastric Cancer.Y.J. HA, S.N. YOON, Y.J. JEON, D.H. CHO, S.A. ROH, B.S. KIM, H.J. KIM, S.Y. KIM, Y.S. KIM, J.C.KIM (Seoul; Daejeon; Gyeoggi-Do, Republic of Korea) ...........................................................................

De-alcoholization of Paclitaxel Injection for Clinical Application. I. TSUKIYAMA, M. TAKEUCHI, F. ABE,T. KISI, H. SAITO, Y. OBAYASHI, K. WATANABE, A. WAKATSUKI, K.-I. MIYAMOTO, T. HASEGAWA(Aichi-gun, Aichi; Kanazawa, Ishikawa, Japan) .....................................................................................

Modulation of PGE2-induced EP4 Expression on Snail Signaling and the Impact on Epithelial-MesenchymalTransition: Significance of EP4 Antagonism. H.N. KIM, N.K. NARAYANAN, S. LASANO, B.NARAYANAN (Tuxedo, NY, USA) ........................................................................................................

Clinical Studies

Review: Impact of Cyclooxygenase-2 in Breast Cancer. F. HOELLEN, K. KELLING, C. DITTMER, K.DIEDRICH, M. FRIEDRICH, M. THILL (Luebeck; Krefeld, Germany) ....................................................

Review: Estrogen Pathway Polymorphisms and Mammographic Density. I. DUMAS, C. DIORIO (QuebecCity, QC, Canada) ..............................................................................................................................

Review: Targeting AKT Protein Kinase in Gastric Cancer. K. ALMHANNA, J. STROSBERG, M. MALAFA(Tampa, FL, USA) ..............................................................................................................................

Feasibility of Image-guided Radiotherapy Based on Tomotherapy for the Treatment of Locally Advanced AnalCarcinoma. N.P. NGUYEN, J. VOCK, T. SROKA, R. KHAN, S. JANG, A. CHI, M. BETZ, L. EWELL, D.COHEN, R.P. VO, M. MILLS, V. VINH-HUNG (Galveston, TX, USA; Bern; Geneva, Switzerland) ............


4728

4273

4277

4283

4291

4301

4307

4315

4329

4339

4347

4359

4369

4387

4393

*

*

*

Primary Peritoneal Carcinoma in Complete Remission: a Case Report. J. RAMOS, K.S. GUNTURU, S.KRISHNAMOORTHY, B. KENNEY, M.W. SAIF (New Haven, CT; New York, NY, USA)..........................

Loss of p27KIP1 Expression in Fully-staged Node-negative Breast Cancer: Association with Lack of HormoneReceptors in T1a/b, but not T1c Infiltrative Ductal Carcinoma. D. MIRCHANDANI, D.F. ROSES, G.INGHIRAMI, A. ZELENIUCH-JACQUOTTE, J. CANGIARELLA, A. GUTH, R.A. SAFYAN, S.C.FORMENTI, M. PAGANO, F. MUGGIA (New York, NY, USA) ..............................................................

Triple Induction Chemotherapy and Chemoradiotherapy for Locally Advanced Esophageal Cancer. A Phase IIStudy. W. EISTERER, A. DE VRIES, D. KENDLER, B. SPECHTENHAUSER, A. KÖNIGSRAINER, H.NEHODA, I. VIRGOLINI, P. LUKAS, O. BECHTER, E. WÖLL, D. ÖFNER (Innsbruck; Feldkirch; Kufstein;St. Johann; Zams; Salzburg, Austria; Tübingen, Germany) ......................................................................

Intraepidermal Nerve Fibre Density in Cancer Patients Receiving Adjuvant Chemotherapy. M.J. KOSKINEN,A.-L. KAUTIO, M.L. HAANPÄÄ, H.K. HAAPASALO, P.-L. KELLOKUMPU-LEHTINEN, T. SAARTO,A.J. HIETAHARJU (Tampere; Helsinki, Finland) ...................................................................................

First Study of Oral Artenimol-R in Advanced Cervical Cancer: Clinical Benefit, Tolerability and TumorMarkers. F. H. JANSEN, I. ADOUBI, K.C. COMOE, T. DE CNODDER, N. JANSEN, A. TSCHULAKOW,T. EFFERTH (Abidjan, Côte d’Ivoire; Liège, Belgium; Mainz, Germany) ..................................................

Impaired Bone Microenvironment: Correlation between Bone Density and Presence of Disseminated TumorCells. B. KRAEMER, R. ROTHMUND, M. BANYS, N. KRAWCZYK, E.-F. SOLOMAYER, C. MACK,D. WALLWIENER, T. FEHM (Tuebingen; Hamburg; Homburg, Germany) ................................................

Immunohistochemical Study of VEGF Expression in Oral Squamous Cell Carcinomas: Correlation with themTOR-HIF-1α Pathway. T. NARUSE, G. KAWASAKI, S. YANAMOTO, A. MIZUNO, M. UMEDA(Nagasaki, Japan) ...............................................................................................................................

Oxaliplatin, Irinotecan and Cetuximab in Advanced Gastric Cancer. A Multicenter Phase II Trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT). E. WÖLL, R. GREIL, W.EISTERER, O. BECHTER, M.A. FRIDRIK, B. GRÜNBERGER, A. ZABERNIGG, B. MAYRBAURL,G. RUSS, M. DLASKA, P. OBRIST, J. THALER (Zams; Salzburg; Innsbruck; Linz; Vienna; Kufstein;Wels, Austria) ..............................................................................................................................

PCA3 Score vs PSA Free/Total Accuracy in Prostate Cancer Diagnosis at Repeat Saturation Biopsy. P. PEPE,F. ARAGONA (Catania, Italy) .............................................................................................................

The EMT Status in the Primary Tumor Does Not Predict Postoperative Recurrence or Disease-free Survival inLung Adenocarcinoma. Y. CHIKAISHI, H. URAMOTO, F. TANAKA (Kitakyushu, Japan) .........................

Correlation between IDH1 Gene Mutation Status and Survival of Patients Treated for Recurrent Glioma. S.LV, E. TEUGELS, J. SADONES, E. QUARTIER, M. HUYLEBROUCK, S. DU FOUR, M. LE MERCIER,O. DE WITTE, I. SALMON, A. MICHOTTE, J. DE GRÈVE, B. NEYNS (Brussels, Belgium) ..................

Effect of Maintenance Chemotherapy with Gemcitabine and Paclitaxel on Recurrent Squamous Cell Carcinomaof the Bladder: A Case Report. Y. MIYATA, S.-I. WATANABE, H. TAKAHASHI, Y. SAGARA, T. MATSUO,K. OHBA, H. SAKAI (Nagasaki, Japan) ..............................................................................................

External Validation of a Laparoscopic-based Score to Evaluate Resectability for Patients with Advanced OvarianCancer Undergoing Interval Debulking Surgery. E. CHEREAU, V. LAVOUE, M. BALLESTER, C.COUTANT, F. SELLE, A. CORTEZ, E. DARAÏ, J. LEVEQUE, R. ROUZIER (Paris; Rennes, France) ......

Anaplastic Oligodendroglial Tumors Harboring 1p/19q Deletion Can Be Successfully Treated withoutRadiotherapy. Y. IWADATE, T. MATSUTANI, N. SHINOZAKI, N. SAEKI (Chiba City, Chiba, Japan) ......


4729

4397

4401

4407

4413

4417

4423

4429

4439

4445

4451

4457

4465

4469

4475

Synchronous Double Tumor of Breast Cancer and Gastrointestinal Stromal Tumor in a Patient withNeurofibromatosis Type 1: Report of a Case. H. TAKEUCHI, S. HIROSHIGE, K. HASHIMOTO, T.KUSUMOTO, Y. YOSHIKAWA, Y. MUTO (Beppu, Japan) .....................................................................

Clinical and Histopathological Profile of Primary or Secondary Osteosarcoma of the Jaws. F. ANGIERO, F.MOLTRASIO, G. CATTORETTI, M.G. VALENTE (Genoa; Milan, Italy) ................................................

The Cancer Stem Cell Antigens CD133, BCRP1/ABCG2 and CD117/c-KIT Are Not Associated withPrognosis in Resected Early-stage Non-small Cell Lung Cancer. E. HERPEL, K. JENSEN, T. MULEY, A.WARTH, P.A. SCHNABEL, M. MEISTER, F.J.F. HERTH, H. DIENEMANN, M. THOMAS, S.GOTTSCHLING (Heidelberg, Germany) ................................................................................................

Evidence for Acute Vascular Toxicity of Cisplatin-based Chemotherapy in Patients with Germ Cell Tumour. K.-P. DIECKMANN, W.J. STRUSS, U. BUDDE (Hamburg, Germany) ...................................................

Circulating CD95-ligand as a Potential Prognostic Marker for Recurrence in Patients with SynchronousColorectal Liver Metastases. F.J.H. HOOGWATER, N. SNOEREN, M.W. NIJKAMP, A.C. GUNNING, W.J.VAN HOUDT, M.T. DE BRUIJN, E.E. VOEST, R. VAN HILLEGERSBERG, O. KRANENBURG, I.H.M.BOREL RINKES (Utrecht, Netherlands) ...............................................................................................

Dissection of Unsuspicious Para-aortic Lymph Nodes Does Not Improve Prognosis of Advanced EndometrialCarcinoma with Intra- or Extra-abdominal Metastasis. Y. UEDA, M. OKAZAWA, T. ENOMOTO, T.EGAWA-TAKATA, KIMURA TOSHIHIRO, K. YOSHINO, M. FUJITA, Y. OHTA, S. KAMIURA,KIMURA TADASHI (Osaka, Japan) .................................................................................................

Continuous Administration of EGFR-TKIs Following Radiotherapy after Disease Progression in BoneLesions for Non-small Cell Lung Cancer. M. INOMATA, T. SHUKUYA, T. TAKAHASHI, A. ONO, Y.NAKAMURA, A. TSUYA, H. KENMOTSU, T. NAITO, H. MURAKAMI, H. HARADA, M. ENDO, N.YAMAMOTO (Shizuoka; Toyama; Tokyo, Japan) ................................................................................

Hypersensitivity Reactions Associated with Platinum-containing Antineoplastic Agents for ThoracicMalignancies. M. TAMIYA, H. KUHARA, T. HIRASHIMA, Y. KONDO, M. SANTO, N. MORISHITA, H.SUZUKI, S. SASADA, N. OKAMOTO, M. KOBAYASHI, I. KAWASE (Osaka; Tokyo, Japan) ...............

Carbonic Anhydrase IX, Hypoxia-inducible Factor-1α, Ezrin and Glucose Transporter-1 as Predictors ofDisease Outcome in Rectal Cancer: Multivariate Cox Survival Models following Data Reduction by PrincipalComponent Analysis of the Clinicopathological Predictors. E.A. KORKEILA, J. SUNDSTRÖM, S.PYRHÖNEN, K. SYRJÄNEN (Turku, Finland) .................................................................................

Retrospective Study of Patients with Brain Metastases from Melanoma Receiving Concurrent Whole-brainRadiation and Temozolomide. N. DEVITO, M. YU, R. CHEN, E. PAN (Tampa, FL, USA) ....................

Perioperative Non-tumorous Factors Associated with Survival in HCC Patients Who UnderwentHepatectomy. A. NANASHIMA, T. ABO, K. HAMASAKI, K. WAKATA, T. TOMINAGA, S. HIDAKA, H.TAKESHITA, T. NAGAYASU (Nagasaki, Japan) ...............................................................................

Initial Experience with Hepatic Intraarterial Fotemustine and Interferon Alpha 2b Combination for Treatmentof Liver Tumors. F.V. VITALE, P. ROMEO, E.M. DI MAGGIO, A. PARISI, E. MALAPONTE, S. CALÌ,F. VASTA, V. PANEBIANCO, D. ARCORIA, F. FERRAÙ (Taormina; Catania, Italy) .........................

Prospective Study Evaluating the Plasma Concentrations of Twenty-six Cytokines and Response toMorphine Treatment in Cancer Patients. C. MAKIMURA, T. ARAO, H. MATSUOKA, M. TAKEDA, H.KIYOTA, J. TSURUTANI, Y. FUJITA, K. MATSUMOTO, H. KIMURA, M. OTSUKA, A. KOYAMA,C.K. IMAMURA, T. YAMANAKA, K. TANAKA, K. NISHIO, K. NAKAGAWA (Osaka, Sakai; Habikino,Osaka; Tokyo; Fukuoka, Japan) ........................................................................................................


4730

4481

4485

4491

4501

4507

4513

4519

4525

4529

4537

4545

4553

4561

Impact of Chemotherapy for Colorectal Cancer on Regulatory T-Cells and Tumor Immunity. K. MAEDA, S.HAZAMA, K. TOKUNO, S. KAN, Y. MAEDA, Y. WATANABE, R. KAMEI, Y. SHINDO, N. MAEDA, K.YOSHIMURA, S. YOSHINO, M. OKA (Yamaguchi, Japan) ...............................................................

Radiofrequency Ablation for Intrahepatic Cholangiocarcinoma: Retrospective Analysis of a Single CentreExperience. A. GIORGIO, G. CALISTI, G. DE STEFANO, N. FARELLA, A. DI SARNO, F.AMENDOLA, U. SCOGNAMIGLIO, V. GIORGIO (Naples; Rome, Italy) .............................................

Trans-Arterial Chemoembolization of Metastatic Colorectal Carcinoma to the Liver Adopting DC Bead®,Drug-eluting Bead Loaded with Irinotecan: Results of a Phase II Clinical Study. C. ALIBERTI, G.FIORENTINI, P.C. MUZZIO, F. POMERRI, M. TILLI, S. DALLARA, G. BENEA (Padova; Pesaro;Ferrrara, Italy) ........................................................................................................................

Docetaxel, Nedaplatin, and S-1 (DGS) Chemotherapy for Advanced Esophageal Carcinoma: A Phase I Dose-escalation Study. Y. TANAKA, K. YOSHIDA, S. OSADA, K. YAMAGUCHI, T. TAKAHASHI (Gifu City,Gifu, Japan) ...................................................................................................................................

Long-term Survival Following Resection of Brain Metastases from Pancreatic Cancer. J. LEMKE, T.F.E.BARTH, M. JUCHEMS, T. KAPAPA, D. HENNE-BRUNS, M. KORNMANN (Ulm, Germany) .............

Comparison of Lymphangiogenesis between Primary Colorectal Cancer and Corresponding Liver Metastases.A. SCHOPPMANN, D. TAMANDL, B. HERBERGER, F. LANGLE, P. BIRNER, S. GELEFF, T.GRÜNBERGER, S.F. SCHOPPMANN (Vienna, Austria) ...................................................................

Salvage Chemotherapy for Ovarian Carcinoma Recurring During or After Consolidation Chemotherapy withPaclitaxel. Y. MIYOSHI, Y. UEDA, A. MORIMOTO, T. YOKOYAMA, S. MATSUZAKI, E. KOBAYASHI,KIMURA TOSHIHIRO, K. YOSHINO, M. FUJITA, T. ENOMOTO, KIMURA TADASHI (Suita, Osaka,Japan) ........................................................................................................................................

Clinical Significance of BRAF Gene Mutations in Patients with Non-small Cell Lung Cancer. M.KOBAYASHI, M. SONOBE, T. TAKAHASHI, A. YOSHIZAWA, M. ISHIKAWA, R. KIKUCHI, K.OKUBO, C.-L. HUANG, H. DATE (Kyoto, Japan) ............................................................................

Weekly Paclitaxel in Combination with Doxifluridine for Peritoneally Disseminated Gastric Cancer withMalignant Ascites. I. TAKEYOSHI, F. MAKITA, S. IWAZAKI, H. ISHIKAWA, S. KAKINUMA, Y. SATO,T. OHYA, K. NAKAGAMI, N. TOMIZAWA, M. IZUMI, I. KOBAYASHI, Y. TANAHASHI, J.KOBAYASHI, N. KAMOSHITA, S. KAWATE, Y. SUNOSE, I. SAKAMOTO, D. YOSHINARI, T.YAMADA, T. OKABE (Maebashi; Shibukawa; Tatebayashi; Takasaki; Gunma; Fujiyoshida, Yamanashi;Usui; Koriyama, Fukushima; Ojiya, Niigata; Ogawa, Saitama; Suto, Kumamoto, Japan) ........................

The Prognostic Significance of HER2 Overexpression in Non-small Cell Lung Cancer. M. TAKENAKA, T.HANAGIRI, S. SHINOHARA, T. KUWATA, Y. CHIKAISHI, S. OKA, Y. SHIGEMATSU, Y. NAGATA,H. SHIMOKAWA, M. NAKAGAWA, H. URAMOTO, T. SO, F. TANAKA (Kitakyushu, Japan) ..............

Single-agent Paclitaxel in Advanced Anal Cancer after Failure of Cisplatin and 5-Fluorouracil Chemotherapy.A. ABBAS, E. NEHME, M. FAKIH (Buffalo, NY; Ann Arbor, MI, USA) .............................................

Clinical Characteristics and Treatment Outcomes of Hepatocellular Carcinoma with Inferior Vena Cava/HeartInvasion. Y.H. CHUN, S.H. AHN, J.Y. PARK, D.Y. KIM, K.-H. HAN, C.Y. CHON, S.J. BYUN, S.U.KIM (Seoul, South Korea) ...............................................................................................................

Clinical Significance of Hypermethylation Status in NSCLC: Evaluation of a 30-Gene Panel in Patientswith Advanced Disease. M. PESEK, M. KOPECKOVA, L. BENESOVA, A. MESZAROSOVA, P.MUKENSNABL, F. BRUHA, M. MINARIK (Pilsen; Prague, Czech Republic) .....................................


4731

4569

4575

4581

4589

4599

4605

4613

4619

4625

4631

4637

4641

4647

Growth Factors and Breast Tumors, Comparison of Selected Growth Factors with Traditional Tumor Markers.R. KUCERA, M. CERNA, A. NARSANSKA, S. SVOBODOVA, M. STRAKOVA, J. VRZALOVA, R.FUCHSOVA, I. TRESKOVA, T. KYDLICEK, V. TRESKA, L. PECEN, O. TOPOLCAN, P. PAZDIORA(Pilsen; Prague, Czech Republic) .....................................................................................................

Multi-center Phase II Study of FLOX for Advanced Colorectal Cancer Patients in Japan: SWIFT 3 Study.T. KATO, N. NAGATA, M. FUJII, H. TAKEMOTO, K. KONDO, Y. OKUYAMA, H. TOMINAGA, J.SAKAMOTO, H. MISHIMA (Hyogo; Kitakyushu; Osaka; Sakai; Nagoya; Kyoto; Hiroshima, Japan) .......

Low Dihydropyrimidine Dehydrogenase Correlates with Prolonged Survival in Patients with LungAdenocarcinoma Treated with 5-Fluorouracil. Y. SHINTANI, M. INOUE, Y. FUNAKOSHI, A.MATSUMURA, M. OHTA, H. MAEDA, M. OKUMURA (Osaka, Japan) ............................................

Reviews (pages 4083, 4359, 4369, 4387)


4732

4653

4657

4665

*

Subject Index(Figures refer to page numbers)

A20 lymphoma, β-glucan, cyclophosphamide, regulatory T-cell, 1169

A46, Pantoea agglomerans, LPS, LPSp, LPSa46,macrophage, M-CSF, GM-CSF, 2467

AAV, CXCR4, gene therapy, bioluminescence, breastcancer, 1627

ABC proteins, hepatocellular carcinoma, liver resection,multidrug resistance, tyrosine kinase, 3883

ABCB1 transporter, hydantoin derivatives, Colo 205 andColo 320 colon adenocarcinoma cells, multidrugresistance, efflux pump, apoptosis, 3285

ABCB1 transporter, multidrug-resistant cancer cells, MDRmouse T-lymphoma cells, P-glycoprotein,phenothiazines, thioridazine, apoptosis, 4201

Abdominal tumor, low-grade myofibroblastic sarcoma,2989

Ablation of liver metastases, CT-guided high-dose-ratebrachytherapy, CT-HDRBT, ovarian cancer,metachronous liver metastasis, 2597

Absorption, LPS, endotoxin, oral administration, toxicity,lipopolysaccharide, review, 2431

Acceleration, prostate cancer, radiotherapy,hypofractionation, amifostine, cytoprotection, 1745

Acetoxycoumarins, cell viability, cell cycle, lethal dose,2017

ACI rat serum, zeranol, breast cancer, mitogenic activity,481

Acidification, colon cancer, metformin, phenformin, 2-deoxyglucose, 421

ACNU, glioma, oligodendroglioma, 1p19q, 1p, PAV,procarbazine, vincristine, chemotherapy, 4475

Acridine orange, osteosarcoma, pulmonary metastasis,photodynamic therapy, flash-wave light,fluorovisualization, 4163

Κ-Αctin, hepatocellular carcinoma, survival, postoperativeprognosis, 2037

Actin cytoskeleton, cell migration, nuclear localization,Ror1, receptor tyrosine kinase, 4239

Activation loop, proteasome inhibitor, receptor tyrosinekinase, multiple myeloma, ER stress, FGFR3, Lys650Glumutation, K650E, bortezomide, plasma cell malignancy,113

Active metabolite of irinotecan, SN-38, glucuronidation,SN-38 glucuronide (SN-38G), panipenem,pharmacokinetics, 2915

Activin A, maspin, androgen receptor, upper urinary tracturothelial carcinoma, prognosis, 1713

Acute effect, hypofractionated radiotherapy, prostatecancer, intermediate risk, image guided radiation therapy,hormonotherapy, 3555

Acute lymphoblastic leukemia, minimal residual disease,flow cytometry, children, early response, 1453

Acute myelogenous leukemia, deferasirox, iron chelationtherapy, iron overload, chemotherapy-resistant, completeremission, 1741

Acute myeloid leukemia, immunotherapy, interleukin-2,peptide vaccination, cerebrospinal fluid, CSF, flow ofCSF, chloroma, 2343

ADAGIO study, imatinib, gastrointestinal stromal tumor,adherence, 1407

ADAM, MMP, TIMP, solid cancer nest, invasive front,colorectal cancer, 1567

ADAMTS1, breast cancer, amphiregulin, xenograft,immunotherapy, 3839

ADCC, lapatinib, HER2, breast cancer, herceptin, 2999Adenocarcinoma, BRAF mutation, KRAS, EGFR, ERBB2

mutation, V600E, lung cancer, squamous cell carcinoma,SSCP, 4619

Adenocarcinoma, Ki-67, PCNA, recurrence, lung, 4277Adenocarcinoma, MACC1, recurrence, lung cancer, 1141Adenosine triphosphate, thymidylate synthase, ERCC1,

drug screening assay, colorectal neoplasm, 3843Adenovirus, prodrug activation, HNSCC, ganciclovir,

thymidine kinase, apoptosis, 3851ADH-1, adrenocortical carcinoma, dynamic contrast

enhancing magnetic resonance imaging (DCE-MRI),phase-I, N-cadherin, 3921

ADH1B, alcohol-dehydrogenase, polymorphism, oralcancer, laryngeal cancer, 677

Adherence, imatinib, gastrointestinal stromal tumor,ADAGIO study, 1407

Adhesion molecules, colorectal cancer, biological activity,tumor markers, angiogenetic factors, metalloproteinases,373

Adhesion molecules, prostate cancer, vitamin D analog,ZK191784, MMP-2, MMP-9, 4091

Adjuvant chemotherapy, cancer, neurotoxicity, docetaxel,intraepidermal nerve fibres, neuropathy, skin biopsies,oxaliplatin, 4413

Adjuvant chemotherapy, colorectal cancer, MTHFR C677T,MTR A2756G, toxicity, survival, 3057

Adjuvant chemotherapy, colorectal cancer, pulmonarymetastases, TS, OPRT, ERCC1, BRCA1, MVD, 2763

Adjuvant chemotherapy, endometrial carcinoma, para-aorticlymph node dissection, prognosis, 4513

Adjuvant chemotherapy, sequential therapy, breast cancer, 1483ADM, colorectal cancer, prognostic factor, hypoxia, 507ADOC, thymic carcinoma, chemotherapy, refractory, S-1, 299Adrenal imaging, adrenocortical tumors, Cushing’s

syndrome, cancer, CT, MR, review, 2923Adrenocortical carcinoma, ADH-1, dynamic contrast

enhancing magnetic resonance imaging (DCE-MRI),phase-I, N-cadherin, 3921


4733

Adrenocortical tumors, Cushing’s syndrome, adrenalimaging, cancer, CT, MR, review, 2923

Adriamycin, cardiotoxicity, fatigue, myotoxicity, 2023Advanced esophageal cancer, combined chemotherapy,

docetaxel, CDDP, 5-FU, 633Advanced gastric cancer, AKT, PI3K, chemoresistance,

review, 4387Advanced gastric cancer, triplet combination chemotherapy,

paclitaxel, cisplatin, S-1, feasibility study, 3085Advanced hepatocellular carcinoma (HCC), cetuximab,

hepatic intra-arterial chemotherapy (HAIC), 3927Advanced imaging modes, breast cancer, screening

mammography, microcalcification, high-frequencyultrasound, 2575

Advanced NSCLC, LAT1, CD98, recurrence, EGFRmutation, prognosis, chemotherapy. Ki-67, p-Akt, p-mTOR, 3775

Advanced prostate cancer, castrate-resistant prostate cancer,predictors of survival, time to castration resistance,chemotherapy, 1475

Adverse effects, assessment, chemotherapy, neurotoxicity,peripheral neuropathy, 3493

Adverse event, paclitaxel (PTX), alcohol intolerance, de-alcoholization, pharmacokinetics, 4339

Afatinib, BIBF 1120, colorectal cancer, phase II,pharmacokinetics, 2271

AFP-IgM immune complexes, hepatocellular carcinoma,biomarker, alpha-fetoprotein, 687

AG1478, HNSCC, EGFR, polymorphism, Erk-1/2,cetuximab, 59

Age, breast cancer, grade, immunohistochemistry, measlesvirus, p53, 913

Age, colon cancer, microsatellite instability, tumor location,early onset, 967

AKT, advanced gastric cancer, PI3K, chemoresistance,review, 4387

Akt, HGF, c-Met, NK4, CT26, 5-fluorouracil, Erk1/2,thymidylate synthase, 2217

Akt, medicinal herb, bioactivity, p53 pathway, apoptosis,Ruta graveolens, 233

AKT, melanoma, sorafenib, fluvastatin, JNK, 3259Akt, non-seminomatous testicular cancer, PTEN, p27Kip1,

subcellular distribution, 3783AKT, ovarian cancer, gene mutations, BRCA 1/2, TP53,

PI3K, BRAF, KRAS, review, 2661AKT, ovarian cancer, methyl-2-cyano-3, 12-dioxooleana-1,

9(11)-dien-28-oate (CDDO-Me), apoptosis, NF-κB,mTOR, 3673

AKT1, medullary thyroid carcinoma, gene mutations, RET,HRAS, KRAS, NRAS, BRAF, CTNNB1, mutationalscreening, 4179

Alcohol intolerance, paclitaxel (PTX), de-alcoholization,pharmacokinetics, adverse event, 4339

Alcohol-dehydrogenase, ADH1B, polymorphism, oralcancer, laryngeal cancer, 677

Allogeneic stem cell transplantation, hemorrhagic cystitis,BK virus, review, 939

Alpha subunits, medulloblastoma, atypicalteratoid/rhabdoid tumours, Na+/K+-ATPase,immunohistochemistry, 953

Alpha-fetoprotein, hepatocellular carcinoma, biomarker,AFP-IgM immune complexes, 687

Alternative splicing, angiogenesis, autologous stem celltransplantation, chick chorioallantoic membrane assay,high-dose chemotherapy, placental growth factor,vascular endothelial growth factor, VEGFR1, 3115

Alternative splicing, insulin-like growth factor 1, MG-63osteosarcoma cells, 4259

Amifostine, prostate cancer, radiotherapy,hypofractionation, acceleration, cytoprotection, 1745

2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine, Apc,C57Bl/6J, min mice, FVB, intestinal carcinogenesis, 785

5-aminolevulinic acid, sonodynamic therapy, focusedultrasound, glioma, deep-seated, rat model, 2527

5-aminolevulinic acid, sonodynamic therapy, SAS cell,mitochondrion, apoptosis, 39

Amphiregulin, breast cancer, ADAMTS1, xenograft,immunotherapy, 3839

Anal cancer, 5-FU, cisplatin, paclitaxel, 4637Anal cancer, chemoradiation, image-guided radiotherapy,

tomotherapy, 4393Anaphylatoxin, antisense pepitide, complementary peptide,

inflammation, sepsis, cytokine storm, 2511Anaplastic ependymoma, multifocal recurrence,

temozolomide, 1023Anaplastic gliomas, long-term administration,

temozolomide, 3873Anastrazole, total estrogen blockade, high-dose

chemotherapy, leuprorelin, premenopausal breast cancer,VEGF, 671

Anastrozole, aromatase inhibitors, anti-estrogens, breastcancer, steroid sulfatase, tamoxifen, postmenopausalwomen, 1367

Anastrozole, breast cancer, radiotherapy, ipsilateral breasttumor recurrence, tamoxifen, 367

Androgen receptor, combination strategy, flutamide,prostate cancer, prostate-specific antigen, resveratrol,3323

Androgen receptor, maspin, activin A, upper urinary tracturothelial carcinoma, prognosis, 1713

Androgen receptor, prostate cancer, EBP1, mRNAtranslation, 3129

Angiogenesis, alternative splicing, autologous stem celltransplantation, chick chorioallantoic membrane assay,high-dose chemotherapy, placental growth factor,vascular endothelial growth factor, VEGFR1, 3115


4734

Angiogenesis, breast cancer, image analysis, CD34, MVD,vessel identification, 4053

Angiogenesis, cancer, CD105, endoglin, tumor, review, 2283Angiogenesis, colon cancer, orthotopic model, GFP,

fluorescent protein imaging (FPI), MRI, selenium, 387Angiogenesis, colon cancer, thrombin, vascular endothelial

growth factor, vascular endothelial growth factorreceptor-2, coagulation factor, 843

Angiogenesis, dihydroartemisinin, pancreatic cancer, cellproliferation, apoptosis, optical imaging, 1549

Angiogenesis, VEGF, mTOR, HIF-1α, oral cancer, 4429Angiogenesis, VEGFR2, tyrosine kinase inhibitor, drug

resistance, endothelial cells, HUVEC, 2787Angiogenetic factors, colorectal cancer, biological activity,

tumor markers, metalloproteinases, adhesion molecules,373

Angiogenic factor, vascular tube formation, cervical cancer,antiangiogenic therapy, 2609

Angiogenic factors, angiogenin, endoglin, endostatin,cervical cancer, 2651

Angiogenic factors, cervical cancer, VEGF, angiogenin,endoglin, 2589

Angiogenic factors, vascular endothelial growth factor,basic fibroblast growth factor, endostatin, cervical cancer,2645

Angiogenin, angiogenic factors, cervical cancer, VEGF,endoglin, 2589

Angiogenin, angiogenic factors, endoglin, endostatin,cervical cancer, 2651

Angiography, hepatocellular carcinoma, 1H MRI, apparentdiffusion coefficient, extracellular space, benzamideriboside, therapy response, motion effect, 2045

Angiotensin II type 1 receptor antagonist, osteosarcoma,metastasis, CV11974, 123

Animal models, neural stem cells, suicide genes, prodrugs,invasive tumors, gene-directed enzyme prodrug therapyreview, 1249

Annexin V-FITC/PI assay, hepatocellular carcinoma,human zinc finger 23, real-time RT-PCR, apoptosis, 3595

Anoikis, metastasis, invasion, migration, renieramycin M,lung cancer cells, 193

Antagonist, laryngeal cancer, glutamate receptor,proliferation, ERK1/2 kinase, 565

Antiangiogenic therapy, angiogenic factor, vascular tubeformation, cervical cancer, 2609

Antiangiogenic therapy, hepatitis B virus, hepatocellularcarcinoma, prognosis, 4007

Antiapoptosis, colorectal cancer, gamma radiation,microarray, RT-PCR, REG4, NEIL2, BIRC5, 4147

Antibacterial activity, conformation, hydrophobicity, bis-quarternary compound, 2561

Anticancer agents, sphingomylinase, Cox-2, caspase-3,apoptosis, p53, cell cycle, 1345

Anticancer drug, apoptosis, cell-to-cell interaction,adhesion molecules, characteristics of cancer cells,anticancer drug resistance, chemotherapy, drugsensitivity, drug resistance-relating factors, geneexpression analysis, evaluation and prediction ofpharmacological effects, screening systems, 3237

Anticancer drug resistance, cell-to-cell interaction,adhesion molecules, characteristics of cancer cells,chemotherapy, apoptosis, drug sensitivity, drugresistance-relating factors, gene expression analysis,evaluation and prediction of pharmacological effects,screening systems, 3237

Anticancer drugs, sphingomyelinase, p53, Bax, cell cycle,apoptosis, 871

Anticancer models, cat-SAR, DTP, breast cancer,computational toxicology, 3247

Anticancer therapeutic agents, benzo[c]phenanthridinealkaloids, sanguinarine, oral squamous cell carcinoma, 2841

Anticancer, (+)-spongistatin 1, natural product, mitosis,xenograft model, 2773

Anticancer, branched-chain fatty acids, antitumor, humanbreast cancer, human colon cancer, HT-29, MCF-7, 3165

Anticancer, heparan sulfate, chitosan, breast cancer, cellproliferation, FGF-2, 1321

Anti-estrogens, aromatase inhibitors, breast cancer, steroidsulfatase, tamoxifen, anastrozole, postmenopausalwomen, 1367

Antigen presentation, γδ T-Cells, cytotoxic T-cells, 2419Antimetastasis, sunitinib, antitumor, VEGF, VEGFR,

phosphorylation, mammary cancer, 1225Antineoplastic, carboplatin, cisplatin, hypersensitivity,

thoracic malignancy, immunoglobulin E, 4525Antioxidant enzyme expression, selenoprotein, colon

cancer, glutathione, thioredoxin, 2693Antiproliferative activity, isopentenyladenosine, cytokinins,

modified nucleosides, 3401Antisense oligonucleotide, cyclin D, cyclin E, cyclin-

dependent kinase, retinoblastoma protein, non-small lungcancer cells, pleural mesothelioma cells, apoptosis,kinases, phosphatases, 3683

Antisense pepitide, complementary peptide, anaphylatoxin,inflammation, sepsis, cytokine storm, 2511

Antisense, interleukin-6, interleukin-6 receptor, breastcancer, MCF-7, oligodeoxynucleotides, 2899

Antitumor activity, Bcr-Abl, CML, Daedalea gibbosa,kinase, medicinal mushrooms, oleic acid,autophosphorylation, 177

Antitumor effect, Her-2/neu, peptide, vaccine, B-cellepitope, 3361

Antitumor effect, ultrasound, mono-l-aspartyl chlorin e6,sonodynamic therapy, sarcoma 180, colon 26, 501

Antitumor immunity, colorectal cancer, regulatory T-cells,FOLFOX, FOLFIRI, 4569


4735

Antitumor, branched-chain fatty acids, anticancer, humanbreast cancer, human colon cancer, HT-29, MCF-7, 3165

Antitumor, sunitinib, antimetastasis, VEGF, VEGFR,phosphorylation, mammary cancer, 1225

Anti-VEGF therapy, vascular endothelial growth factor,VEGF, gene expression, bevacizumab, epithelial ovariancancer, 731

Anxiety, STAI test, form Y-2, cancer risk, breast cancer,1801

Α-Particle radiation, 238-plutonium, Monte Carlosimulations, bystander effect, micronucleus assay, 2113

Apc, min mice, 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine, C57Bl/6J, FVB, intestinal carcinogenesis,785

APE1, Ref-1, macrophages, inflammatory response, 379ApoD, breast cancer, DAX-1, ERα, prognosis, 443Apoptosis, adenovirus, prodrug activation, HNSCC,

ganciclovir, thymidine kinase, 3851Apoptosis, anticancer agents, sphingomylinase, Cox-2,

caspase-3, p53, cell cycle, 1345Apoptosis, anticancer drugs, sphingomyelinase, p53, Bax,

cell cycle, 871Apoptosis, antisense oligonucleotide, cyclin D, cyclin E,

cyclin-dependent kinase, retinoblastoma protein, non-small lung cancer cells, pleural mesothelioma cells,kinases, phosphatases, 3683

Apoptosis, arsenic trioxide, arsenic acid, organic arsenicals,T-lymphoblastoid leukemia, daunorubicin resistance,4169

Apoptosis, belinostat, bortezomib, pancreas cancer, histonedeacetylase inhibitor, proteasome inhibitor,hepatocellular cancer, metabolomics, 1093

Apoptosis, breast cancer, genistein, quercetin, NFκB, 3301Apoptosis, cancer, endometrium, Bcl-2, p53, E-cadherin,

estrogen receptor, progesterone receptor, 4191Apoptosis, cannabinoids, prostate cancer cell lines, protein

tyrosine phosphatases, dual-specificity phosphatases,3799

Apoptosis, celecoxib, cytotoxicity, neuroblastoma, valproicacid, 2231

Apoptosis, cyclosporine A, human lung adenocarcinomacell, lung transplantation, caspase, 2129

Apoptosis, dihydroartemisinin, pancreatic cancer, cellproliferation, angiogenesis, optical imaging, 1549

Apoptosis, etomidate, Bax, Bcl-xl, caspase-3, RAW264.7cells, 2203

Apoptosis, gallic acid (GA), human leukemia HL-60 cells,death receptor-mediated pathways, mitochondria-mediated pathways, 2821

Apoptosis, gastric carcinoma, carcinomatosis, glycolysis,energetic metabolism, necrosis, citrate, 797

Apoptosis, hepatocellular carcinoma, human zinc finger 23,real-time RT-PCR, annexin V-FITC/PI assay, 3595

Apoptosis, hydantoin derivatives, Colo 205 and Colo 320colon adenocarcinoma cells, multidrug resistance, effluxpump, ABCB1 transporter, 3285

Apoptosis, lactoferrin, IGBP1, PP2Ac, lung adeno-carcinoma, 529

Apoptosis, laryngal squamous cell carcinoma, microRNA,proliferation, 3859

Apoptosis, liver metastases, invasion front, FAS, TRAIL,colorectal cancer, 1215

Apoptosis, medicinal herb, bioactivity, p53 pathway, Rutagraveolens, Akt, 233

Apoptosis, medulloblastoma, vincristine, lomustine,chemotherapy, 1721

Apoptosis, multidrug-resistant cancer cells, MDR mouse T-lymphoma cells, ABCB1 transporter, P-glycoprotein,phenothiazines, thioridazine, 4201

Apoptosis, neuroblastoma, radiotherapy, neem leaf extract,transcriptional response, 161

Apoptosis, oral squamous cell carcinomas, toombak, genes,cell cycle regulation, intermediate filament proteins,Sudan, 3345

Apoptosis, ovarian cancer, methyl-2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oate (CDDO-Me), AKT,NF-κB, mTOR, 3673

Apoptosis, PEDF, c-FLIP, HCC, p38, PPARγ,hepatocellular carcinoma, 1173

Apoptosis, phenethyl isothiocyanate, cell cycle arrest,mitochondria, caspases, prostate cancer DU 145 cells, 1691

Apoptosis, photodynamic therapy, PDT, glycoconjugatedchlorin, gastric cancer, colon cancer, 763

Apoptosis, PSK, HL-60, cell proliferation, caspase-3activation, 2733

Apoptosis, radiation, pemetrexed, human mesothelioma cellline, radiosensitivity, 2847

Apoptosis, SN1 methylating agents, O6-methylguanine-DNA methyltransferase (MGMT), RNA-binding proteins,N-methyl-N-nitrosourea, 4291

Apoptosis, sonodynamic therapy, 5-aminolevulinic acid,SAS cell, mitochondrion, 39

Apoptosis, TNF-alpha, hepatoma, proteomics, 2-DE, LC-MS/MS, 2059

Apoptosis, TRAIL, histone deacetylase inhibitor, LBH589,colon cancer, 3385

Apoptosis, triptolide, medicinal compounds, proteasomeinhibitors, cancer therapy, 1

Apoptosis, Zanthoxylum ailanthoides Sieb and Zucc.,human colon adenocarcinoma cell, colo 205 cells,caspases, flavone, 1667

Apparent diffusion coefficient, hepatocellular carcinoma,1H MRI, extracellular space, benzamide riboside,angiography, therapy response, motion effect, 2045

Arf-induced senescence, leiomyoma, HMGA2, MDM2antagonists, fibroid cells, 753


4736

Arg194Trp, polymorphism, XRCC1, Arg399Gln, GSTP1Ile104Val, GSTT1, GSTM1, gastric cancer, survival, 705

Arg399Gln, polymorphism, XRCC1, Arg194Trp, GSTP1Ile104Val, GSTT1, GSTM1, gastric cancer, survival, 705

Aromatase inhibitors, anti-estrogens, breast cancer, steroidsulfatase, tamoxifen, anastrozole, postmenopausalwomen, 1367

Arsenic acid, arsenic trioxide, organic arsenicals, T-lymphoblastoid leukemia, daunorubicin resistance,apoptosis, 4169

Arsenic trioxide, arsenic acid, organic arsenicals, T-lymphoblastoid leukemia, daunorubicin resistance,apoptosis, 4169

Artemisinin dimers, dihydroartemisinin, rat, breast cancercells, 4111

Artenimol, cervical cancer, artesunate, clinical symptoms,tumour markers, 4417

Arterial blood pressure, parathyroid tumors,hyperparathyroidism, serum calcium, PTH, arterialhypertension, elderly, 3969

Arterial hypertension, parathyroid tumors,hyperparathyroidism, arterial blood pressure, serumcalcium, PTH, elderly, 3969

Artesunate, cervical cancer, artenimol, clinical symptoms,tumour markers, 4417

Artificial neural network, 1, 2, 3, 4-tetrahydroisoquinolins,QSAR, tumor-specificity index, semi-empiricalmolecular-orbital method, 4231

Ascites, paclitaxel, doxifluridine, gastric cancer, 4625Assessment, chemotherapy, neurotoxicity, peripheral

neuropathy, adverse effects, 3493Astrocytes, radioprotection, radiosensitivity, central

nervous system, lymphoma, 33Astrocytomas, epigenetics, DNA methylation, histone

deacetylases, decitabine, 1337Athymic mice, low-grade liposarcoma, soft tissue sarcoma,

xenograft, vascularisation, 4061ATL, HTLV-1, leukemia, Hyptis verticillata jacq, multidrug

resistance, 4251ATL, HTLV-1, tetramethylnaphthalene, inhibitor, cell cycle,

2241ATM, 3-indole, cell cycle arrest, ATR, SMAD3, xenograft

model, lung cancer cells, 203ATR, 3-indole, cell cycle arrest, ATM, SMAD3, xenograft

model, lung cancer cells, 203Atypical teratoid/rhabdoid tumours, medulloblastoma,

Na+/K+-ATPase, alpha subunits, immunohistochemistry,953

AURKA, MT477, tumor growth, NRF2, 1181Autologous stem cell transplantation, alternative splicing,

angiogenesis, chick chorioallantoic membrane assay,high-dose chemotherapy, placental growth factor,vascular endothelial growth factor, VEGFR1, 3115

Automated 3D imaging, breast cancer, screening,mammography, ultrasound, 2569

Autophosphorylation, antitumor activity, Bcr-Abl, CML,Daedalea gibbosa, kinase, medicinal mushrooms, oleicacid, 177

Axillary clearing, breast cancer, sentinel node, sentinelnode biopsy, axillary node sampling, axillarylymphadenectomy, 693

Axillary lymphadenectomy, breast cancer, sentinel node,sentinel node biopsy, axillary node sampling, axillaryclearing, 693

Axillary node sampling, breast cancer, sentinel node,sentinel node biopsy, axillary lymphadenectomy, axillaryclearing, 693

Ayurvedic medicine, prostate cancer, cytotoxicity, triphala,gallic acid, 3739

AZD0530, HNSCC, phase II, Src, saracatinib, 2495-azacytidine, epigenetics, bladder cancer, DNA

methylation, chemotherapy, chemoresistance, 3757Azomymethane, CD133, colon cancer, tumorigenesis,

dextran sodium sulphate, 4273Baboon, esophagus, gastric reflux, mucus metaplasia, 2187BamHI W1/I1, EBV polymorphism, XhoI restriction site,

EBV-associated gastric cancer, Latin America, 3607BAP, lung cancer, non-small cell lung cancer, bone

metastases, bone remodeling markers, N-telopeptide oftype I collegen, NTx, bone alkaline phosphatase, 3879

Base of tongue cancer, tonsillar cancer, oropharyngealcancer, head and neck cancer, HPV, review, 1515

Basic fibroblast growth factor, angiogenic factors, vascularendothelial growth factor, endostatin, cervical cancer,2645

Bax, anticancer drugs, sphingomyelinase, p53, cell cycle,apoptosis, 871

Bax, etomidate, apoptosis, Bcl-xl, caspase-3, RAW264.7cells, 2203

BBN, bladder cancer, BCG-CWS, liposome, rat, 2065BBN, gemcitabine, sirolimus, mice, urothelial lesion, 1637B-cell epitope, Her-2/neu, peptide, vaccine, antitumor

effect, 3361B-cell lymphoma, dectin-1, beta-glucan, CD86,

proliferation, cell death, 4195B-Cell lymphoma, marginal zone lymphoma, radiation

therapy, local tumor control, 3935BCG-CWS, bladder cancer, liposome, BBN, rat, 2065Bcl-2, cancer, endometrium, apoptosis, p53, E-cadherin,

estrogen receptor, progesterone receptor, 4191BCL-2, lung cancer, paclitaxel-based chemoradiotherapy,

MDR1, radiosensitivity, 1431BCL2, non-Hodgkin’s lymphoma, lutetium-177,

somatostatin receptor, 3143Bcl-xl, etomidate, apoptosis, Bax, caspase-3, RAW264.7

cells, 2203


4737

Bcr-Abl, antitumor activity, CML, Daedalea gibbosa,kinase, medicinal mushrooms, oleic acid,autophosphorylation, 177

BCRP1, non-small cell lung cancer, cancer stem cellantigens, biomarkers, prognosis, CD133, CD117, tissuemicroarrays, 4491

Beckwith-Wiedemann syndrome, oxidative stress,potassium ascorbate, 3973

Belinostat, bortezomib, pancreas cancer, histonedeacetylase inhibitor, proteasome inhibitor,hepatocellular cancer, apoptosis, metabolomics, 1093

Benign liver lesions, breast cancer liver metastases, liversurgery, tumour markers, prognostic factors, differentaldiagnosis, 1447

Benign breast disease, personality, type C, hopelessness,cancer risk, 4019

Benzamide riboside, hepatocellular carcinoma, 1H MRI,apparent diffusion coefficient, extracellular space,angiography, therapy response, motion effect, 2045

Benzo[a]quinolizin derivatives, multidrug resistance, P-glycoprotein, 921

Benzo[c]phenanthridine alkaloids, sanguinarine, anticancertherapeutic agents, oral squamous cell carcinoma, 2841

Beta-catenin, oral carcinogenesis, immunohistochemistry,tongue, mice, 2805

Beta-glucan, dectin-1, B-cell lymphoma, CD86,proliferation, cell death, 4195

Beta-glucan, β-glucan, dendritic cells, maturation,immunomodulator, 1647

Bevacizumab, capecitabine, oxaliplatin, cetuximab, phaseII, metastatic colorectal cancer, 255

Bevacizumab, diffuse intrinsic pontine glioma,chemotherapy, temozolomide, rofecoxib, inflammatoryprocesses, 2265

Bevacizumab, FOLFIRI, XELIRI, colorectal cancer,efficacy, safety, 1777

Bevacizumab, hyperthermia, doxorubicin, platinum-refractory, ovarian cancer, 2675

Bevacizumab, IDH1 mutation, glioma, cetuximab,sunitinib, 4457

Bevacizumab, ovarian cancer, platinum-resistant, 2679Bevacizumab, paclitaxel, breast cancer, vascular endothelial

growth factor receptors, 3007Bevacizumab, panitumumab, metastatic colorectal cancer,

treatment, 1033Bevacizumab, primary peritoneal carcinoma, erlotinib, 4397Bevacizumab, safety, pediatrics, VEGF, 3953Bevacizumab, vascular endothelial growth factor, VEGF,

gene expression, anti-VEGF therapy, epithelial ovariancancer, 731

Bexarotene, pharmacogenomics, SNPs, RXR, lung cancer,2303

BEZ235, lung cancer, EGFR, P13K/mTOR inhibitor, 849

BI 2536, polo-like kinase 1, cholangiocarcinoma, 5-fluorouracil, gemcitabine, 3289

BIBF 1120, afatinib, colorectal cancer, phase II,pharmacokinetics, 2271

Bilateral erythematous breast hypertrophy, gastric cancer,low back pain, pregnancy, 681

Bioactivity, medicinal herb, p53 pathway, apoptosis, Rutagraveolens, Akt, 233

Biochemical relapse, docetaxel, prostate cancer,chemotherapy, 973

Biological activity, colorectal cancer, tumor markers,angiogenetic factors, metalloproteinases, adhesionmolecules, 373

Bioluminescence, AAV, CXCR4, gene therapy, breastcancer, 1627

Biomarker, breast cancer, triple negative, 2389Biomarker, cell-free DNA, circulation, non-invasive,

review, 2623Biomarker, colorectal cancer, surgery, liver metastases,

CD95-ligand, 4507Biomarker, cytokeratin 4, fascin, tissue microarray,

squamous cell carcinoma, esophagus, 945Biomarker, hepatocellular carcinoma, AFP-IgM immune

complexes, alpha-fetoprotein, 687Biomarker, rectal cancer, radiotherapy, chemotherapy,

prognostic factor, carbonic anhydrase IX, hypoxia-inducible factor-1a, ezrin, glucose transporter-1, 4529

Biomarker, thyroid cancer, diagnosis, sensitivity,specificity, metastasis, immunohistochemistry, 3433

Biomarkers, cetuximab, colorectal cancer, irinotecan,oxaliplatin, 2149

Biomarkers, diagnosis, early detection, head and neckcancer, review, 1161

Biomarkers, non-small cell lung cancer, cancer stem cellantigens, prognosis, CD133, CD117, BCRP1, tissuemicroarrays, 4491

Biomarkers, ovarian cancer, diagnosis, enzyme-linkedimmunosorbent assay, cathepsin, matrixmetalloproteinase-9, heparanase, 3423

Biopsy, ischemia, immunohistochemistry, xenografts,phospho-proteins, pre-analytical variables, 2073

BIRC5, antiapoptosis, colorectal cancer, gamma radiation,microarray, RT-PCR, REG4, NEIL2, 4147

Bisphosphonate, osteonecrosis, mandible, BRONJ, 2313Bisphosphonates, circulating tumor cells, disseminated

tumor cells, 3623Bis-quarternary compound, conformation, antibacterial

activity, hydrophobicity, 2561BK virus, hemorrhagic cystitis, allogeneic stem cell

transplantation, review, 939BK virus, human polyomavirus, JC virus, hemotopoetic

stem cell transplantation, cerebrospinal fluid, KI, WU,3489


4738

Bladder cancer, BCG-CWS, liposome, BBN, rat, 2065Bladder cancer, circulating tumor cells, disseminated tumor

cells, detection, prostate cancer, renal cell carcinoma,chemotherapy, review, 2053

Bladder cancer, epigenetics, DNA methylation,chemotherapy, chemoresistance, 5-azacytidine, 3757

Bladder cancer, extented lymphadenectomy, lymph nodemetastasis, radical cystectomy, lymph node density,cancer-specific survival, short review, 271

Bladder cancer, metastasis suppressor-1, MTSS1, cellularmigration, invasion, metastasis, 3205

Bladder cancer, mitomycin C, intravesical chemotherapy,929

Bladder cancer, recurrence, intravesical chemotherapy,continuous saline bladder irrigation, 1471

Bladder cancer, squamous cell carcinoma, recurrence,gemcitabine, paclitaxel, 4465

Bladder cancer, transitional carcinoma, lymphovascularinvasion, upper tract transitional carcinoma, prognosticrole, review, 3503

Bladder cancer, TURBT, radiochemotherapy, radiationtherapy, 985

Bladder carcinoma, interleukin-2, CD8highCD57+

lymphocytes, recurrences, 699Blood plasma, non-small cell lung cancer, TIMP1, mRNA,

DFI, survival, 4031Blood–brain barrier, intravenous curcumin, post-traumatic

sequelae, hippocampus, striatum, brain stem, 907Blood−brain barrier, metastasis, extravasation, brain

endothelial cells, COX-2, 4307BNCT, boron tracedrug, BODIPY, curcuminoid, neutron

dynamic therapy, dynamic drug, thermal neutronirradiation, 2477

BNIP3, ras, CD47, cancer, programmed cell death, 4N1K,2869

BODIPY, boron tracedrug, curcuminoid, neutron dynamictherapy, dynamic drug, thermal neutron irradiation,BNCT, 2477

Bone alkaline phosphatase, lung cancer, non-small celllung cancer, bone metastases, bone remodeling markers,N-telopeptide of type I collegen, NTx, BAP, 3879

Bone marrow carcinomatosis, breast cancer, metastasis, 4025Bone marrow, breast cancer, disseminated tumor cells,

bone mineral density, quantitative ultrasonometry, 4423Bone marrow, breast cancer, disseminated tumor cells,

prognosis, follow-up, 2749Bone metastases, lung cancer, non-small cell lung cancer,

bone remodeling markers, N-telopeptide of type Icollegen, NTx, bone alkaline phosphatase, BAP, 3879

Bone metastasis, MMP-13, type I collagen, integrin,MAPK, 1307

Bone metastasis, non-small cell lung cancer, gefitinib,erlotinib, resistance, radiotherapy, EGFR-TKIs, 4519

Bone metastasis, polybisphosphonate, prostate cancer, 4141Bone mineral density, breast cancer, disseminated tumor

cells, bone marrow, quantitative ultrasonometry, 4423Bone remodeling markers, lung cancer, non-small cell lung

cancer, bone metastases, N-telopeptide of type I collegen,NTx, bone alkaline phosphatase, BAP, 3879

Bone, high hydrostatic pressure, revitalization, tissueengineering, 1235

Borderline-resectable T4, DCF, induction chemotherapy,esophageal cancer, cisplatin, 5-fluorouracil, docetaxel,3535

Boron tracedrug, BODIPY, curcuminoid, neutron dynamictherapy, dynamic drug, thermal neutron irradiation,BNCT, 2477

Bortezomib, belinostat, pancreas cancer, histonedeacetylase inhibitor, proteasome inhibitor,hepatocellular cancer, apoptosis, metabolomics, 1093

Bortezomib, cisplatin, CTR1, drug combination,proteasomal degradation, synergism, drug uptake, drugresistance, 2757

Bortezomib, multiple myeloma, once-weeklyadministration, dexamethasone, gastrointestinal adverseevents, 2297

Bortezomide, proteasome inhibitor, receptor tyrosinekinase, activation loop, multiple myeloma, ER stress,FGFR3, Lys650Glu mutation, K650E, plasma cellmalignancy, 113

Bowel injury, laparoscopic radical prostatectomy, LRP,prostatic neoplasm, rectal injury, robotic-assistedlaparoscopic prostatectomy, RALP, robotics, 3497

BPF, fistula, operation, lung cancer, risk factor, concurrentdisease, perioperative complication, infection, 619

BRAF mutation, KRAS, EGFR, ERBB2 mutation, V600E,lung cancer, adenocarcinoma, squamous cell carcinoma,SSCP, 4619

BRAF, medullary thyroid carcinoma, gene mutations, RET,HRAS, KRAS, NRAS, AKT1, CTNNB1, mutationalscreening, 4179

BRAF, ovarian cancer, gene mutations, BRCA 1/2, TP53,PI3K, AKT, KRAS, review, 2661

Brain endothelial cells, metastasis, extravasation,blood−brain barrier, COX-2, 4307

Brain metastases, breast cancer, human mammaglobin,PCR, 1061

Brain metastases, metastastic melanoma, melanoma,temozolomide, whole-brain radiation, 4537

Brain metastasis, circulating tumor cells, CTCs, prostatecancer, immunomagnetic beads, GFP, chick embryo,metastatic assay, fluorescence imaging, 3125

Brain metastasis, pancreatic cancer, pancreatic neoplasms,long-term survivors, surgery, 4599

Brain neoplasms, magnetic resonance spectroscopy,radiotherapy, prognosis, prospective studies, 3559


4739

Brain stem, intravenous curcumin, blood–brain barrier,post-traumatic sequelae, hippocampus, striatum, 907

Brain tumor, quality control, survival, pediatric neuro-oncology, 661

Brain tumors, cytomegalovirus, glioblastoma, etiology, 959Branched-chain fatty acids, anticancer, antitumor, human

breast cancer, human colon cancer, HT-29, MCF-7, 3165BRCA 1/2, ovarian cancer, gene mutations, TP53, PI3K,

AKT, BRAF, KRAS, review, 2661BRCA, pancreatic cancer, iniparib, chemotherapy, 1417BRCA1, colorectal cancer, pulmonary metastases, TS,

OPRT, ERCC1, MVD, adjuvant chemotherapy, 2763Breakpoint distribution, Inv(3)(q21q26), t(3;3)(q21;q26),

chromosomal abnormalities, fluorescent in situhybridization, 3441

Breast cancer cell lines, estrogen receptor, flow cytometry,RT-PCR, Western blotting, 521

Breast cancer cells, artemisinin dimers, dihydroartemisinin,rat, 4111

Breast cancer liver metastases, liver surgery, tumourmarkers, prognostic factors, differental diagnosis, benignliver lesions, 1447

Breast cancer metastasis, silibinin, CD44, EGFR, EGF,TGF-α, MMP-9, 3767

Breast cancer recurrence, insulin-like growth factor-1, IGF-1, tamoxifen-resistance, oestrogen resistance, oestrogenreceptor-alpha, EGFR, 23

Breast cancer, AAV, CXCR4, gene therapy,bioluminescence, 1627

Breast cancer, ADAMTS1, amphiregulin, xenograft,immunotherapy, 3839

Breast cancer, age, grade, immunohistochemistry, measlesvirus, p53, 913

Breast cancer, anastrozole, radiotherapy, ipsilateral breasttumor recurrence, tamoxifen, 367

Breast cancer, angiogenesis, image analysis, CD34, MVD,vessel identification, 4053

Breast cancer, aromatase inhibitors, anti-estrogens, steroidsulfatase, tamoxifen, anastrozole, postmenopausalwomen, 1367

Breast cancer, bone marrow carcinomatosis, metastasis,4025

Breast cancer, brain metastases, human mammaglobin,PCR, 1061

Breast cancer, breast disease, Sifneos score, 3101Breast cancer, carboplatin, RAD001, everolimus, mTOR

inhibitor, 2713Breast cancer, cat-SAR, anticancer models, DTP,

computational toxicology, 3247Breast cancer, caveolin-1, polymorphic genotypes, 3511Breast cancer, chemotherapy, dose-dense, sICAM-1,

sVCAM-1, 2617Breast cancer, cortactin, tissue microarray, 293

Breast cancer, cyclooxygenase, COX-2, tumor,prostaglandin, carcinogenesis, 4359

Breast cancer, DAPK, tissue microarray, 3633Breast cancer, DAX-1, ApoD, ERα, prognosis, 443Breast cancer, disseminated tumor cells, bone marrow,

bone mineral density, quantitative ultrasonometry, 4423Breast cancer, disseminated tumor cells, bone marrow,

prognosis, follow-up, 2749Breast cancer, epigenetic regulation, histone-modifier

genes, histone acetyltransferases, histonemethyltransferases, 4115

Breast cancer, erythropoietin, erythropoietin receptor,erythropoiesis stimulating agents, 1189

Breast cancer, E-selectin, liver metastasis, endothelium,pro-inflammatory microenv ironment, 3219

Breast cancer, fiberoptic ductoscopy, nipple discharge,3517

Breast cancer, FKBP52, geldanamycin, heat-shock proteins,lumican, 2095

Breast cancer, gastrointestinal stromal tumor,neurofibromatosis type 1, 4481

Breast cancer, genistein, p90RSK, cell proliferation, T47Dcells, 209

Breast cancer, genistein, quercetin, apoptosis, NFκB, 3301Breast cancer, GLI2, PTHrP, osteolysis, 6-thioguanine,

2705Breast cancer, growth factors, tumor markers, CA 15-3,

CEA, IGF1, EGF, HGF, 4653Breast cancer, gynecological cancer, online tumor

conference, interdisciplinary therapy management,second opinion, continuous medical training, 2669

Breast cancer, heparan sulfate, chitosan, anticancer, cellproliferation, FGF-2, 1321

Breast cancer, HuR, histological status, prognosis, 303Breast cancer, interleukin-6, interleukin-6 receptor, MCF-7,

antisense, oligodeoxynucleotides, 2899Breast cancer, kallikrein-related peptidase 5, KLK5, KLK7,

3093Breast cancer, lapatinib, HER2, ADCC, Herceptin, 2999Breast cancer, lapatinib, imatinib, EGFR, ErbB2, c-ABL,

RTK, 789Breast cancer, lymphatic microvessel density, molecular

classification, VEGF-C, VEGFR-3, 1757Breast cancer, mammography, calcification, prognostic

factor, 2327Breast cancer, meloxicam, paclitaxel, neuropathy, JBCRN,

3567Breast cancer, metallothionein, MT-I/II, Ki-67, MCM-2,

3027Breast cancer, methylation, RASSF1A, prognosis, 2975Breast cancer, metronomic, cyclophosphamide,

doxorubicin, cardiotoxicity, rats, 215Breast cancer, mitotic counts, prognosis, 97


4740

Breast cancer, MtDNA mutation, D-loop region, plasma,mitochondrial DNA, 4267

Breast cancer, neoadjuvant chemotherapy, trastuzumab,pCR, 3041

Breast cancer, p27, node dissection, stage I, estrogenreceptor, progesterone receptor, 4401

Breast cancer, paclitaxel, bevacizumab, vascular endothelialgrowth factor receptors, 3007

Breast cancer, PPARγ, PPARG, T0070907, migration,invasion, 813

Breast cancer, primary culture, chemotherapeutics, therapypersonalization, oncogramme, individualized tumourresponse testing, 139

Breast cancer, recurrence, operation, survival,polychemotherapy, 277

Breast cancer, RGM, prostate cancer, prognosis, 1703Breast cancer, screening mammography, microcalcification,

high-frequency ultrasound, advanced imaging modes,2575

Breast cancer, screening, mammography, ultrasound,automated 3D imaging, 2569

Breast cancer, sentinel lymph node, OSNA, cytokeratin 19,intra-operative method, 585

Breast cancer, sentinel node, sentinel node biopsy, axillarynode sampling, axillary lymphadenectomy, axillaryclearing, 693

Breast cancer, sequential therapy, adjuvant chemotherapy,1483

Breast cancer, single nucleotide polymorphisms, estrogenpathway, steroid hormones, mammographic breastdensity, review, 4369

Breast cancer, STAI test, form Y-2, cancer risk, anxiety,1801

Breast cancer, stem cells, pre-metastatic niche, metastasis,CD133, prognosis, 1315

Breast cancer, thromoboembolism, chemotherapy, 2383Breast cancer, triple negative breast cancer, TEM8,

immunohistochemistry, lymph node metastasis, 3417Breast cancer, triple negative, biomarker, 2389Breast cancer, ubiquitin–proteasome system, extracellular

proteasome, 2197Breast cancer, vitamin D, colorectal cancer, prostate cancer,

lung cancer, 3619Breast cancer, zeranol, ACI rat serum, mitogenic activity,

481Breast carcinoma cells, metastasis, HPA, E-selectin, P-

selectin, SCID mouse, lectin, colon adenocarcinoma,1589

Breast disease, breast cancer, Sifneos score, 3101Breast disease, depression, risk of cancer, 1065Breast disease, psychosocial factors, psychiatric drugs, 739Breast metastasis, gastric adenocarcinoma, signet-ring

adenocarcinoma, skin, immunohistochemistry, 2373

Breast neoplasms, vitamin D, 25-hydroxyvitamin D,case–control studies, epidemiology, meta-analysis,prevention, 2939

Breast ultrasound, pre-operative therapy, prediction oftherapy response, sonography, sphericity, 4039

Breast, ductal carcinoma in situ, lumpectomy, mastectomy,menopause, hormone replacement therapy, 1783

BRONJ, bisphosphonate, osteonecrosis, mandible, 2313Brushing cytology, cholangiocarcinoma, MSX2, 1011Bystander effect, α-Particle radiation, 238-plutonium,

Monte Carlo simulations, micronucleus assay, 2113C57Bl/6J, min mice, 2-amino-1-methyl-6-phenylimidazo[4,

5-b]pyridine, Apc, FVB, intestinal carcinogenesis, 785C7orf24, γ-glutamyl cyclotransferase, osteosarcoma, 1297CA 15-3, growth factors, breast cancer, tumor markers,

CEA, IGF1, EGF, HGF, 4653C-ABL, breast cancer, lapatinib, imatinib, EGFR, ErbB2,

RTK, 789E-Cadherin, cancer, endometrium, apoptosis, Bcl-2, p53,

estrogen receptor, progesterone receptor, 4191E-Cadherin, EMT, gamma catenin, vimentin, fibronectin,

lung adenocarcinoma, 4451E-Cadherin, P53, cancer, endometrium, apoptosis, Bcl-2,

estrogen receptor, progesterone receptor, 4191N-Cadherin, adrenocortical carcinoma, ADH-1, dynamic

contrast enhancing magnetic resonance imaging (DCE-MRI), phase-I, 3921

Cadherins, immunohistochemistry, prognosis, OSCC, oralsquamous cell carcinoma, 4211

CAIRO2, KRAS, p53, colorectal, oxaliplatin, 5-fluorouracil,capecitabine, clinical, sequence analysis, 1379

Calcification, breast cancer, mammography, prognosticfactor, 2327

Cancer cell seeding, green fluorescent protein, redfluorescent protein, real-time imaging, lung, liver,muscle, 3665

Cancer cells, sodium meta-arsenite, stem cells, telomerelength, telomerase activity, 4315

Cancer diagnosis, PCA3, PSA free/total, prostate cancer,saturation prostate biopsy, repeat biopsy, 4445

Cancer epidemiology, ovarian cancer, clinical cancerregistry, 2657

Cancer risk, bening breast disease, personality, type C,hopelessness, 4019

Cancer risk, cervical cancer, GSTM1, GSTT1, geneticpolymorphism, human papillomavirus, 3051

Cancer risk, personality, type C, commitment, 4013Cancer risk, STAI test, form Y-2, breast cancer, anxiety, 1801Cancer stem cell antigens, non-small cell lung cancer,

biomarkers, prognosis, CD133, CD117, BCRP1, tissuemicroarrays, 4491

Cancer stem cell, recurrence, CD marker, CD133, CD44,rectal cancer, 495


4741

Cancer susceptibility, genetic polymorphisms, DNA-repairgenes, metabolizing genes, CYP1A1, CYP1E1, XRCC1,1359

Cancer therapy, notch, stem cells, pancreatic cancer, signalpathway, natural agents, drug resistance, review, 1105

Cancer therapy, triptolide, medicinal compounds,proteasome inhibitors, apoptosis, 1

Cancer vaccine, Wilms’ tumor 1 (WT1), myeloid dendriticcell, immunotherapy, 2447

Cancer, adrenocortical tumors, Cushing’s syndrome,adrenal imaging, CT, MR, review, 2923

Cancer, angiogenesis, CD105, endoglin, tumor, review,2283

Cancer, drug delivery, liposome, vincristine, folate receptor,drug targeting, 1521

Cancer, endometrium, apoptosis, Bcl-2, p53, E-cadherin,estrogen receptor, progesterone receptor, 4191

Cancer, glutamate receptor, PCR, shRNA, NR1, GLUR4,KA2, NR2D, 3181

Cancer, immunotherapy, prediction, survival, CD8, CD57,review, 639

Cancer, KRAP, KRAS, target, obesity, diabetes, review,2413

Cancer, melatonin, endometrial proliferation, rats, 2637Cancer, neurotoxicity, adjuvant chemotherapy, docetaxel,

intraepidermal nerve fibres, neuropathy, skin biopsies,oxaliplatin, 4413

Cancer, ras, BNIP3, CD47, programmed cell death, 4N1K,2869

Cancer-specific survival, bladder cancer, extentedlymphadenectomy, lymph node metastasis, radicalcystectomy, lymph node density, short review, 271

Cannabinoids, apoptosis, prostate cancer cell lines, proteintyrosine phosphatases, dual-specificity phosphatases,3799

Capecitabine, 5-FU, hyperammonemia, encephalopathy,metastatic rectal adenocarcinoid, 335

Capecitabine, chemotherapy, fluorouracil, gemcitabine,colon cancer, 2971

Capecitabine, KRAS, p53, colorectal, oxaliplatin, 5-fluorouracil, clinical, CAIRO2, sequence analysis,1379

Capecitabine, metastatic breast cancer, triple-negative,HER2-negative, prognostic factors, 1079

Capecitabine, oxaliplatin, bevacizumab, cetuximab, phaseII, metastatic colorectal cancer, 255

Carbonic anhydrase IX, rectal cancer, radiotherapy,chemotherapy, prognostic factor, biomarker, hypoxia-inducible factor-1a, ezrin, glucose transporter-1, 4529

Carboplatin, chemotherapy, paclitaxel, vinorelbine, non-small cell lung cancer, 317

Carboplatin, cisplatin, hypersensitivity, antineoplastic,thoracic malignancy, immunoglobulin E, 4525

Carboplatin, RAD001, everolimus, breast cancer, mTORinhibitor, 2713

Carcinogenesis, Cav-1, polymorphism, nasopharyngealcarcinoma, 3629

Carcinogenesis, Cox-2, polymorphism, prostate cancer,221

Carcinogenesis, cyclooxygenase, COX-2, breast cancer,tumor, prostaglandin, 4359

Carcinogenesis, lung cancer, lung inflammation, lungtumors, K-ras mutations, mouse, 2877

Carcinoid, PTEN, serotonin, 1153Carcinoma cell lines, P-Glycoprotein, chemotherapy,

inhibition of multidrug resistance, osteosarcoma celllines, siRNA, 2813

Carcinomatosis, gastric carcinoma, glycolysis, energeticmetabolism, apoptosis, necrosis, citrate, 797

Cardiotoxicity, adriamycin, fatigue, myotoxicity, 2023Cardiotoxicity, metronomic, cyclophosphamide,

doxorubicin, breast cancer, rats, 215Case–control studies, vitamin D, 25-hydroxyvitamin D,

breast neoplasms, epidemiology, meta-analysis,prevention, 2939

Caspase, cyclosporine A, human lung adenocarcinoma cell,apoptosis, lung transplantation, 2129

Caspase-3 activation, PSK, apoptosis, HL-60, cellproliferation, 2733

Caspase-3, anticancer agents, sphingomylinase, Cox-2,apoptosis, p53, cell cycle, 1345

Caspase-3, etomidate, apoptosis, Bax, Bcl-xl, RAW264.7cells, 2203

Caspases, phenethyl isothiocyanate, cell cycle arrest,apoptosis, mitochondria, prostate cancer DU 145 cells,1691

Caspases, Zanthoxylum ailanthoides Sieb and Zucc., humancolon adenocarcinoma cell, colo 205 cells, apoptosis,flavone, 1667

Castrate-resistant prostate cancer, predictors of survival,time to castration resistance, chemotherapy, advancedprostate cancer, 1475

Β-Catenin, KL-6 mucin, MUC1, gastric cancer, invasionfront, 535

Beta-Catenin, oral carcinogenesis, immunohistochemistry,tongue, mice, 2805

β-Catenin, MUC1, KL-6 mucin, gastric cancer, invasionfront, 535

Cathepsin, cytokines, proliferation, lung cancer cells, 47Cathepsin, ovarian cancer, diagnosis, biomarkers, enzyme-

linked immunosorbent assay, matrix metalloproteinase-9,heparanase, 3423

Cationised gelatin, NK4, gene therapy, cisplatin, squamouscell carcinoma, 105

Cat-SAR, anticancer models, DTP, breast cancer,computational toxicology, 3247


4742

Catumaxomab, ovarian cancer, relapse, intraperitoneal,surgical tumor debulking, operative morbidity, operativemortality, 2603

Cav-1, polymorphism, nasopharyngeal carcinoma,carcinogenesis, 3629

Caveolin-1, breast cancer, polymorphic genotypes, 3511Caveolin-1, prostate cancer, single nucleotide

polymorphism, DNA repair, 745CCN family, esophageal cancer, WISP-1, WISP-1v, 991CCND1 1722, cyclin D1, polymorphism, upper tract

urothelial cancer, 1043CCND1, cyclin D1, polymorphism, lung cancer, smoking,

Taiwanese, 3601CCND3, minichromosome maintenance proteins, MCMs,

cyclin D3, Hodgkin lymphoma, survival, 3585CD marker, cancer stem cell, recurrence, CD133, CD44,

rectal cancer, 495CD105, angiogenesis, cancer, endoglin, tumor, review,

2283CD117, gastrointestinal stromal tumors (GISTs), Ras-Raf-

ERK/MAPK Pathway, PI3K-Akt/mTOR pathway,insulin-like growth factor 1 receptor (IGF1R), 3019

CD117, non-small cell lung cancer, cancer stem cellantigens, biomarkers, prognosis, CD133, BCRP1, tissuemicroarrays, 4491

CD133, breast cancer, stem cells, pre-metastatic niche,metastasis, prognosis, 1315

CD133, cancer stem cell, recurrence, CD marker, CD44,rectal cancer, 495

CD133, colon cancer, tumorigenesis, azomymethane,dextran sodium sulphate, 4273

CD133, non-small cell lung cancer, cancer stem cellantigens, biomarkers, prognosis, CD117, BCRP1, tissuemicroarrays, 4491

CD14, polymorphism, ulcerative colitis, DNA methylation,p22PHOX, MBL, 933

CD34, angiogenesis, breast cancer, image analysis, MVD,vessel identification, 4053

CD44, cancer stem cell, recurrence, CD marker, CD133,rectal cancer, 495

CD44, memory T- cell, tumor-infiltrating lymphocytes,melanoma, 4099

CD44, renal cell carcinoma, circulating tumor cells,CellSearch, cytokeratins, 4219

CD44, silibinin, EGFR, EGF, TGF-α, MMP-9, breastcancer metastasis, 3767

CD44-CD41, PC3 side fraction, normoxia, hypoxia, 487CD47, ras, BNIP3, cancer, programmed cell death, 4N1K,

2869CD57, cancer, immunotherapy, prediction, survival, CD8,

review, 639CD8, cancer, immunotherapy, prediction, survival, CD57,

review, 639

CD86, dectin-1, beta-glucan, B-cell lymphoma,proliferation, cell death, 4195

CD86, myeloma, YT, interleukin-2, cytotoxicity, 475CD8highCD57+ lymphocytes, bladder carcinoma,

interleukin-2, recurrences, 699CD95-ligand, colorectal cancer, surgery, liver metastases,

biomarker, 4507CD98, LAT1, mesothelioma, hypoxia, prognosis, mTOR,

4075CD98, LAT1, recurrence, advanced NSCLC, EGFR

mutation, prognosis, chemotherapy. Ki-67, p-Akt, p-mTOR, 3775

CDDO-Me, ovarian cancer, methyl-2-cyano-3, 12-dioxooleana-1, apoptosis, AKT, NF-κB, mTOR, 3673

CDDP, advanced esophageal cancer, combinedchemotherapy, docetaxel, 5-FU, 633

CDHP, S-1, 5-fluorouracil, Phase I, FBAL, tegafur, FT,reversible dihydropyrimidine dehydrogenase, DPD,gimeracil, solid tumors, 625

CDK4, lipid nanoparticles, siRNA, down-regulation, 1619CDKN1A/WAF/CIP1, p53, p21, polymorphism,

endometriosis, genotype, 4301CEA, growth factors, breast cancer, tumor markers,

CA 15-3, IGF1, EGF, HGF, 4653Celecoxib, apoptosis, cytotoxicity, neuroblastoma, valproic

acid, 2231Cell culture, circulating tumor cells, CTCs, microfiltration

by size, real-time quantitative reverse transcriptase-polymerase chain reaction, qRT-PCR, molecular biology,cytomorphology, FISH, lung cancer, 427

Cell cycle arrest, 3-Indole, ATM, ATR, SMAD3, Xenograftmodel, lung cancer cells, 203

Cell cycle arrest, phenethyl isothiocyanate, apoptosis,mitochondria, caspases, prostate cancer DU 145 cells,1691

Cell cycle arrest, pomegranate, pancreatic cancer cells,phytochemicals, 2699

Cell cycle arrest, tumor suppressors, DNA N-methyltransferase, ERK, 2723

Cell cycle regulation, oral squamous cell carcinomas,toombak, genes, apoptosis, intermediate filamentproteins, Sudan, 3345

Cell cycle, acetoxycoumarins, cell viability, lethal dose,2017

Cell cycle, anticancer agents, sphingomylinase, Cox-2,caspase-3, apoptosis, p53, 1345

Cell cycle, anticancer drugs, sphingomyelinase, p53, Bax,apoptosis, 871

Cell cycle, cyclin B1, p53, squamous cell carcinoma, headand neck cancer, 3151

Cell cycle, glioma, EGFR, temozolomide, 3253Cell cycle, glioma, PTEN, temozolomide, ionizing

radiation, radiosensitivity, 1653


4743

Cell cycle, HTLV-1, ATL, tetramethylnaphthalene,inhibitor, 2241

Cell cycle, radiation sensitivity, esophageal cancer, gastriccancer, hypoxia, reoxygenation, 3369

Cell death, chalcone, glioblastoma, G2/M blockage, 3213Cell death, cigarette smoking, Swedish-type smokeless

tobacco, Snus, ethanol, human normal cells, endothelialcells, fibroblasts, 1527

Cell death, dectin-1, beta-glucan, B-cell lymphoma, CD86,proliferation, 4195

Cell death, ionizing radiation, temozolomide,immunogenicity, Hsp70, 3727

Cell death, pancreatic neoplasm, prostate neoplasm, nuclearmatrix proteins, natriuretic peptides, 395

Cell line, hepatitis C virus, liver tumour, sarcomatoidtumour, culture, spectral karyotyping, xenograft, 129

Cell migration, actin cytoskeleton, nuclear localization,Ror1, receptor tyrosine kinase, 4239

Cell proliferation, dihydroartemisinin, pancreatic cancer,apoptosis, angiogenesis, optical imaging, 1549

Cell proliferation, genistein, breast cancer, p90RSK, T47Dcells, 209

Cell proliferation, heparan sulfate, chitosan, anticancer,breast cancer, FGF-2, 1321

Cell proliferation, PSK, apoptosis, HL-60, caspase-3activation, 2733

Cell proliferation, zeranol, protein disulfide isomerase,mammary tumorigenesis, 1659

Cell viability, acetoxycoumarins, cell cycle, lethal dose, 2017Cell viability, indole, telomerase, prostate cancer,

diethylstilbestrol, 3733Cell-cycle arrest, 3-oxoolean-12-en-27-oic acid, lung

cancer cells, 2179Cell-free DNA, circulation, non-invasive, biomarker,

review, 2623CellSearch, renal cell carcinoma, circulating tumor cells,

cytokeratins, CD44, 4219Cell-to-cell interaction, adhesion molecules, characteristics

of cancer cells, anticancer drug resistance, chemotherapy,apoptosis, drug sensitivity, drug resistance-relatingfactors, gene expression analysis, evaluation andprediction of pharmacological effects, screening systems,3237

Cellular migration, metastasis suppressor-1, MTSS1,invasion, bladder cancer, metastasis, 3205

Central nervous system, radioprotection, radiosensitivity,astrocytes, lymphoma, 33

C-erbB-3, lung cancer, NSCLC, erlotinib, EGFR, 281Cerebrospinal fluid, acute myeloid leukemia,

immunotherapy, interleukin-2, peptide vaccination, CSF,flow of CSF, chloroma, 2343

Cerebrospinal fluid, human polyomavirus, BK virus, JC virus,hematopoetic stem cell transplantation, KI, WU, 3489

Cervical cancer, angiogenic factor, vascular tube formation,antiangiogenic therapy, 2609

Cervical cancer, angiogenic factors, angiogenin, endoglin,endostatin, 2651

Cervical cancer, angiogenic factors, vascular endothelialgrowth factor, basic fibroblast growth factor, endostatin,2645

Cervical cancer, angiogenic factors, VEGF, angiogenin,endoglin, 2589

Cervical cancer, artesunate, artenimol, clinical symptoms,tumour markers, 4417

Cervical cancer, C-reactive protein, CRP, CRP1919(rs1417938), CRP2667 (rs1800947), CRP3872 (rs1205),CRP5237 (rs2808630), gene polymorphism, prognosis,single nucleotide polymorphism, 2259

Cervical cancer, GSTM1, GSTT1, genetic polymorphism,human papillomavirus, cancer risk, 3051

Cervical cancer, indoleamine-2, 3-dioxygenase,immunomodulation, quinolinic acid, kynurenic acid,2629

Cervical cancer, parametrium, micrometastasis,immunohistochemistry, 243

Cervical cancer, squamous cell carcinoma, stage IB-IIB,concurrent chemoradiotherapy, locoregional recurrence,1437

Cervical carcinoma, prognosis, iNOS, guanylyl cyclase,phosphodiesterase, 2319

Cetuximab, advanced hepatocellular carcinoma (HCC),hepatic intra-arterial chemotherapy (HAIC), 3927

Cetuximab, capecitabine, oxaliplatin, bevacizumab, phaseII, metastatic colorectal cancer, 255

Cetuximab, colorectal cancer, irinotecan, oxaliplatin,biomarkers, 2149

Cetuximab, gastric cancer, irinotecan, oxaliplatin, KRASphase II trial, 4439

Cetuximab, gastric cancer, S-1, thymidylate synthase, 3691Cetuximab, HNSCC, EGFR, polymorphism, Erk-1/2,

AG1478, 59Cetuximab, IDH1 mutation, glioma, sunitinib,

bevacizumab, 4457Cetuximab, pancreatic neoplasm, erlotinib, chemotherapy,

chemoresistance, chemosensitivity, 1039CEUS, HCC, dysplastic nodule, vascularity,

characterization, cirrhosis, 3977C-FLIP, PEDF, HCC, p38, PPARγ, hepatocellular

carcinoma, apoptosis, 1173Chalcone, glioblastoma, G2/M blockage, cell death, 3213Characteristics of cancer cells, cell-to-cell interaction,

adhesion molecules, anticancer drug resistance,chemotherapy, apoptosis, drug sensitivity, drugresistance-relating factors, gene expression analysis,evaluation and prediction of pharmacological effects,screening systems, 3237


4744

Cheek, hemangiopericytoma, solitary fibrous tumor, oralcavity, soft tissue, 719

Chemoimmunotherapy, hepatocellular carcinoma, hepaticintraarterial therapy, interferon, fotemustine, 4553

Chemokine, tumour, microvesicles, monocyte, 1329Chemo-naive, EGFR mutation, erlotinib, non-small cell

lung cancer, platinum doublet, 3457Chemoprevention, lung cancer, combined treatment, mouse

model, 3279Chemoprevention, serum 25(OH)D, vitamin D, toxicity,

607Chemoradiation, anal cancer, image-guided radiotherapy,

tomotherapy, 4393Chemoradiation, rectal cancer, neoadjuvant therapy,

complete clinical response, non-operative management,review, 1795

Chemoradiotherapy, double gastric and esophageal cancer,complete response, 2339

Chemoradiotherapy, metastatic anal cancer, cisplatin, S-1,3983

Chemoradiotherapy, pancreatic cancer, gemcitabine, intra-arterial therapy, 3909

Chemoresistance, advanced gastric cancer, AKT, PI3K,review, 4387

Chemoresistance, epigenetics, bladder cancer, DNAmethylation, chemotherapy, 5-azacytidine, 3757

Chemoresistance, pancreatic neoplasm, erlotinib,cetuximab, chemotherapy, chemosensitivity, 1039

Chemoresistance, virotherapy, pancreatic cancer,gemcitabine, PDAC, GFP, 1279

Chemosensitivity, esophageal cancer, IL-6, cisplatin, 67Chemosensitivity, lung adenocarcinoma, 5-fluorouracil,

dihydropyrimidine dehydrogenase, thymidylate synthase,4665

Chemosensitivity, pancreatic neoplasm, erlotinib,cetuximab, chemotherapy, chemoresistance, 1039

Chemosensitivity, single nucleotide polymorphisms(SNPs), gastric cancer (GC), docetaxel, DNASE2B,HTRIE, 4329

Chemotherapeutics, breast cancer, primary culture, therapypersonalization, oncogramme, individualized tumourresponse testing, 139

Chemotherapy resistance, ovarian cancer, claudin-4, 1271Chemotherapy, assessment, neurotoxicity, peripheral

neuropathy, adverse effects, 3493Chemotherapy, BRCA, pancreatic cancer, iniparib, 1417Chemotherapy, breast cancer, dose-dense, sICAM-1,

sVCAM-1, 2617Chemotherapy, carboplatin, paclitaxel, vinorelbine, non-

small cell lung cancer, 317Chemotherapy, castrate-resistant prostate cancer, predictors

of survival, time to castration resistance, advancedprostate cancer, 1475

Chemotherapy, cell-to-cell interaction, adhesion molecules,characteristics of cancer cells, anticancer drug resistance,apoptosis, drug sensitivity, drug resistance-relatingfactors, gene expression analysis, evaluation andprediction of pharmacological effects, screening systems,3237

Chemotherapy, circulating tumor cells, disseminated tumorcells, detection, prostate cancer, bladder cancer, renal cellcarcinoma, review, 2053

Chemotherapy, circulating tumor cells, metastatic breastcancer, therapy efficacy, 979

Chemotherapy, colorectal, neuroendocrine cancer, smallcell cancer, cisplatin, etoposide, 975

Chemotherapy, diffuse intrinsic pontine glioma,temozolomide, rofecoxib, bevacizumab, inflammatoryprocesses, 2265

Chemotherapy, docetaxel, nedaplatin, S1, esophagealcarcinoma, phase I, 4589

Chemotherapy, docetaxel, prostate cancer, biochemicalrelapse, 973

Chemotherapy, endometrial cancer, prognosis, survival,radiotherapy, 3483

Chemotherapy, epigenetics, bladder cancer, DNAmethylation, chemoresistance, 5-azacytidine, 3757

Chemotherapy, ERas, gastric cancer, CPT-11, rapamycin,3353

Chemotherapy, FLOX regimen, metastatic colorectalcancer, phase II study, 5-FU, leucovorin, oxaliplatin,4657

Chemotherapy, 5-fluorouracil, gemcitabine, colon cancer,capecitabine, 2971

Chemotherapy, glioma, oligodendroglioma, 1p19q, 1p,PAV, ACNU, procarbazine, vincristine, 4475

Chemotherapy, GLUT-1, rectal cancer, radiotherapy,tumour regression, prognosis, 311

Chemotherapy, HIF-1α, esophageal neoplasm,radiotherapy, 2351

Chemotherapy, histone deacetylase inhibitor, multidrugresistant, sarcoma, PCI-24781, 1115

Chemotherapy, medulloblastoma, vincristine, lomustine,apoptosis, 1721

Chemotherapy, metastatic gastric cancer, review, 3543Chemotherapy, non-anticoagulant heparins, heparins, 411Chemotherapy, paclitaxel, doxifluridine, gastric cancer,

thymidine phosphorylase, 287Chemotherapy, pancreatic neoplasm, erlotinib, cetuximab,

chemoresistance, chemosensitivity, 1039Chemotherapy, P-glycoprotein, inhibition of multidrug

resistance, osteosarcoma cell lines, carcinoma cell lines,siRNA, 2813

Chemotherapy, rectal cancer, radiotherapy, prognosticfactor, biomarker, carbonic anhydrase IX, hypoxia-inducible factor-1a, ezrin, glucose transporter-1, 4529


4745

Chemotherapy, small cell lung cancer, TRAIL, paclitaxel,3193

Chemotherapy, thromoboembolism, breast cancer, 2383Chemotherapy, thymic carcinoma, ADOC, refractory, S-1,

299Chemotherapy, urachal cancer, recurrence, gemcitabine,

cisplatin, 2335Chemotherapy. Ki-67, LAT1, CD98, recurrence, advanced

NSCLC, EGFR mutation, prognosis, p-Akt, p-mTOR,3775

Chemotherapy-resistant, deferasirox, iron chelation therapy,iron overload, acute myelogenous leukemia, completeremission, 1741

Chick chorioallantoic membrane assay, alternative splicing,angiogenesis, autologous stem cell transplantation, high-dose chemotherapy, placental growth factor, vascularendothelial growth factor, VEGFR1, 3115

Chick embryo, circulating tumor cells, CTCs, prostatecancer, immunomagnetic beads, GFP, brain metastasis,metastatic assay, fluorescence imaging, 3125

Chief cells, polyp, gastric, fundic glend polyps, 1789Child’s classification, hepatocellular carcinoma, liver

cirrhosis, MELD-score, nonhepatic cancer, survivalprobability, TNM classification, 2931

Children, minimal residual disease, acute lymphoblasticleukemia, flow cytometry, early response, 1453

Chitosan, heparan sulfate, anticancer, breast cancer, cellproliferation, FGF-2, 1321

Chloroma, acute myeloid leukemia, immunotherapy,interleukin-2, peptide vaccination, cerebrospinal fluid,CSF, flow of CSF, 2343

Cholangiocarcinoma, MSX2, brushing cytology, 1011Cholangiocarcinoma, polo-like kinase 1, 5-fluorouracil,

gemcitabine, BI 2536, 3289Cholangiocellular carcinoma, Na+, H+ exchange, oxidative

stress, liver cancer, 459Choline-deficient L-amino acid-defined diet, Stk11, Lkb1,

hepatocellular carcinoma, nitrosamine, rat, 543Chromophobe renal cell carcinoma, renal cell carcinoma,

renal oncocytoma, fluorescence in situ hybridization,tissue sections, isolated nuclei, 3137

Chromophobe renal cell carcinoma, temsirolimus, mTOR,sorafenib, interferon, 331

Chromosomal abnormalities, Inv(3)(q21q26),t(3;3)(q21;q26), breakpoint distribution, fluorescent insitu hybridization, 3441

Chronic esophagitis, mutations, polymorphisms, TP53,FHIT, esophageal carcinoma, 1685

Chronic psychological stress, macrophage, LPS, priming,IP-PA1, review, 2437

Cigarette smoking, Swedish-type smokeless tobacco, Snus,ethanol, human normal cells, cell death, endothelial cells,fibroblasts, 1527

Cigarette smoking, tobacco-caused cancer, race, 3891Circulating cancer cells, GFP, prostate cancer, PC-3,

orthotopic, immunomagnetic beads, isolation,fluorescence, imaging, culture, 1535

Circulating dendritic cells, myeloid DC, dentritic cells,pancreatic cancer, prognostic factor, survival analysis,3827

Circulating tumor cells, bisphosphonates, disseminatedtumor cells, 3623

Circulating tumor cells, colon cancer, immunologicaldetection methods, metastasis, 613

Circulating tumor cells, CTCs, microfiltration by size, real-time quantitative reverse transcriptase-polymerase chainreaction, qRT-PCR, molecular biology, cytomorphology,FISH, cell culture, lung cancer, 427

Circulating tumor cells, CTCs, prostate cancer,immunomagnetic beads, GFP, chick embryo, brainmetastasis, metastatic assay, fluorescence imaging, 3125

Circulating tumor cells, disseminated tumor cells,detection, prostate cancer, bladder cancer, renal cellcarcinoma, chemotherapy, review, 2053

Circulating tumor cells, metastatic breast cancer,chemotherapy, therapy efficacy, 979

Circulating tumor cells, renal cell carcinoma, CellSearch,cytokeratins, CD44, 4219

Circulation, cell-free DNA, non-invasive, biomarker,review, 2623

Cirrhosis, CEUS, HCC, dysplastic nodule, vascularity,characterization, 3977

Cirrhosis, hepatocellular carcinoma, percutaneous ablation,percutaneous ethanol injection, radiofrequency ablation,randomized controlled trial, 2291

Cirrhosis, radiofrequency ablation, RFA, intrahepaticcholangio-carcinoma, ICC, 4575

Cisplatin, anal cancer, 5-FU, paclitaxel, 4637Cisplatin, carboplatin, hypersensitivity, antineoplastic,

thoracic malignancy, immunoglobulin E, 4525Cisplatin, colorectal, neuroendocrine cancer, small cell

cancer, chemotherapy, etoposide, 975Cisplatin, CTR1, bortezomib, drug combination,

proteasomal degradation, synergism, drug uptake, drugresistance, 2757

Cisplatin, DCF, induction chemotherapy, borderline-resectable T4, esophageal cancer, 5-fluorouracil,docetaxel, 3535

Cisplatin, drug resistance, drug combination, synergism,quercetin, thymoquinone, oxaliplatin, 3789

Cisplatin, esophageal cancer, IL-6, chemosensitivity, 67Cisplatin, estrogen receptor beta, ovarian cancer, prognostic

factor, immunohistochemistry, 711Cisplatin, gastric cancer, gastroesophageal junction

adenocarcinoma, DCF, docetaxel, 5-fluorouracil, G-CSF,2379


4746

Cisplatin, germ cell tumour, thrombosis, hypercoagulation,vascular toxicity, von Willebrand factor, 4501

Cisplatin, head and neck neoplasms, ERCC1 protein, DNArepair, radiation, 4135

Cisplatin, metastatic anal cancer, chemoradiotherapy, S-1,3983

Cisplatin, neoadjuvant chemoradiotherapy, gastric cancer,S-1, 3079

Cisplatin, neoadjuvant therapy, radiochemotherapy,esophageal cancer, docetaxel, phase II trials, 4407

Cisplatin, NK4, gene therapy, cationised gelatin, squamouscell carcinoma, 105

Cisplatin, ovarian cancer, consolidation chemotherapy,recurrent, salvage chemotherapy, treatment-free interval,paclitaxel, irinotecan, 4613

Cisplatin, ovarian cancer, curcumin, EGCG, synergism,drug combination, 1131

Cisplatin, PAMAM dendrimers, encapsulation, intracellulardelivery, resistance, SMVT, ovarian cancer cell lines, 897

Cisplatin, recurrent cervical cancer, oral etoposide, second-line chemotherapy, feasibility study, 3063

Cisplatin, small cell lung cancer, topotecan, 3449Cisplatin, triplet combination chemotherapy, paclitaxel, S-

1, advanced gastric cancer, feasibility study, 3085Cisplatin, urachal cancer, recurrence, gemcitabine,

chemotherapy, 2335Citrate, gastric carcinoma, carcinomatosis, glycolysis,

energetic metabolism, apoptosis, necrosis, 797Class III β-tubulin, histoculture drug response assay, non-

small cell lung cancer, predictive marker, vinorelbine, 999Claudin-1, prognostic factor, recurrence, rectal cancer,

2517Claudin-4, ovarian cancer, chemotherapy resistance, 1271Cl-F-ara-A, clofarabine, clofarabine triphosphate, Cl-F-ara-

ATP, isocratic HPLC, leukemia cells, 2863Cl-F-ara-ATP, clofarabine, Cl-F-ara-A, clofarabine

triphosphate, isocratic HPLC, leukemia cells, 2863Clinical cancer registry, ovarian cancer, cancer

epidemiology, 2657Clinical symptoms, cervical cancer, artesunate, artenimol,

tumour markers, 4417Clinical trial, fenretinide, LXS oral powder, phase I, 961Clinical, KRAS, p53, colorectal, oxaliplatin, 5-fluorouracil,

capecitabine, CAIRO2, sequence analysis, 1379Clioquinol, zinc, cyclin D1, miR-302C, MCF-7 cells, 2739Clofarabine triphosphate, clofarabine, Cl-F-ara-A, Cl-F-ara-

ATP, isocratic HPLC, leukemia cells, 2863Clofarabine, Cl-F-ara-A, clofarabine triphosphate, Cl-F-ara-

ATP, isocratic HPLC, leukemia cells, 2863Clonogenic assay, human lung cancer cell lines, surviving

fraction, doubling time, radiobiology model, 1125Clonogenic cell survival, radiation sensitivity, huachansu,

lung cancer cells, inhibition of DNA repair, 2141

C-Met, HGF, NK4, CT26, 5-fluorouracil, Akt, Erk1/2,thymidylate synthase, 2217

CML, antitumor activity, Bcr-Abl, Daedalea gibbosa,kinase, medicinal mushrooms, oleic acid,autophosphorylation, 177

coagulation factor, colon cancer, thrombin, vascularendothelial growth factor, vascular endothelial growthfactor receptor-2, angiogenesis, 843

Co-culture, hyperthermia, thermal cancer therapy, hepaticstellate cells, fibrosis, HCC, transwell, 3713

Colo 205 and Colo 320 colon adenocarcinoma cells,hydantoin derivatives, multidrug resistance, efflux pump,ABCB1 transporter, apoptosis, 3285

Colo 205 cells, Zanthoxylum ailanthoides Sieb and Zucc.,human colon adenocarcinoma cell, caspases, apoptosis,flavone, 1667

Colon 26, ultrasound, mono-l-aspartyl chlorin e6, antitumoreffect, sonodynamic therapy, sarcoma 180, 501

Colon adenocarcinoma, metastasis, HPA, E-selectin, P-selectin, SCID mouse, lectin, breast carcinoma cells,1589

Colon cancer metastasis, epithelial-mesenchymal transition(EMT), endothelin axis, endothelin A and B receptor(ETAR and ETBR), phosphatase and tensin homolog(PTEN), 861

Colon cancer, CD133, tumorigenesis, azomymethane,dextran sodium sulphate, 4273

Colon cancer, chemotherapy, fluorouracil, gemcitabine,capecitabine, 2971

Colon cancer, circulating tumor cells, immunologicaldetection methods, metastasis, 613

Colon cancer, cyclooxygenase, COX-2, W-APC, rightcolon, left colon, 2191

Colon cancer, metformin, phenformin, 2-deoxyglucose,acidification, 421

Colon cancer, microsatellite instability, tumor location, age,early onset, 967

Colon cancer, monocyte differentiation, macrophage, MCP-1, 2493

Colon cancer, NFκB, IκBα, IKKβ, p38, peroxynitrite,nitration, 1607

Colon cancer, orthotopic model, GFP, fluorescent proteinimaging (FPI), MRI, selenium, angiogenesis, 387

Colon cancer, photodynamic therapy, PDT,glycoconjugated chlorin, apoptosis, gastric cancer, 763

Colon cancer, prognosis, left colon, right colon, sigmoid,survival, gender, 2347

Colon cancer, RRM2, KRAS, 2535Colon cancer, selenoprotein, glutathione, thioredoxin,

antioxidant enzyme expression, 2693Colon cancer, thrombin, vascular endothelial growth factor,

vascular endothelial growth factor receptor-2,coagulation factor, angiogenesis, 843


4747

Colon cancer, thymidine kinase1, 5’(3’)-deoxyribonucleotidase, fluorothymidine, proliferation,lung cancer, 2135

Colon cancer, TRAIL, histone deacetylase inhibitor,LBH589, apoptosis, 3385

Colorectal cancer, ADAM, MMP, TIMP, solid cancer nest,invasive front, 1567

Colorectal cancer, adjuvant chemotherapy, MTHFR C677T,MTR A2756G, toxicity, survival, 3057

Colorectal cancer, ADM, prognostic factor, hypoxia, 507Colorectal cancer, afatinib, BIBF 1120, phase II,

pharmacokinetics, 2271Colorectal cancer, antiapoptosis, gamma radiation,

microarray, RT-PCR, REG4, NEIL2, BIRC5, 4147Colorectal cancer, apoptosis, liver metastases, invasion

front, FAS, TRAIL, 1215Colorectal cancer, bevacizumab, FOLFIRI, XELIRI,

efficacy, safety, 1777Colorectal cancer, biological activity, tumor markers,

angiogenetic factors, metalloproteinases, adhesionmolecules, 373

Colorectal cancer, cetuximab, irinotecan, oxaliplatin,biomarkers, 2149

Colorectal cancer, Egfl8, quantitative polymerase chainreaction, 2249

Colorectal cancer, glycated apolipoprotein B, immuno-histochemistry, 555

Colorectal cancer, HOPX, gene methylation, 2889Colorectal cancer, insulin-like growth factor, IGF-1, IGF-

1R, 2541Colorectal cancer, integrins, survival, polymorphisms,

single nucleotide polymorphisms, 1373Colorectal cancer, KRAS, microRNA, PTEN, miR-221/222,

3D culture, 2453Colorectal cancer, liver metastases, lung metastases,

synchronous, metachronous, 1049Colorectal cancer, lymphangiogenesis, lymphovascular

invasion, liver metastases, VEGF-C, 4605Colorectal cancer, OSMR, quantitative methylation-specific

PCR, 1293Colorectal cancer, p16INK4a, methylation, 1643Colorectal cancer, polymorphism, MMP2, VEGF, HIF1A,

SNP, 575Colorectal cancer, prognostic factor, stanniocalcin 1, PCR,

325Colorectal cancer, pulmonary metastases, TS, OPRT,

ERCC1, BRCA1, MVD, adjuvant chemotherapy, 2763Colorectal cancer, regulatory T-cells, antitumor immunity,

FOLFOX, FOLFIRI, 4569Colorectal cancer, soluble leptin receptor, tumor stage,

3381Colorectal cancer, surgery, liver metastases, biomarker,

CD95-ligand, 4507

Colorectal cancer, ulcerative colitis, surveillance, 2499Colorectal cancer, vitamin D, breast cancer, prostate

cancer, lung cancer, 3619Colorectal cancer, wnt pathway, immunohistochemistry,

LGR5, stem cell marker, 263Colorectal carcinoma, cysteine-histidine-rich protein

(PINCH), epithelial mesenchymal transition (EMT),vascular endothelial growth factor (VEGF), FAS, 4127

Colorectal neoplasm, thymidylate synthase, ERCC1,adenosine triphosphate, drug screening assay, 3843

Colorectal, KRAS, p53, oxaliplatin, 5-fluorouracil,capecitabine, clinical, CAIRO2, sequence analysis, 1379

Colorectal, neuroendocrine cancer, small cell cancer,chemotherapy, cisplatin, etoposide, 975

Combination strategy, androgen receptor, flutamide,prostate cancer, prostate-specific antigen, resveratrol,3323

Combination therapy, gefitinib, radiation, EGFR, predictor,melanoma, 2883

Combined chemotherapy, advanced esophageal cancer,docetaxel, CDDP, 5-FU, 633

Combined treatment, lung cancer, chemoprevention, mousemodel, 3279

Commitment, personality, type C, cancer risk, 4013Complementary peptide, antisense pepitide, anaphylatoxin,

inflammation, sepsis, cytokine storm, 2511Complete clinical response, rectal cancer, chemoradiation,

neoadjuvant therapy, non-operative management, review,1795

Complete remission, deferasirox, iron chelation therapy,iron overload, acute myelogenous leukemia,chemotherapy-resistant, 1741

Complete response, double gastric and esophageal cancer,chemoradiotherapy, 2339

Complete response, early-stage esophageal cancer, S-1 plusCDDP, 1019

Complete tumor resection, ovarian cancer relapse,secondary cytoreductive surgery, predictive factor, tumorresidual, 2583

Complication, esophageal squamous cell carcinoma,neoadjuvant chemoradiotherapy, pathological response,prognosis, 3073

Computational toxicology, cat-SAR, anticancer models,DTP, breast cancer, 3247

Concurrent chemoradiotherapy, cervical cancer, squamouscell carcinoma, stage IB-IIB, locoregional recurrence,1437

Concurrent disease, BPF, fistula, operation, lung cancer,risk factor, perioperative complication, infection, 619

Conformation, antibacterial activity, hydrophobicity, bis-quarternary compound, 2561

Conservative management, grade 2, grade 3, endometrialcancer, fertility, 3047


4748

Consolidation chemotherapy, ovarian cancer, recurrent,salvage chemotherapy, treatment-free interval, paclitaxel,cisplatin, irinotecan, 4613

Continuous medical training, gynecological cancer, breastcancer, online tumor conference, interdisciplinary therapymanagement, second opinion, 2669

Continuous saline bladder irrigation, bladder cancer,recurrence, intravesical chemotherapy, 1471

Contrast-enhanced ultrasonography, prostate cancer,transrectal ultrasonography, 1421

Copper overload, reactive oxygen species, pyruvatedehydrogenase, Long Evans Cinnamon, 3395

Cortactin, breast cancer, tissue microarray, 293Cox-2, anticancer agents, sphingomylinase, caspase-3,

apoptosis, p53, cell cycle, 1345COX-2, cyclooxygenase, breast cancer, tumor,

prostaglandin, carcinogenesis, 4359COX-2, cyclooxygenase, W-APC, right colon, left colon,

colon cancer, 2191COX-2, metastasis, extravasation, blood−brain barrier,

brain endothelial cells, 4307Cox-2, polymorphism, carcinogenesis, prostate cancer, 221CPT-11, ERas, gastric cancer, chemotherapy, rapamycin, 3353C-reactive protein, cervical cancer, CRP, CRP1919

(rs1417938), CRP2667 (rs1800947), CRP3872 (rs1205),CRP5237 (rs2808630), gene polymorphism, prognosis,single nucleotide polymorphism, 2259

CRM197, HB-EGF, doxorubicin, T-ALL, 2483CRM197, ovarian cancer, HB-EGF, targeted therapy, 2461CRP, cervical cancer, C-reactive protein, CRP1919

(rs1417938), CRP2667 (rs1800947), CRP3872 (rs1205),CRP5237 (rs2808630), gene polymorphism, prognosis,single nucleotide polymorphism, 2259

CRP1919 (rs1417938), cervical cancer, C-reactive protein,CRP, CRP2667 (rs1800947), CRP3872 (rs1205),CRP5237 (rs2808630), gene polymorphism, prognosis,single nucleotide polymorphism, 2259




Cryoimmunology, cryotreatment, renal cell carcinoma,immunotherapy, 2927

Cryotreatment, cryoimmunology, renal cell carcinoma,immunotherapy, 2927

CSF, acute myeloid leukemia, immunotherapy, interleukin-2,peptide vaccination, cerebrospinal fluid, flow of CSF,chloroma, 2343

CT, adrenocortical tumors, Cushing’s syndrome, adrenalimaging, cancer, MR, review, 2923

CT26, HGF, c-Met, NK4, 5-fluorouracil, Akt, Erk1/2,thymidylate synthase, 2217

CTCs, circulating tumor cells, microfiltration by size, real-time quantitative reverse transcriptase-polymerase chainreaction, qRT-PCR, molecular biology, cytomorphology,FISH, cell culture, lung cancer, 427

CTCs, circulating tumor cells, prostate cancer,immunomagnetic beads, GFP, chick embryo, brainmetastasis, metastatic assay, fluorescence imaging,3125

CT-guided high-dose-rate brachytherapy, CT-HDRBT,ovarian cancer, metachronous liver metastasis, ablation ofliver metastases, 2597

CT-HDRBT, CT-guided high-dose-rate brachytherapy,ovarian cancer, metachronous liver metastasis, ablation ofliver metastases, 2597

CTNNB1, medullary thyroid carcinoma, gene mutations,RET, HRAS, KRAS, NRAS, BRAF, AKT1, mutationalscreening, 4179

CTR1, cisplatin, bortezomib, drug combination,proteasomal degradation, synergism, drug uptake, drugresistance, 2757

Culture, GFP, prostate cancer, PC-3, orthotopic, circulatingcancer cells, immunomagnetic beads, isolation,fluorescence, imaging, 1535

Culture, hepatitis C virus, liver tumour, sarcomatoidtumour, cell line, spectral karyotyping, xenograft, 129

Curcumin analog, multiple myeloma, NF-κB, PI3K/AKT,JAK/STAT3, IRF4, 3719

Curcumin, ovarian cancer, cisplatin, EGCG, synergism,drug combination, 1131

Curcuminoid, boron tracedrug, BODIPY, neutron dynamictherapy, dynamic drug, thermal neutron irradiation,BNCT, 2477

Cushing’s syndrome, adrenocortical tumors, adrenalimaging, cancer, CT, MR, review, 2923

CV11974, osteosarcoma, metastasis, angiotensin II type 1receptor antagonist, 123

CXCR4, AAV, gene therapy, bioluminescence, breastcancer, 1627

Cyclin B1, cell cycle, p53, squamous cell carcinoma, headand neck cancer, 3151

Cyclin D, antisense oligonucleotide, cyclin E, cyclin-dependent kinase, retinoblastoma protein, non-small lungcancer cells, pleural mesothelioma cells, apoptosis,kinases, phosphatases, 3683

Cyclin D1, CCND1 1722, polymorphism, upper tracturothelial cancer, 1043


4749

Cyclin D1, CCND1, polymorphism, lung cancer, smoking,Taiwanese, 3601

Cyclin D1, clioquinol, zinc, miR-302C, MCF-7 cells, 2739Cyclin D1, polymorphism, oral cancer, smoking, 227Cyclin D3, minichromosome maintenance proteins, MCMs,

CCND3, Hodgkin lymphoma, survival, 3585Cyclin E, antisense oligonucleotide, cyclin D, cyclin-

dependent kinase, retinoblastoma protein, non-small lungcancer cells, pleural mesothelioma cells, apoptosis,kinases, phosphatases, 3683

Cyclin-dependent kinase, antisense oligonucleotide, cyclinD, cyclin E, retinoblastoma protein, non-small lungcancer cells, pleural mesothelioma cells, apoptosis,kinases, phosphatases, 3683

Cyclooxygenase, COX-2, breast cancer, tumor,prostaglandin, carcinogenesis, 4359

Cyclooxygenase, COX-2, W-APC, right colon, left colon,colon cancer, 2191

Cyclooxygenase-2, 5-FU resistance, thymidylate synthase,etodolac, 2893

Cyclophosphamide, metronomic, doxorubicin, breastcancer, cardiotoxicity, rats, 215

Cyclophosphamide, β-glucan, A20 lymphoma, regulatoryT-cell, 1169

Cyclosporine, isolated lung perfusion, sarcoma lungmetastases, p-gp modulation, doxorubicin, valspodar,2121

Cyclosporine A, human lung adenocarcinoma cell,apoptosis, lung transplantation, caspase, 2129

CYP1A1, genetic polymorphisms, cancer susceptibility,DNA-repair genes, metabolizing genes, CYP1E1,XRCC1, 1359

CYP1E1, genetic polymorphisms, cancer susceptibility,DNA-repair genes, metabolizing genes, CYP1A1,XRCC1, 1359

Cysteine-histidine-rich protein (PINCH), colorectalcarcinoma, epithelial mesenchymal transition (EMT),vascular endothelial growth factor (VEGF), FAS, 4127

Cytogenetics, hyperdiploid multiple myeloma, tumorprogression, 1599

Cytokeratin 19, breast cancer, sentinel lymph node, OSNA,intra-operative method, 585

Cytokeratin 4, fascin, biomarker, tissue microarray,squamous cell carcinoma, esophagus, 945

Cytokeratin 8, radioimmunotherapy, HNSCC, SCID mice,xenografts, radio-labeled monoclonal antibody, 3315

Cytokeratins, monoTotal, lung cancer, tumour markers,3107

Cytokeratins, renal cell carcinoma, circulating tumor cells,CellSearch, CD44, 4219

Cytokine storm, antisense pepitide, complementary peptide,anaphylatoxin, inflammation, sepsis, 2511

Cytokines, cathepsin, proliferation, lung cancer cells, 47

Cytokines, morphine, plasma, MIP-1α, IL-12, 4561Cytokines, voluntary running, metastasis, mice, 3337Cytokinins, isopentenyladenosine, modified nucleosides,

antiproliferative activity, 3401Cytology, DNA ploidy, image analysis, cytometry,

hematoxylin staining, Feulgen staining, Papanicolaoustaining, 53

Cytology, endometrial brush, endometrial cancer,endometrial pathology, screening test, uterobrush, 3469

Cytology, epidermal growth factor receptor (EGFR), lungcancer, fiberbronchoscopy, diagnosis, 4207

Cytomegalovirus, brain tumors, glioblastoma, etiology, 959Cytometry, DNA ploidy, image analysis, cytology,


Cytomorphology, circulating tumor cells, CTCs,microfiltration by size, real-time quantitative reversetranscriptase-polymerase chain reaction, qRT-PCR,molecular biology, FISH, cell culture, lung cancer, 427

Cytoprotection, prostate cancer, radiotherapy,hypofractionation, acceleration, amifostine, 1745

Cytoreductive surgery, ovarian cancer, residual disease,prediction models, 4043

Cytosine deaminase, endometrial cancer, engineered stemcells, interferon-β, 2853

Cytoskeleton, paxillin, phosphatase, PP-1, TGF-β, 3159Cytotherapy, mesenchymal stem cells, gene therapy,

hepatocellular carcinoma, 3705Cytotoxic T-cells, γδ T-cells, antigen presentation, 2419Cytotoxicity, apoptosis, celecoxib, neuroblastoma, valproic

acid, 2231Cytotoxicity, endocytosis, glycosylated antitumor ether

lipid, mechanism of action, methyl-β-cyclodextrin, 3809Cytotoxicity, ferrocene, ethynyl phosphine, gold, platinum,

HeLa, 825Cytotoxicity, hENT1, gemcitabine, I3C, pancreatic cancer,

3171Cytotoxicity, myeloma, YT, CD86, interleukin-2, 475Cytotoxicity, oxaliplatin, phytochemicals, ovarian cancer

cell lines, synergism, 4283Cytotoxicity, prostate cancer, triphala, gallic acid,

Ayurvedic medicine, 3739Cytotoxicity, trihaloacetylazulenes, QSAR, semiempirical

molecular-orbital method, 515Dacarbazine, imexon, melanoma, additivity, drug

combinations, 2781Daedalea gibbosa, antitumor activity, Bcr-Abl, CML,

kinase, medicinal mushrooms, oleic acid,autophosphorylation, 177

DAPK, breast cancer, tissue microarray, 3633Daunorubicin resistance, arsenic trioxide, arsenic acid,

organic arsenicals, T-lymphoblastoid leukemia,apoptosis, 4169


4750

DAX-1, breast cancer, ApoD, ERα, prognosis, 443DC Bead, liver directed therapy, metastatic colon cancer,

irinotecan, transarterial chemoembolization, DEBIRI,4581

DC, vaccine, whole tumor cell, IFN-γ, ELISPOT, 3995DCEMR, prostate cancer, PCA3 urinary test, MRSI, 1399DCF, gastric cancer, gastroesophageal junction

adenocarcinoma, docetaxel, cisplatin, 5-fluorouracil, G-CSF, 2379

DCF, induction chemotherapy, borderline-resectable T4,esophageal cancer, cisplatin, 5-fluorouracil, docetaxel, 3535

3D culture, KRAS, microRNA, colorectal cancer, PTEN,miR-221/222, 2453

2-DE, TNF-alpha, hepatoma, proteomics, LC-MS/MS,apoptosis, 2059

2-DE, tubulin alpha-6 chain, HCV-HCC, proteomics, MS,3331

De-alcoholization, paclitaxel (PTX), alcohol intolerance,pharmacokinetics, adverse event, 4339

Death receptor-mediated pathways, gallic acid (GA),human leukemia HL-60 cells, apoptosis, mitochondria-mediated pathways, 2821

DEBIRI, liver directed therapy, metastatic colon cancer,irinotecan, transarterial chemoembolization, DC Bead,4581

Decitabine, astrocytomas, epigenetics, DNA methylation,histone deacetylases, 1337

Dectin-1, beta-glucan, B-cell lymphoma, CD86,proliferation, cell death, 4195

Dectin-2 gene expression, microarray analysis, signalingpathway, macrophage, lignin-carbohydrate complex,LPS, LEM, 1241

Deep-seated, sonodynamic therapy, focused ultrasound, 5-aminolevulinic acid, glioma, rat model, 2527

Deferasirox, iron chelation therapy, iron overload, acutemyelogenous leukemia, chemotherapy-resistant, completeremission, 1741

Del(20q), interphase FISH, MDS, normal karyotype,del(5q), 1007

Del(5q), interphase FISH, MDS, normal karyotype,del(20q), 1007

Demethylation, MAGE, non-small cell lung cancerNSCLC, expression, 171

Dendritic cell therapy, melanoma, small bowel,intussusception, disease-free survival, 3579

Dendritic cell, nucleotide, insoluble protein, T lymphocytes, immunotherapy, 881

Dendritic cells, β-glucan, beta-glucan, maturation,immunomodulator, 1647

Dentritic cells, myeloid DC, pancreatic cancer, prognosticfactor, survival analysis, circulating dendritic cells, 3827

2-Deoxyglucose, colon cancer, metformin, phenformin,acidification, 421

5’(3’)-Deoxyribonucleotidase, thymidine kinase1,fluorothymidine, proliferation, lung cancer, colon cancer,2135

Depression, breast disease, risk of cancer, 1065Detection, circulating tumor cells, disseminated tumor

cells, prostate cancer, bladder cancer, renal cellcarcinoma, chemotherapy, review, 2053

Dexamethasone, multiple myeloma, bortezomib, once-weekly administration, gastrointestinal adverse events,2297

Dextran sodium sulphate, CD133, colon cancer,tumorigenesis, azomymethane, 4273

DFI, non-small cell lung cancer, TIMP1, mRNA, survival,blood plasma, 4031

Diabetes, KRAP, KRAS, target, cancer, obesity, review, 2413Diagnosis, biomarkers, early detection, head and neck

cancer, review, 1161Diagnosis, epidermal growth factor receptor (EGFR), lung

cancer, cytology, fiberbronchoscopy, 4207Diagnosis, ovarian cancer, biomarkers, enzyme-linked

immunosorbent assay, cathepsin, matrixmetalloproteinase-9, heparanase, 3423

Diagnosis, thyroid cancer, biomarker, sensitivity,specificity, metastasis, immunohistochemistry, 3433

Diethylstilbestrol, indole, telomerase, prostate cancer, cellviability, 3733

Differental diagnosis, breast cancer liver metastases, liversurgery, tumour markers, prognostic factors, benign liverlesions, 1447

Diffuse intrinsic pontine glioma, chemotherapy,temozolomide, rofecoxib, bevacizumab, inflammatoryprocesses, 2265

Dihydroartemisinin, artemisinin dimers, rat, breast cancercells, 4111

Dihydroartemisinin, pancreatic cancer, cell proliferation,apoptosis, angiogenesis, optical imaging, 1549

Dihydropyrimidine dehydrogenase, lung adenocarcinoma,5-fluorouracil, thymidylate synthase, chemosensitivity,4665

Dihydropyrimidine dehydrogenase, oral squamous cellcarcinoma, thymidylate synthase, lymph node metastasis,KAI1/CD82, 3521

12-Dioxooleana-1, ovarian cancer, methyl-2-cyano-3,9(11)-dien-28-oate (CDDO-Me), apoptosis, AKT, NF-κB, mTOR, 3673

3-Dioxygenase, indoleamine-2, immunomodulation,cervical cancer, quinolinic acid, kynurenic acid, 2629

Disease-free survival, melanoma, small bowel,intussusception, dendritic cell therapy, 3579

Disseminated histiocytic sarcoma, quantitative PCR,immunohistochemistry, HMGB1, RAGE, 1541

Disseminated tumor cells, bisphosphonates, circulatingtumor cells, 3623


4751

Disseminated tumor cells, breast cancer, bone marrow,bone mineral density, quantitative ultrasonometry, 4423

Disseminated tumor cells, breast cancer, bone marrow,prognosis, follow-up, 2749

Disseminated tumor cells, circulating tumor cells,detection, prostate cancer, bladder cancer, renal cellcarcinoma, chemotherapy, review, 2053

Distal margins, rectal cancer, hyperthermo-chemo-radiationtherapy, HCRT, tumor response, 3963

D-loop region, MtDNA mutation, breast cancer, plasma,mitochondrial DNA, 4267

DNA interaction and fragmentation, quinazoliniminiumsalts, tumor cell proliferation, Ki-67 expression,macromolecule syntheses, multiple mitotic figures,nuclei, micronuclei, 2083

DNA methylation, astrocytomas, epigenetics, histonedeacetylases, decitabine, 1337

DNA methylation, epigenetics, bladder cancer,chemotherapy, chemoresistance, 5-azacytidine, 3757

DNA methylation, polymorphism, ulcerative colitis, CD14,p22PHOX, MBL, 933

DNA N-methyl transferase, tumor suppressors, cell cyclearrest, ERK, 2723

DNA ploidy, image analysis, cytometry, cytology,hematoxylin staining, Feulgen staining, Papanicolaoustaining, 53

DNA repair, caveolin-1, prostate cancer, single nucleotidepolymorphism, 745

DNA repair, head and neck neoplasms, ERCC1 protein,cisplatin, radiation, 4135

DNA repair, X-ray repair cross-complementing group 1,XRCC1, polymorphism, skin cancer, meta-analysis, 3945

DNA-repair genes, genetic polymorphisms, cancersusceptibility, metabolizing genes, CYP1A1, CYP1E1,XRCC1, 1359

DNASE2B, single nucleotide polymorphisms (SNPs),gastric cancer (GC), chemosensitivity, docetaxel, HTRIE,4329

Docetaxel, advanced esophageal cancer, combinedchemotherapy, CDDP, 5-FU, 633

Docetaxel, cancer, neurotoxicity, adjuvant chemotherapy,intraepidermal nerve fibres, neuropathy, skin biopsies,oxaliplatin, 4413

Docetaxel, chemotherapy, nedaplatin, S1, esophagealcarcinoma, phase I, 4589

Docetaxel, DCF, induction chemotherapy, borderline-resectable T4, esophageal cancer, cisplatin, 5-fluorouracil, 3535

Docetaxel, gastric cancer, gastroesophageal junctionadenocarcinoma, DCF, cisplatin, 5-fluorouracil, G-CSF,2379

Docetaxel, neoadjuvant therapy, radiochemotherapy,esophageal cancer, cisplatin, phase II trials, 4407

Docetaxel, prostate cancer, chemotherapy, biochemicalrelapse, 973

Docetaxel, single nucleotide polymorphisms (SNPs),gastric cancer (GC), chemosensitivity, DNASE2B,HTRIE, 4329

Docetaxel, stealth liposomes, PEG liposomes, locoregionalchemotherapy, liver metastases, hepatic arterial infusion,153

Dose-dense, breast cancer, chemotherapy, sICAM-1,sVCAM-1, 2617

Double gastric and esophageal cancer, chemoradiotherapy,complete response, 2339

Doubling time, human lung cancer cell lines, survivingfraction, radiobiology model, clonogenic assay, 1125

Down-regulation, lipid nanoparticles, CDK4, siRNA, 1619Doxifluridine, paclitaxel, gastric cancer, ascites, 4625Doxifluridine, paclitaxel, gastric cancer, thymidine

phosphorylase, chemotherapy, 287Doxorubicin, HB-EGF, CRM197, T-ALL, 2483Doxorubicin, hyperthermia, bevacizumab, platinum-

refractory, ovarian cancer, 2675Doxorubicin, isolated lung perfusion, sarcoma lung

metastases, p-gp modulation, cyclosporine, valspodar,2121

Doxorubicin, metronomic, cyclophosphamide, breastcancer, cardiotoxicity, rats, 215

DPD, S-1, 5-fluorouracil, Phase I, FBAL, tegafur, FT,reversible dihydropyrimidine dehydrogenase, gimeracil,CDHP, solid tumors, 625

Drug combination, cisplatin, CTR1, bortezomib,proteasomal degradation, synergism, drug uptake, drugresistance, 2757

Drug combination, drug resistance, synergism, quercetin,thymoquinone, cisplatin, oxaliplatin, 3789

Drug combination, ovarian cancer, cisplatin, curcumin,EGCG, synergism, 1131

Drug combinations, imexon, dacarbazine, melanoma,additivity, 2781

Drug delivery, cancer, liposome, vincristine, folate receptor,drug targeting, 1521

Drug resistance, cisplatin, CTR1, bortezomib, drugcombination, proteasomal degradation, synergism, druguptake, 2757

Drug resistance, drug combination, synergism, quercetin,thymoquinone, cisplatin, oxaliplatin, 3789

Drug resistance, notch, stem cells, pancreatic cancer,signal pathway, natural agents, cancer therapy, review,1105

Drug resistance, VEGFR2, tyrosine kinase inhibitor,angiogenesis, endothelial cells, HUVEC, 2787

Drug screening assay, thymidylate synthase, ERCC1, adenosine triphosphate, colorectal neoplasm,3843


4752

Drug sensitivity, drug resistance-relating factors, geneexpression analysis, cell-to-cell interaction, adhesionmolecules, characteristics of cancer cells, anticancer drugresistance, chemotherapy, apoptosis, evaluation and predictionof pharmacological effects, screening systems, 3237

Drug targeting, drug delivery, cancer, liposome, vincristine,folate receptor, 1521

Drug uptake, cisplatin, CTR1, bortezomib, drugcombination, proteasomal degradation, synergism, drugresistance, 2757

DTP, cat-SAR, anticancer models, breast cancer,computational toxicology, 3247

Dual-specificity phosphatases, cannabinoids, apoptosis,prostate cancer cell lines, protein tyrosine phosphatases,3799

Ductal carcinoma in situ, breast, lumpectomy, mastectomy,menopause, hormone replacement therapy, 1783

Ductal pleomorphic carcinoma, male breast,histopathology, immunohistochemistry, 3069

Dynamic contrast enhancing magnetic resonance imaging(DCE-MRI), adrenocortical carcinoma, ADH-1, phase-I,N-cadherin, 3921

Dynamic drug, boron tracedrug, BODIPY, curcuminoid,neutron dynamic therapy, thermal neutron irradiation,BNCT, 2477

Dysplastic nevi, immune response, melanocyte, melanoma,regression, 3697

Dysplastic nodule, CEUS, HCC, vascularity,characterization, cirrhosis, 3977

Eag1, epithelial to mesenchymal transition, lung cancer,potassium channels, TGF-β, 1265

EAP, gefitinib, non-small cell lung cancer, NSCLC,epidermal growth factor receptor, EGFR, skin toxicity,expanded access programme, 2949

Early detection, biomarkers, diagnosis, head and neckcancer, review, 1161

Early onset, colon cancer, microsatellite instability, tumorlocation, age, 967

Early response, minimal residual disease, acutelymphoblastic leukemia, flow cytometry, children, 1453

Early-stage esophageal cancer, S-1 plus CDDP, completeresponse, 1019

EBP1, prostate cancer, mRNA translation, androgenreceptor, 3129

EBV polymorphism, BamHI W1/I1, XhoI restriction site,EBV-associated gastric cancer, Latin America, 3607

EBV-associated gastric cancer, EBV polymorphism, BamHIW1/I1, XhoI restriction site, Latin America, 3607

E-Cadherin, cancer, endometrium, apoptosis, Bcl-2, p53,estrogen receptor, progesterone receptor, 4191

E-Cadherin, EMT, gamma catenin, vimentin, fibronectin,lung adenocarcinoma, 4451

ECM, EMMPRIN, Fyn, integrin, oral SCC, 1205

Efficacy, bevacizumab, FOLFIRI, XELIRI, colorectalcancer, safety, 1777

Efflux pump, hydantoin derivatives, Colo 205 and Colo320 colon adenocarcinoma cells, multidrug resistance,ABCB1 transporter, apoptosis, 3285

EGCG, ovarian cancer, cisplatin, curcumin, synergism,drug combination, 1131

EGF, growth factors, breast cancer, tumor markers, CA 15-3, CEA, IGF1, HGF, 4653

EGF, silibinin, CD44, EGFR, TGF-α, MMP-9, breastcancer metastasis, 3767

Egfl8, colorectal cancer, quantitative polymerase chainreaction, 2249

EGFL8, gastric cancer, quantitative polymerase chainreaction, 3377

EGFR mutation, chemo-naive, erlotinib, non-small celllung cancer, platinum doublet, 3457

EGFR mutation, LAT1, CD98, recurrence, advancedNSCLC, prognosis, chemotherapy. Ki-67, p-Akt, p-mTOR, 3775

EGFR mutation, NSCLC, methylation, MLPA, targetedtherapy, gene methylation, TKIs, smoking, 4647

EGFR tyrosine kinase inhibitor, EGFR, HER2, NSCLC,oncogene addiction, 4155

EGFR, BEZ235, lung cancer, P13K/mTOR inhibitor, 849EGFR, BRAF mutation, KRAS, ERBB2 mutation, V600E,

lung cancer, adenocarcinoma, squamous cell carcinoma,SSCP, 4619

EGFR, breast cancer, lapatinib, imatinib, ErbB2, c-ABL,RTK, 789

EGFR, gefitinib, non-small cell lung cancer, NSCLC,epidermal growth factor receptor, skin toxicity, expandedaccess programme, EAP, 2949

EGFR, gefitinib, radiation, combination therapy, predictor,melanoma, 2883

EGFR, glioma, cell cycle, temozolomide, 3253EGFR, HER2, EGFR tyrosine kinase inhibitor, NSCLC,

oncogene addiction, 4155EGFR, HNSCC, polymorphism, Erk-1/2, AG1478,

cetuximab, 59EGFR, insulin-like growth factor-1, IGF-1, tamoxifen-

resistance, oestrogen resistance, breast cancer recurrence,oestrogen receptor-alpha, 23

EGFR, Ki-67, translational research, squamous cellcarcinoma, head and neck cancer, 665

EGFR, lung cancer, NSCLC, erlotinib, c-erbB-3, 281EGFR, mutation, estrogen receptor, lung cancer, 855EGFR, mutation, methylation, tobacco smoking, lung

adenocarcinoma, FHIT, RASSF1A, RUNX3, 1211EGFR, silibinin, CD44, EGF, TGF-α, MMP-9, breast

cancer metastasis, 3767EGFR-TKIs, non-small cell lung cancer, gefitinib,

erlotinib, resistance, bone metastasis, radiotherapy, 4519


4753

Elderly, parathyroid tumors, hyperparathyroidism, arterialblood pressure, serum calcium, PTH, arterialhypertension, 3969

Electroporation, oligonucleotides, siRNA, miRNA, review,4083

ELISA, HB-EGF, ovarian cancer, 2553ELISPOT, DC, vaccine, whole tumor cell, IFN-γ, 3995EMMPRIN, Fyn, integrin, oral SCC, ECM, 1205EMT, E-cadherin, gamma catenin, vimentin, fibronectin,

lung adenocarcinoma, 4451Encapsulation, PAMAM dendrimers, intracellular delivery,

resistance, SMVT, cisplatin, ovarian cancer cell lines, 897Encephalopathy, 5-FU, hyperammonemia, capecitabine,

metastatic rectal adenocarcinoid, 335Endocytosis, cytotoxicity, glycosylated antitumor ether

lipid, mechanism of action, methyl-β-cyclodextrin, 3809Endoglin, angiogenesis, cancer, CD105, tumor, review,

2283Endoglin, angiogenic factors, angiogenin, endostatin,

cervical cancer, 2651Endoglin, angiogenic factors, cervical cancer, VEGF,

angiogenin, 2589Endometrial brush, cytology, endometrial cancer,

endometrial pathology, screening test, uterobrush, 3469Endometrial cancer, conservative management, grade 2,

grade 3, fertility, 3047Endometrial cancer, cytology, endometrial brush,

endometrial pathology, screening test, uterobrush, 3469Endometrial cancer, engineered stem cells, cytosine

deaminase, interferon-β, 2853Endometrial cancer, prognosis, survival, radiotherapy,

chemotherapy, 3483Endometrial carcinoma, para-aortic lymph node dissection,

adjuvant chemotherapy, prognosis, 4513Endometrial pathology, cytology, endometrial brush,

endometrial cancer, screening test, uterobrush, 3469Endometrial proliferation, melatonin, cancer, rats, 2637Endometrial stromal sarcoma, t(10;17) translocation,

neuroectodermal, 2367Endometriosis, p53, p21, CDKN1A/WAF/CIP1,

polymorphism, genotype, 4301Endometrium, cancer, apoptosis, Bcl-2, p53, E-cadherin,

estrogen receptor, progesterone receptor, 4191Endostatin, angiogenic factors, angiogenin, endoglin,

cervical cancer, 2651Endostatin, angiogenic factors, vascular endothelial growth

factor, basic fibroblast growth factor, cervical cancer,2645

Endothelial cells, cigarette smoking, Swedish-typesmokeless tobacco, Snus, ethanol, human normal cells,cell death, fibroblasts, 1527

Endothelial cells, HAVcR-1, tight junction, tight junctionregulation, 467

Endothelial cells, VEGFR2, tyrosine kinase inhibitor, drugresistance, angiogenesis, HUVEC, 2787

Endothelin A and B receptor (ETAR and ETBR), coloncancer metastasis, epithelial-mesenchymal transition(EMT), endothelin axis, phosphatase and tensin homolog(PTEN), 861

Endothelin axis, colon cancer metastasis, epithelial-mesenchymal transition (EMT), endothelin A and Breceptor (ETAR and ETBR), phosphatase and tensinhomolog (PTEN), 861

Endothelium, breast cancer, E-selectin, liver metastasis,pro-inflammatory microenv ironment, 3219

Endotoxin, LPS, oral administration, toxicity, absorption,lipopolysaccharide, review, 2431

Energetic metabolism, gastric carcinoma, carcinomatosis,glycolysis, apoptosis, necrosis, citrate, 797

Engineered stem cells, endometrial cancer, cytosinedeaminase, interferon-β, 2853

Enterocolitis, radiation therapy, risk factor, leg edema,postoperative radiotherapy, gynecological malignancies,3527

Enzyme-linked immunosorbent assay, ovarian cancer,diagnosis, biomarkers, cathepsin, matrixmetalloproteinase-9, heparanase, 3423

EP4, prostate cancer, PGE2, p-Akt, Snail, epithelial-mesenchymal transition, 4347

Epidemiology, vitamin D, 25-hydroxyvitamin D, breastneoplasms, case–control studies, meta-analysis,prevention, 2939

Epidermal growth factor receptor (EGFR), lung cancer,cytology, fiberbronchoscopy, diagnosis, 4207

Epidermal growth factor receptor, gefitinib, non-small celllung cancer, NSCLC, EGFR, skin toxicity, expandedaccess programme, EAP, 2949

Epigenetic modifiers, kidney, toxicity, ROS, p66shc,mitochondria, 3267

Epigenetic regulation, breast cancer, histone-modifiergenes, histone acetyltransferases, histonemethyltransferases, 4115

Epigenetics, astrocytomas, DNA methylation, histonedeacetylases, decitabine, 1337

Epigenetics, bladder cancer, DNA methylation,chemotherapy, chemoresistance, 5-azacytidine, 3757

Epithelial-mesenchymal transition (EMT), cysteine-histidine-rich protein (PINCH), colorectal carcinoma,vascular endothelial growth factor (VEGF), FAS, 4127

Epithelial-mesenchymal transition, lung cancer, potassiumchannels, Eag1, TGF-β, 1265

Epithelial-mesenchymal transition (EMT), colon cancermetastasis, endothelin axis, endothelin A and B receptor(ETAR and ETBR), phosphatase and tensin homolog(PTEN), 861


4754

Epithelial-mesencymal transition, prostate cancer, PGE2,EP4, p-Akt, Snail, 4347

Epithelial ovarian cancer, vascular endothelial growthfactor, VEGF, gene expression, anti-VEGF therapy,bevacizumab, 731

ER stress, proteasome inhibitor, receptor tyrosine kinase,activation loop, multiple myeloma, FGFR3, Lys650Glumutation, K650E, bortezomide, plasma cell malignancy, 113

ERas, gastric cancer, chemotherapy, CPT-11, rapamycin,3353

ERBB2 mutation, BRAF mutation, KRAS, EGFR, V600E,lung cancer, adenocarcinoma, squamous cell carcinoma,SSCP, 4619

ErbB2, breast cancer, lapatinib, imatinib, EGFR, c-ABL,RTK, 789

ERCC1 protein, head and neck neoplasms, cisplatin, DNArepair, radiation, 4135

ERCC1, colorectal cancer, pulmonary metastases, TS,OPRT, BRCA1, MVD, adjuvant chemotherapy, 2763

ERCC1, thymidylate synthase, adenosine triphosphate,drug screening assay, colorectal neoplasm, 3843

ERK, pancreatic cancer, gemcitabine, resistance,lenalidomide, 3747

ERK, tumor suppressors, cell cycle arrest, DNA N-methyltransferase, 2723

ERK1/2 kinase, laryngeal cancer, glutamate receptor,antagonist, proliferation, 565

Erk1/2, HGF, c-Met, NK4, CT26, 5-fluorouracil, Akt,thymidylate synthase, 2217

Erk-1/2, HNSCC, EGFR, polymorphism, AG1478,cetuximab, 59

Erlotinib, chemo-naive, EGFR mutation, non-small celllung cancer, platinum doublet, 3457

Erlotinib, lung cancer, NSCLC, EGFR, c-erbB-3, 281Erlotinib, non-small cell lung cancer, gefitinib, resistance,

bone metastasis, radiotherapy, EGFR-TKIs, 4519Erlotinib, non-small cell lung cancer, third-line treatment,

gefitinib, review, 649Erlotinib, pancreatic neoplasm, cetuximab, chemotherapy,

chemoresistance, chemosensitivity, 1039Erlotinib, primary peritoneal carcinoma, bevacizumab, 4397Erythropoiesis stimulating agents, erythropoietin, breast

cancer, erythropoietin receptor, 1189Erythropoietin receptor, erythropoietin, breast cancer,

erythropoiesis stimulating agents, 1189Erythropoietin, breast cancer, erythropoietin receptor,

erythropoiesis stimulating agents, 1189ERα, breast cancer, DAX-1, ApoD, prognosis, 443E-Selectin, breast cancer, liver metastasis, endothelium,

pro-inflammatory microenv ironment, 3219E-Selectin, metastasis, HPA, P-selectin, SCID mouse,

lectin, breast carcinoma cells, colon adenocarcinoma,1589

Esophageal cancer, CCN family, WISP-1, WISP-1v, 991Esophageal cancer, DCF, induction chemotherapy,

borderline-resectable T4, cisplatin, 5-fluorouracil,docetaxel, 3535

Esophageal cancer, IL-6, cisplatin, chemosensitivity, 67Esophageal cancer, neoadjuvant therapy,

radiochemotherapy, docetaxel, cisplatin, phase II trials,4407

Esophageal cancer, radiation sensitivity, gastric cancer,hypoxia, cell cycle, reoxygenation, 3369

Esophageal carcinoma, chemotherapy, docetaxel,nedaplatin, S1, phase I, 4589

Esophageal carcinoma, mutations, polymorphisms, TP53,FHIT, chronic esophagitis, 1685

Esophageal neoplasm, HIF-1α, radiotherapy, chemotherapy,2351

Esophageal squamous cell carcinoma, neoadjuvantchemoradiotherapy, pathological response, complication,prognosis, 3073

Esophagus, baboon, gastric reflux, mucus metaplasia, 2187Esophagus, cytokeratin 4, fascin, biomarker, tissue

microarray, squamous cell carcinoma, 945Estrogen pathway, single nucleotide polymorphisms,

steroid hormones, mammographic breast density, breastcancer, review, 4369

Estrogen receptor beta, ovarian cancer, prognostic factor,immunohistochemistry, cisplatin, 711

Estrogen receptor, breast cancer cell lines, flow cytometry,RT-PCR, Western blotting, 521

Estrogen receptor, cancer, endometrium, apoptosis, Bcl-2,p53, E-cadherin, progesterone receptor, 4191

Estrogen receptor, EGFR, mutation, lung cancer, 855Estrogen receptor, p27, breast cancer, node dissection,

stage I, progesterone receptor, 4401Ethanol, cigarette smoking, Swedish-type smokeless

tobacco, Snus, human normal cells, cell death,endothelial cells, fibroblasts, 1527

Ethnicity, prostate cancer, neuroendocrine differentiation,3897

Ethynyl phosphine, ferrocene, gold, platinum, cytotoxicity,HeLa, 825

Etiology, brain tumors, cytomegalovirus, glioblastoma, 959Etodolac, 5-FU resistance, thymidylate synthase,

cyclooxygenase-2, 2893Etomidate, apoptosis, Bax, Bcl-xl, caspase-3, RAW264.7

cells, 2203Etoposide, colorectal, neuroendocrine cancer, small cell

cancer, chemotherapy, cisplatin, 975Evaluation and prediction of pharmacological effects, cell-

to-cell interaction, adhesion molecules, characteristics ofcancer cells, anticancer drug resistance, chemotherapy,apoptosis, drug sensitivity, drug resistance-relating factors,gene expression analysis, screening systems, 3237


4755

Everolimus, carboplatin, RAD001, breast cancer, mTORinhibitor, 2713

Expanded access programme, gefitinib, non-small cell lungcancer, NSCLC, epidermal growth factor receptor,EGFR, skin toxicity, EAP, 2949

Extented lymphadenectomy, bladder cancer, lymph nodemetastasis, radical cystectomy, lymph node density,cancer-specific survival, short review, 271

Extracellular proteasome, ubiquitin–proteasome system,breast cancer, 2197

Extracellular space, hepatocellular carcinoma, 1H MRI,apparent diffusion coefficient, benzamide riboside,angiography, therapy response, motion effect, 2045

Extravasation, metastasis, blood−brain barrier, brainendothelial cells, COX-2, 4307

Ezrin, rectal cancer, radiotherapy, chemotherapy, prognosticfactor, biomarker, carbonic anhydrase IX, hypoxia-inducible factor-1a, glucose transporter-1, 4529

FAS, apoptosis, liver metastases, invasion front, TRAIL,colorectal cancer, 1215

FAS, cysteine-histidine-rich protein (PINCH), colorectalcarcinoma, epithelial mesenchymal transition (EMT),vascular endothelial growth factor (VEGF), 4127

Fascin, cytokeratin 4, biomarker, tissue microarray,squamous cell carcinoma, esophagus, 945

Fatigue, adriamycin, cardiotoxicity, myotoxicity, 2023FBAL, S-1, 5-fluorouracil, Phase I, tegafur, FT, reversible

dihydropyrimidine dehydrogenase, DPD, gimeracil,CDHP, solid tumors, 625

FDG-PET, uterine cervical cancer, lymph node, MRI, 3865Feasibility study, recurrent cervical cancer, oral etoposide,

cisplatin, second-line chemotherapy, 3063Feasibility study, triplet combination chemotherapy,

paclitaxel, cisplatin, S-1, advanced gastric cancer, 3085Fenretinide, LXS oral powder, phase I, clinical trial, 961Ferrocene, ethynyl phosphine, gold, platinum, cytotoxicity,

HeLa, 825Fertility, conservative management, grade 2, grade 3,

endometrial cancer, 3047Feulgen staining, DNA ploidy, image analysis, cytometry,

cytology, hematoxylin staining, Papanicolaou staining, 53FGF-2, heparan sulfate, chitosan, anticancer, breast cancer,

cell proliferation, 1321FGFR3, proteasome inhibitor, receptor tyrosine kinase,

activation loop, multiple myeloma, ER stress, Lys650Glumutation, K650E, bortezomide, plasma cell malignancy, 113

FHIT, EGFR, mutation, methylation, tobacco smoking,lung adenocarcinoma, RASSF1A, RUNX3, 1211

FHIT, mutations, polymorphisms, TP53, chronicesophagitis, esophageal carcinoma, 1685

Fiberbronchoscopy, epidermal growth factor receptor(EGFR), lung cancer, cytology, diagnosis, 4207

Fiberoptic ductoscopy, breast cancer, nipple discharge, 3517

Fibroblasts, cigarette smoking, Swedish-type smokelesstobacco, Snus, ethanol, human normal cells, cell death,endothelial cells, 1527

Fibroid cells, leiomyoma, Arf-induced senescence,HMGA2, MDM2 antagonists, 753

Fibronectin, EMT, E-cadherin, gamma catenin, vimentin,lung adenocarcinoma, 4451

Fibrosarcoma, progression, inflammation-associatedcarcinogenesis, non-nuclear protein, 1259

Fibrosis, hyperthermia, thermal cancer therapy, hepaticstellate cells, HCC, HepG2, 1583

Fibrosis, hyperthermia, thermal cancer therapy, hepaticstellate cells, HCC, transwell, co-culture, 3713

FISH, circulating tumor cells, CTCs, microfiltration bysize, real-time quantitative reverse transcriptase-polymerase chain reaction, qRT-PCR, molecular biology,cytomorphology, cell culture, lung cancer, 427

Fistula, BPF, operation, lung cancer, risk factor, concurrentdisease, perioperative complication, infection, 619

FKBP52, breast cancer, geldanamycin, heat-shock proteins,lumican, 2095

Flash-wave light, acridine orange, osteosarcoma,pulmonary metastasis, photodynamic therapy,fluorovisualization, 4163

Flavone, Zanthoxylum ailanthoides Sieb and Zucc., humancolon adenocarcinoma cell, colo 205 cells, caspases,apoptosis, 1667

Flow cytometry, estrogen receptor, breast cancer cell lines,RT-PCR, Western blotting, 521

Flow cytometry, minimal residual disease, acutelymphoblastic leukemia, children, early response, 1453

Flow of CSF, acute myeloid leukemia, immunotherapy,interleukin-2, peptide vaccination, cerebrospinal fluid,CSF, chloroma, 2343

FLOX regimen, chemotherapy, metastatic colorectal cancer,phase II study, 5-FU, leucovorin, oxaliplatin, 4657

Fluorescence imaging, circulating tumor cells, CTCs,prostate cancer, immunomagnetic beads, GFP, chickembryo, brain metastasis, metastatic assay, 3125

Fluorescence in situ hybridization, renal cell carcinoma,chromophobe renal cell carcinoma, renal oncocytoma,tissue sections, isolated nuclei, 3137

Fluorescence, GFP, prostate cancer, PC-3, orthotopic,circulating cancer cells, immunomagnetic beads,isolation, imaging, culture, 1535

Fluorescent in situ hybridization, Inv(3)(q21q26),t(3;3)(q21;q26), breakpoint distribution, chromosomalabnormalities, 3441

Fluorescent protein imaging (FPI), colon cancer, orthotopicmodel, GFP, MRI, selenium, angiogenesis, 387

Fluorothymidine, thymidine kinase1, 5’(3’)-deoxyribonucleotidase, proliferation, lung cancer, coloncancer, 2135


4756

Fluorouracil, chemotherapy, gemcitabine, colon cancer,capecitabine, 2971

5-Fluorouracil, DCF, induction chemotherapy, borderline-resectable T4, esophageal cancer, cisplatin, docetaxel, 3535

5-Fluorouracil, gastric cancer, gastroesophageal junctionadenocarcinoma, DCF, docetaxel, cisplatin, G-CSF, 2379

5-Fluorouracil, HGF, c-Met, NK4, CT26, Akt, Erk1/2,thymidylate synthase, 2217

5-Fluorouracil, KRAS, p53, colorectal, oxaliplatin,capecitabine, clinical, CAIRO2, sequence analysis, 1379

5-Fluorouracil, lung adenocarcinoma, dihydropyrimidinedehydrogenase, thymidylate synthase, chemosensitivity,4665

5-Fluorouracil, polo-like kinase 1, cholangiocarcinoma,gemcitabine, BI 2536, 3289

5-Fluorouracil, S-1, Phase I, FBAL, tegafur, FT, reversibledihydropyrimidine dehydrogenase, DPD, gimeracil,CDHP, solid tumors, 625

Fluorovisualization, acridine orange, osteosarcoma,pulmonary metastasis, photodynamic therapy, flash-wavelight, 4163

Flutamide, androgen receptor, combination strategy,prostate cancer, prostate-specific antigen, resveratrol,3323

Fluvastatin, melanoma, sorafenib, JNK, AKT, 3259Focused ultrasound, sonodynamic therapy, 5-

aminolevulinic acid, glioma, deep-seated, rat model,2527

Folate receptor, drug delivery, cancer, liposome, vincristine,drug targeting, 1521

FOLFIRI, bevacizumab, XELIRI, colorectal cancer,efficacy, safety, 1777

FOLFIRI, colorectal cancer, regulatory T-cells, antitumorimmunity, FOLFOX, 4569

FOLFOX, colorectal cancer, regulatory T-cells, antitumorimmunity, FOLFIRI, 4569

Follow-up, breast cancer, disseminated tumor cells, bonemarrow, prognosis, 2749

Form Y-2, STAI test, cancer risk, breast cancer, anxiety,1801

Fotemustine, hepatocellular carcinoma, hepatic intraarterialtherapy, interferon, chemoimmunotherapy, 4553

FOXP3, lung cancer, NSCLC, immunohistochemistry,lymph node, metastasis, 1677

Free testosterone (FT), prolactin (PRL), luteinizinghormone (LH), total testosterone (TT), prostate-specificantigen (PSA), prostate cancer, 3913

Free testosterone, luteinizing hormone, LH, totaltestosterone, TT, FT, prostate-specific antigen, PSA,prostate cancer, 1071

FT, luteinizing hormone, LH, total testosterone, TT, freetestosterone, prostate-specific antigen, PSA, prostatecancer, 1071

FT, S-1, 5-fluorouracil, Phase I, FBAL, tegafur, reversibledihydropyrimidine dehydrogenase, DPD, gimeracil,CDHP, solid tumors, 625

5-FU, advanced esophageal cancer, combinedchemotherapy, docetaxel, CDDP, 633

5-FU, anal cancer, cisplatin, paclitaxel, 46375-FU, chemotherapy, FLOX regimen, metastatic colorectal

cancer, phase II study, leucovorin, oxaliplatin, 46575-FU, hyperammonemia, encephalopathy, capecitabine,

metastatic rectal adenocarcinoid, 3355-FU, resistance, thymidylate synthase, cyclooxygenase-2,

etodolac, 28935-FU, stealth liposomes, PEG liposomes, locoregional

chemotherapy, liver metastases, 147Fundic glend polyps, polyp, gastric, chief cells, 1789FUS1, tumor suppressor gene, sarcoma, RT-PCR,

immunohistochemistry, growth inhibition, 11Fusion gene, prostate cancer, microRNA, TMPRSS2:ERG,

403FVB, min mice, 2-amino-1-methyl-6-phenylimidazo[4,

5-b]pyridine, Apc, C57Bl/6J, intestinal carcinogenesis,785

Fyn, EMMPRIN, integrin, oral SCC, ECM, 1205G2/M blockage, chalcone, glioblastoma, cell death, 3213G2/M phase arrest, N-heterocyclic indolyl glyoxylamides,

p53-independent apoptosis, human lung cancer cells,radiosensitivity, 3407

Gag and env genes, HTLV-1, RNA interference, shRNA,2173

Galectin-1, mucin-1, galectin-3, leiomyosarcoma,leiomyoma, myometrium, 451

Galectin-3, mucin-1, galectin-1, leiomyosarcoma,leiomyoma, myometrium, 451

Gallic acid (GA), human leukemia HL-60 cells, apoptosis,death receptor-mediated pathways, mitochondria-mediated pathways, 2821

Gallic acid, prostate cancer, cytotoxicity, triphala,Ayurvedic medicine, 3739

Gamma catenin, EMT, E-cadherin, vimentin, fibronectin,lung adenocarcinoma, 4451

Gamma radiation, antiapoptosis, colorectal cancer,microarray, RT-PCR, REG4, NEIL2, BIRC5, 4147

Gamma-delta T-cell, renal cell carcinoma, prognosis factor,1027

Ganciclovir, adenovirus, prodrug activation, HNSCC,thymidine kinase, apoptosis, 3851

Gankyrin, overexpression, oral squamous cell carcinoma,2683

Gastric adenocarcinoma, signet-ring adenocarcinoma,breast metastasis, skin, immunohistochemistry, 2373

Gastric atrophy, polymorphism, Helicobacter pylori,intestinal metaplasia, XRCC1, GSTP1, GSTT1, GSTM1,1459


4757

Gastric cancer (GC), single nucleotide polymorphisms(SNPs), chemosensitivity, docetaxel, DNASE2B, HTRIE,4329

Gastric cancer, cetuximab, irinotecan, oxaliplatin, KRASphase II trial, 4439

Gastric cancer, cetuximab, S-1, thymidylate synthase, 3691Gastric cancer, EGFL8, quantitative polymerase chain

reaction, 3377Gastric cancer, ERas, chemotherapy, CPT-11, rapamycin,

3353Gastric cancer, gastroesophageal junction adenocarcinoma,

DCF, docetaxel, cisplatin, 5-fluorouracil, G-CSF, 2379Gastric cancer, KL-6 mucin, MUC1, β-catenin, invasion

front, 535Gastric cancer, low back pain, pregnancy, bilateral

erythematous breast hypertrophy, 681Gastric cancer, lymph node dissection, prognosis, staging,

2361Gastric cancer, neoadjuvant chemoradiotherapy, S-1,

cisplatin, 3079Gastric cancer, paclitaxel, doxifluridine, ascites, 4625Gastric cancer, paclitaxel, doxifluridine, thymidine

phosphorylase, chemotherapy, 287Gastric cancer, photodynamic therapy, PDT,

glycoconjugated chlorin, apoptosis, colon cancer, 763Gastric cancer, polymorphism, XRCC1, Arg399Gln,

Arg194Trp, GSTP1 Ile104Val, GSTT1, GSTM1, survival,705

Gastric cancer, radiation sensitivity, esophageal cancer,hypoxia, cell cycle, reoxygenation, 3369

Gastric cancer, TFPI2, methylation, 3835Gastric cancer, TIP60, quantitative real-time PCR, 77Gastric carcinoma, carcinomatosis, glycolysis, energetic

metabolism, apoptosis, necrosis, citrate, 797Gastric reflux, esophagus, baboon, mucus metaplasia, 2187Gastric, polyp, chief cells, fundic glend polyps, 1789Gastroesophageal junction adenocarcinoma, gastric cancer,

DCF, docetaxel, cisplatin, 5-fluorouracil, G-CSF, 2379Gastrointestinal adverse events, multiple myeloma,

bortezomib, once-weekly administration, dexamethasone,2297

Gastrointestinal stromal tumor, breast cancer,neurofibromatosis type 1, 4481

Gastrointestinal stromal tumor, imatinib, adherence,ADAGIO study, 1407

Gastrointestinal stromal tumor, sunitinib, pneumatosisintestinalis, 3429

Gastrointestinal stromal tumors (GISTs), Ras-Raf-ERK/MAPK Pathway, PI3K-Akt/mTOR pathway, insulin-like growth factor 1 receptor (IGF1R), CD117, 3019

Gc1f1f protein, Gc-derived macrophage-activating factorprecursor, preGcMAF, 1f1f subtype of Gc protein,phagocytic activity, mouse peritoneal macrophages, 2489

Gc-derived macrophage-activating factor precursor,preGcMAF, 1f1f subtype of Gc protein, Gc1f1f protein,phagocytic activity, mouse peritoneal macrophages, 2489

G-CSF, gastric cancer, gastroesophageal junctionadenocarcinoma, DCF, docetaxel, cisplatin, 5-fluorouracil, 2379

Gc protein, Gc-derived macrophage-activating factorprecursor, preGcMAF, Gc1f1f protein, phagocyticactivity, mouse peritoneal macrophages, 2489

Gefitinib, non-small cell lung cancer, erlotinib, resistance,bone metastasis, radiotherapy, EGFR-TKIs, 4519

Gefitinib, non-small cell lung cancer, NSCLC, epidermalgrowth factor receptor, EGFR, skin toxicity, expandedaccess programme, EAP, 2949

Gefitinib, non-small cell lung cancer, third-line treatment,erlotinib, review, 649

Gefitinib, radiation, combination therapy, EGFR, predictor,melanoma, 2883

Gelatinase, matrix metalloproteinases, tongue carcinoma,green fluorescent protein, xenograft, peptide, 3659

Geldanamycin, breast cancer, FKBP52, heat-shockproteins, lumican, 2095

Gemcitabine, BBN, sirolimus, mice, urothelial lesion,1637

Gemcitabine, chemotherapy, fluorouracil, colon cancer,capecitabine, 2971

Gemcitabine, hENT1, cytotoxicity, I3C, pancreatic cancer,3171

Gemcitabine, NKG2D, MICA, MICB, HCC,immunotherapy, 2505

Gemcitabine, pancreatic cancer, intra-arterial therapy,chemoradiotherapy, 3909

Gemcitabine, pancreatic cancer, resistance, ERK,lenalidomide, 3747

Gemcitabine, polo-like kinase 1, cholangiocarcinoma, 5-fluorouracil, BI 2536, 3289

Gemcitabine, squamous cell carcinoma, bladder cancer,recurrence, paclitaxel, 4465

Gemcitabine, urachal cancer, recurrence, cisplatin,chemotherapy, 2335

Gemcitabine, virotherapy, pancreatic cancer,chemoresistance, PDAC, GFP, 1279

Gender, prognosis, left colon, right colon, sigmoid,survival, colon cancer, 2347

Gene expression, vascular endothelial growth factor,VEGF, anti-VEGF therapy, bevacizumab, epithelialovarian cancer, 731

Gene methylation, HOPX, colorectal cancer, 2889Gene methylation, NSCLC, methylation, MLPA, targeted

therapy, TKIs, smoking, EGFR mutation, 4647Gene mutations, medullary thyroid carcinoma, RET, HRAS,

KRAS, NRAS, BRAF, AKT1, CTNNB1, mutationalscreening, 4179


4758

Gene mutations, ovarian cancer, BRCA 1/2, TP53, PI3K,AKT, BRAF, KRAS, review, 2661

Gene polymorphism, cervical cancer, C-reactive protein,CRP, CRP1919 (rs1417938), CRP2667 (rs1800947),CRP3872 (rs1205), CRP5237 (rs2808630), prognosis,single nucleotide polymorphism, 2259

Gene therapy, AAV, CXCR4, bioluminescence, breastcancer, 1627

Gene therapy, mesenchymal stem cells, cytotherapy,hepatocellular carcinoma, 3705

Gene therapy, NK4, cationised gelatin, cisplatin, squamouscell carcinoma, 105

Gene-directed enzyme prodrug therapy review, neural stemcells, suicide genes, prodrugs, invasive tumors, animalmodels, 1249

Genes, oral squamous cell carcinomas, toombak, apoptosis,cell cycle regulation, intermediate filament proteins,Sudan, 3345

Genetic polymorphism, cervical cancer, GSTM1, GSTT1,human papillomavirus, cancer risk, 3051

Genetic polymorphisms, cancer susceptibility, DNA-repairgenes, metabolizing genes, CYP1A1, CYP1E1, XRCC1,1359

Genistein, breast cancer, p90RSK, cell proliferation, T47Dcells, 209

Genistein, breast cancer, quercetin, apoptosis, NFκB, 3301Genotype, p53, p21, CDKN1A/WAF/CIP1, polymorphism,

endometriosis, 4301Germ cell tumour, cisplatin, thrombosis, hypercoagulation,

vascular toxicity, von Willebrand factor, 4501GFP, circulating tumor cells, CTCs, prostate cancer,

immunomagnetic beads, chick embryo, brain metastasis,metastatic assay, fluorescence imaging, 3125

GFP, colon cancer, orthotopic model, fluorescent proteinimaging (FPI), MRI, selenium, angiogenesis, 387

GFP, magnetic resonance imaging, micro-computedtomography, optical reflectance imaging, tumor volume,molecular imaging, RFP, 2907

GFP, prostate cancer, PC-3, orthotopic, circulating cancercells, immunomagnetic beads, isolation, fluorescence,imaging, culture, 1535

GFP, virotherapy, pancreatic cancer, chemoresistance,gemcitabine, PDAC, 1279

Gimeracil, S-1, 5-fluorouracil, Phase I, FBAL, tegafur, FT,reversible dihydropyrimidine dehydrogenase, DPD,CDHP, solid tumors, 625

Glabridin, UVB, normal human keratinocytes, 18β-glycyrrhetinic acid, ROS, 2209

GLI2, PTHrP, osteolysis, breast cancer, 6-thioguanine,2705

Glioblastoma model, mKate2, mCherry, intracranial, liveimaging, temozolomide, 2161

Glioblastoma, brain tumors, cytomegalovirus, etiology, 959

Glioblastoma, chalcone, G2/M blockage, cell death, 3213Glioma, EGFR, cell cycle, temozolomide, 3253Glioma, IDH1 mutation, cetuximab, sunitinib,

bevacizumab, 44571p, Glioma, oligodendroglioma, 1p19q, PAV, ACNU,

procarbazine, vincristine, chemotherapy, 4475Glioma, 1p19q, oligodendroglioma, 1p, PAV, ACNU,

procarbazine, vincristine, chemotherapy, 4475Glioma, oligodendroglioma, 1p19q, 1p, PAV, ACNU,

procarbazine, vincristine, chemotherapy, 4475Glioma, PTEN, cell cycle, temozolomide, ionizing

radiation, radiosensitivity, 1653Glioma, resveratrol, invasion, TNF-α, urokinase

plasminogen activator, 4223Glioma, sonodynamic therapy, focused ultrasound,

5-aminolevulinic acid, deep-seated, rat model, 2527Beta-glucan, dectin-1, B-cell lymphoma, CD86,

proliferation, cell death, 4195Beta-glucan, β-glucan, dendritic cells, maturation,

immunomodulator, 1647Glucose transporter-1, hypoxia, hypoxia-inducible factor

1α, preoperative chemoradiotherapy, rectal cancer, 1559Glucose transporter-1, rectal cancer, radiotherapy,

chemotherapy, prognostic factor, biomarker, carbonicanhydrase IX, hypoxia-inducible factor-1a, ezrin, 4529

Glucuronidation, active metabolite of irinotecan, SN-38,SN-38 glucuronide (SN-38G), panipenem,pharmacokinetics, 2915

GLUR4, glutamate receptor, cancer, PCR, shRNA, NR1,KA2, NR2D, 3181

GLUT-1, rectal cancer, chemotherapy, radiotherapy, tumourregression, prognosis, 311

Β-Glucan, beta-glucan, dendritic cells, maturation,immunomodulator, 1647

Β-Glucan, cyclophosphamide, A20 lymphoma, regulatoryT-cell, 1169

Glutamate receptor, cancer, PCR, shRNA, NR1, GLUR4,KA2, NR2D, 3181

Glutamate receptor, laryngeal cancer, antagonist,proliferation, ERK1/2 kinase, 565

γ-Glutamyl cyclotransferase, C7orf24, osteosarcoma,1297

Glutathione, selenoprotein, colon cancer, thioredoxin,antioxidant enzyme expression, 2693

Glycated apolipoprotein B, colorectal cancer, immuno-histochemistry, 555

Glycoconjugated chlorin, photodynamic therapy, PDT,apoptosis, gastric cancer, colon cancer, 763

Glycolysis, gastric carcinoma, carcinomatosis, energeticmetabolism, apoptosis, necrosis, citrate, 797

P-Glycoprotein, chemotherapy, inhibition of multidrugresistance, osteosarcoma cell lines, carcinoma cell lines,siRNA, 2813


4759

P-Glycoprotein, multidrug resistance, benzo[a]quinolizinderivatives, 921

P-Glycoprotein, multidrug-resistant cancer cells, MDRmouse T-lymphoma cells, ABCB1 transporter,phenothiazines, thioridazine, apoptosis, 4201

Glycosylated antitumor ether lipid, cytotoxicity,endocytosis, mechanism of action, methyl-β-cyclodextrin, 3809

18β-Glycyrrhetinic acid, UVB, normal humankeratinocytes, glabridin, ROS, 2209

GM-CSF, Pantoea agglomerans, A46, LPS, LPSp, LPSa46,macrophage, M-CSF, 2467

Gold, ferrocene, ethynyl phosphine, platinum, cytotoxicity,HeLa, 825

Grade 2, conservative management, grade 3, endometrialcancer, fertility, 3047

Grade 3, conservative management, grade 2, endometrialcancer, fertility, 3047

Grade, age, breast cancer, immunohistochemistry, measlesvirus, p53, 913

Grade, SDF1β, RCC, T-cell infiltration, 2797Green fluorescent protein, matrix metalloproteinases,

gelatinase, tongue carcinoma, xenograft, peptide, 3659Green fluorescent protein, red fluorescent protein, cancer

cell seeding, real-time imaging, lung, liver, muscle, 3665Growth factors, breast cancer, tumor markers, CA 15-3,

CEA, IGF1, EGF, HGF, 4653Growth inhibition, tumor suppressor gene, FUS1, sarcoma,

RT-PCR, immunohistochemistry, 11GSTM1, cervical cancer, GSTT1, genetic polymorphism,

human papillomavirus, cancer risk, 3051GSTM1, polymorphism, Helicobacter pylori, gastric

atrophy, intestinal metaplasia, XRCC1, GSTP1, GSTT1,1459

GSTM1, polymorphism, XRCC1, Arg399Gln, Arg194Trp,GSTP1 Ile104Val, GSTT1, gastric cancer, survival, 705

GSTP1 Ile104Val, polymorphism, XRCC1, Arg399Gln,Arg194Trp, GSTT1, GSTM1, gastric cancer, survival, 705

GSTP1, polymorphism, Helicobacter pylori, gastricatrophy, intestinal metaplasia, XRCC1, GSTT1, GSTM1,1459

GSTT1, cervical cancer, GSTM1, genetic polymorphism,human papillomavirus, cancer risk, 3051

GSTT1, polymorphism, Helicobacter pylori, gastricatrophy, intestinal metaplasia, XRCC1, GSTP1, GSTM1,1459

GSTT1, polymorphism, XRCC1, Arg399Gln, Arg194Trp,GSTP1 Ile104Val, GSTM1, gastric cancer, survival, 705

Guanylyl cyclase, cervical carcinoma, prognosis, iNOS,phosphodiesterase, 2319

Gynecological cancer, breast cancer, online tumorconference, interdisciplinary therapy management,second opinion, continuous medical training, 2669

Gynecological malignancies, radiation therapy, risk factor,enterocolitis, leg edema, postoperative radiotherapy, 3527

H+ exchange, Na+, oxidative stress, cholangiocellularcarcinoma, liver cancer, 459

γ-H2AX, radiation therapy, spinal cord, radiationmyelopathy, 561

HAVcR-1, tight junction, endothelial cells, tight junctionregulation, 467

HB-EGF, CRM197, doxorubicin, T-ALL, 2483HB-EGF, ovarian cancer, ELISA, 2553HB-EGF, ovarian cancer, targeted therapy, CRM197, 2461HCC, CEUS, dysplastic nodule, vascularity, cirrhosis, 3977HCC, gemcitabine, NKG2D, MICA, MICB,

immunotherapy, 2505HCC, hyperthermia, thermal cancer therapy, hepatic stellate

cells, fibrosis, HepG2, 1583HCC, hyperthermia, thermal cancer therapy, hepatic stellate

cells, fibrosis, transwell, co-culture, 3713HCC, PEDF, c-FLIP, p38, PPARγ, hepatocellular

carcinoma, apoptosis, 1173HCRT, rectal cancer, hyperthermo-chemo-radiation therapy,

distal margins, tumor response, 3963HCV-HCC, tubulin alpha-6 chain, proteomics, 2-DE, MS,

3331Head and neck cancer, biomarkers, diagnosis, early

detection, review, 1161Head and neck cancer, cyclin B1, cell cycle, p53,

squamous cell carcinoma, 3151Head and neck cancer, EGFR, Ki-67, translational research,

squamous cell carcinoma, 665Head and neck cancer, p38 MAPK, STAT1, STAT3,

phosphorylation, 3819Head and neck cancer, tonsillar cancer, base of tongue

cancer, oropharyngeal cancer, HPV, revie, 1515Head and neck neoplasms, ERCC1 protein, cisplatin, DNA

repair, radiation, 4135Head and neck squamous cell carcinoma HNSCC, levisticum

officinale lovage, oral cavity squamous cell carcinomaOCSCC, natural product, pharmacogenomics, 185

Head and neck squamous cell carcinoma HNSCC, Thymusvulgaris L. (thyme), oral cavity squamous cell carcinomaOCSCC, natural product, pharmacogenomics, 81

Heart, hepatocellular carcinoma, inferior vena cava,prognosis, 4641

Heat-shock proteins, breast cancer, FKBP52,geldanamycin, lumican, 2095

Hedgehog, leukemia, notch, wnt, γ-secretase inhibitor, 893Hedgehog, leukemia, self-renewal, 781HeLa, ferrocene, ethynyl phosphine, gold, platinum,

cytotoxicity, 825Helicobacter pylori, polymorphism, gastric atrophy,

intestinal metaplasia, XRCC1, GSTP1, GSTT1, GSTM1,1459


4760

Hemangiopericytoma, solitary fibrous tumor, oral cavity,cheek, soft tissue, 719

Hematoporphyrin monomethyl ether, ovarian cancer,hyprocrellin B, intracellular metabolism, subcellularlocalization, phototoxicity, 3229

Hematoxylin staining, DNA ploidy, image analysis,cytometry, cytology, Feulgen staining, Papanicolaoustaining, 53

Hemorrhagic cystitis, allogeneic stem cell transplantation,BK virus, review, 939

Hemotopoetic stem cell transplantation, humanpolyomavirus, BK virus, JC virus, cerebrospinal fluid,KI, WU, 3489

HENT1, gemcitabine, cytotoxicity, I3C, pancreatic cancer,3171

Heparan sulfate, chitosan, anticancer, breast cancer, cellproliferation, FGF-2, 1321

Heparan sulfate, proteoglycans, xenograft, HepG2 cells,immunotherapy, liver cancer, 4067

Heparanase, ovarian cancer, diagnosis, biomarkers,enzyme-linked immunosorbent assay, cathepsin, matrixmetalloproteinase-9, 3423

Heparins, non-anticoagulant heparins, chemotherapy, 411

Hepatectomy, hepatocellular carcinoma, perioperativefactors, uncontrolled ascites, prognosis, 4545

Hepatic arterial infusion, stealth liposomes, PEGliposomes, docetaxel, locoregional chemotherapy, livermetastases, 153

Hepatic intra-arterial chemotherapy (HAIC), advancedhepatocellular carcinoma (HCC), cetuximab, 3927

Hepatic intra-arterial infusion, irinotecan, metabolites,plasma disposition, pharmacokinetics, 3573

Hepatic intraarterial therapy, hepatocellular carcinoma,interferon, fotemustine, chemoimmunotherapy, 4553

Hepatic stellate cells, hyperthermia, thermal cancer therapy,fibrosis, HCC, HepG2, 1583

Hepatic stellate cells, hyperthermia, thermal cancer therapy,fibrosis, HCC, transwell, co-culture, 3713

Hepatitis B virus, antiangiogenic therapy, hepatocellularcarcinoma, prognosis, 4007

Hepatitis C virus, liver tumour, sarcomatoid tumour, cellline, culture, spectral karyotyping, xenograft, 129

Hepatocellular cancer, belinostat, bortezomib, pancreascancer, histone deacetylase inhibitor, proteasomeinhibitor, apoptosis, metabolomics, 1093

Hepatocellular carcinoma, 1H MRI, apparent diffusioncoefficient, extracellular space, benzamide riboside,angiography, therapy response, motion effect, 2045

Hepatocellular carcinoma, antiangiogenic therapy, hepatitisB virus, prognosis, 4007

Hepatocellular carcinoma, biomarker, AFP-IgM immunecomplexes, alpha-fetoprotein, 687

Hepatocellular carcinoma, child’s classification, livercirrhosis, MELD-score, nonhepatic cancer, survivalprobability, TNM classification, 2931

Hepatocellular carcinoma, cirrhosis, percutaneous ablation,percutaneous ethanol injection, radiofrequency ablation,randomized controlled trial, 2291

Hepatocellular carcinoma, heart, inferior vena cava,prognosis, 4641

Hepatocellular carcinoma, hepatic intraarterial therapy,interferon, fotemustine, chemoimmunotherapy, 4553

Hepatocellular carcinoma, human zinc finger 23, real-timeRT-PCR, annexin V-FITC/PI assay, apoptosis, 3595

Hepatocellular carcinoma, liver resection, multidrugresistance, ABC proteins, tyrosine kinase, 3883

Hepatocellular carcinoma, lymph node metastasis,transarterial chemoembolization, resection, 3991

Hepatocellular carcinoma, MACC 1, quantitative real-timePCR, 777

Hepatocellular carcinoma, mesenchymal stem cells, genetherapy, cytotherapy, 3705

Hepatocellular carcinoma, miriplatin, transarterialchemoembolization, 2983

Hepatocellular carcinoma, non-cirrhotic livers, viralhepatitis, 1055

Hepatocellular carcinoma, PEDF, c-FLIP, HCC, p38,PPARγ, apoptosis, 1173

Hepatocellular carcinoma, perioperative factors,uncontrolled ascites, hepatectomy, prognosis, 4545

Hepatocellular carcinoma, Stk11, Lkb1, nitrosamine,choline-deficient L-amino acid-defined diet, rat, 543

Hepatocellular carcinoma, vimentin, quantitativemethylation-specific PCR, 1289

Hepatocellular carcinoma, κ-actin, survival, postoperativeprognosis, 2037

Hepatoma, TNF-alpha, proteomics, 2-DE, LC-MS/MS,apoptosis, 2059

HepG2 cells, heparan sulfate, proteoglycans, xenograft,immunotherapy, liver cancer, 4067

HepG2, hyperthermia, thermal cancer therapy, hepaticstellate cells, fibrosis, HCC, 1583

HER2, EGFR, EGFR tyrosine kinase inhibitor, NSCLC,oncogene addiction, 4155

HER2, lapatinib, ADCC, breast cancer, Herceptin, 2999

HER2, non-small cell lung cancer, surgical resection,immunohistochemical staining, prognosis, 4631

Her-2/neu, peptide, vaccine, B-cell epitope, antitumoreffect, 3361

HER2-negative, metastatic breast cancer, capecitabine,triple-negative, prognostic factors, 1079

HER2-positive, S-1, trastuzumab, metastatic breast cancer,3035

Herceptin, lapatinib, HER2, ADCC, breast cancer, 2999


4761

N-Heterocyclic indolyl glyoxylamides, p53-independentapoptosis, G2/M phase arrest, human lung cancer cells,radiosensitivity, 3407

HGF, c-Met, NK4, CT26, 5-fluorouracil, Akt, Erk1/2,thymidylate synthase, 2217

HGF, growth factors, breast cancer, tumor markers, CA 15-3, CEA, IGF1, EGF, 4653

HIF, NSCLC, prognostic factors, NOTCH, lung cancer,1603

HIF1A, polymorphism, colorectal cancer, MMP2, VEGF,SNP, 575

HIF-1α, esophageal neoplasm, radiotherapy, chemotherapy,2351

HIF-1α, VEGF, mTOR, angiogenesis, oral cancer, 4429High hydrostatic pressure, bone, revitalization, tissue

engineering, 1235High-dose chemotherapy, alternative splicing, angiogenesis,

autologous stem cell transplantation, chickchorioallantoic membrane assay, placental growth factor,vascular endothelial growth factor, VEGFR1, 3115

High-dose chemotherapy, total estrogen blockade,leuprorelin, anastrazole, premenopausal breast cancer,VEGF, 671

High-frequency ultrasound, breast cancer, screeningmammography, microcalcification, advanced imagingmodes, 2575

Hippocampus, intravenous curcumin, blood–brain barrier,post-traumatic sequelae, striatum, brain stem, 907

Histoculture drug response assay, non-small cell lung cancer,class III β-tubulin, predictive marker, vinorelbine, 999

Histological status, HuR, breast cancer, prognosis, 303Histone acetyltransferases, breast cancer, epigenetic

regulation, histone-modifier genes, histonemethyltransferases, 4115

Histone deacetylase inhibitor, belinostat, bortezomib,pancreas cancer, proteasome inhibitor, hepatocellularcancer, apoptosis, metabolomics, 1093

Histone deacetylase inhibitor, chemotherapy, multidrugresistant, sarcoma, PCI-24781, 1115

Histone deacetylase inhibitor, TRAIL, LBH589, coloncancer, apoptosis, 3385

Histone deacetylases, astrocytomas, epigenetics, DNAmethylation, decitabine, 1337

Histone methyltransferases, breast cancer, epigeneticregulation, histone-modifier genes, histoneacetyltransferases, 4115

Histone-modifier genes, breast cancer, epigeneticregulation, histone acetyltransferases, histonemethyltransferases, 4115

Histopathology, male breast, ductal pleomorphiccarcinoma, immunohistochemistry, 3069

HL-60, PSK, apoptosis, cell proliferation, caspase-3activation, 2733

HMGA2, leiomyoma, Arf-induced senescence, MDM2antagonists, fibroid cells, 753

HMGB1, quantitative PCR, immunohistochemistry, RAGE,disseminated histiocytic sarcoma, 1541

HNSCC, adenovirus, prodrug activation, ganciclovir,thymidine kinase, apoptosis, 3851

HNSCC, EGFR, polymorphism, Erk-1/2, AG1478,cetuximab, 59

HNSCC, phase II, Src, AZD0530, saracatinib, 249HNSCC, radioimmunotherapy, SCID mice, xenografts,

radio-labeled monoclonal antibody, cytokeratin 8, 3315Hodgkin lymphoma, minichromosome maintenance

proteins, MCMs, cyclin D3, CCND3, survival, 3585HOGG1, XPD, polymorphism, urothelial carcinoma, 3939Hopelessness, bening breast disease, personality, type C,

cancer risk, 4019HOPX, colorectal cancer, gene methylation, 2889Hormonal therapy, prostate cancer, patients’ satisfaction,

radiation, surgery, 3903Hormone replacement therapy, ductal carcinoma in situ,

breast, lumpectomy, mastectomy, menopause, 1783Hormonotherapy, hypofractionated radiotherapy, prostate

cancer, intermediate risk, acute effect, image guidedradiation therapy, 3555

HPA, metastasis, E-selectin, P-selectin, SCID mouse, lectin,breast carcinoma cells, colon adenocarcinoma, 1589

HPV, tonsillar cancer, base of tongue cancer, oropharyngealcancer, head and neck cancer, review, 1515

HRAS, medullary thyroid carcinoma, gene mutations, RET,KRAS, NRAS, BRAF, AKT1, CTNNB1, mutationalscreening, 4179

HRRM2, non-small cell lung cancer, ribonucleotidereductase, p53R2, 3475

Hsp70, ionizing radiation, temozolomide, immunogenicity,cell death, 3727

Hsp90 inhibitor, NVP-AUY922, oral squamous cellcarcinoma, 1197

HT-29, branched-chain fatty acids, anticancer, antitumor,human breast cancer, human colon cancer, MCF-7, 3165

HTLV-1, ATL, leukemia, Hyptis verticillata jacq, multidrugresistance, 4251

HTLV-1, ATL, tetramethylnaphthalene, inhibitor, cell cycle,2241

HTLV-1, gag and env genes, RNA interference, shRNA,2173

HTRIE, single nucleotide polymorphisms (SNPs), gastriccancer (GC), chemosensitivity, docetaxel, DNASE2B,4329

Huachansu, radiation sensitivity, clonogenic cell survival,lung cancer cells, inhibition of DNA repair, 2141

Human breast cancer, branched-chain fatty acids,anticancer, antitumor, human colon cancer, HT-29, MCF-7, 3165


4762

Human colon adenocarcinoma cell, Zanthoxylumailanthoides Sieb and Zucc., colo 205 cells, caspases,apoptosis, flavone, 1667

Human colon cancer, branched-chain fatty acids,anticancer, antitumor, human breast cancer, HT-29, MCF-7, 3165

Human leukemia HL-60 cells, gallic acid (GA), apoptosis,death receptor-mediated pathways, mitochondria-mediated pathways, 2821

Human lung adenocarcinoma cell, cyclosporine A,apoptosis, lung transplantation, caspase, 2129

Human lung cancer cell lines, surviving fraction, doublingtime, radiobiology model, clonogenic assay, 1125

Human lung cancer cells, N-heterocyclic indolylglyoxylamides, p53-independent apoptosis, G2/M phasearrest, radiosensitivity, 3407

Human mammaglobin, breast cancer, brain metastases,PCR, 1061

Human mesothelioma cell line, radiation, pemetrexed,radiosensitivity, apoptosis, 2847

Human normal cells, cigarette smoking, Swedish-typesmokeless tobacco, Snus, ethanol, cell death, endothelialcells, fibroblasts, 1527

Human papillomavirus, cervical cancer, GSTM1, GSTT1,genetic polymorphism, cancer risk, 3051

Human polyomavirus, BK virus, JC virus, hematopoietic stemcell transplantation, cerebrospinal fluid, KI, WU, 3489

Human zinc finger 23, hepatocellular carcinoma, real-timeRT-PCR, annexin V-FITC/PI assay, apoptosis, 3595

HuR, breast cancer, histological status, prognosis, 303HUVEC, VEGFR2, tyrosine kinase inhibitor, drug

resistance, angiogenesis, endothelial cells, 2787Hybrid steroidal alkylators, uridine phosphorylase, in silico

molecular docking, in vitro assay, mitrogen mustards,pancreatic cancer cells, 831

Hydantoin derivatives, Colo 205 and Colo 320 colonadenocarcinoma cells, multidrug resistance, efflux pump,ABCB1 transporter, apoptosis, 3285

Hydrophobicity, conformation, antibacterial activity, bis-quarternary compound, 2561

8-Hydroxydeoxyguanosine, oxidative stress, ovarian cancer,reactive oxygen species, 1411

25-Hydroxyvitamin D, vitamin D, breast neoplasms,case–control studies, epidemiology, meta-analysis,prevention, 2939

Hyperammonemia, 5-FU, encephalopathy, capecitabine,metastatic rectal adenocarcinoid, 335

Hypercoagulation, germ cell tumour, cisplatin, thrombosis,vascular toxicity, von Willebrand factor, 4501

Hyperdiploid multiple myeloma, cytogenetics, tumorprogression, 1599

Hyperosteoidosis, meningioma en plaque, somatostatin,hyperostosis, 591

Hyperostosis, meningioma en plaque, somatostatin,hyperosteoidosis, 591

Hyperparathyroidism, parathyroid tumors, arterial bloodpressure, serum calcium, PTH, arterial hypertension,elderly, 3969

Hyperpigmentation, pemetrexed, skin toxicity, 1753Hypersensitivity, carboplatin, cisplatin, antineoplastic,

thoracic malignancy, immunoglobulin E, 4525Hyperthermia, bevacizumab, doxorubicin, platinum-

refractory, ovarian cancer, 2675Hyperthermia, thermal cancer therapy, hepatic stellate cells,

fibrosis, HCC, HepG2, 1583Hyperthermia, thermal cancer therapy, hepatic stellate cells,

fibrosis, HCC, transwell, co-culture, 3713Hyperthermo-chemo-radiation therapy, rectal cancer,

HCRT, distal margins, tumor response, 3963Hypofractionated radiotherapy, prostate cancer,

intermediate risk, acute effect, image guided radiationtherapy, hormonotherapy, 3555

Hypofractionation, prostate cancer, radiotherapy,acceleration, amifostine, cytoprotection, 1745

Hypoxia, ADM, colorectal cancer, prognostic factor, 507Hypoxia, CD44-CD41, PC3 side fraction, normoxia, 487Hypoxia, glucose transporter-1, hypoxia-inducible factor

1α, preoperative chemoradiotherapy, rectal cancer, 1559Hypoxia, LAT1, CD98, mesothelioma, prognosis, mTOR,

4075Hypoxia, radiation sensitivity, esophageal cancer, gastric

cancer, cell cycle, reoxygenation, 3369Hypoxia-inducible factor 1α, glucose transporter-1,

hypoxia, preoperative chemoradiotherapy, rectal cancer,1559

Hypoxia-inducible factor-1a, rectal cancer, radiotherapy,chemotherapy, prognostic factor, biomarker, carbonicanhydrase IX, ezrin, glucose transporter-1, 4529

Hyprocrellin B, ovarian cancer, hematoporphyrinmonomethyl ether, intracellular metabolism, subcellularlocalization, phototoxicity, 3229

Hyptis verticillata jacq, HTLV-1, ATL, leukemia, multidrugresistance, 4251

I3C, hENT1, gemcitabine, cytotoxicity, pancreatic cancer,3171

ICC, radiofrequency ablation, RFA, intrahepatic cholangio-carcinoma, cirrhosis, 4575

IDH1 mutation, glioma, cetuximab, sunitinib, bevacizumab,4457

IFN-γ, DC, vaccine, whole tumor cell, ELISPOT, 3995IGBP1, lactoferrin, PP2Ac, apoptosis, lung adeno-

carcinoma, 529IGF-1, colorectal cancer, insulin-like growth factor, IGF-

1R, 2541IGF1, growth factors, breast cancer, tumor markers, CA 15-3,

CEA, EGF, HGF, 4653


4763

IGF-1, insulin-like growth factor-1, tamoxifen-resistance,oestrogen resistance, breast cancer recurrence, oestrogenreceptor-alpha, EGFR, 23

IGF-1R, colorectal cancer, insulin-like growth factor, IGF-1, 2541

IGF-1R, phosphorylated MEK, Ras/Raf/MEK/ERKpathway, orthotopic mouse model of osteosarcoma, lungmetastasis, 1147

IKKβ, NFκB, IκBα, p38, peroxynitrite, nitration, coloncancer, 1607

IL-12, cytokines, morphine, plasma, MIP-1α, 4561IL-6, esophageal cancer, cisplatin, chemosensitivity, 67Image analysis, angiogenesis, breast cancer, CD34, MVD,

vessel identification, 4053Image analysis, DNA ploidy, cytometry, cytology,


Image guided radiation therapy, hypofractionatedradiotherapy, prostate cancer, intermediate risk, acuteeffect, hormonotherapy, 3555

Image-guided radiotherapy, anal cancer, chemoradiation,tomotherapy, 4393

Imaging, GFP, prostate cancer, PC-3, orthotopic,circulating cancer cells, immunomagnetic beads,isolation, fluorescence, culture, 1535

Imatinib, breast cancer, lapatinib, EGFR, ErbB2, c-ABL,RTK, 789

Imatinib, gastrointestinal stromal tumor, adherence,ADAGIO study, 1407

Imexon, dacarbazine, melanoma, additivity, drugcombinations, 2781

Immune response, dysplastic nevi, melanocyte, melanoma,regression, 3697

Immunogenicity, ionizing radiation, temozolomide, celldeath, Hsp70, 3727

Immunoglobulin E, carboplatin, cisplatin, hypersensitivity,antineoplastic, thoracic malignancy, 4525

Immunohistochemical staining, HER2, non-small cell lungcancer, surgical resection, prognosis, 4631

Immunohistochemistry, age, breast cancer, grade, measlesvirus, p53, 913

Immunohistochemistry, cadherins, prognosis, OSCC, oralsquamous cell carcinoma, 4211

Immunohistochemistry, cervical cancer, parametrium,micrometastasis, 243

Immunohistochemistry, estrogen receptor beta, ovariancancer, prognostic factor, cisplatin, 711

Immunohistochemistry, FOXP3, lung cancer, NSCLC,lymph node, metastasis, 1677

Immunohistochemistry, gastric adenocarcinoma, signet-ringadenocarcinoma, breast metastasis, skin, 2373

Immuno-histochemistry, glycated apolipoprotein B,colorectal cancer, 555

Immunohistochemistry, ischemia, xenografts, phospho-proteins, pre-analytical variables, biopsy, 2073

Immunohistochemistry, male breast, ductal pleomorphiccarcinoma, histopathology, 3069

Immunohistochemistry, medulloblastoma, atypicalteratoid/rhabdoid tumours, Na+/K+-ATPase, alphasubunits, 953

Immuno-histochemistry, non-Hodgkin’s lymphoma, YB-1,prognosis, 2963

Immunohistochemistry, oral carcinogenesis, beta-catenin,tongue, mice, 2805

Immunohistochemistry, prostaglandin E2 receptor, renalcell carcinoma, pathological features, survival, 597

Immunohistochemistry, quantitative PCR, HMGB1, RAGE,disseminated histiocytic sarcoma, 1541

Immunohistochemistry, thyroid cancer, biomarker,diagnosis, sensitivity, specificity, metastasis, 3433

Immunohistochemistry, triple negative breast cancer,TEM8, breast cancer, lymph node metastasis, 3417

Immunohistochemistry, tumor suppressor gene, FUS1,sarcoma, RT-PCR, growth inhibition, 11

Immunohistochemistry, wnt pathway, colorectal cancer,LGR5, stem cell marker, 263

Immunological detection methods, circulating tumor cells,colon cancer, metastasis, 613

Immunomagnetic beads, circulating tumor cells, CTCs,prostate cancer, GFP, chick embryo, brain metastasis,metastatic assay, fluorescence imaging, 3125

Immunomagnetic beads, GFP, prostate cancer, PC-3,orthotopic, circulating cancer cells, isolation,fluorescence, imaging, culture, 1535

Immunomodulation, immunotherapy, tumor models, naturalkiller cells, Parapoxvirus ovis, Orf virus, 4185

Immunomodulation, indoleamine-2, 3-dioxygenase,cervical cancer, quinolinic acid, kynurenic acid, 2629

Immunomodulator, β-glucan, beta-glucan, dendritic cells,maturation, 1647

Immunotherapy, acute myeloid leukemia, interleukin-2,peptide vaccination, cerebrospinal fluid, CSF, flow ofCSF, chloroma, 2343

Immunotherapy, breast cancer, ADAMTS1, amphiregulin,xenograft, 3839

Immunotherapy, cancer, prediction, survival, CD8, CD57,review, 639

Immunotherapy, cryoimmunology, cryotreatment, renal cellcarcinoma, 2927

Immunotherapy, gemcitabine, NKG2D, MICA, MICB,HCC, 2505

Immunotherapy, heparan sulfate, proteoglycans, xenograft,HepG2 cells, liver cancer, 4067

Immunotherapy, immunomodulation, tumor models, naturalkiller cells, Parapoxvirus ovis, Orf virus, 4185


4764

Immunotherapy, nucleotide, insoluble protein, dendriticcell, T lymphocytes, 881

Immunotherapy, Wilms’ tumor 1 (WT1), myeloid dendriticcell, cancer vaccine, 2447

Immunotherapy, WT1 peptide vaccine, ovarian cancer, 2441In silico molecular docking, uridine phosphorylase, hybrid

steroidal alkylators, in vitro assay, mitrogen mustards,pancreatic cancer cells, 831

In vitro assay, uridine phosphorylase, hybrid steroidalalkylators, in silico molecular docking, mitrogenmustards, pancreatic cancer cells, 831

Individualized tumour response testing, breast cancer,primary culture, chemotherapeutics, therapypersonalization, oncogramme, 139

3-Indole, cell cycle arrest, ATM, ATR, SMAD3, Xenograftmodel, lung cancer cells, 203

Indole, telomerase, prostate cancer, diethylstilbestrol, cellviability, 3733

Indoleamine-2, 3-dioxygenase, immunomodulation,cervical cancer, quinolinic acid, kynurenic acid, 2629

Induction chemotherapy, DCF, borderline-resectable T4,esophageal cancer, cisplatin, 5-fluorouracil, docetaxel,3535

Infection, BPF, fistula, operation, lung cancer, risk factor,concurrent disease, perioperative complication, 619

Inferior vena cava, heart, hepatocellular carcinoma,prognosis, 4641

Inflammation, antisense pepitide, complementary peptide,anaphylatoxin, sepsis, cytokine storm, 2511

Inflammation-associated carcinogenesis, progression,fibrosarcoma, non-nuclear protein, 1259

Inflammatory processes, diffuse intrinsic pontine glioma,chemotherapy, temozolomide, rofecoxib, bevacizumab,2265

Inflammatory response, APE1, Ref-1, macrophages, 379Inhibition of DNA repair, radiation sensitivity, clonogenic

cell survival, huachansu, lung cancer cells, 2141Inhibition of multidrug resistance, P-glycoprotein,

chemotherapy, osteosarcoma cell lines, carcinoma celllines, siRNA, 2813

Inhibitor, HTLV-1, ATL, tetramethylnaphthalene, cell cycle,2241

Iniparib, BRCA, pancreatic cancer, chemotherapy, 1417INOS, cervical carcinoma, prognosis, guanylyl cyclase,

phosphodiesterase, 2319Insoluble protein, nucleotide, dendritic cell, T lymphocytes,

immunotherapy, 881Insulin-like growth factor 1 receptor (IGF1R),

gastrointestinal stromal tumors (GISTs), Ras-Raf-ERK/MAPK pathway, PI3K-Akt/mTOR pathway,CD117, 3019

Insulin-like growth factor 1, MG-63 osteosarcoma cells,alternative splicing, 4259

Insulin-like growth factor, colorectal cancer, IGF-1, IGF-1R, 2541

Insulin-like growth factor-1, IGF-1, tamoxifen-resistance,oestrogen resistance, breast cancer recurrence, oestrogenreceptor-alpha, EGFR, 23

Integrin, EMMPRIN, Fyn, oral SCC, ECM, 1205Integrin, MMP-13, bone metastasis, type I collagen,

MAPK, 1307Integrins, colorectal cancer, survival, polymorphisms,

single nucleotide polymorphisms, 1373Interdisciplinary therapy management, gynecological

cancer, breast cancer, online tumor conference, secondopinion, continuous medical training, 2669

Interferon, chromophobe renal cell carcinoma,temsirolimus, mTOR, sorafenib, 331

Interferon, hepatocellular carcinoma, hepatic intraarterialtherapy, fotemustine, chemoimmunotherapy, 4553

Interferon-β, endometrial cancer, engineered stem cells,cytosine deaminase, 2853

Interleukin-2, acute myeloid leukemia, immunotherapy,peptide vaccination, cerebrospinal fluid, CSF, flow ofCSF, chloroma, 2343

Interleukin-2, bladder carcinoma, CD8highCD57+

lymphocytes, recurrences, 699Interleukin-2, myeloma, YT, CD86, cytotoxicity, 475Interleukin-6 receptor, interleukin-6, breast cancer, MCF-7,

antisense, oligodeoxynucleotides, 2899Interleukin-6, interleukin-6 receptor, breast cancer, MCF-7,

antisense, oligodeoxynucleotides, 2899Interleukin-6, oncostatin M, VEGF, u-PA, prostate cancer, 3273Interleukin-6, signal transducer and activator of

transcription 3, pancreatic cancer, 2029Intermediate filament proteins, oral squamous cell

carcinomas, toombak, genes, apoptosis, cell cycleregulation, Sudan, 3345

Intermediate risk, hypofractionated radiotherapy, prostatecancer, acute effect, image guided radiation therapy,hormonotherapy, 3555

Interphase FISH, MDS, normal karyotype, del(5q),del(20q), 1007

Interval debulking surgery, ovarian cancer, staginglaparoscopy, optimal logistic regression, 4469

Intestinal carcinogenesis, min mice, 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine, Apc, C57Bl/6J, FVB, 785

Intestinal metaplasia, polymorphism, Helicobacter pylori,gastric atrophy, XRCC1, GSTP1, GSTT1, GSTM1, 1459

Intra-arterial therapy, pancreatic cancer, gemcitabine,chemoradiotherapy, 3909

Intracellular delivery, PAMAM dendrimers, encapsulation,resistance, SMVT, cisplatin, ovarian cancer cell lines, 897

Intracellular metabolism, ovarian cancer, hyprocrellin B,hematoporphyrin monomethyl ether, subcellularlocalization, phototoxicity, 3229


4765

Intracranial, mKate2, mCherry, glioblastoma model, liveimaging, temozolomide, 2161

Intraepidermal nerve fibres, cancer, neurotoxicity, adjuvantchemotherapy, docetaxel, neuropathy, skin biopsies,oxaliplatin, 4413

Intrahepatic cholangio-carcinoma, radiofrequency ablation,RFA, ICC, cirrhosis, 4575

Intra-operative method, breast cancer, sentinel lymph node,OSNA, cytokeratin 19, 585

Intraperitoneal, ovarian cancer, relapse, catumaxomab,surgical tumor debulking, operative morbidity, operativemortality, 2603

Intravenous curcumin, blood–brain barrier, post-traumaticsequelae, hippocampus, striatum, brain stem, 907

Intravesical chemotherapy, bladder cancer, recurrence,continuous saline bladder irrigation, 1471

Intravesical chemotherapy, mitomycin C, bladder cancer, 929Intussusception, melanoma, small bowel, disease-free

survival, dendritic cell therapy, 3579Inv(3)(q21q26), t(3;3)(q21;q26), breakpoint distribution,

chromosomal abnormalities, fluorescent in situhybridization, 3441

Invasion front, apoptosis, liver metastases, FAS, TRAIL,colorectal cancer, 1215

Invasion front, KL-6 mucin, MUC1, gastric cancer, β-catenin, 535

Invasion, metastasis suppressor-1, MTSS1, cellularmigration, bladder cancer, metastasis, 3205

Invasion, metastasis, anoikis, migration, renieramycin M,lung cancer cells, 193

Invasion, PPARγ, breast cancer, PPARG, T0070907,migration, 813

Invasion, resveratrol, glioma, TNF-α, urokinaseplasminogen activator, 4223

Invasive front, ADAM, MMP, TIMP, solid cancer nest,colorectal cancer, 1567

Invasive tumors, neural stem cells, suicide genes, prodrugs,animal models, gene-directed enzyme prodrug therapyreview, 1249

Iodine radioisotopes, thyroid neoplasms, thyroglobulin,TENIS syndrome, 2109

Ionizing radiation, glioma, PTEN, cell cycle,temozolomide, radiosensitivity, 1653

Ionizing radiation, phosphorylation of p53, radiation-sensitivity, 2255

Ionizing radiation, temozolomide, immunogenicity, celldeath, Hsp70, 3727

IP-PA1, macrophage, LPS, priming, chronic psychologicalstress, review, 2437

Ipsilateral breast tumor recurrence, breast cancer,anastrozole, radiotherapy, tamoxifen, 367

IRF4, multiple myeloma, curcumin analog, NF-κB,PI3K/AKT, JAK/STAT3, 3719

Irinotecan, cetuximab, colorectal cancer, oxaliplatin,biomarkers, 2149

Irinotecan, gastric cancer, cetuximab, oxaliplatin, KRASphase II trial, 4439

Irinotecan, liver directed therapy, metastatic colon cancer,transarterial chemoembolization, DEBIRI, DC Bead, 4581

Irinotecan, metabolites, hepatic intra-arterial infusion,plasma disposition, pharmacokinetics, 3573

Irinotecan, metastatic colorectal cancer, pharmacogenetics,359

Irinotecan, ovarian cancer, consolidation chemotherapy,recurrent, salvage chemotherapy, treatment-free interval,paclitaxel, cisplatin, 4613

Iron chelation therapy, deferasirox, iron overload, acutemyelogenous leukemia, chemotherapy-resistant, completeremission, 1741

Iron overload, deferasirox, iron chelation therapy, acutemyelogenous leukemia, chemotherapy-resistant, completeremission, 1741

Ischemia, immunohistochemistry, xenografts, phospho-proteins, pre-analytical variables, biopsy, 2073

Isocratic HPLC, clofarabine, Cl-F-ara-A, clofarabinetriphosphate, Cl-F-ara-ATP, leukemia cells, 2863

Isolated lung perfusion, sarcoma lung metastases, p-gpmodulation, doxorubicin, cyclosporine, valspodar, 2121

Isolated nuclei, renal cell carcinoma, chromophobe renalcell carcinoma, renal oncocytoma, fluorescence in situhybridization, tissue sections, 3137

Isolation, GFP, prostate cancer, PC-3, orthotopic,circulating cancer cells, immunomagnetic beads,fluorescence, imaging, culture, 1535

Isopentenyladenosine, cytokinins, modified nucleosides,antiproliferative activity, 3401

IκBα, NFκB, IKKβ, p38, peroxynitrite, nitration, coloncancer, 1607

JAK/STAT3, multiple myeloma, curcumin analog, NF-κB,PI3K/AKT, IRF4, 3719

Jaw bones, osteosarcoma, maxilla, mandible, 4485JBCRN, meloxicam, paclitaxel, neuropathy, breast cancer,

3567JC virus, human polyomavirus, BK virus, hemotopoetic

stem cell transplantation, cerebrospinal fluid, KI, WU,3489

JNK, melanoma, sorafenib, fluvastatin, AKT, 3259K650E, proteasome inhibitor, receptor tyrosine kinase,

activation loop, multiple myeloma, ER stress, FGFR3,Lys650Glu mutation, bortezomide, plasma cellmalignancy, 113

KA2, glutamate receptor, cancer, PCR, shRNA, NR1,GLUR4, NR2D, 3181

KAI1/CD82, oral squamous cell carcinoma, thymidylatesynthase, dihydropyrimidine dehydrogenase, lymph nodemetastasis, 3521


4766

Kallikrein-related peptidase 5, breast cancer, KLK5, KLK7,3093

KI, human polyomavirus, BK virus, JC virus,hematopoietic stem cell transplantation, cerebrospinalfluid, WU, 3489

Ki-67 expression, quinazoliniminium salts, tumor cellproliferation, macromolecule syntheses, DNA interactionand fragmentation, multiple mitotic figures, nuclei,micronuclei, 2083

Ki-67, breast cancer, metallothionein, MT-I/II, MCM-2, 3027Ki-67, EGFR, translational research, squamous cell

carcinoma, head and neck cancer, 665Ki-67, non-small lung cancer, metallothionein, MT,

MCM-2, 2833Ki-67, PCNA, recurrence, lung, adenocarcinoma, 4277Kidney, epigenetic modifiers, toxicity, ROS, p66shc,

mitochondria, 3267Kinase, antitumor activity, Bcr-Abl, CML, Daedalea

gibbosa, medicinal mushrooms, oleic acid,autophosphorylation, 177

Kinases, antisense oligonucleotide, cyclin D, cyclin E,cyclin-dependent kinase, retinoblastoma protein, non-small lung cancer cells, pleural mesothelioma cells,apoptosis, phosphatases, 3683

KIT, Merkel cell carcinoma, sequence variation, mutation,807

KL-6 mucin, MUC1, gastric cancer, β-catenin, invasionfront, 535

KLK5, breast cancer, kallikrein-related peptidase 5, KLK7,3093

KLK7, breast cancer, kallikrein-related peptidase 5, KLK5,3093

KRAP, KRAS, target, cancer, obesity, diabetes, review,2413

K-ras mutations, lung cancer, lung inflammation, lungtumors, mouse, carcinogenesis, 2877

KRAS phase II trial, gastric cancer, cetuximab, irinotecan,oxaliplatin, 4439

KRAS, BRAF mutation, EGFR, ERBB2 mutation, V600E,lung cancer, adenocarcinoma, squamous cell carcinoma,SSCP, 4619

KRAS, KRAP, target, cancer, obesity, diabetes, review,2413

KRAS, medullary thyroid carcinoma, gene mutations, RET,HRAS, NRAS, BRAF, AKT1, CTNNB1, mutationalscreening, 4179

KRAS, microRNA, colorectal cancer, PTEN, miR-221/222,3D culture, 2453

KRAS, ovarian cancer, gene mutations, BRCA 1/2, TP53,PI3K, AKT, BRAF, review, 2661

KRAS, p53, colorectal, oxaliplatin, 5-fluorouracil,capecitabine, clinical, CAIRO2, sequence analysis, 1379

KRAS, RRM2, colon cancer, 2535

Kynurenic acid, indoleamine-2, 3-dioxygenase,immunomodulation, cervical cancer, quinolinic acid,2629

Lactoferrin, IGBP1, PP2Ac, apoptosis, lung adeno-carcinoma, 529

Laparoscopic radical prostatectomy, bowel injury, LRP,prostatic neoplasm, rectal injury, robotic-assistedlaparoscopic prostatectomy, RALP, robotics, 3497

Lapatinib, breast cancer, imatinib, EGFR, ErbB2, c-ABL,RTK, 789

Lapatinib, HER2, ADCC, breast cancer, Herceptin, 2999Laryngal squamous cell carcinoma, microRNA,

proliferation, apoptosis, 3859Laryngeal cancer, ADH1B, alcohol-dehydrogenase,

polymorphism, oral cancer, 677Laryngeal cancer, glutamate receptor, antagonist,

proliferation, ERK1/2 kinase, 565LAT1, CD98, mesothelioma, hypoxia, prognosis, mTOR,

4075LAT1, CD98, recurrence, advanced NSCLC, EGFR


Latin America, EBV polymorphism, BamHI W1/I1, XhoIrestriction site, EBV-associated gastric cancer, 3607

LBH589, TRAIL, histone deacetylase inhibitor, coloncancer, apoptosis, 3385

LC-MS/MS, TNF-alpha, hepatoma, proteomics, 2-DE,apoptosis, 2059

LC-MS/MS, two-dimensional gel electrophoresis,pancreatic cancer, TS-1, proteomics, 2103

Lectin, metastasis, HPA, E-selectin, P-selectin, SCIDmouse, breast carcinoma cells, colon adenocarcinoma,1589

Left colon, cyclooxygenase, COX-2, W-APC, right colon,colon cancer, 2191

Left colon, prognosis, right colon, sigmoid, survival, coloncancer, gender, 2347

Leg edema, radiation therapy, risk factor, enterocolitis,postoperative radiotherapy, gynecological malignancies,3527

Leiomyoma, Arf-induced senescence, HMGA2, MDM2antagonists, fibroid cells, 753

Leiomyoma, mucin-1, galectin-1, galectin-3,leiomyosarcoma, myometrium, 451

Leiomyosarcoma, mucin-1, galectin-1, galectin-3,leiomyoma, myometrium, 451

LEM, microarray analysis, dectin-2 gene expression,signaling pathway, macrophage, lignin-carbohydratecomplex, LPS, 1241

Lenalidomide, pancreatic cancer, gemcitabine, resistance,ERK, 3747

Lethal dose, acetoxycoumarins, cell viability, cell cycle,2017


4767

Leucovorin, chemotherapy, FLOX regimen, metastaticcolorectal cancer, phase II study, 5-FU, oxaliplatin, 4657

Leukemia cells, clofarabine, Cl-F-ara-A, clofarabinetriphosphate, Cl-F-ara-ATP, isocratic HPLC, 2863

Leukemia, hedgehog, self-renewal, 781Leukemia, HTLV-1, ATL, Hyptis verticillata jacq,

multidrug resistance, 4251Leukemia, notch, wnt, hedgehog, γ-secretase inhibitor, 893Leukocytapheresis, ulcerative colitis, UC-associated

colorectal cancer, 2547Leuprorelin, total estrogen blockade, high-dose

chemotherapy, anastrazole, premenopausal breast cancer,VEGF, 671

Level V, posterior triangle, neck dissection, 3959Levisticum officinale lovage, oral cavity squamous cell

carcinoma OCSCC, head and neck squamous cellcarcinoma HNSCC, natural product, pharmacogenomics,185

LGR5, wnt pathway, colorectal cancer,immunohistochemistry, stem cell marker, 263

LH, luteinizing hormone, total testosterone, TT, freetestosterone, FT, prostate-specific antigen, PSA, prostatecancer, 1071

Lignin-carbohydrate complex, microarray analysis, dectin-2gene expression, signaling pathway, macrophage, LPS,LEM, 1241

Lipid nanoparticles, CDK4, siRNA, down-regulation, 1619Lipid nanoparticles, microfluidics, oligonucleotide, 771Lipopolysaccharide, LPS, endotoxin, oral administration,

toxicity, absorption, review, 2431Liposome, bladder cancer, BCG-CWS, BBN, rat, 2065Liposome, drug delivery, cancer, vincristine, folate

receptor, drug targeting, 1521Live imaging, mKate2, mCherry, glioblastoma model,

intracranial, temozolomide, 2161Liver cancer, heparan sulfate, proteoglycans, xenograft,

HepG2 cells, immunotherapy, 4067Liver cancer, Na+, H+ exchange, oxidative stress,

cholangiocellular carcinoma, 459Liver cirrhosis, child’s classification, hepatocellular

carcinoma, MELD-score, nonhepatic cancer, survivalprobability, TNM classification, 2931

Liver directed therapy, metastatic colon cancer, irinotecan,transarterial chemoembolization, DEBIRI, DC Bead,4581

Liver function tests, uveal melanoma, metastasis, tumormarkers, OPN, S-100β, MIA, TPS, 351

Liver hypertrophy, portal vein embolisation, tumorprogression, serum markers, 339

Liver metastases, apoptosis, invasion front, FAS, TRAIL,colorectal cancer, 1215

Liver metastases, colorectal cancer, lung metastases,synchronous, metachronous, 1049

Liver metastases, colorectal cancer, surgery, biomarker,CD95-ligand, 4507

Liver metastases, lymphangiogenesis, lymphovascularinvasion, colorectal cancer, VEGF-C, 4605

Liver metastases, stealth liposomes, PEG liposomes, 5-FU,locoregional chemotherapy, 147

Liver metastases, stealth liposomes, PEG liposomes,docetaxel, locoregional chemotherapy, hepatic arterialinfusion, 153

Liver metastasis, breast cancer, E-selectin, endothelium,pro-inflammatory microenv ironment, 3219

Liver resection, hepatocellular carcinoma, multidrugresistance, ABC proteins, tyrosine kinase, 3883

Liver surgery, breast cancer liver metastases, tumourmarkers, prognostic factors, differental diagnosis, benignliver lesions, 1447

Liver tumour, hepatitis C virus, sarcomatoid tumour, cellline, culture, spectral karyotyping, xenograft, 129

Liver, green fluorescent protein, red fluorescent protein,cancer cell seeding, real-time imaging, lung, muscle,3665

Lkb1, Stk11, hepatocellular carcinoma, nitrosamine,choline-deficient L-amino acid-defined diet, rat, 543

Local tumor control, B-Cell lymphoma, marginal zonelymphoma, radiation therapy, 3935

Locoregional chemotherapy, stealth liposomes, PEGliposomes, 5-FU, liver metastases, 147

Locoregional chemotherapy, stealth liposomes, PEGliposomes, docetaxel, liver metastases, hepatic arterialinfusion, 153

Locoregional recurrence, cervical cancer, squamous cellcarcinoma, stage IB-IIB, concurrent chemoradiotherapy,1437

Lomustine, medulloblastoma, vincristine, apoptosis,chemotherapy, 1721

Long Evans Cinnamon, reactive oxygen species, pyruvatedehydrogenase, copper overload, 3395

Long-term administration, anaplastic gliomas,temozolomide, 3873

Long-term survivors, pancreatic cancer, pancreaticneoplasms, surgery, brain metastasis, 4599

Low back pain, gastric cancer, pregnancy, bilateralerythematous breast hypertrophy, 681

Low-grade liposarcoma, athymic mice, soft tissue sarcoma,xenograft, vascularisation, 4061

Low-grade myofibroblastic sarcoma, abdominal tumor,2989

Low-intensity ultrasound, sonodynamic therapy,sonosensitizers, review, 2425

LPS, endotoxin, oral administration, toxicity, absorption,lipopolysaccharide, review, 2431

LPS, macrophage, priming, IP-PA1, chronic psychologicalstress, review, 2437


4768

LPS, microarray analysis, dectin-2 gene expression,signaling pathway, macrophage, lignin-carbohydratecomplex, LEM, 1241

LPS, Pantoea agglomerans, A46, LPSp, LPSa46,macrophage, M-CSF, GM-CSF, 2467

LPSa46, Pantoea agglomerans, A46, LPS, LPSp,macrophage, M-CSF, GM-CSF, 2467

LPSp, Pantoea agglomerans, A46, LPS, LPSa46,macrophage, M-CSF, GM-CSF, 2467

LRP, bowel injury, laparoscopic radical prostatectomy,prostatic neoplasm, rectal injury, robotic-assistedlaparoscopic prostatectomy, RALP, robotics, 3497

Lumican, breast cancer, FKBP52, geldanamycin, heat-shock proteins, 2095

Lumpectomy, ductal carcinoma in situ, breast, mastectomy,menopause, hormone replacement therapy, 1783

Lung adenocarcinoma, 5-fluorouracil, dihydropyrimidinedehydrogenase, thymidylate synthase, chemosensitivity,4665

Lung adenocarcinoma, EGFR, mutation, methylation,tobacco smoking, FHIT, RASSF1A, RUNX3, 1211

Lung adenocarcinoma, EMT, E-cadherin, gamma catenin,vimentin, fibronectin, 4451

Lung adeno-carcinoma, lactoferrin, IGBP1, PP2Ac,apoptosis, 529

Lung cancer cells, 3-Indole, cell cycle arrest, ATM, ATR,SMAD3, xenograft model, 203

Lung cancer cells, 3-oxoolean-12-en-27-oic acid, cell-cyclearrest, 2179

Lung cancer cells, cathepsin, cytokines, proliferation, 47Lung cancer cells, metastasis, anoikis, invasion, migration,

renieramycin M, 193Lung cancer cells, radiation sensitivity, clonogenic cell

survival, huachansu, inhibition of DNA repair, 2141Lung cancer risk, paraoxonase 1, PON1, polymorphism,

SNP, 2225Lung cancer, BEZ235, EGFR, P13K/mTOR inhibitor, 849Lung cancer, BPF, fistula, operation, risk factor, concurrent

disease, perioperative complication, infection, 619Lung cancer, BRAF mutation, KRAS, EGFR, ERBB2

mutation, V600E, adenocarcinoma, squamous cellcarcinoma, SSCP, 4619

Lung cancer, chemoprevention, combined treatment, mousemodel, 3279

Lung cancer, circulating tumor cells, CTCs, microfiltrationby size, real-time quantitative reverse transcriptase-polymerase chain reaction, qRT-PCR, molecular biology,cytomorphology, FISH, cell culture, 427

Lung cancer, cyclin D1, CCND1, polymorphism, smoking,Taiwanese, 3601

Lung cancer, EGFR, mutation, estrogen receptor, 855Lung cancer, epidermal growth factor receptor (EGFR),

cytology, fiberbronchoscopy, diagnosis, 4207

Lung cancer, epithelial to mesenchymal transition,potassium channels, Eag1, TGF-β, 1265

Lung cancer, FOXP3, NSCLC, immunohistochemistry,lymph node, metastasis, 1677

Lung cancer, lung inflammation, lung tumors, K-rasmutations, mouse, carcinogenesis, 2877

Lung cancer, MACC1, recurrence, adenocarcinoma, 1141Lung cancer, monoTotal, cytokeratins, tumour markers,

3107Lung cancer, non-small cell lung cancer, bone metastases,

bone remodeling markers, N-telopeptide of type Icollegen, NTx, bone alkaline phosphatase, BAP, 3879

Lung cancer, NSCLC, erlotinib, EGFR, c-erbB-3, 281Lung cancer, NSCLC, prognostic factors, HIF, NOTCH,

1603Lung cancer, paclitaxel-based chemoradiotherapy, BCL-2,

MDR1, radiosensitivity, 1431Lung cancer, pharmacogenomics, SNPs, bexarotene, RXR,

2303Lung cancer, thymidine kinase1, 5’(3’)-

deoxyribonucleotidase, fluorothymidine, proliferation,colon cancer, 2135

Lung cancer, vitamin D, colorectal cancer, breast cancer,prostate cancer, 3619

Lung inflammation, lung cancer, lung tumors, K-rasmutations, mouse, carcinogenesis, 2877

Lung metastases, colorectal cancer, liver metastases,synchronous, metachronous, 1049

Lung metastasis, IGF-1R, phosphorylated MEK,Ras/Raf/MEK/ERK pathway, orthotopic mouse model ofosteosarcoma, 1147

Lung transplantation, cyclosporine A, human lungadenocarcinoma cell, apoptosis, caspase, 2129

Lung tumors, lung cancer, lung inflammation, K-rasmutations, mouse, carcinogenesis, 2877

Lung, green fluorescent protein, red fluorescent protein,cancer cell seeding, real-time imaging, liver, muscle,3665

Lung, Ki-67, PCNA, recurrence, adenocarcinoma, 4277Luteinizing hormone (LH), prolactin (PRL), total

testosterone (TT), free testosterone (FT), prostate-specific antigen (PSA), prostate cancer, 3913

Luteinizing hormone, LH, total testosterone, TT, freetestosterone, FT, prostate-specific antigen, PSA, prostatecancer, 1071

Lutetium-177, non-Hodgkin’s lymphoma, BCL2,somatostatin receptor, 3143

LXS oral powder, fenretinide, phase I, clinical trial, 961Lymph node density, bladder cancer, extented

lymphadenectomy, lymph node metastasis, radicalcystectomy, cancer-specific survival, short review, 271

Lymph node dissection, gastric cancer, prognosis, staging,2361


4769

Lymph node metastasis, bladder cancer, extentedlymphadenectomy, radical cystectomy, lymph nodedensity, cancer-specific survival, short review, 271

Lymph node metastasis, hepatocellular carcinoma,transarterial chemoembolization, resection, 3991

Lymph node metastasis, oral squamous cell carcinoma,thymidylate synthase, dihydropyrimidine dehydrogenase,KAI1/CD82, 3521

Lymph node metastasis, sialic fibronectin, thyroidmalignant neoplasma, MoAb Jt-95, 1395

Lymph node metastasis, triple negative breast cancer,TEM8, breast cancer, immunohistochemistry, 3417

Lymph node, FOXP3, lung cancer, NSCLC,immunohistochemistry, metastasis, 1677

Lymph node, skin cancer, non-melanoma, metastasis,literature review, sentinel lymph node biopsy, 1443

Lymph node, uterine cervical cancer, FDG-PET, MRI,3865

Lymphangiogenesis, lymphovascular invasion, livermetastases, colorectal cancer, VEGF-C, 4605

Lymphatic microvessel density, breast cancer, molecularclassification, VEGF-C, VEGFR-3, 1757

Lymphoma, radioprotection, radiosensitivity, astrocytes,central nervous system, 33

Lymphovascular invasion, bladder cancer, transitionalcarcinoma, upper tract transitional carcinoma, prognosticrole, review, 3503

Lymphovascular invasion, lymphangiogenesis, livermetastases, colorectal cancer, VEGF-C, 4605

Lys650Glu mutation, proteasome inhibitor, receptortyrosine kinase, activation loop, multiple myeloma, ERstress, FGFR3, K650E, bortezomide, plasma cellmalignancy, 113

MACC 1, quantitative real-time PCR, hepatocellularcarcinoma, 777

MACC1, recurrence, lung cancer, adenocarcinoma, 1141

Macromolecule syntheses, quinazoliniminium salts, tumorcell proliferation, Ki-67 expression, DNA interactionand fragmentation, multiple mitotic figures, nuclei,micronuclei, 2083

Macrophage, LPS, priming, IP-PA1, chronic psychologicalstress, review, 2437

Macrophage, microarray analysis, dectin-2 gene expression,signaling pathway, lignin-carbohydrate complex, LPS,LEM, 1241

Macrophage, monocyte differentiation, colon cancer, MCP-1, 2493

Macrophage, Pantoea agglomerans, A46, LPS, LPSp,LPSa46, M-CSF, GM-CSF, 2467

Macrophages, APE1, Ref-1, inflammatory response, 379MAGE, non-small cell lung cancer NSCLC, expression,

demethylation, 171

Magnetic resonance imaging, micro-computed tomography,optical reflectance imaging, tumor volume, molecularimaging, GFP, RFP, 2907

Magnetic resonance spectroscopy, brain neoplasms,radiotherapy, prognosis, prospective studies, 3559

Male breast, ductal pleomorphic carcinoma, histopathology,immunohistochemistry, 3069

Malignant fibrous histiocytoma, osteosarcoma, MAPKsignaling pathway, 549

Mammary cancer, sunitinib, antitumor, antimetastasis,VEGF, VEGFR, phosphorylation, 1225

Mammary tumorigenesis, zeranol, cell proliferation, proteindisulfide isomerase, 1659

Mammographic breast density, single nucleotidepolymorphisms, estrogen pathway, steroid hormones,breast cancer, review, 4369

Mammography, breast cancer, calcification, prognosticfactor, 2327

Mammography, breast cancer, screening, ultrasound,automated 3D imaging, 2569

Mandible, bisphosphonate, osteonecrosis, BRONJ, 2313Mandible, osteosarcoma, jaw bones, maxilla, 4485MAPK signaling pathway, osteosarcoma, malignant fibrous

histiocytoma, 549MAPK, MMP-13, bone metastasis, type I collagen,

integrin, 1307MAPK, thyroid hormones, proliferation, PI3K, 89Marginal zone lymphoma, B-Cell lymphoma, radiation

therapy, local tumor control, 3935Maspin, activin A, androgen receptor, upper urinary tract

urothelial carcinoma, prognosis, 1713Mastectomy, ductal carcinoma in situ, breast, lumpectomy,

menopause, hormone replacement therapy, 1783Matrix metalloproteinase-9, ovarian cancer, diagnosis,

biomarkers, enzyme-linked immunosorbent assay,cathepsin, heparanase, 3423

Matrix metalloproteinases, gelatinase, tongue carcinoma,green fluorescent protein, xenograft, peptide, 3659

Maturation, β-glucan, beta-glucan, dendritic cells,immunomodulator, 1647

Maxilla, osteosarcoma, jaw bones, mandible, 4485MBL, polymorphism, ulcerative colitis, DNA methylation,

CD14, p22PHOX, 933MCF-7 cells, clioquinol, zinc, cyclin D1, miR-302C, 2739MCF-7, branched-chain fatty acids, anticancer, antitumor,

human breast cancer, human colon cancer, HT-29, 3165MCF-7, interleukin-6, interleukin-6 receptor, breast cancer,

antisense, oligodeoxynucleotides, 2899MCherry, mKate2, glioblastoma model, intracranial, live

imaging, temozolomide, 2161MCM-2, breast cancer, metallothionein, MT-I/II, Ki-67, 3027MCM-2, non-small lung cancer, metallothionein, MT, Ki-

67, 2833


4770

MCMs, minichromosome maintenance proteins, cyclin D3,CCND3, Hodgkin lymphoma, survival, 3585

MCP-1, monocyte differentiation, macrophage, coloncancer, 2493

M-CSF, Pantoea agglomerans, A46, LPS, LPSp, LPSa46,macrophage, GM-CSF, 2467

MDM2 antagonists, leiomyoma, Arf-induced senescence,HMGA2, fibroid cells, 753

MDR mouse T-lymphoma cells, multidrug-resistant cancercells, ABCB1 transporter, P-glycoprotein,phenothiazines, thioridazine, apoptosis, 4201

MDR1, lung cancer, paclitaxel-based chemoradiotherapy,BCL-2, radiosensitivity, 1431

MDS, interphase FISH, normal karyotype, del(5q),del(20q), 1007

Measles virus, age, breast cancer, grade,immunohistochemistry, p53, 913

Mechanism of action, cytotoxicity, endocytosis,glycosylated antitumor ether lipid, methyl-β-cyclodextrin, 3809

Medicinal compounds, triptolide, proteasome inhibitors,apoptosis, cancer therapy, 1

Medicinal herb, bioactivity, p53 pathway, apoptosis, Rutagraveolens, Akt, 233

Medicinal mushrooms, antitumor activity, Bcr-Abl, CML,Daedalea gibbosa, kinase, oleic acid,autophosphorylation, 177

Medullary thyroid carcinoma, gene mutations, RET, HRAS,KRAS, NRAS, BRAF, AKT1, CTNNB1, mutationalscreening, 4179

Medulloblastoma, atypical teratoid/rhabdoid tumours, Na+/K+-ATPase, alpha subunits, immunohistochemistry, 953

Medulloblastoma, vincristine, lomustine, apoptosis,chemotherapy, 1721

Melanocyte, dysplastic nevi, immune response, melanoma,regression, 3697

Melanoma, dysplastic nevi, immune response, melanocyte,regression, 3697

Melanoma, gefitinib, radiation, combination therapy,EGFR, predictor, 2883

Melanoma, imexon, dacarbazine, additivity, drugcombinations, 2781

Melanoma, memory T- cell, CD44, tumor-infiltratinglymphocytes, 4099

Melanoma, metastastic melanoma, brain metastases,temozolomide, whole-brain radiation, 4537

Melanoma, small bowel, intussusception, disease-freesurvival, dendritic cell therapy, 3579

Melanoma, sorafenib, fluvastatin, JNK, AKT, 3259Melatonin, cancer, endometrial proliferation, rats, 2637MELD-score, child’s classification, hepatocellular

carcinoma, liver cirrhosis, nonhepatic cancer, survivalprobability, TNM classification, 2931

Meloxicam, paclitaxel, neuropathy, breast cancer, JBCRN,3567

Memory T- cell, CD44, tumor-infiltrating lymphocytes,melanoma, 4099

Meningioma en plaque, somatostatin, hyperostosis,hyperosteoidosis, 591

Menopause, ductal carcinoma in situ, breast, lumpectomy,mastectomy, hormone replacement therapy, 1783

Merkel cell carcinoma, KIT, sequence variation, mutation,807

Mesenchymal stem cells, gene therapy, cytotherapy,hepatocellular carcinoma, 3705

Mesothelioma, LAT1, CD98, hypoxia, prognosis, mTOR,4075

Mesothelioma, renal failure, tumor markers, N-ERC/mesothelin, osteopontin, 1427

Meta-analysis, vitamin D, 25-hydroxyvitamin D, breastneoplasms, case–control studies, epidemiology,prevention, 2939

Meta-analysis, X-ray repair cross-complementing group 1,XRCC1, polymorphism, DNA repair, skin cancer, 3945

Metabolites, irinotecan, hepatic intra-arterial infusion,plasma disposition, pharmacokinetics, 3573

Metabolizing genes, genetic polymorphisms, cancersusceptibility, DNA-repair genes, CYP1A1, CYP1E1,XRCC1, 1359

Metabolomics, belinostat, bortezomib, pancreas cancer,histone deacetylase inhibitor, proteasome inhibitor,hepatocellular cancer, apoptosis, 1093

Metachronous liver metastasis, CT-guided high-dose-ratebrachytherapy, CT-HDRBT, ovarian cancer, ablation ofliver metastases, 2597

Metachronous, colorectal cancer, liver metastases, lungmetastases, synchronous, 1049

Metalloproteinases, colorectal cancer, biological activity,tumor markers, angiogenetic factors, adhesion molecules,373

Metallothionein, breast cancer, MT-I/II, Ki-67, MCM-2,3027

Metallothionein, non-small lung cancer, MT, Ki-67, MCM-2, 2833

Metastasis suppressor-1, MTSS1, cellular migration,invasion, bladder cancer, metastasis, 3205

Metastasis, anoikis, invasion, migration, renieramycin M,lung cancer cells, 193

Metastasis, breast cancer, bone marrow carcinomatosis,4025

Metastasis, breast cancer, stem cells, pre-metastatic niche,CD133, prognosis, 1315

Metastasis, circulating tumor cells, colon cancer,immunological detection methods, 613

Metastasis, extravasation, blood−brain barrier, brainendothelial cells, COX-2, 4307


4771

Metastasis, FOXP3, lung cancer, NSCLC,immunohistochemistry, lymph node, 1677

Metastasis, HPA, E-selectin, P-selectin, SCID mouse,lectin, breast carcinoma cells, colon adenocarcinoma,1589

Metastasis, metastasis suppressor-1, MTSS1, cellularmigration, invasion, bladder cancer, 3205

Metastasis, methylenetetrahydrofolate reductase MTHFR,smoking, recurrence, oral cancer, 2395

Metastasis, osteosarcoma, angiotensin II type 1 receptorantagonist, CV11974, 123

Metastasis, palladin, neuroendocrine carcinomas, 2957Metastasis, skin cancer, non-melanoma, lymph node,

literature review, sentinel lymph node biopsy, 1443Metastasis, thyroid cancer, biomarker, diagnosis,

sensitivity, specificity, immunohistochemistry, 3433Metastasis, uveal melanoma, liver function tests, tumor

markers, OPN, S-100β, MIA, TPS, 351Metastasis, uveal melanoma, tumor markers, OPN, S-100β,

MIA, TPS, 345Metastasis, voluntary running, cytokines, mice, 3337Metastastic melanoma, melanoma, brain metastases,

temozolomide, whole-brain radiation, 4537Metastatic anal cancer, chemoradiotherapy, cisplatin, S-1,

3983Metastatic assay, circulating tumor cells, CTCs, prostate

cancer, immunomagnetic beads, GFP, chick embryo,brain metastasis, fluorescence imaging, 3125

Metastatic breast cancer, capecitabine, triple-negative,HER2-negative, prognostic factors, 1079

Metastatic breast cancer, circulating tumor cells,chemotherapy, therapy efficacy, 979

Metastatic breast cancer, HER2-positive, S-1, trastuzumab,3035

Metastatic breast cancer, oxaliplatin, off-label use, 1765Metastatic colon cancer, liver directed therapy, irinotecan,

transarterial chemoembolization, DEBIRI, DC Bead,4581

Metastatic colorectal cancer, capecitabine, oxaliplatin,bevacizumab, cetuximab, phase II, 255

Metastatic colorectal cancer, chemotherapy, FLOXregimen, phase II study, 5-FU, leucovorin, oxaliplatin,4657

Metastatic colorectal cancer, irinotecan, pharmacogenetics,359

Metastatic colorectal cancer, panitumumab, bevacizumab,treatment, 1033

Metastatic gastric cancer, chemotherapy, review, 3543Metastatic rectal adenocarcinoid, 5-FU, hyperammonemia,

encephalopathy, capecitabine, 335Metastatic renal cell carcinoma, sunitinib, sequential

treatment regimen, tyrosine kinase inhibitor, mTORinhibitor, 3507

Metformin, colon cancer, phenformin, 2-deoxyglucose,acidification, 421

Methyl-2-cyano-3, ovarian cancer, 12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), apoptosis, AKT, NF-κB, mTOR, 3673

Methylation, breast cancer, RASSF1A, prognosis, 2975Methylation, EGFR, mutation, tobacco smoking, lung

adenocarcinoma, FHIT, RASSF1A, RUNX3, 1211Methylation, NSCLC, MLPA, targeted therapy, gene

methylation, TKIs, smoking, EGFR mutation, 4647Methylation, p16INK4a, colorectal cancer, 1643Methylation, TFPI2, gastric cancer, 3835Methylenetetrahydrofolate reductase MTHFR, smoking,

metastasis, recurrence, oral cancer, 2395O6-Methylguanine-DNA methyltransferase (MGMT), SN1

methylating agents, apoptosis, RNA-binding proteins, N-methyl-N-nitrosourea, 4291

Methyl-β-cyclodextrin, cytotoxicity, endocytosis,glycosylated antitumor ether lipid, mechanism of action,3809

N-methyl-N-nitrosourea, SN1 methylating agents,apoptosis, O6-methylguanine-DNA methyltransferase(MGMT), RNA-binding proteins, 4291

Metronomic, cyclophosphamide, doxorubicin, breastcancer, cardiotoxicity, rats, 215

MG-63 osteosarcoma cells, insulin-like growth factor 1,alternative splicing, 4259

MIA, uveal melanoma, metastasis, liver function tests,tumor markers, OPN, S-100β, TPS, 351

MIA, uveal melanoma, metastasis, tumor markers, OPN, S-100β, TPS, 345

MICA, gemcitabine, NKG2D, MICB, HCC,immunotherapy, 2505

MICB, gemcitabine, NKG2D, MICA, HCC,immunotherapy, 2505

Mice, BBN, gemcitabine, sirolimus, urothelial lesion, 1637Mice, oral carcinogenesis, immunohistochemistry, beta-

catenin, tongue, 2805Mice, voluntary running, metastasis, cytokines, 3337Microarray analysis, dectin-2 gene expression, signaling

pathway, macrophage, lignin-carbohydrate complex,LPS, LEM, 1241

Microarray, antiapoptosis, colorectal cancer, gammaradiation, RT-PCR, REG4, NEIL2, BIRC5, 4147

Microcalcification, breast cancer, screening mammography,high-frequency ultrasound, advanced imaging modes, 2575

Micro-computed tomography, magnetic resonance imaging,optical reflectance imaging, tumor volume, molecularimaging, GFP, RFP, 2907

Microfiltration by size, circulating tumor cells, CTCs, real-time quantitative reverse transcriptase-polymerase chainreaction, qRT-PCR, molecular biology, cytomorphology,FISH, cell culture, lung cancer, 427


4772

Microfluidics, oligonucleotide, lipid nanoparticles, 771Micrometastasis, cervical cancer, parametrium,

immunohistochemistry, 243Micronuclei, quinazoliniminium salts, tumor cell

proliferation, Ki-67 expression, macromoleculesyntheses, DNA interaction and fragmentation, multiplemitotic figures, nuclei, 2083

Micronucleus assay, α-particle radiation, 238-plutonium,Monte Carlo simulations, bystander effect, 2113

MicroRNA, KRAS, colorectal cancer, PTEN, miR-221/222,3D culture, 2453

MicroRNA, laryngal squamous cell carcinoma,proliferation, apoptosis, 3859

MicroRNA, prostate cancer, Fusion gene, TMPRSS2:ERG,403

Microsatellite instability, colon cancer, tumor location, age,early onset, 967

Microvesicles, tumour, chemokine, monocyte, 1329Migration, metastasis, anoikis, invasion, renieramycin M,

lung cancer cells, 193Migration, PPARγ, breast cancer, PPARG, T0070907,

invasion, 813Min mice, 2-amino-1-methyl-6-phenylimidazo[4, 5-

b]pyridine, Apc, C57Bl/6J, FVB, intestinalcarcinogenesis, 785

Minichromosome maintenance proteins, MCMs, cyclin D3,CCND3, Hodgkin lymphoma, survival, 3585

Minimal residual disease, acute lymphoblastic leukemia,flow cytometry, children, early response, 1453

MIP-1α, cytokines, morphine, plasma, IL-12, 4561MiR-221/222, KRAS, microRNA, colorectal cancer, PTEN,

3D culture, 2453MiR-302C, clioquinol, zinc, cyclin D1, MCF-7 cells, 2739Miriplatin, hepatocellular carcinoma, transarterial

chemoembolization, 2983MiRNA, electroporation, oligonucleotides, siRNA, review,

4083Mitochondria, epigenetic modifiers, kidney, toxicity, ROS,

p66shc, 3267Mitochondria, phenethyl isothiocyanate, cell cycle arrest,

apoptosis, caspases, prostate cancer DU 145 cells, 1691Mitochondrial DNA, MtDNA mutation, D-loop region,

breast cancer, plasma, 4267Mitochondria-mediated pathways, gallic acid (GA), human

leukemia HL-60 cells, apoptosis, death receptor-mediatedpathways, 2821

Mitochondrion, sonodynamic therapy, 5-aminolevulinicacid, SAS cell, apoptosis, 39

Mitogenic activity, zeranol, ACI rat serum, breast cancer, 481Mitomycin C, intravesical chemotherapy, bladder cancer,

929Mitosis, (+)-Spongistatin 1, anticancer, natural product,

xenograft model, 2773

Mitotic counts, breast cancer, prognosis, 97Mitrogen mustards, uridine phosphorylase, hybrid steroidal

alkylators, in silico molecular docking, in vitro assay,pancreatic cancer cells, 831

MKate2, mCherry, glioblastoma model, intracranial, liveimaging, temozolomide, 2161

MLPA, NSCLC, methylation, targeted therapy, genemethylation, TKIs, smoking, EGFR mutation, 4647

MMP, ADAM, TIMP, solid cancer nest, invasive front,colorectal cancer, 1567

MMP-13, bone metastasis, type I collagen, integrin,MAPK, 1307

MMP2, polymorphism, colorectal cancer, VEGF, HIF1A,SNP, 575

MMP-2, prostate cancer, vitamin D analog, ZK191784,MMP-9, adhesion molecules, 4091

MMP-9, prostate cancer, vitamin D analog, ZK191784,MMP-2, adhesion molecules, 4091

MMP-9, silibinin, CD44, EGFR, EGF, TGF-α, breastcancer metastasis, 3767

MoAb Jt-95, sialic fibronectin, thyroid malignantneoplasma, lymph node metastasis, 1395

Modified nucleosides, isopentenyladenosine, cytokinins,antiproliferative activity, 3401

Molecular biology, circulating tumor cells, CTCs,microfiltration by size, real-time quantitative reversetranscriptase-polymerase chain reaction, qRT-PCR,cytomorphology, FISH, cell culture, lung cancer, 427

Molecular classification, breast cancer, lymphaticmicrovessel density, VEGF-C, VEGFR-3, 1757

Molecular imaging, magnetic resonance imaging, micro-computed tomography, optical reflectance imaging,tumor volume, GFP, RFP, 2907

Monocyte differentiation, macrophage, colon cancer, MCP-1, 2493

Monocyte, tumour, microvesicles, chemokine, 1329Mono-l-aspartyl chlorin e6, ultrasound, antitumor effect,

sonodynamic therapy, sarcoma 180, colon 26, 501MonoTotal, lung cancer, cytokeratins, tumour markers,

3107Monte Carlo simulations, α-particle radiation, 238-

plutonium, bystander effect, micronucleus assay, 2113Morphine, cytokines, plasma, MIP-1α, IL-12, 4561Motion effect, hepatocellular carcinoma, 1H MRI, apparent

diffusion coefficient, extracellular space, benzamideriboside, angiography, therapy response, 2045

Mouse model, lung cancer, chemoprevention, combinedtreatment, 3279

Mouse peritoneal macrophages, Gc-derived macrophage-activating factor precursor, preGcMAF, 1f1f subtype ofGc protein, Gc1f1f protein, phagocytic activity, 2489

Mouse, lung cancer, lung inflammation, lung tumors, K-rasmutations, carcinogenesis, 2877


4773

MR, adrenocortical tumors, Cushing’s syndrome, adrenalimaging, cancer, CT, review, 2923

MRI, colon cancer, orthotopic model, GFP, fluorescentprotein imaging (FPI), selenium, angiogenesis, 387

1H MRI, hepatocellular carcinoma, apparent diffusioncoefficient, extracellular space, benzamide riboside,angiography, therapy response, motion effect, 2045

MRI, uterine cervical cancer, FDG-PET, lymph node, 3865MRNA translation, prostate cancer, EBP1, androgen

receptor, 3129MRNA, non-small cell lung cancer, TIMP1, DFI, survival,

blood plasma, 4031MRSI, prostate cancer, PCA3 urinary test, DCEMR, 1399MS, tubulin alpha-6 chain, HCV-HCC, proteomics, 2-DE,

3331MSX2, cholangiocarcinoma, brushing cytology, 1011MT, non-small lung cancer, metallothionein, Ki-67,

MCM-2, 2833MT477, tumor growth, NRF2, AURKA, 1181MtDNA mutation, D-loop region, breast cancer, plasma,

mitochondrial DNA, 4267MTHFR C677T, colorectal cancer, adjuvant chemotherapy,

MTR A2756G, toxicity, survival, 3057MT-I/II, breast cancer, metallothionein, Ki-67, MCM-2,

3027MTOR inhibitor, carboplatin, RAD001, everolimus, breast

cancer, 2713MTOR inhibitor, sunitinib, metastatic renal cell carcinoma,

sequential treatment regimen, tyrosine kinase inhibitor, 3507MTOR, chromophobe renal cell carcinoma, temsirolimus,

sorafenib, interferon, 331MTOR, LAT1, CD98, mesothelioma, hypoxia, prognosis,

4075MTOR, ovarian cancer, methyl-2-cyano-3, 12-dioxooleana-

1, 9(11)-dien-28-oate (CDDO-Me), apoptosis, AKT, NF-κB, 3673

MTOR, VEGF, HIF-1α, angiogenesis, oral cancer, 4429MTR A2756G, colorectal cancer, adjuvant chemotherapy,

MTHFR C677T, toxicity, survival, 3057MTSS1, metastasis suppressor-1, cellular migration,

invasion, bladder cancer, metastasis, 3205MUC1, KL-6 mucin, gastric cancer, β-catenin, invasion

front, 535Mucin-1, galectin-1, galectin-3, leiomyosarcoma,

leiomyoma, myometrium, 451Mucus metaplasia, esophagus, baboon, gastric reflux, 2187Multidrug resistance, hepatocellular carcinoma, liver

resection, ABC proteins, tyrosine kinase, 3883Multidrug resistance, hydantoin derivatives, Colo 205 and

Colo 320 colon adenocarcinoma cells, efflux pump,ABCB1 transporter, apoptosis, 3285

Multidrug resistance, P-glycoprotein, benzo[a]quinolizinderivatives, 921

Multidrug resistant, histone deacetylase inhibitor,chemotherapy, sarcoma, PCI-24781, 1115

Multidrug-resistant cancer cells, MDR mouse T-lymphomacells, ABCB1 transporter, P-glycoprotein,phenothiazines, thioridazine, apoptosis, 4201

Multidrug resistance, HTLV-1, ATL, leukemia, Hyptisverticillata jacq, 4251

Multifocal recurrence, anaplastic ependymoma,temozolomide, 1023

Multiple mitotic figures, quinazoliniminium salts, tumorcell proliferation, Ki-67 expression, macromoleculesyntheses, DNA interaction and fragmentation, nuclei,micronuclei, 2083

Multiple myeloma, bortezomib, once-weeklyadministration, dexamethasone, gastrointestinal adverseevents, 2297

Multiple myeloma, curcumin analog, NF-κB, PI3K/AKT,JAK/STAT3, IRF4, 3719

Multiple myeloma, proteasome inhibitor, receptor tyrosinekinase, activation loop, ER stress, FGFR3, Lys650Glumutation, K650E, bortezomide, plasma cell malignancy,113

Multiple myeloma, signal transduction, Wnt pathway,myeloma, myeloma therapy, review, 725

Muscle, green fluorescent protein, red fluorescent protein,cancer cell seeding, real-time imaging, lung, liver, 3665

Mutation, EGFR, estrogen receptor, lung cancer, 855Mutation, EGFR, methylation, tobacco smoking, lung

adenocarcinoma, FHIT, RASSF1A, RUNX3, 1211Mutation, Merkel cell carcinoma, KIT, sequence variation,

807Mutational screening, medullary thyroid carcinoma, gene

mutations, RET, HRAS, KRAS, NRAS, BRAF, AKT1,CTNNB1, 4179

Mutations, polymorphisms, TP53, FHIT, chronicesophagitis, esophageal carcinoma, 1685

MVD, angiogenesis, breast cancer, image analysis, CD34,vessel identification, 4053

MVD, colorectal cancer, pulmonary metastases, TS, OPRT,ERCC1, BRCA1, adjuvant chemotherapy, 2763

Myeloid DC, dentritic cells, pancreatic cancer, prognosticfactor, survival analysis, circulating dendritic cells, 3827

Myeloid dendritic cell, Wilms’ tumor 1 (WT1), cancervaccine, immunotherapy, 2447

Myeloma therapy, multiple myeloma, signal transduction,Wnt pathway, myeloma, review, 725

Myeloma, multiple myeloma, signal transduction, Wntpathway, myeloma therapy, review, 725

Myeloma, YT, CD86, interleukin-2, cytotoxicity, 475Myeloproliferative neoplasm, non-Hodgkin’s lymphoma,

portal vein thrombosis, 1467Myometrium, mucin-1, galectin-1, galectin-3,

leiomyosarcoma, leiomyoma, 451


4774

Myotoxicity, adriamycin, cardiotoxicity, fatigue, 2023Na+, H+ exchange, oxidative stress, cholangiocellular

carcinoma, liver cancer, 459Na+/K+-ATPase, medulloblastoma, atypical

teratoid/rhabdoid tumours, alpha subunits,immunohistochemistry, 953

Nasopharyngeal carcinoma, Cav-1, polymorphism,carcinogenesis, 3629

Natriuretic peptides, cell death, pancreatic neoplasm,prostate neoplasm, nuclear matrix proteins, 395

Natural agents, notch, stem cells, pancreatic cancer, signalpathway, cancer therapy, drug resistance, review, 1105

Natural killer cells, immunotherapy, immunomodulation,tumor models, Parapoxvirus ovis, Orf virus, 4185

Natural product, (+)-Spongistatin 1, anticancer, mitosis,xenograft model, 2773

Natural product, Levisticum officinale lovage, oral cavitysquamous cell carcinoma OCSCC, head and necksquamous cell carcinoma HNSCC, pharmacogenomics, 185

Natural product, Thymus vulgaris L. (thyme), oral cavitysquamous cell carcinoma OCSCC, head and necksquamous cell carcinoma HNSCC, pharmacogenomics, 81

N-cadherin, adrenocortical carcinoma, ADH-1, dynamiccontrast enhancing magnetic resonance imaging (DCE-MRI), phase-I, 3921

Neck dissection, posterior triangle, level V, 3959Necrosis, gastric carcinoma, carcinomatosis, glycolysis,

energetic metabolism, apoptosis, citrate, 797Nedaplatin, chemotherapy, docetaxel, S1, esophageal

carcinoma, phase I, 4589Neem leaf extract, neuroblastoma, radiotherapy, apoptosis,

transcriptional response, 161NEIL2, antiapoptosis, colorectal cancer, gamma radiation,

microarray, RT-PCR, REG4, BIRC5, 4147Neoadjuvant chemoradiotherapy, esophageal squamous cell

carcinoma, pathological response, complication,prognosis, 3073

Neoadjuvant chemoradiotherapy, gastric cancer, S-1,cisplatin, 3079

Neoadjuvant chemotherapy, breast cancer, trastuzumab,pCR, 3041

Neoadjuvant therapy, radiochemotherapy, esophagealcancer, docetaxel, cisplatin, phase II trials, 4407

Neoadjuvant therapy, rectal cancer, chemoradiation,complete clinical response, non-operative management,review, 1795

Neoadjuvant therapy, response prediction, squamous-cellesophageal cancer, tumor-associated proteins, 1769

N-ERC/mesothelin, renal failure, mesothelioma, tumormarkers, osteopontin, 1427

Neural stem cells, suicide genes, prodrugs, invasive tumors,animal models, gene-directed enzyme prodrug therapyreview, 1249

Neuroblastoma, apoptosis, celecoxib, cytotoxicity, valproicacid, 2231

Neuroblastoma, radiotherapy, neem leaf extract, apoptosis,transcriptional response, 161

Neuroectodermal, endometrial stromal sarcoma, t(10;17)translocation, 2367

Neuroendocrine cancer, colorectal, small cell cancer,chemotherapy, cisplatin, etoposide, 975

Neuroendocrine carcinomas, palladin, metastasis, 2957Neuroendocrine differentiation, prostate cancer, ethnicity,

3897Neurofibromatosis type 1, breast cancer, gastrointestinal

stromal tumor, 4481Neuropathy, cancer, neurotoxicity, adjuvant chemotherapy,

docetaxel, intraepidermal nerve fibres, skin biopsies,oxaliplatin, 4413

Neuropathy, meloxicam, paclitaxel, breast cancer, JBCRN,3567

Neurotoxicity, assessment, chemotherapy, peripheralneuropathy, adverse effects, 3493

Neurotoxicity, cancer, adjuvant chemotherapy, docetaxel,intraepidermal nerve fibres, neuropathy, skin biopsies,oxaliplatin, 4413

Neutron dynamic therapy, boron tracedrug, BODIPY,curcuminoid, dynamic drug, thermal neutron irradiation,BNCT, 2477

Neutrophil-lymphocyte ratio, non-small cell lung cancer,survival, 2995

NFκB, breast cancer, genistein, quercetin, apoptosis, 3301NFκB, IκBα, IKKβ, p38, peroxynitrite, nitration, colon

cancer, 1607NF-κB, multiple myeloma, curcumin analog, PI3K/AKT,

JAK/STAT3, IRF4, 3719NF-κB, ovarian cancer, methyl-2-cyano-3, 12-dioxooleana-

1, 9(11)-dien-28-oate (CDDO-Me), apoptosis, AKT,mTOR, 3673

N-Heterocyclic indolyl glyoxylamides, p53-independentapoptosis, G2/M phase arrest, human lung cancer cells,radiosensitivity, 3407

Nipple discharge, fiberoptic ductoscopy, breast cancer,3517

Nitration, NFκB, IκBα, IKKβ, p38, peroxynitrite, coloncancer, 1607

Nitrosamine, Stk11, Lkb1, hepatocellular carcinoma,choline-deficient L-amino acid-defined diet, rat, 543

4N1K, ras, BNIP3, CD47, cancer, programmed cell death,2869

NK4, gene therapy, cationised gelatin, cisplatin, squamouscell carcinoma, 105

NK4, HGF, c-Met, CT26, 5-fluorouracil, Akt, Erk1/2,thymidylate synthase, 2217

NKG2D, gemcitabine, MICA, MICB, HCC,immunotherapy, 2505


4775

N-Methyl-N-nitrosourea, SN1 methylating agents,apoptosis, O6-methylguanine-DNA methyltransferase(MGMT), RNA-binding proteins, 4291

Node dissection, p27, breast cancer, stage I, estrogenreceptor, progesterone receptor, 4401

Non-anticoagulant heparins, chemotherapy, heparins, 411Non-cirrhotic livers, hepatocellular carcinoma, viral

hepatitis, 1055Nonhepatic cancer, child’s classification, hepatocellular

carcinoma, liver cirrhosis, MELD-score, survivalprobability, TNM classification, 2931

Non-Hodgkin’s lymphoma, BCL2, lutetium-177,somatostatin receptor, 3143

Non-Hodgkin’s lymphoma, myeloproliferative neoplasm,portal vein thrombosis, 1467

Non-Hodgkin’s lymphoma, YB-1, prognosis, immuno-histochemistry, 2963

Non-invasive, cell-free DNA, circulation, biomarker,review, 2623

Non-melanoma, skin cancer, lymph node, metastasis,literature review, sentinel lymph node biopsy, 1443

Non-nuclear protein, progression, inflammation-associatedcarcinogenesis, fibrosarcoma, 1259

Non-operative management, rectal cancer, chemoradiation,neoadjuvant therapy, complete clinical response, review,1795

Non-seminomatous testicular cancer, PTEN, Akt, p27Kip1,subcellular distribution, 3783

Non-small cell lung cancer NSCLC, MAGE, expression,demethylation, 171

Non-small cell lung cancer, cancer stem cell antigens,biomarkers, prognosis, CD133, CD117, BCRP1, tissuemicroarrays, 4491

Non-small cell lung cancer, chemo-naive, EGFR mutation,erlotinib, platinum doublet, 3457

Non-small cell lung cancer, chemotherapy, carboplatin,paclitaxel, vinorelbine, 317

Non-small cell lung cancer, gefitinib, erlotinib, resistance,bone metastasis, radiotherapy, EGFR-TKIs, 4519

Non-small cell lung cancer, gefitinib, NSCLC, epidermalgrowth factor receptor, EGFR, skin toxicity, expandedaccess programme, EAP, 2949

Non-small cell lung cancer, HER2, surgical resection,immunohistochemical staining, prognosis, 4631

Non-small cell lung cancer, histoculture drug response assay,class III β-tubulin, predictive marker, vinorelbine, 999

Non-small cell lung cancer, lung cancer, bone metastases,bone remodeling markers, N-telopeptide of type Icollegen, NTx, bone alkaline phosphatase, BAP, 3879

Non-small cell lung cancer, neutrophil-lymphocyte ratio,survival, 2995

Non-small cell lung cancer, ribonucleotide reductase,p53R2, hRRM2, 3475

Non-small cell lung cancer, third-line treatment, erlotinib,gefitinib, review, 649

Non-small cell lung cancer, TIMP1, mRNA, DFI, survival,blood plasma, 4031

Non-small cell lung cancer, TXNDC5, thioredoxin, proteindisulphide isomerase, 1577

Non-small lung cancer cells, antisense oligonucleotide,cyclin D, cyclin E, cyclin-dependent kinase,retinoblastoma protein, pleural mesothelioma cells,apoptosis, kinases, phosphatases, 3683

Non-small lung cancer, metallothionein, MT, Ki-67, MCM-2, 2833

Non-solid type (Por2), poorly differentiated colorectaladenocarcinomas, solid type (Por1), 3463

Normal human keratinocytes, UVB, 18β-glycyrrhetinicacid, glabridin, ROS, 2209

Normal karyotype, interphase FISH, MDS, del(5q),del(20q), 1007

Normoxia, CD44-CD41, PC3 side fraction, hypoxia, 487Notch, leukemia, wnt, hedgehog, γ-secretase inhibitor, 893NOTCH, NSCLC, prognostic factors, HIF, lung cancer,

1603Notch, stem cells, pancreatic cancer, signal pathway,

natural agents, cancer therapy, drug resistance, review,1105

NR1, glutamate receptor, cancer, PCR, shRNA, GLUR4,KA2, NR2D, 3181

NR2D, glutamate receptor, cancer, PCR, shRNA, NR1,GLUR4, KA2, 3181

NRAS, medullary thyroid carcinoma, gene mutations, RET,HRAS, KRAS, BRAF, AKT1, CTNNB1, mutationalscreening, 4179

NRF2, MT477, tumor growth, AURKA, 1181NSAID, prostate cancer, PSA, statins, thiazide diuretic,

1735NSCLC, EGFR, HER2, EGFR tyrosine kinase inhibitor,

oncogene addiction, 4155NSCLC, FOXP3, lung cancer, immunohistochemistry,

lymph node, metastasis, 1677NSCLC, gefitinib, non-small cell lung cancer, epidermal

growth factor receptor, EGFR, skin toxicity, expandedaccess programme, EAP, 2949

NSCLC, lung cancer, erlotinib, EGFR, c-erbB-3, 281NSCLC, methylation, MLPA, targeted therapy, gene

methylation, TKIs, smoking, EGFR mutation, 4647NSCLC, prognostic factors, HIF, NOTCH, lung cancer,

1603N-telopeptide of type I collegen, lung cancer, non-small

cell lung cancer, bone metastases, bone remodelingmarkers, NTx, bone alkaline phosphatase, BAP, 3879

NTx, lung cancer, non-small cell lung cancer, bonemetastases, bone remodeling markers, N-telopeptide oftype I collegen, bone alkaline phosphatase, BAP, 3879


4776

Nuclear localization, actin cytoskeleton, cell migration,Ror1, receptor tyrosine kinase, 4239

Nuclear matrix proteins, cell death, pancreatic neoplasm,prostate neoplasm, natriuretic peptides, 395

Nuclei, quinazoliniminium salts, tumor cell proliferation,Ki-67 expression, macromolecule syntheses, DNAinteraction and fragmentation, multiple mitotic figures,micronuclei, 2083

Nucleotide, insoluble protein, dendritic cell, Tlymphocytes, immunotherapy, 881

NVP-AUY922, Hsp90 inhibitor, oral squamous cellcarcinoma, 1197

O6-Methylguanine-DNA methyltransferase (MGMT), SN1methylating agents, apoptosis, RNA-binding proteins, N-methyl-N-nitrosourea, 4291

Obesity, KRAP, KRAS, target, cancer, diabetes, review, 2413Oestrogen receptor-alpha, insulin-like growth factor-1,

IGF-1, tamoxifen-resistance, oestrogen resistance, breastcancer recurrence, EGFR, 23

Oestrogen resistance, insulin-like growth factor-1, IGF-1,tamoxifen-resistance, breast cancer recurrence, oestrogenreceptor-alpha, EGFR, 23

Off-label use, oxaliplatin, metastatic breast cancer, 1765Oleic acid, antitumor activity, Bcr-Abl, CML, Daedalea

gibbosa, kinase, medicinal mushrooms,autophosphorylation, 177

Oligodendroglioma, glioma, 1p19q, 1p, PAV, ACNU,procarbazine, vincristine, chemotherapy, 4475

Oligodeoxynucleotides, interleukin-6, interleukin-6receptor, breast cancer, MCF-7, antisense, 2899

Oligonucleotide, microfluidics, lipid nanoparticles, 771Oligonucleotides, electroporation, siRNA, miRNA, review,

4083Once-weekly administration, multiple myeloma,

bortezomib, dexamethasone, gastrointestinal adverseevents, 2297

Oncogene addiction, EGFR, HER2, EGFR tyrosine kinaseinhibitor, NSCLC, 4155

Oncogramme, breast cancer, primary culture,chemotherapeutics, therapy personalization,individualized tumour response testing, 139

Oncostatin M, interleukin-6, VEGF, u-PA, prostate cancer,3273

Online tumor conference, gynecological cancer, breastcancer, interdisciplinary therapy management, secondopinion, continuous medical training, 2669

Operation, BPF, fistula, lung cancer, risk factor, concurrentdisease, perioperative complication, infection, 619

Operation, breast cancer, recurrence, survival,polychemotherapy, 277

Operative morbidity, ovarian cancer, relapse,intraperitoneal, catumaxomab, surgical tumor debulking,operative mortality, 2603

Operative mortality, ovarian cancer, relapse, intraperitoneal,catumaxomab, surgical tumor debulking, operativemorbidity, 2603

OPN, uveal melanoma, metastasis, liver function tests,tumor markers, S-100β, MIA, TPS, 351

OPN, uveal melanoma, metastasis, tumor markers, S-100β,MIA, TPS, 345

OPRT, colorectal cancer, pulmonary metastases, TS,ERCC1, BRCA1, MVD, adjuvant chemotherapy, 2763

Optical imaging, dihydroartemisinin, pancreatic cancer, cellproliferation, apoptosis, angiogenesis, 1549

Optical reflectance imaging, magnetic resonance imaging,micro-computed tomography, tumor volume, molecularimaging, GFP, RFP, 2907

Optimal logistic regression, ovarian cancer, intervaldebulking surgery, staging laparoscopy, 4469

Oral administration, LPS, endotoxin, toxicity, absorption,lipopolysaccharide, review, 2431

Oral cancer, ADH1B, alcohol-dehydrogenase,polymorphism, laryngeal cancer, 677

Oral cancer, cyclin D1, polymorphism, smoking, 227Oral cancer, methylenetetrahydrofolate reductase MTHFR,

smoking, metastasis, recurrence, 2395Oral cancer, VEGF, mTOR, HIF-1α, angiogenesis, 4429Oral carcinogenesis, immunohistochemistry, beta-catenin,

tongue, mice, 2805Oral cavity squamous cell carcinoma OCSCC, Levisticum

officinale lovage, head and neck squamous cellcarcinoma HNSCC, natural product, pharmacogenomics,185

Oral cavity squamous cell carcinoma OCSCC, Thymusvulgaris L. (thyme), head and neck squamous cellcarcinoma HNSCC, natural product, pharmacogenomics, 81

Oral cavity, hemangiopericytoma, solitary fibrous tumor,cheek, soft tissue, 719

Oral etoposide, recurrent cervical cancer, cisplatin, second-line chemotherapy, feasibility study, 3063

Oral SCC, EMMPRIN, Fyn, integrin, ECM, 1205Oral squamous cell carcinoma, benzo[c]phenanthridine

alkaloids, sanguinarine, anticancer therapeutic agents,2841

Oral squamous cell carcinoma, cadherins,immunohistochemistry, prognosis, OSCC, 4211

Oral squamous cell carcinoma, gankyrin, overexpression,2683

Oral squamous cell carcinoma, Hsp90 inhibitor, NVP-AUY922, 1197

Oral squamous cell carcinoma, thymidylate synthase,dihydropyrimidine dehydrogenase, lymph nodemetastasis, KAI1/CD82, 3521

Oral squamous cell carcinomas, toombak, genes, apoptosis,cell cycle regulation, intermediate filament proteins,Sudan, 3345


4777

Orf virus, immunotherapy, immunomodulation, tumormodels, natural killer cells, Parapoxvirus ovis, 4185

Organic arsenicals, arsenic trioxide, arsenic acid, T-lymphoblastoid leukemia, daunorubicin resistance,apoptosis, 4169

Oropharyngeal cancer, tonsillar cancer, base of tonguecancer, head and neck cancer, HPV, revie, 1515

Orthotopic model, colon cancer, GFP, fluorescent proteinimaging (FPI), MRI, selenium, angiogenesis, 387

Orthotopic mouse model of osteosarcoma, IGF-1R,phosphorylated MEK, Ras/Raf/MEK/ERK pathway, lungmetastasis, 1147

Orthotopic, GFP, prostate cancer, PC-3, circulating cancercells, immunomagnetic beads, isolation, fluorescence,imaging, culture, 1535

OSCC, cadherins, immunohistochemistry, prognosis, oralsquamous cell carcinoma, 4211

OSMR, quantitative methylation-specific PCR, colorectalcancer, 1293

OSNA, breast cancer, sentinel lymph node, cytokeratin 19,intra-operative method, 585

Osteolysis, GLI2, PTHrP, breast cancer, 6-thioguanine,2705

Osteonecrosis, bisphosphonate, mandible, BRONJ, 2313Osteopontin, renal failure, mesothelioma, tumor markers,

N-ERC/mesothelin, 1427Osteosarcoma cell lines, P-Glycoprotein, chemotherapy,

inhibition of multidrug resistance, carcinoma cell lines,siRNA, 2813

Osteosarcoma, acridine orange, pulmonary metastasis,photodynamic therapy, flash-wave light,fluorovisualization, 4163

Osteosarcoma, C7orf24, γ-glutamyl cyclotransferase, 1297Osteosarcoma, jaw bones, maxilla, mandible, 4485Osteosarcoma, malignant fibrous histiocytoma, MAPK

signaling pathway, 549Osteosarcoma, metastasis, angiotensin II type 1 receptor

antagonist, CV11974, 123Outcome, thromoboembolism, breast cancer, chemotherapy,

2383Ovarian cancer cell lines, oxaliplatin, phytochemicals,

synergism, cytotoxicity, 4283Ovarian cancer cell lines, PAMAM dendrimers,

encapsulation, intracellular delivery, resistance, SMVT,cisplatin, 897

Ovarian cancer relapse, secondary cytoreductive surgery,predictive factor, tumor residual, complete tumorresection, 2583

Ovarian cancer, 8-hydroxydeoxyguanosine, oxidative stress,reactive oxygen species, 1411

Ovarian cancer, bevacizumab, platinum-resistant, 2679Ovarian cancer, cisplatin, curcumin, EGCG, synergism,

drug combination, 1131

Ovarian cancer, claudin-4, chemotherapy resistance, 1271Ovarian cancer, clinical cancer registry, cancer

epidemiology, 2657Ovarian cancer, consolidation chemotherapy, recurrent,

salvage chemotherapy, treatment-free interval, paclitaxel,cisplatin, irinotecan, 4613

Ovarian cancer, CT-guided high-dose-rate brachytherapy,CT-HDRBT, metachronous liver metastasis, ablation ofliver metastases, 2597

Ovarian cancer, cytoreductive surgery, residual disease,prediction models, 4043

Ovarian cancer, diagnosis, biomarkers, enzyme-linkedimmunosorbent assay, cathepsin, matrixmetalloproteinase-9, heparanase, 3423

Ovarian cancer, estrogen receptor beta, prognostic factor,immunohistochemistry, cisplatin, 711

Ovarian cancer, gene mutations, BRCA 1/2, TP53, PI3K,AKT, BRAF, KRAS, review, 2661

Ovarian cancer, HB-EGF, ELISA, 2553Ovarian cancer, HB-EGF, targeted therapy, CRM197, 2461Ovarian cancer, hyperthermia, bevacizumab, doxorubicin,

platinum-refractory, 2675Ovarian cancer, hyprocrellin B, hematoporphyrin

monomethyl ether, intracellular metabolism, subcellularlocalization, phototoxicity, 3229

Ovarian cancer, interval debulking surgery, staginglaparoscopy, optimal logistic regression, 4469

Ovarian cancer, methyl-2-cyano-3, 12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), apoptosis, AKT, NF-κB, mTOR, 3673

Ovarian cancer, relapse, intraperitoneal, catumaxomab,surgical tumor debulking, operative morbidity, operativemortality, 2603

Ovarian cancer, WT1 peptide vaccine, immunotherapy,2441

Overexpression, gankyrin, oral squamous cell carcinoma,2683

Oxaliplatin, cancer, neurotoxicity, adjuvant chemotherapy,docetaxel, intraepidermal nerve fibres, neuropathy, skinbiopsies, 4413

Oxaliplatin, capecitabine, bevacizumab, cetuximab, phaseII, metastatic colorectal cancer, 255

Oxaliplatin, cetuximab, colorectal cancer, irinotecan,biomarkers, 2149

Oxaliplatin, chemotherapy, FLOX regimen, metastaticcolorectal cancer, phase II study, 5-FU, leucovorin, 4657

Oxaliplatin, drug resistance, drug combination, synergism,quercetin, thymoquinone, cisplatin, 3789

Oxaliplatin, gastric cancer, cetuximab, irinotecan, KRASphase II trial, 4439

Oxaliplatin, KRAS, p53, colorectal, 5-fluorouracil,capecitabine, clinical, CAIRO2, sequence analysis, 1379

Oxaliplatin, off-label use, metastatic breast cancer, 1765


4778

Oxaliplatin, phytochemicals, ovarian cancer cell lines,synergism, cytotoxicity, 4283

Oxidative stress, 8-hydroxydeoxyguanosine, ovarian cancer,reactive oxygen species, 1411

Oxidative stress, Beckwith-Wiedemann syndrome,potassium ascorbate, 3973

Oxidative stress, Na+, H+ exchange, cholangiocellularcarcinoma, liver cancer, 459

3-Oxoolean-12-en-27-oic acid, cell-cycle arrest, lungcancer cells, 2179

P13K/mTOR inhibitor, BEZ235, lung cancer, EGFR, 849P16INK4a, methylation, colorectal cancer, 1643P21, p53, CDKN1A/WAF/CIP1, polymorphism,

endometriosis, genotype, 4301P22PHOX, polymorphism, ulcerative colitis, DNA

methylation, CD14, MBL, 933P27, breast cancer, node dissection, stage I, estrogen

receptor, progesterone receptor, 4401p27Kip1, non-seminomatous testicular cancer, PTEN, Akt,

subcellular distribution, 3783P38 MAPK, head and neck cancer, STAT1, STAT3,

phosphorylation, 3819P38, NFκB, IκBα, IKKβ, peroxynitrite, nitration, colon

cancer, 1607P38, PEDF, c-FLIP, HCC, PPARγ, hepatocellular

carcinoma, apoptosis, 1173P53 pathway, medicinal herb, bioactivity, apoptosis, Ruta

graveolens, Akt, 233P53, age, breast cancer, grade, immunohistochemistry,

measles virus, 913P53, anticancer agents, sphingomylinase, Cox-2, caspase-3,

apoptosis, cell cycle, 1345P53, anticancer drugs, sphingomyelinase, Bax, cell cycle,

apoptosis, 871P53, cancer, endometrium, apoptosis, Bcl-2, E-cadherin,

estrogen receptor, progesterone receptor, 4191P53, cyclin B1, cell cycle, squamous cell carcinoma, head

and neck cancer, 3151P53, KRAS, colorectal, oxaliplatin, 5-fluorouracil,

capecitabine, clinical, CAIRO2, sequence analysis, 1379P53, p21, CDKN1A/WAF/CIP1, polymorphism,

endometriosis, genotype, 4301P53-independent apoptosis, N-heterocyclic indolyl

glyoxylamides, G2/M phase arrest, human lung cancercells, radiosensitivity, 3407

P53R2, non-small cell lung cancer, ribonucleotidereductase, hRRM2, 3475

P66shc, epigenetic modifiers, kidney, toxicity, ROS,mitochondria, 3267

P90RSK, genistein, breast cancer, cell proliferation, T47Dcells, 209

Paclitaxel (PTX), alcohol intolerance, de-alcoholization,pharmacokinetics, adverse event, 4339

Paclitaxel, anal cancer, 5-FU, cisplatin, 4637Paclitaxel, bevacizumab, breast cancer, vascular endothelial

growth factor receptors, 3007Paclitaxel, chemotherapy, carboplatin, vinorelbine, non-

small cell lung cancer, 317Paclitaxel, doxifluridine, gastric cancer, ascites, 4625Paclitaxel, doxifluridine, gastric cancer, thymidine

phosphorylase, chemotherapy, 287Paclitaxel, meloxicam, neuropathy, breast cancer, JBCRN,

3567Paclitaxel, ovarian cancer, consolidation chemotherapy,

recurrent, salvage chemotherapy, treatment-free interval,cisplatin, irinotecan, 4613

Paclitaxel, small cell lung cancer, TRAIL, chemotherapy,3193

Paclitaxel, squamous cell carcinoma, bladder cancer,recurrence, gemcitabine, 4465

Paclitaxel, triplet combination chemotherapy, cisplatin, S-1,advanced gastric cancer, feasibility study, 3085

Paclitaxel-based chemoradiotherapy, lung cancer, BCL-2,MDR1, radiosensitivity, 1431

P-Akt, LAT1, CD98, recurrence, advanced NSCLC, EGFRmutation, prognosis, chemotherapy. Ki-67, p-mTOR,3775

P-Akt, prostate cancer, PGE2, EP4, Snail, epithelial-mesencymal transition, 4347

Palladin, neuroendocrine carcinomas, metastasis, 2957PAMAM dendrimers, encapsulation, intracellular delivery,

resistance, SMVT, cisplatin, ovarian cancer cell lines,897

Pancreas cancer, belinostat, bortezomib, histonedeacetylase inhibitor, proteasome inhibitor,hepatocellular cancer, apoptosis, metabolomics, 1093

Pancreatic cancer cells, pomegranate, phytochemicals, cellcycle arrest, 2699

Pancreatic cancer cells, uridine phosphorylase, hybridsteroidal alkylators, in silico molecular docking, in vitroassay, mitrogen mustards, 831

Pancreatic cancer, BRCA, iniparib, chemotherapy, 1417Pancreatic cancer, dihydroartemisinin, cell proliferation,

apoptosis, angiogenesis, optical imaging, 1549Pancreatic cancer, gemcitabine, intra-arterial therapy,

chemoradiotherapy, 3909Pancreatic cancer, gemcitabine, resistance, ERK,

lenalidomide, 3747Pancreatic cancer, hENT1, gemcitabine, cytotoxicity, I3C,

3171Pancreatic cancer, interleukin-6, signal transducer and

activator of transcription 3, 2029Pancreatic cancer, myeloid DC, dentritic cells, prognostic

factor, survival analysis, circulating dendritic cells, 3827Pancreatic cancer, notch, stem cells, signal pathway, natural

agents, cancer therapy, drug resistance, review, 1105


4779

Pancreatic cancer, pancreatic neoplasms, long-termsurvivors, surgery, brain metastasis, 4599

Pancreatic cancer, two-dimensional gel electrophoresis,LC-MS/MS, TS-1, proteomics, 2103

Pancreatic cancer, virotherapy, chemoresistance,gemcitabine, PDAC, GFP, 1279

Pancreatic neoplasm, cell death, prostate neoplasm, nuclearmatrix proteins, natriuretic peptides, 395

Pancreatic neoplasm, erlotinib, cetuximab, chemotherapy,chemoresistance, chemosensitivity, 1039

Pancreatic neoplasms, pancreatic cancer, long-termsurvivors, surgery, brain metastasis, 4599

Panipenem, active metabolite of irinotecan, SN-38,glucuronidation, SN-38 glucuronide (SN-38G),pharmacokinetics, 2915

Panitumumab, metastatic colorectal cancer, bevacizumab,treatment, 1033

Pantoea agglomerans, A46, LPS, LPSp, LPSa46,macrophage, M-CSF, GM-CSF, 2467

Papanicolaou staining, DNA ploidy, image analysis,cytometry, cytology, hematoxylin staining, Feulgenstaining, 53

Para-aortic lymph node dissection, endometrial carcinoma,adjuvant chemotherapy, prognosis, 4513

Parametrium, cervical cancer, micrometastasis,immunohistochemistry, 243

Paraoxonase 1, PON1, polymorphism, lung cancer risk,SNP, 2225

Parapoxvirus ovis, immunotherapy, immunomodulation,tumor models, natural killer cells, Orf virus, 4185

Parathyroid tumors, hyperparathyroidism, arterial bloodpressure, serum calcium, PTH, arterial hypertension,elderly, 3969

Pathological features, prostaglandin E2 receptor, renal cellcarcinoma, survival, immunohistochemistry, 597

Pathological response, esophageal squamous cellcarcinoma, neoadjuvant chemoradiotherapy,complication, prognosis, 3073

Patients’ satisfaction, prostate cancer, radiation, surgery,hormonal therapy, 3903

PAV, glioma, oligodendroglioma, 1p19q, 1p, ACNU,procarbazine, vincristine, chemotherapy, 4475

Paxillin, cytoskeleton, phosphatase, PP-1, TGF-β, 3159PC3 side fraction, CD44-CD41, normoxia, hypoxia, 487PC-3, GFP, prostate cancer, orthotopic, circulating cancer

cells, immunomagnetic beads, isolation, fluorescence,imaging, culture, 1535

PCA3 urinary test, prostate cancer, MRSI, DCEMR, 1399PCA3, PSA free/total, prostate cancer, saturation prostate

biopsy, repeat biopsy, cancer diagnosis, 4445PCI-24781, histone deacetylase inhibitor, chemotherapy,

multidrug resistant, sarcoma, 1115PCNA, Ki-67, recurrence, lung, adenocarcinoma, 4277

PCR, breast cancer, brain metastases, humanmammaglobin, 1061

PCR, breast cancer, neoadjuvant chemotherapy,trastuzumab, 3041

PCR, glutamate receptor, cancer, shRNA, NR1, GLUR4,KA2, NR2D, 3181

PCR, prognostic factor, stanniocalcin 1, colorectal cancer,325

PDAC, virotherapy, pancreatic cancer, chemoresistance,gemcitabine, GFP, 1279

PDT, photodynamic therapy, glycoconjugated chlorin,apoptosis, gastric cancer, colon cancer, 763

PEDF, c-FLIP, HCC, p38, PPARγ, hepatocellularcarcinoma, apoptosis, 1173

Pediatric neuro-oncology, quality control, brain tumor,survival, 661

Pediatrics, bevacizumab, safety, VEGF, 3953PEG liposomes, stealth liposomes, 5-FU, locoregional

chemotherapy, liver metastases, 147PEG liposomes, stealth liposomes, docetaxel, locoregional

chemotherapy, liver metastases, hepatic arterial infusion,153

Pelvic nodal involvement, prostate cancer, serum totaltestosterone, 3615

Pemetrexed, radiation, human mesothelioma cell line,radiosensitivity, apoptosis, 2847

Pemetrexed, skin toxicity, hyperpigmentation, 1753Peptide vaccination, acute myeloid leukemia,

immunotherapy, interleukin-2, cerebrospinal fluid, CSF,flow of CSF, chloroma, 2343

Peptide, Her-2/neu, vaccine, B-cell epitope, antitumoreffect, 3361

Peptide, matrix metalloproteinases, gelatinase, tonguecarcinoma, green fluorescent protein, xenograft, 3659

Percutaneous ablation, hepatocellular carcinoma, cirrhosis,percutaneous ethanol injection, radiofrequency ablation,randomized controlled trial, 2291

Percutaneous ethanol injection, hepatocellular carcinoma,cirrhosis, percutaneous ablation, radiofrequency ablation,randomized controlled trial, 2291

Perioperative complication, BPF, fistula, operation, lungcancer, risk factor, concurrent disease, infection, 619

Perioperative factors, hepatocellular carcinoma,uncontrolled ascites, hepatectomy, prognosis, 4545

Peripheral neuropathy, assessment, chemotherapy,neurotoxicity, adverse effects, 3493

Peroxynitrite, NFκB, IκBα, IKKβ, p38, nitration, coloncancer, 1607

Personality, bening breast disease, type C, hopelessness,cancer risk, 4019

Personality, type C, commitment, cancer risk, 4013PGE2, prostate cancer, EP4, p-Akt, Snail, epithelial-

mesencymal transition, 4347


4780

P-Glycoprotein, chemotherapy, inhibition of multidrugresistance, osteosarcoma cell lines, carcinoma cell lines,siRNA, 2813

P-Glycoprotein, multidrug resistance, benzo[a]quinolizinderivatives, 921

P-Glycoprotein, multidrug-resistant cancer cells, MDRmouse T-lymphoma cells, ABCB1 transporter,phenothiazines, thioridazine, apoptosis, 4201

P-gp modulation, isolated lung perfusion, sarcoma lungmetastases, doxorubicin, cyclosporine, valspodar, 2121

Phagocytic activity, Gc-derived macrophage-activatingfactor precursor, preGcMAF, 1f1f subtype of Gc protein,Gc1f1f protein, mouse peritoneal macrophages, 2489

Pharmacogenetics, irinotecan, metastatic colorectal cancer,359

Pharmacogenomics, Levisticum officinale lovage, oralcavity squamous cell carcinoma OCSCC, head and necksquamous cell carcinoma HNSCC, natural product, 185

Pharmacogenomics, SNPs, bexarotene, RXR, lung cancer, 2303Pharmacogenomics, Thymus vulgaris L. (thyme), oral

cavity squamous cell carcinoma OCSCC, head and necksquamous cell carcinoma HNSCC, natural product, 81

Pharmacokinetics, active metabolite of irinotecan, SN-38,glucuronidation, SN-38 glucuronide (SN-38G),panipenem, 2915

Pharmacokinetics, afatinib, BIBF 1120, colorectal cancer,phase II, 2271

Pharmacokinetics, irinotecan, metabolites, hepatic intra-arterial infusion, plasma disposition, 3573

Pharmacokinetics, paclitaxel (PTX), alcohol intolerance,de-alcoholization, adverse event, 4339

Phase I, chemotherapy, docetaxel, nedaplatin, S1,esophageal carcinoma, 4589

Phase I, fenretinide, LXS oral powder, clinical trial, 961Phase I, S-1, 5-fluorouracil, FBAL, tegafur, FT, reversible


Phase II study, chemotherapy, FLOX regimen, metastaticcolorectal cancer, 5-FU, leucovorin, oxaliplatin, 4657

Phase II trials, neoadjuvant therapy, radiochemotherapy,esophageal cancer, docetaxel, cisplatin, 4407

Phase II, afatinib, BIBF 1120, colorectal cancer,pharmacokinetics, 2271

Phase II, capecitabine, oxaliplatin, bevacizumab,cetuximab, metastatic colorectal cancer, 255

Phase II, HNSCC, Src, AZD0530, saracatinib, 249Phase-I, adrenocortical carcinoma, ADH-1, dynamic

contrast enhancing magnetic resonance imaging (DCE-MRI), N-cadherin, 3921

Phenethyl isothiocyanate, cell cycle arrest, apoptosis,mitochondria, caspases, prostate cancer DU 145 cells, 1691

Phenformin, colon cancer, metformin, 2-deoxyglucose,acidification, 421

Phenothiazines, multidrug-resistant cancer cells, MDRmouse T-lymphoma cells, ABCB1 transporter, P-glycoprotein, thioridazine, apoptosis, 4201

Phosphatase and tensin homolog (PTEN), colon cancermetastasis, epithelial-mesenchymal transition (EMT),endothelin axis, endothelin A and B receptor (ETAR andETBR), 861

Phosphatase, cytoskeleton, paxillin, PP-1, TGF-β, 3159Phosphatases, antisense oligonucleotide, cyclin D, cyclin E,

cyclin-dependent kinase, retinoblastoma protein, non-small lung cancer cells, pleural mesothelioma cells,apoptosis, kinases, 3683

Phosphodiesterase, cervical carcinoma, prognosis, iNOS,guanylyl cyclase, 2319

Phospho-proteins, ischemia, immunohistochemistry,xenografts, pre-analytical variables, biopsy, 2073

Phosphorylated MEK, IGF-1R, Ras/Raf/MEK/ERKpathway, orthotopic mouse model of osteosarcoma, lungmetastasis, 1147

Phosphorylation of p53, ionizing radiation, radiation-sensitivity, 2255

Phosphorylation, head and neck cancer, p38 MAPK,STAT1, STAT3, 3819

Phosphorylation, sunitinib, antitumor, antimetastasis,VEGF, VEGFR, mammary cancer, 1225

Photodynamic therapy, acridine orange, osteosarcoma,pulmonary metastasis, flash-wave light,fluorovisualization, 4163

Photodynamic therapy, PDT, glycoconjugated chlorin,apoptosis, gastric cancer, colon cancer, 763

Phototoxicity, ovarian cancer, hyprocrellin B,hematoporphyrin monomethyl ether, intracellularmetabolism, subcellular localization, 3229

Phytochemicals, oxaliplatin, ovarian cancer cell lines,synergism, cytotoxicity, 4283

Phytochemicals, pomegranate, pancreatic cancer cells, cellcycle arrest, 2699

PI3K, advanced gastric cancer, AKT, chemoresistance,review, 4387

PI3K, ovarian cancer, gene mutations, BRCA 1/2, TP53,AKT, BRAF, KRAS, review, 2661

PI3K, thyroid hormones, proliferation, MAPK, 89PI3K/AKT, multiple myeloma, curcumin analog, NF-κB,

JAK/STAT3, IRF4, 3719PI3K-Akt/mTOR pathway, gastrointestinal stromal

tumors (GISTs), Ras-Raf-ERK/MAPK Pathway,insulin-like growth factor 1 receptor (IGF1R), CD117,3019

Placental growth factor, alternative splicing, angiogenesis,autologous stem cell transplantation, chickchorioallantoic membrane assay, high-dosechemotherapy, vascular endothelial growth factor,VEGFR1, 3115


4781

Plasma cell malignancy, proteasome inhibitor, receptortyrosine kinase, activation loop, multiple myeloma, ER stress, FGFR3, Lys650Glu mutation, K650E,bortezomide, 113

Plasma disposition, irinotecan, metabolites, hepatic intra-arterial infusion, pharmacokinetics, 3573

Plasma, cytokines, morphine, MIP-1α, IL-12, 4561Plasma, MtDNA mutation, D-loop region, breast cancer,

mitochondrial DNA, 4267Platinum doublet, chemo-naive, EGFR mutation, erlotinib,

non-small cell lung cancer, 3457Platinum, ferrocene, ethynyl phosphine, gold, cytotoxicity,

HeLa, 825Platinum-refractory, hyperthermia, bevacizumab,

doxorubicin, ovarian cancer, 2675Platinum-resistant, bevacizumab, ovarian cancer, 2679Pleural mesothelioma cells, antisense oligonucleotide,

cyclin D, cyclin E, cyclin-dependent kinase,retinoblastoma protein, non-small lung cancer cells,apoptosis, kinases, phosphatases, 3683

238-Plutonium, α-Particle radiation, Monte Carlosimulations, bystander effect, micronucleus assay, 2113

P-mTOR, LAT1, CD98, recurrence, advanced NSCLC,EGFR mutation, prognosis, chemotherapy. Ki-67, p-Akt,3775

Pneumatosis intestinalis, sunitinib, gastrointestinal stromaltumor, 3429

Polo-like kinase 1, cholangiocarcinoma, 5-fluorouracil,gemcitabine, BI 2536, 3289

Polybisphosphonate, bone metastasis, prostate cancer, 4141Polychemotherapy, breast cancer, recurrence, operation,

survival, 277Polymorphic genotypes, caveolin-1, breast cancer, 3511Polymorphism, ADH1B, alcohol-dehydrogenase, oral

cancer, laryngeal cancer, 677Polymorphism, Cav-1, nasopharyngeal carcinoma,

carcinogenesis, 3629Polymorphism, CCND1 1722, cyclin D1, upper tract

urothelial cancer, 1043Polymorphism, colorectal cancer, MMP2, VEGF, HIF1A,

SNP, 575Polymorphism, Cox-2, carcinogenesis, prostate cancer, 221Polymorphism, cyclin D1, CCND1, lung cancer, smoking,

Taiwanese, 3601Polymorphism, cyclin D1, oral cancer, smoking, 227Polymorphism, Helicobacter pylori, gastric atrophy,

intestinal metaplasia, XRCC1, GSTP1, GSTT1, GSTM1,1459

Polymorphism, HNSCC, EGFR, Erk-1/2, AG1478,cetuximab, 59

Polymorphism, hOGG1, XPD, urothelial carcinoma, 3939Polymorphism, p53, p21, CDKN1A/WAF/CIP1,

endometriosis, genotype, 4301

Polymorphism, paraoxonase 1, PON1, lung cancer risk,SNP, 2225

Polymorphism, ulcerative colitis, DNA methylation, CD14,p22PHOX, MBL, 933

Polymorphism, X-ray repair cross-complementing group 1,XRCC1, DNA repair, skin cancer, meta-analysis, 3945

Polymorphism, XRCC1, Arg399Gln, Arg194Trp, GSTP1Ile104Val, GSTT1, GSTM1, gastric cancer, survival, 705

Polymorphisms, integrins, colorectal cancer, survival,single nucleotide polymorphisms, 1373

Polymorphisms, mutations, TP53, FHIT, chronicesophagitis, esophageal carcinoma, 1685

Polyp, gastric, chief cells, fundic glend polyps, 1789Pomegranate, pancreatic cancer cells, phytochemicals, cell

cycle arrest, 2699PON1, paraoxonase 1, polymorphism, lung cancer risk,

SNP, 2225Poorly differentiated colorectal adenocarcinomas, solid

type (Por1), non-solid type (Por2), 3463Portal vein embolisation, liver hypertrophy, tumor

progression, serum markers, 339Portal vein thrombosis, myeloproliferative neoplasm, non-

Hodgkin’s lymphoma, 1467Posterior triangle, level V, neck dissection, 3959Postmenopausal women, aromatase inhibitors, anti-

estrogens, breast cancer, steroid sulfatase, tamoxifen,anastrozole, 1367

Postoperative prognosis, κ-actin, hepatocellular carcinoma,survival, 2037

Postoperative radiotherapy, radiation therapy, risk factor,enterocolitis, leg edema, gynecological malignancies,3527

Post-traumatic sequelae, intravenous curcumin, blood–brainbarrier, hippocampus, striatum, brain stem, 907

Potassium ascorbate, oxidative stress, Beckwith-Wiedemann syndrome, 3973

Potassium channels, epithelial to mesenchymal transition,lung cancer, Eag1, TGF-β, 1265

PP-1, cytoskeleton, paxillin, phosphatase, TGF-β, 3159PP2Ac, lactoferrin, IGBP1, apoptosis, lung adeno-

carcinoma, 529PPARG, PPARγ, breast cancer, T0070907, migration,

invasion, 813PPARγ, breast cancer, PPARG, T0070907, migration,

invasion, 813PPARγ, PEDF, c-FLIP, HCC, p38, hepatocellular

carcinoma, apoptosis, 1173Pre-analytical variables, ischemia, immunohistochemistry,

xenografts, phospho-proteins, biopsy, 2073Prediction models, ovarian cancer, cytoreductive surgery,

residual disease, 4043Prediction of therapy response, breast ultrasound, pre-

operative therapy, sonography, sphericity, 4039


4782

Prediction, cancer, immunotherapy, survival, CD8, CD57,review, 639

Predictive factor, ovarian cancer relapse, secondarycytoreductive surgery, tumor residual, complete tumorresection, 2583

Predictive marker, histoculture drug response assay, non-small cell lung cancer, class III β-tubulin, vinorelbine,999

Predictor, gefitinib, radiation, combination therapy, EGFR,melanoma, 2883

Predictors of survival, castrate-resistant prostate cancer,time to castration resistance, chemotherapy, advancedprostate cancer, 1475

PreGcMAF, Gc-derived macrophage-activating factorprecursor, 1f1f subtype of Gc protein, Gc1f1f protein,phagocytic activity, mouse peritoneal macrophages, 2489

Pregnancy, gastric cancer, low back pain, bilateralerythematous breast hypertrophy, 681

Premenopausal breast cancer, total estrogen blockade, high-dose chemotherapy, leuprorelin, anastrazole, VEGF, 671

Pre-metastatic niche, breast cancer, stem cells, metastasis,CD133, prognosis, 1315

Preoperative chemoradiotherapy, glucose transporter-1,hypoxia, hypoxia-inducible factor 1α, rectal cancer, 1559

Pre-operative therapy, breast ultrasound, prediction oftherapy response, sonography, sphericity, 4039

Prevention, vitamin D, 25-hydroxyvitamin D, breastneoplasms, case–control studies, epidemiology, meta-analysis, 2939

Primary culture, breast cancer, chemotherapeutics, therapypersonalization, oncogramme, individualized tumourresponse testing, 139

Primary peritoneal carcinoma, bevacizumab, erlotinib, 4397Primary serous-papillary peritoneal carcinoma,

retroperitoneal lymph nodes, spread pattern, review, 1387Priming, macrophage, LPS, IP-PA1, chronic psychological

stress, review, 2437Procarbazine, glioma, oligodendroglioma, 1p19q, 1p, PAV,

ACNU, vincristine, chemotherapy, 4475Prodrug activation, adenovirus, HNSCC, ganciclovir,

thymidine kinase, apoptosis, 3851Prodrugs, neural stem cells, suicide genes, invasive tumors,

animal models, gene-directed enzyme prodrug therapyreview, 1249

Progesterone receptor, cancer, endometrium, apoptosis,Bcl-2, p53, E-cadherin, estrogen receptor, 4191

Progesterone receptor, p27, breast cancer, node dissection,stage I, estrogen receptor, 4401

Prognosis factor, renal cell carcinoma, gamma-delta T-cell,1027

Prognosis, antiangiogenic therapy, hepatitis B virus,hepatocellular carcinoma, 4007

Prognosis, breast cancer, DAX-1, ApoD, ERα, 443

Prognosis, breast cancer, disseminated tumor cells, bonemarrow, follow-up, 2749

Prognosis, breast cancer, methylation, RASSF1A, 2975Prognosis, breast cancer, stem cells, pre-metastatic niche,

metastasis, CD133, 1315Prognosis, cadherins, immunohistochemistry, OSCC, oral

squamous cell carcinoma, 4211Prognosis, cervical cancer, C-reactive protein, CRP,

CRP1919 (rs1417938), CRP2667 (rs1800947), CRP3872(rs1205), CRP5237 (rs2808630), gene polymorphism,single nucleotide polymorphism, 2259

Prognosis, cervical carcinoma, iNOS, guanylyl cyclase,phosphodiesterase, 2319

Prognosis, endometrial cancer, survival, radiotherapy,chemotherapy, 3483

Prognosis, endometrial carcinoma, para-aortic lymph nodedissection, adjuvant chemotherapy, 4513

Prognosis, esophageal squamous cell carcinoma,neoadjuvant chemoradiotherapy, pathological response,complication, 3073

Prognosis, gastric cancer, lymph node dissection, staging,2361

Prognosis, GLUT-1, rectal cancer, chemotherapy,radiotherapy, tumour regression, 311

Prognosis, heart, hepatocellular carcinoma, inferior venacava, 4641

Prognosis, hepatocellular carcinoma, perioperative factors,uncontrolled ascites, hepatectomy, 4545

Prognosis, HER2, non-small cell lung cancer, surgicalresection, immunohistochemical staining, 4631

Prognosis, HuR, breast cancer, histological status, 303Prognosis, LAT1, CD98, mesothelioma, hypoxia, mTOR,

4075Prognosis, LAT1, CD98, recurrence, advanced NSCLC,

EGFR mutation, chemotherapy. Ki-67, p-Akt, p-mTOR,3775

Prognosis, left colon, right colon, sigmoid, survival, coloncancer, gender, 2347

Prognosis, magnetic resonance spectroscopy, brainneoplasms, radiotherapy, prospective studies, 3559

Prognosis, maspin, activin A, androgen receptor, upperurinary tract urothelial carcinoma, 1713

Prognosis, mitotic counts, breast cancer, 97Prognosis, non-Hodgkin’s lymphoma, YB-1, immuno-

histochemistry, 2963Prognosis, non-small cell lung cancer, cancer stem cell

antigens, biomarkers, CD133, CD117, BCRP1, tissuemicroarrays, 4491

Prognosis, RGM, breast cancer, prostate cancer, 1703Prognostic factor, ADM, colorectal cancer, hypoxia, 507Prognostic factor, breast cancer, mammography,

calcification, 2327Prognostic factor, claudin-1, recurrence, rectal cancer, 2517


4783

Prognostic factor, estrogen receptor beta, ovarian cancer,immunohistochemistry, cisplatin, 711

Prognostic factor, myeloid DC, dentritic cells, pancreaticcancer, survival analysis, circulating dendritic cells, 3827

Prognostic factor, rectal cancer, radiotherapy,chemotherapy, biomarker, carbonic anhydrase IX,hypoxia-inducible factor-1a, ezrin, glucose transporter-1,4529

Prognostic factor, stanniocalcin 1, PCR, colorectal cancer,325

Prognostic factors, breast cancer liver metastases, liversurgery, tumour markers, differental diagnosis, benignliver lesions, 1447

Prognostic factors, metastatic breast cancer, capecitabine,triple-negative, HER2-negative, 1079

Prognostic factors, NSCLC, HIF, NOTCH, lung cancer, 1603Prognostic role, bladder cancer, transitional carcinoma,

lymphovascular invasion, upper tract transitionalcarcinoma, review, 3503

Programmed cell death, ras, BNIP3, CD47, cancer, 4N1K,2869

Progression, inflammation-associated carcinogenesis,fibrosarcoma, non-nuclear protein, 1259

Pro-inflammatory microenv ironment, breast cancer, E-selectin, liver metastasis, endothelium, 3219

Prolactin (PRL), luteinizing hormone (LH), totaltestosterone (TT), free testosterone (FT), prostate-specific antigen (PSA), prostate cancer, 3913

Proliferation, cathepsin, cytokines, lung cancer cells, 47Proliferation, dectin-1, beta-glucan, B-cell lymphoma,

CD86, cell death, 4195Proliferation, laryngal squamous cell carcinoma,

microRNA, apoptosis, 3859Proliferation, laryngeal cancer, glutamate receptor,

antagonist, ERK1/2 kinase, 565Proliferation, thymidine kinase1, 5’(3’)-

deoxyribonucleotidase, fluorothymidine, lung cancer,colon cancer, 2135

Proliferation, thyroid hormones, PI3K, MAPK, 89Prospective studies, magnetic resonance spectroscopy, brain

neoplasms, radiotherapy, prognosis, 3559Prostaglandin E2 receptor, renal cell carcinoma,

pathological features, survival, immunohistochemistry,597

Prostaglandin, cyclooxygenase, COX-2, breast cancer,tumor, carcinogenesis, 4359

Prostate cancer cell lines, cannabinoids, apoptosis, proteintyrosine phosphatases, dual-specificity phosphatases,3799

Prostate cancer DU 145 cells, phenethyl isothiocyanate,cell cycle arrest, apoptosis, mitochondria, caspases, 1691

Prostate cancer, androgen receptor, combination strategy,flutamide, prostate-specific antigen, resveratrol, 3323

Prostate cancer, caveolin-1, single nucleotidepolymorphism, DNA repair, 745

Prostate cancer, circulating tumor cells, CTCs,immunomagnetic beads, GFP, chick embryo, brainmetastasis, metastatic assay, fluorescence imaging, 3125

Prostate cancer, circulating tumor cells, disseminated tumorcells, detection, bladder cancer, renal cell carcinoma,chemotherapy, review, 2053

Prostate cancer, Cox-2, polymorphism, carcinogenesis, 221Prostate cancer, cytotoxicity, triphala, gallic acid,

Ayurvedic medicine, 3739Prostate cancer, docetaxel, chemotherapy, biochemical

relapse, 973Prostate cancer, EBP1, mRNA translation, androgen

receptor, 3129Prostate cancer, GFP, PC-3, orthotopic, circulating cancer

cells, immunomagnetic beads, isolation, fluorescence,imaging, culture, 1535

Prostate cancer, hypofractionated radiotherapy, intermediaterisk, acute effect, image guided radiation therapy,hormonotherapy, 3555

Prostate cancer, indole, telomerase, diethylstilbestrol, cellviability, 3733

Prostate cancer, luteinizing hormone, LH, totaltestosterone, TT, free testosterone, FT, prostate-specificantigen, PSA, 1071

Prostate cancer, microRNA, Fusion gene, TMPRSS2:ERG,403

Prostate cancer, neuroendocrine differentiation, ethnicity,3897

Prostate cancer, oncostatin M, interleukin-6, VEGF, u-PA,3273

Prostate cancer, patients’ satisfaction, radiation, surgery,hormonal therapy, 3903

Prostate cancer, PCA3 urinary test, MRSI, DCEMR, 1399Prostate cancer, PCA3, PSA free/total, saturation prostate

biopsy, repeat biopsy, cancer diagnosis, 4445Prostate cancer, PGE2, EP4, p-Akt, Snail, epithelial-

mesencymal transition, 4347Prostate cancer, polybisphosphonate, bone metastasis, 4141Prostate cancer, prolactin (PRL), luteinizing hormone (LH),

total testosterone (TT), free testosterone (FT), prostate-specific antigen (PSA), 3913

Prostate cancer, PSA, statins, NSAID, thiazide diuretic, 1735Prostate cancer, radiotherapy, hypofractionation,

acceleration, amifostine, cytoprotection, 1745Prostate cancer, RGM, breast cancer, prognosis, 1703Prostate cancer, serum total testosterone, pelvic nodal

involvement, 3615Prostate cancer, transrectal ultrasonography, contrast-

enhanced ultrasonography, 1421Prostate cancer, vitamin D analog, ZK191784, MMP-2,

MMP-9, adhesion molecules, 4091


4784

Prostate cancer, vitamin D, colorectal cancer, breast cancer,lung cancer, 3619

Prostate neoplasm, cell death, pancreatic neoplasm, nuclearmatrix proteins, natriuretic peptides, 395

Prostate-specific antigen (PSA), prolactin (PRL),luteinizing hormone (LH), total testosterone (TT), freetestosterone (FT), prostate cancer, 3913

Prostate-specific antigen, androgen receptor, combinationstrategy, flutamide, prostate cancer, resveratrol, 3323

Prostate-specific antigen, luteinizing hormone, LH, totaltestosterone, TT, free testosterone, FT, PSA, prostatecancer, 1071

Prostatic neoplasm, bowel injury, laparoscopic radicalprostatectomy, LRP, rectal injury, robotic-assistedlaparoscopic prostatectomy, RALP, robotics, 3497

Proteasomal degradation, cisplatin, CTR1, bortezomib,drug combination, synergism, drug uptake, drugresistance, 2757

Proteasome inhibitor, belinostat, bortezomib, pancreascancer, histone deacetylase inhibitor, hepatocellularcancer, apoptosis, metabolomics, 1093

Proteasome inhibitor, receptor tyrosine kinase, activation loop,multiple myeloma, ER stress, FGFR3, Lys650Glu mutation,K650E, bortezomide, plasma cell malignancy, 113

Proteasome inhibitors, triptolide, medicinal compounds,apoptosis, cancer therapy, 1

Protein disulfide isomerase, zeranol, cell proliferation,mammary tumorigenesis, 1659

Protein disulphide isomerase, non-small cell lung cancer,TXNDC5, thioredoxin, 1577

Protein tyrosine phosphatases, cannabinoids, apoptosis,prostate cancer cell lines, dual-specificity phosphatases,3799

Proteoglycans, heparan sulfate, xenograft, HepG2 cells,immunotherapy, liver cancer, 4067

Proteomics, TNF-alpha, hepatoma, 2-DE, LC-MS/MS,apoptosis, 2059

Proteomics, tubulin alpha-6 chain, HCV-HCC, 2-DE, MS,3331

Proteomics, two-dimensional gel electrophoresis, LC-MS/MS, pancreatic cancer, TS-1, 2103

PSA free/total, PCA3, prostate cancer, saturation prostatebiopsy, repeat biopsy, cancer diagnosis, 4445

PSA, luteinizing hormone, LH, total testosterone, TT, freetestosterone, FT, prostate-specific antigen, prostatecancer, 1071

PSA, prostate cancer, statins, NSAID, thiazide diuretic,1735

P-Selectin, metastasis, HPA, E-selectin, SCID mouse,lectin, breast carcinoma cells, colon adenocarcinoma,1589

PSK, apoptosis, HL-60, cell proliferation, caspase-3activation, 2733

Psychiatric drugs, breast disease, psychosocial factors, 739Psychosocial factors, breast disease, psychiatric drugs, 739PTEN, carcinoid, serotonin, 1153PTEN, glioma, cell cycle, temozolomide, ionizing

radiation, radiosensitivity, 1653PTEN, KRAS, microRNA, colorectal cancer, miR-221/222,

3D culture, 2453PTEN, non-seminomatous testicular cancer, Akt, p27Kip1,

subcellular distribution, 3783PTH, parathyroid tumors, hyperparathyroidism, arterial

blood pressure, serum calcium, arterial hypertension,elderly, 3969

PTHrP, GLI2, osteolysis, breast cancer, 6-thioguanine, 2705Pulmonary metastases, colorectal cancer, TS, OPRT,

ERCC1, BRCA1, MVD, adjuvant chemotherapy, 2763Pulmonary metastasis, acridine orange, osteosarcoma,

photodynamic therapy, flash-wave light,fluorovisualization, 4163

Pyruvate dehydrogenase, reactive oxygen species, LongEvans Cinnamon, copper overload, 3395

QRT-PCR, circulating tumor cells, CTCs, microfiltration bysize, real-time quantitative reverse transcriptase-polymerase chain reaction, molecular biology,cytomorphology, FISH, cell culture, lung cancer, 427

QSAR, 1, 2, 3, 4-tetrahydroisoquinolins, tumor-specificityindex, semi-empirical molecular-orbital method, artificialneural network, 4231

QSAR, trihaloacetylazulenes, cytotoxicity, semiempiricalmolecular-orbital method, 515

Quality control, brain tumor, survival, pediatric neuro-oncology, 661

Quantitative methylation-specific PCR, OSMR, colorectalcancer, 1293

Quantitative methylation-specific PCR, vimentin,hepatocellular carcinoma, 1289

Quantitative PCR, immunohistochemistry, HMGB1, RAGE,disseminated histiocytic sarcoma, 1541

Quantitative polymerase chain reaction, Egfl8, colorectalcancer, 2249

Quantitative polymerase chain reaction, EGFL8, gastriccancer, 3377

Quantitative real-time PCR, MACC 1, hepatocellularcarcinoma, 777

Quantitative real-time PCR, TIP60, gastric cancer, 77Quantitative ultrasonometry, breast cancer, disseminated

tumor cells, bone marrow, bone mineral density, 4423Quercetin, breast cancer, genistein, apoptosis, NFκB, 3301Quercetin, drug resistance, drug combination, synergism,

thymoquinone, cisplatin, oxaliplatin, 3789Quinazoliniminium salts, tumor cell proliferation, Ki-67

expression, macromolecule syntheses, DNA interactionand fragmentation, multiple mitotic figures, nuclei,micronuclei, 2083


4785

Quinolinic acid, indoleamine-2, 3-dioxygenase,immunomodulation, cervical cancer, kynurenic acid,2629

Race, cigarette smoking, tobacco-caused cancer, 3891RAD001, carboplatin, everolimus, breast cancer, mTOR

inhibitor, 2713Radiation myelopathy, radiation therapy, spinal cord,

γ-H2AX, 561Radiation sensitivity, clonogenic cell survival, huachansu,

lung cancer cells, inhibition of DNA repair, 2141Radiation sensitivity, esophageal cancer, gastric cancer,

hypoxia, cell cycle, reoxygenation, 3369Radiation therapy, B-Cell lymphoma, marginal zone

lymphoma, local tumor control, 3935Radiation therapy, bladder cancer, TURBT,

radiochemotherapy, 985Radiation therapy, risk factor, enterocolitis, leg edema,

postoperative radiotherapy, gynecological malignancies,3527

Radiation therapy, spinal cord, radiation myelopathy, γ-H2AX, 561

Radiation, gefitinib, combination therapy, EGFR, predictor,melanoma, 2883

Radiation, head and neck neoplasms, ERCC1 protein,cisplatin, DNA repair, 4135

Radiation, pemetrexed, human mesothelioma cell line,radiosensitivity, apoptosis, 2847

Radiation, prostate cancer, patients’ satisfaction, surgery,hormonal therapy, 3903

Radiation-sensitivity, ionizing radiation, phosphorylation ofp53, 2255

Radical cystectomy, bladder cancer, extentedlymphadenectomy, lymph node metastasis, lymph nodedensity, cancer-specific survival, short review, 271

Radiobiology model, human lung cancer cell lines,surviving fraction, doubling time, clonogenic assay, 1125

Radiochemotherapy, bladder cancer, TURBT, radiationtherapy, 985

Radiochemotherapy, neoadjuvant therapy, esophagealcancer, docetaxel, cisplatin, phase II trials, 4407

Radiofrequency ablation, hepatocellular carcinoma,cirrhosis, percutaneous ablation, percutaneous ethanolinjection, randomized controlled trial, 2291

Radiofrequency ablation, RFA, intrahepatic cholangio-carcinoma, ICC, cirrhosis, 4575

Radioimmunotherapy, HNSCC, SCID mice, xenografts,radio-labeled monoclonal antibody, cytokeratin 8, 3315

Radio-labeled monoclonal antibody, radioimmunotherapy,HNSCC, SCID mice, xenografts, cytokeratin 8, 3315

Radioprotection, radiosensitivity, astrocytes, centralnervous system, lymphoma, 33

Radiosensitivity, glioma, PTEN, cell cycle, temozolomide,ionizing radiation, 1653

Radiosensitivity, lung cancer, paclitaxel-basedchemoradiotherapy, BCL-2, MDR1, 1431

Radiosensitivity, N-heterocyclic indolyl glyoxylamides,p53-independent apoptosis, G2/M phase arrest, humanlung cancer cells, 3407

Radiosensitivity, radiation, pemetrexed, humanmesothelioma cell line, apoptosis, 2847

Radiosensitivity, radioprotection, astrocytes, centralnervous system, lymphoma, 33

Radiotherapy, breast cancer, anastrozole, ipsilateral breasttumor recurrence, tamoxifen, 367

Radiotherapy, endometrial cancer, prognosis, survival,chemotherapy, 3483

Radiotherapy, GLUT-1, rectal cancer, chemotherapy,tumour regression, prognosis, 311

Radiotherapy, HIF-1α, esophageal neoplasm,chemotherapy, 2351

Radiotherapy, magnetic resonance spectroscopy, brainneoplasms, prognosis, prospective studies, 3559

Radiotherapy, neuroblastoma, neem leaf extract, apoptosis,transcriptional response, 161

Radiotherapy, non-small cell lung cancer, gefitinib,erlotinib, resistance, bone metastasis, EGFR-TKIs, 4519

Radiotherapy, prostate cancer, hypofractionation,acceleration, amifostine, cytoprotection, 1745

Radiotherapy, rectal cancer, chemotherapy, prognosticfactor, biomarker, carbonic anhydrase IX, hypoxia-inducible factor-1a, ezrin, glucose transporter-1, 4529

RAGE, quantitative PCR, immunohistochemistry, HMGB1,disseminated histiocytic sarcoma, 1541

RALP, bowel injury, laparoscopic radical prostatectomy,LRP, prostatic neoplasm, rectal injury, robotic-assistedlaparoscopic prostatectomy, robotics, 3497

Randomized controlled trial, hepatocellular carcinoma,cirrhosis, percutaneous ablation, percutaneous ethanolinjection, radiofrequency ablation, 2291

Rapamycin, ERas, gastric cancer, chemotherapy, CPT-11,3353

Ras, BNIP3, CD47, cancer, programmed cell death, 4N1K,2869

Ras/Raf/MEK/ERK pathway, IGF-1R, phosphorylatedMEK, orthotopic mouse model of osteosarcoma, lungmetastasis, 1147

Ras-Raf-ERK/MAPK pathway, gastrointestinal stromaltumors (GISTs), PI3K-Akt/mTOR pathway, insulin-likegrowth factor 1 receptor (IGF1R), CD117, 3019

RASSF1A, breast cancer, methylation, prognosis, 2975RASSF1A, EGFR, mutation, methylation, tobacco

smoking, lung adenocarcinoma, FHIT, RUNX3, 1211Rat model, sonodynamic therapy, focused ultrasound, 5-

aminolevulinic acid, glioma, deep-seated, 2527Rat, artemisinin dimers, dihydroartemisinin, breast cancer

cells, 4111


4786

Rat, bladder cancer, BCG-CWS, liposome, BBN, 2065Rat, Stk11, Lkb1, hepatocellular carcinoma, nitrosamine,

choline-deficient L-amino acid-defined diet, 543Rats, melatonin, cancer, endometrial proliferation, 2637Rats, metronomic, cyclophosphamide, doxorubicin, breast

cancer, cardiotoxicity, 215RAW264.7 cells, etomidate, apoptosis, Bax, Bcl-xl,

caspase-3, 2203RCC, SDF1β, T-cell infiltration, grade, 2797Reactive oxygen species, 8-hydroxydeoxyguanosine,

oxidative stress, ovarian cancer, 1411Reactive oxygen species, pyruvate dehydrogenase, Long

Evans Cinnamon, copper overload, 3395Real-time imaging, green fluorescent protein, red

fluorescent protein, cancer cell seeding, lung, liver,muscle, 3665

Real-time quantitative reverse transcriptase-polymerasechain reaction, circulating tumor cells, CTCs,microfiltration by size, qRT-PCR, molecular biology,cytomorphology, FISH, cell culture, lung cancer, 427

Real-time RT-PCR, hepatocellular carcinoma, human zincfinger 23, annexin V-FITC/PI assay, apoptosis, 3595

Receptor tyrosine kinase, actin cytoskeleton, cell migration,nuclear localization, Ror1, 4239

Receptor tyrosine kinase, proteasome inhibitor, activationloop, multiple myeloma, ER stress, FGFR3, Lys650Glumutation, K650E, bortezomide, plasma cell malignancy,113

Rectal cancer, cancer stem cell, recurrence, CD marker,CD133, CD44, 495

Rectal cancer, chemoradiation, neoadjuvant therapy,complete clinical response, non-operative management,review, 1795

Rectal cancer, claudin-1, prognostic factor, recurrence, 2517Rectal cancer, glucose transporter-1, hypoxia, hypoxia-

inducible factor 1α, preoperative chemoradiotherapy,1559

Rectal cancer, GLUT-1, chemotherapy, radiotherapy,tumour regression, prognosis, 311

Rectal cancer, hyperthermo-chemo-radiation therapy,HCRT, distal margins, tumor response, 3963

Rectal cancer, radiotherapy, chemotherapy, prognosticfactor, biomarker, carbonic anhydrase IX, hypoxia-inducible factor-1a, ezrin, glucose transporter-1, 4529

Rectal injury, bowel injury, laparoscopic radicalprostatectomy, LRP, prostatic neoplasm, robotic-assistedlaparoscopic prostatectomy, RALP, robotics, 3497

Recurrence, bladder cancer, intravesical chemotherapy,continuous saline bladder irrigation, 1471

Recurrence, breast cancer, operation, survival,polychemotherapy, 277

Recurrence, cancer stem cell, CD marker, CD133, CD44,rectal cancer, 495

Recurrence, claudin-1, prognostic factor, rectal cancer,2517

Recurrence, Ki-67, PCNA, lung, adenocarcinoma, 4277Recurrence, LAT1, CD98, advanced NSCLC, EGFR


Recurrence, MACC1, lung cancer, adenocarcinoma, 1141Recurrence, methylenetetrahydrofolate reductase MTHFR,

smoking, metastasis, oral cancer, 2395Recurrence, squamous cell carcinoma, bladder cancer,

gemcitabine, paclitaxel, 4465Recurrence, urachal cancer, gemcitabine, cisplatin,

chemotherapy, 2335Recurrences, bladder carcinoma, interleukin-2,

CD8highCD57+ lymphocytes, 699Recurrent cervical cancer, oral etoposide, cisplatin, second-

line chemotherapy, feasibility study, 3063Recurrent, ovarian cancer, consolidation chemotherapy,

salvage chemotherapy, treatment-free interval, paclitaxel,cisplatin, irinotecan, 4613

Red fluorescent protein, green fluorescent protein, cancercell seeding, real-time imaging, lung, liver, muscle, 3665

Ref-1, APE1, macrophages, inflammatory response, 379Refractory, thymic carcinoma, chemotherapy, ADOC, S-1,

299REG4, antiapoptosis, colorectal cancer, gamma radiation,

microarray, RT-PCR, NEIL2, BIRC5, 4147Regression, dysplastic nevi, immune response, melanocyte,

melanoma, 3697Regulatory T-cell, β-Glucan, cyclophosphamide, A20

lymphoma, 1169Regulatory T-cells, colorectal cancer, antitumor immunity,

FOLFOX, FOLFIRI, 4569Relapse, ovarian cancer, intraperitoneal, catumaxomab,

surgical tumor debulking, operative morbidity, operativemortality, 2603

Renal cell carcinoma, chromophobe renal cell carcinoma,renal oncocytoma, fluorescence in situ hybridization,tissue sections, isolated nuclei, 3137

Renal cell carcinoma, circulating tumor cells, CellSearch,cytokeratins, CD44, 4219

Renal cell carcinoma, circulating tumor cells, disseminatedtumor cells, detection, prostate cancer, bladder cancer,chemotherapy, review, 2053

Renal cell carcinoma, cryoimmunology, cryotreatment,immunotherapy, 2927

Renal cell carcinoma, gamma-delta T-cell, prognosis factor,1027

Renal cell carcinoma, prostaglandin E2 receptor,pathological features, survival, immunohistochemistry,597

Renal failure, mesothelioma, tumor markers, N-ERC/mesothelin, osteopontin, 1427


4787

Renal oncocytoma, renal cell carcinoma, chromophoberenal cell carcinoma, fluorescence in situ hybridization,tissue sections, isolated nuclei, 3137

Renieramycin M, metastasis, anoikis, invasion, migration,lung cancer cells, 193

Reoxygenation, radiation sensitivity, esophageal cancer,gastric cancer, hypoxia, cell cycle, 3369

Repeat biopsy, PCA3, PSA free/total, prostate cancer,saturation prostate biopsy, cancer diagnosis, 4445

Resection, lymph node metastasis, hepatocellularcarcinoma, transarterial chemoembolization, 3991

Residual disease, ovarian cancer, cytoreductive surgery,prediction models, 4043

Resistance, non-small cell lung cancer, gefitinib, erlotinib,bone metastasis, radiotherapy, EGFR-TKIs, 4519

Resistance, PAMAM dendrimers, encapsulation,intracellular delivery, SMVT, cisplatin, ovarian cancercell lines, 897

Resistance, pancreatic cancer, gemcitabine, ERK,lenalidomide, 3747

Response prediction, neoadjuvant therapy, squamous-cellesophageal cancer, tumor-associated proteins, 1769

Resveratrol, androgen receptor, combination strategy,flutamide, prostate cancer, prostate-specific antigen, 3323

Resveratrol, glioma, invasion, TNF-α, urokinaseplasminogen activator, 4223

RET, medullary thyroid carcinoma, gene mutations, HRAS,KRAS, NRAS, BRAF, AKT1, CTNNB1, mutationalscreening, 4179

Retinoblastoma protein, antisense oligonucleotide, cyclinD, cyclin E, cyclin-dependent kinase, non-small lungcancer cells, pleural mesothelioma cells, apoptosis,kinases, phosphatases, 3683

Retroperitoneal lymph nodes, primary serous-papillaryperitoneal carcinoma, spread pattern, review, 1387

Reversible dihydropyrimidine dehydrogenase, S-1, 5-fluorouracil, Phase I, FBAL, tegafur, FT, DPD, gimeracil,CDHP, solid tumors, 625

Review, adrenocortical tumors, Cushing’s syndrome,adrenal imaging, cancer, CT, MR, 2923

Review, advanced gastric cancer, AKT, PI3K,chemoresistance, 4387

Review, angiogenesis, cancer, CD105, endoglin, tumor,2283

Review, biomarkers, diagnosis, early detection, head andneck cancer, 1161

Review, bladder cancer, transitional carcinoma,lymphovascular invasion, upper tract transitionalcarcinoma, prognostic role, 3503

Review, cancer, immunotherapy, prediction, survival, CD8,CD57, 639

Review, cell-free DNA, circulation, non-invasive,biomarker, 2623

Review, chemotherapy, metastatic gastric cancer, 3543Review, circulating tumor cells, disseminated tumor cells,

detection, prostate cancer, bladder cancer, renal cellcarcinoma, chemotherapy, 2053

Review, electroporation, oligonucleotides, siRNA, miRNA,4083

Review, hemorrhagic cystitis, allogeneic stem celltransplantation, BK virus, 939

Review, KRAP, KRAS, target, cancer, obesity, diabetes,2413

Review, low-intensity ultrasound, sonodynamic therapy,sonosensitizers, 2425

Review, LPS, endotoxin, oral administration, toxicity,absorption, lipopolysaccharide, 2431

Review, macrophage, LPS, priming, IP-PA1, chronicpsychological stress, 2437

Review, multiple myeloma, signal transduction, Wntpathway, myeloma, myeloma therapy, 725

Review, non-small cell lung cancer, third-line treatment,erlotinib, gefitinib, 649

Review, notch, stem cells, pancreatic cancer, signalpathway, natural agents, cancer therapy, drug resistance,1105

Review, ovarian cancer, gene mutations, BRCA 1/2, TP53,PI3K, AKT, BRAF, KRAS, 2661

Review, primary serous-papillary peritoneal carcinoma,retroperitoneal lymph nodes, spread pattern, 1387

Review, rectal cancer, chemoradiation, neoadjuvant therapy,complete clinical response, non-operative management,1795

Review, ROCK, Rho kinase, ROCK signaling, ROCKpathways, 3645

Review, single nucleotide polymorphisms, estrogenpathway, steroid hormones, mammographic breastdensity, breast cancer, 4369

Review, tonsillar cancer, base of tongue cancer,oropharyngeal cancer, head and neck cancer, HPV, 1515

Revitalization, high hydrostatic pressure, bone, tissueengineering, 1235

RFA, radiofrequency ablation, intrahepatic cholangio-carcinoma, ICC, cirrhosis, 4575

RFP, magnetic resonance imaging, micro-computedtomography, optical reflectance imaging, tumor volume,molecular imaging, GFP, 2907

RGM, breast cancer, prostate cancer, prognosis, 1703Rho kinase, ROCK, ROCK signaling, ROCK pathways,

review, 3645Ribonucleotide reductase, non-small cell lung cancer,

p53R2, hRRM2, 3475Right colon, cyclooxygenase, COX-2, W-APC, left colon,

colon cancer, 2191Right colon, prognosis, left colon, sigmoid, survival, colon

cancer, gender, 2347


4788

Risk factor, BPF, fistula, operation, lung cancer, concurrentdisease, perioperative complication, infection, 619

Risk factor, radiation therapy, enterocolitis, leg edema,postoperative radiotherapy, gynecological malignancies,3527

Risk of cancer, breast disease, depression, 1065RNA interference, HTLV-1, gag and env genes, shRNA,

2173RNA-binding proteins, SN1 methylating agents, apoptosis,

O6-methylguanine-DNA methyltransferase (MGMT), N-methyl-N-nitrosourea, 4291

Robotic-assisted laparoscopic prostatectomy, bowel injury,laparoscopic radical prostatectomy, LRP, prostaticneoplasm, rectal injury, RALP, robotics, 3497

Robotics, bowel injury, laparoscopic radical prostatectomy,LRP, prostatic neoplasm, rectal injury, robotic-assistedlaparoscopic prostatectomy, RALP, 3497

ROCK pathways, ROCK, Rho kinase, ROCK signaling,review, 3645

ROCK signaling, ROCK, Rho kinase, ROCK pathways,review, 3645

ROCK, Rho kinase, ROCK signaling, ROCK pathways,review, 3645

Rofecoxib, diffuse intrinsic pontine glioma, chemotherapy,temozolomide, bevacizumab, inflammatory processes, 2265

Ror1, actin cytoskeleton, cell migration, nuclearlocalization, receptor tyrosine kinase, 4239

ROS, epigenetic modifiers, kidney, toxicity, p66shc,mitochondria, 3267

ROS, UVB, normal human keratinocytes, 18β-glycyrrhetinic acid, glabridin, 2209

RRM2, KRAS, colon cancer, 2535RTK, breast cancer, lapatinib, imatinib, EGFR, ErbB2, c-

ABL, 789RT-PCR, antiapoptosis, colorectal cancer, gamma radiation,

microarray, REG4, NEIL2, BIRC5, 4147RT-PCR, estrogen receptor, breast cancer cell lines, flow

cytometry, Western blotting, 521RT-PCR, tumor suppressor gene, FUS1, sarcoma,

immunohistochemistry, growth inhibition, 11RUNX3, EGFR, mutation, methylation, tobacco smoking,

lung adenocarcinoma, FHIT, RASSF1A, 1211Ruta graveolens, medicinal herb, bioactivity, p53 pathway,

apoptosis, Akt, 233RXR, pharmacogenomics, SNPs, bexarotene, lung cancer,

2303S-1 plus CDDP, early-stage esophageal cancer, complete

response, 1019S-1, 5-fluorouracil, Phase I, FBAL, tegafur, FT, reversible


S1, chemotherapy, docetaxel, nedaplatin, esophagealcarcinoma, phase I, 4589

S-1, gastric cancer, cetuximab, thymidylate synthase, 3691S-1, HER2-positive, trastuzumab, metastatic breast cancer,

3035S-1, metastatic anal cancer, chemoradiotherapy, cisplatin,

3983S-1, neoadjuvant chemoradiotherapy, gastric cancer,

cisplatin, 3079S-1, thymic carcinoma, chemotherapy, ADOC, refractory,

299S-1, triplet combination chemotherapy, paclitaxel, cisplatin,

advanced gastric cancer, feasibility study, 3085S-100β, uveal melanoma, metastasis, liver function tests,

tumor markers, OPN, MIA, TPS, 351S-100β, uveal melanoma, metastasis, tumor markers, OPN,

MIA, TPS, 345Safety, bevacizumab, FOLFIRI, XELIRI, colorectal cancer,

efficacy, 1777Safety, bevacizumab, pediatrics, VEGF, 3953Salvage chemotherapy, ovarian cancer, consolidation

chemotherapy, recurrent, treatment-free interval,paclitaxel, cisplatin, irinotecan, 4613

Sanguinarine, benzo[c]phenanthridine alkaloids, anticancertherapeutic agents, oral squamous cell carcinoma, 2841

Saracatinib, HNSCC, phase II, Src, AZD0530, 249Sarcoma 180, ultrasound, mono-l-aspartyl chlorin e6,

antitumor effect, sonodynamic therapy, colon 26, 501Sarcoma lung metastases, isolated lung perfusion, p-gp

modulation, doxorubicin, cyclosporin, valspodar, 2121Sarcoma, histone deacetylase inhibitor, chemotherapy,

multidrug resistant, PCI-24781, 1115Sarcoma, tumor suppressor gene, FUS1, RT-PCR,

immunohistochemistry, growth inhibition, 11Sarcomatoid tumour, hepatitis C virus, liver tumour, cell

line, culture, spectral karyotyping, xenograft, 129SAS cell, sonodynamic therapy, 5-aminolevulinic acid,

mitochondrion, apoptosis, 39Saturation prostate biopsy, PCA3, PSA free/total, prostate

cancer, repeat biopsy, cancer diagnosis, 4445SCID mice, radioimmunotherapy, HNSCC, xenografts,

radio-labeled monoclonal antibody, cytokeratin 8, 3315SCID mouse, metastasis, HPA, E-selectin, P-selectin,

lectin, breast carcinoma cells, colon adenocarcinoma,1589

Screening mammography, breast cancer, microcalcification,high-frequency ultrasound, advanced imaging modes,2575

Screening systems, cell-to-cell interaction, adhesionmolecules, characteristics of cancer cells, anticancer drugresistance, chemotherapy, apoptosis, drug sensitivity, drugresistance-relating factors, gene expression analysis,evaluation and prediction of pharmacological effects, 3237

Screening test, cytology, endometrial brush, endometrialcancer, endometrial pathology, uterobrush, 3469


4789

Screening, breast cancer, mammography, ultrasound,automated 3D imaging, 2569

SDF1β, RCC, T-cell infiltration, grade, 2797Second opinion, gynecological cancer, breast cancer, online

tumor conference, interdisciplinary therapy management,continuous medical training, 2669

Secondary cytoreductive surgery, ovarian cancer relapse,predictive factor, tumor residual, complete tumorresection, 2583

Second-line chemotherapy, recurrent cervical cancer, oraletoposide, cisplatin, feasibility study, 3063

γ-Secretase inhibitor, leukemia, notch, wnt, hedgehog, 893E-Selectin, breast cancer, liver metastasis, endothelium,

pro-inflammatory microenv ironment, 3219E-Selectin, metastasis, HPA, P-selectin, SCID mouse, lectin,

breast carcinoma cells, colon adenocarcinoma, 1589Selenium, colon cancer, orthotopic model, GFP, fluorescent

protein imaging (FPI), MRI, angiogenesis, 387Selenoprotein, colon cancer, glutathione, thioredoxin,

antioxidant enzyme expression, 2693Self-renewal, hedgehog, leukemia, 781Semi-empirical molecular-orbital method, 1, 2, 3, 4-

tetrahydroisoquinolins, QSAR, tumor-specificity index,artificial neural network, 4231

Semiempirical molecular-orbital method,trihaloacetylazulenes, QSAR, cytotoxicity, 515

Sentinel lymph node biopsy, skin cancer, non-melanoma,lymph node, metastasis, literature review, 1443

Sentinel lymph node, breast cancer, OSNA, cytokeratin 19,intra-operative method, 585

Sentinel node biopsy, breast cancer, sentinel node, axillarynode sampling, axillary lymphadenectomy, axillaryclearing, 693

Sentinel node, breast cancer, sentinel node biopsy, axillarynode sampling, axillary lymphadenectomy, axillaryclearing, 693

Sepsis, antisense pepitide, complementary peptide,anaphylatoxin, inflammation, cytokine storm, 2511

Sequence analysis, KRAS, p53, colorectal, oxaliplatin, 5-fluorouracil, capecitabine, clinical, CAIRO2, 1379

Sequence variation, Merkel cell carcinoma, KIT, mutation,807

Sequential therapy, adjuvant chemotherapy, breast cancer,1483

Sequential treatment regimen, sunitinib, metastatic renalcell carcinoma, tyrosine kinase inhibitor, mTORinhibitor, 3507

Serotonin, carcinoid, PTEN, 1153Serum 25(OH)D, vitamin D, toxicity, chemoprevention,

607Serum calcium, parathyroid tumors, hyperparathyroidism,

arterial blood pressure, PTH, arterial hypertension,elderly, 3969

Serum markers, portal vein embolisation, liver hypertrophy,tumor progression, 339

Serum total testosterone, prostate cancer, pelvic nodalinvolvement, 3615

Short review, bladder cancer, extented lymphadenectomy,lymph node metastasis, radical cystectomy, lymph nodedensity, cancer-specific survival, 271

ShRNA, glutamate receptor, cancer, PCR, NR1, GLUR4,KA2, NR2D, 3181

ShRNA, HTLV-1, gag and env genes, RNA interference,2173

Sialic fibronectin, thyroid malignant neoplasma, lymphnode metastasis, MoAb Jt-95, 1395

SICAM-1, breast cancer, chemotherapy, dose-dense,sVCAM-1, 2617

Sifneos score, breast disease, breast cancer, 3101Sigmoid, prognosis, left colon, right colon, survival, colon

cancer, gender, 2347Signal pathway, notch, stem cells, pancreatic cancer,

natural agents, cancer therapy, drug resistance, review,1105

Signal transducer and activator of transcription 3,interleukin-6, pancreatic cancer, 2029

Signal transduction, multiple myeloma, Wnt pathway,myeloma, myeloma therapy, review, 725

Signaling pathway, microarray analysis, dectin-2 geneexpression, macrophage, lignin-carbohydrate complex,LPS, LEM, 1241

Signet-ring adenocarcinoma, gastric adenocarcinoma,breast metastasis, skin, immunohistochemistry, 2373

Silibinin, CD44, EGFR, EGF, TGF-α, MMP-9, breastcancer metastasis, 3767

Single nucleotide polymorphism, caveolin-1, prostatecancer, DNA repair, 745

Single nucleotide polymorphism, cervical cancer, C-reactive protein, CRP, CRP1919 (rs1417938), CRP2667(rs1800947), CRP3872 (rs1205), CRP5237 (rs2808630),gene polymorphism, prognosis, 2259

Single nucleotide polymorphisms (SNPs), gastric cancer(GC), chemosensitivity, docetaxel, DNASE2B, HTRIE,4329

Single nucleotide polymorphisms, estrogen pathway,steroid hormones, mammographic breast density, breastcancer, review, 4369

Single nucleotide polymorphisms, integrins, colorectalcancer, survival, polymorphisms, 1373

SiRNA, electroporation, oligonucleotides, miRNA, review,4083

SiRNA, lipid nanoparticles, CDK4, down-regulation, 1619SiRNA, P-glycoprotein, chemotherapy, inhibition of

multidrug resistance, osteosarcoma cell lines, carcinomacell lines, 2813

Sirolimus, BBN, gemcitabine, mice, urothelial lesion, 1637


4790

Skin biopsies, cancer, neurotoxicity, adjuvantchemotherapy, docetaxel, intraepidermal nerve fibres,neuropathy, oxaliplatin, 4413

Skin cancer, non-melanoma, lymph node, metastasis,literature review, sentinel lymph node biopsy, 1443

Skin cancer, X-ray repair cross-complementing group 1,XRCC1, polymorphism, DNA repair, meta-analysis, 3945

Skin toxicity, gefitinib, non-small cell lung cancer,NSCLC, epidermal growth factor receptor, EGFR,expanded access programme, EAP, 2949

Skin toxicity, pemetrexed, hyperpigmentation, 1753Skin, gastric adenocarcinoma, signet-ring adenocarcinoma,

breast metastasis, immunohistochemistry, 2373SMAD3, 3-Indole, cell cycle arrest, ATM, ATR, xenograft

model, lung cancer cells, 203Small bowel, melanoma, intussusception, disease-free

survival, dendritic cell therapy, 3579Small-cell cancer, colorectal, neuroendocrine cancer,

chemotherapy, cisplatin, etoposide, 975Small-cell lung cancer, cisplatin, topotecan, 3449Small-cell lung cancer, TRAIL, paclitaxel, chemotherapy, 3193Smoking, cyclin D1, CCND1, polymorphism, lung cancer,

Taiwanese, 3601Smoking, cyclin D1, polymorphism, oral cancer, 227Smoking, methylenetetrahydrofolate reductase MTHFR,

metastasis, recurrence, oral cancer, 2395Smoking, NSCLC, methylation, MLPA, targeted therapy,

gene methylation, TKIs, EGFR mutation, 4647SMVT, PAMAM dendrimers, encapsulation, intracellular

delivery, resistance, cisplatin, ovarian cancer cell lines,897

SN1 methylating agents, apoptosis, O6-methylguanine-DNA methyltransferase (MGMT), RNA-binding proteins,N-methyl-N-nitrosourea, 4291

SN-38 glucuronide (SN-38G), active metabolite ofirinotecan, SN-38, glucuronidation, panipenem,pharmacokinetics, 2915

SN-38, active metabolite of irinotecan, glucuronidation,SN-38 glucuronide (SN-38G), panipenem,pharmacokinetics, 2915

Snail, prostate cancer, PGE2, EP4, p-Akt, epithelial-mesencymal transition, 4347

SNP, paraoxonase 1, PON1, polymorphism, lung cancerrisk, 2225

SNP, polymorphism, colorectal cancer, MMP2, VEGF,HIF1A, 575

SNPs, pharmacogenomics, bexarotene, RXR, lung cancer,2303

Snus, cigarette smoking, Swedish-type smokeless tobacco,ethanol, human normal cells, cell death, endothelial cells,fibroblasts, 1527

Sodium meta-arsenite, cancer cells, stem cells, telomerelength, telomerase activity, 4315

Soft tissue sarcoma, athymic mice, low-grade liposarcoma,xenograft, vascularisation, 4061

Soft tissue, hemangiopericytoma, solitary fibrous tumor,oral cavity, cheek, 719

Solid cancer nest, ADAM, MMP, TIMP, invasive front,colorectal cancer, 1567

Solid tumors, S-1, 5-fluorouracil, phase I, FBAL, tegafur,FT, reversible dihydropyrimidine dehydrogenase, DPD,gimeracil, CDHP, 625

Solid type (Por1), poorly differentiated colorectaladenocarcinomas, non-solid type (Por2), 3463

Solitary fibrous tumor, hemangiopericytoma, oral cavity,cheek, soft tissue, 719

Soluble leptin receptor, tumor stage, colorectal cancer,3381

Somatostatin receptor, non-Hodgkin’s lymphoma, BCL2,lutetium-177, 3143

Somatostatin, meningioma en plaque, hyperostosis,hyperosteoidosis, 591

Sonodynamic therapy, 5-aminolevulinic acid, SAS cell,mitochondrion, apoptosis, 39

Sonodynamic therapy, focused ultrasound, 5-aminolevulinicacid, glioma, deep-seated, rat model, 2527

Sonodynamic therapy, low-intensity ultrasound,sonosensitizers, review, 2425

Sonodynamic therapy, ultrasound, mono-l-aspartyl chlorine6, antitumor effect, sarcoma 180, colon 26, 501

Sonography, breast ultrasound, pre-operative therapy,prediction of therapy response, sphericity, 4039

Sonosensitizers, low-intensity ultrasound, sonodynamictherapy, review, 2425

Sorafenib, chromophobe renal cell carcinoma,temsirolimus, mTOR, interferon, 331

Sorafenib, melanoma, fluvastatin, JNK, AKT, 3259Spectral karyotyping, hepatitis C virus, liver tumour,

sarcomatoid tumour, cell line, culture, xenograft, 129Sphericity, breast ultrasound, pre-operative therapy,

prediction of therapy response, sonography, 4039Sphingomyelinase, anticancer drugs, p53, Bax, cell cycle,

apoptosis, 871Sphingomyelinase, anticancer agents, Cox-2, caspase-3,

apoptosis, p53, cell cycle, 1345Spinal cord, radiation therapy, radiation myelopathy,

γ-H2AX, 561(+)-Spongistatin 1, anticancer, natural product, mitosis,

xenograft model, 2773Spread pattern, primary serous-papillary peritoneal

carcinoma, retroperitoneal lymph nodes, review, 1387Squamous cell carcinoma, bladder cancer, recurrence,

gemcitabine, paclitaxel, 4465Squamous cell carcinoma, BRAF mutation, KRAS, EGFR,

ERBB2 mutation, V600E, lung cancer, adenocarcinoma,SSCP, 4619


4791

Squamous cell carcinoma, cervical cancer, stage IB-IIB,concurrent chemoradiotherapy, locoregional recurrence,1437

Squamous cell carcinoma, cyclin B1, cell cycle, p53, headand neck cancer, 3151

Squamous cell carcinoma, cytokeratin 4, fascin, biomarker,tissue microarray, esophagus, 945

Squamous cell carcinoma, EGFR, Ki-67, translationalresearch, head and neck cancer, 665

Squamous cell carcinoma, NK4, gene therapy, cationisedgelatin, cisplatin, 105

Squamous-cell esophageal cancer, neoadjuvant therapy,response prediction, tumor-associated proteins, 1769

Src, HNSCC, phase II, AZD0530, saracatinib, 249SSCP, BRAF mutation, KRAS, EGFR, ERBB2 mutation,

V600E, lung cancer, adenocarcinoma, squamous cellcarcinoma, 4619

Stage I, p27, breast cancer, node dissection, estrogenreceptor, progesterone receptor, 4401

Stage IB-IIB, cervical cancer, squamous cell carcinoma,concurrent chemoradiotherapy, locoregional recurrence,1437

Staging laparoscopy, ovarian cancer, interval debulkingsurgery, optimal logistic regression, 4469

Staging, gastric cancer, lymph node dissection, prognosis,2361

STAI test, form Y-2, cancer risk, breast cancer, anxiety,1801

Stanniocalcin 1, prognostic factor, PCR, colorectal cancer,325

STAT1, head and neck cancer, p38 MAPK, STAT3,phosphorylation, 3819

STAT3, head and neck cancer, p38 MAPK, STAT1,phosphorylation, 3819

Statins, prostate cancer, PSA, NSAID, thiazide diuretic, 1735Stealth liposomes, PEG liposomes, 5-FU, locoregional

chemotherapy, liver metastases, 147Stealth liposomes, PEG liposomes, docetaxel, locoregional

chemotherapy, liver metastases, hepatic arterial infusion, 153Stem cell marker, wnt pathway, colorectal cancer,

immunohistochemistry, LGR5, 263Stem cells, breast cancer, pre-metastatic niche, metastasis,

CD133, prognosis, 1315Stem cells, notch, pancreatic cancer, signal pathway, natural

agents, cancer therapy, drug resistance, review, 1105Stem cells, sodium meta-arsenite, cancer cells, telomere

length, telomerase activity, 4315Steroid hormones, single nucleotide polymorphisms,

estrogen pathway, mammographic breast density, breastcancer, review, 4369

Steroid sulfatase, aromatase inhibitors, anti-estrogens,breast cancer, tamoxifen, anastrozole, postmenopausalwomen, 1367

Stk11, Lkb1, hepatocellular carcinoma, nitrosamine,choline-deficient L-amino acid-defined diet, rat, 543

Striatum, intravenous curcumin, blood–brain barrier, post-traumatic sequelae, hippocampus, brain stem, 907

Subcellular distribution, non-seminomatous testicularcancer, PTEN, Akt, p27Kip1, 3783

Subcellular localization, ovarian cancer, hyprocrellin B,hematoporphyrin monomethyl ether, intracellularmetabolism, phototoxicity, 3229

Sudan, oral squamous cell carcinomas, toombak, genes,apoptosis, cell cycle regulation, intermediate filamentproteins, 3345

Suicide genes, neural stem cells, prodrugs, invasive tumors,animal models, gene-directed enzyme prodrug therapyreview, 1249

Sunitinib, antitumor, antimetastasis, VEGF, VEGFR,phosphorylation, mammary cancer, 1225

Sunitinib, IDH1 mutation, glioma, cetuximab,bevacizumab, 4457

Sunitinib, metastatic renal cell carcinoma, sequentialtreatment regimen, tyrosine kinase inhibitor, mTORinhibitor, 3507

Sunitinib, pneumatosis intestinalis, gastrointestinal stromaltumor, 3429

Surgery, colorectal cancer, liver metastases, biomarker,CD95-ligand, 4507

Surgery, pancreatic cancer, pancreatic neoplasms, long-term survivors, brain metastasis, 4599

Surgery, prostate cancer, patients’ satisfaction, radiation,hormonal therapy, 3903

Surgical resection, HER2, non-small cell lung cancer,immunohistochemical staining, prognosis, 4631

Surgical tumor debulking, ovarian cancer, relapse,intraperitoneal, catumaxomab, operative morbidity,operative mortality, 2603

Surveillance, ulcerative colitis, colorectal cancer, 2499Survival analysis, myeloid DC, dentritic cells, pancreatic

cancer, prognostic factor, circulating dendritic cells, 3827Survival probability, child’s classification, hepatocellular

carcinoma, liver cirrhosis, MELD-score, nonhepaticcancer, TNM classification, 2931

Survival, breast cancer, recurrence, operation,polychemotherapy, 277

Survival, cancer, immunotherapy, prediction, CD8, CD57,review, 639

Survival, colorectal cancer, adjuvant chemotherapy,MTHFR C677T, MTR A2756G, toxicity, 3057

Survival, endometrial cancer, prognosis, radiotherapy,chemotherapy, 3483

Survival, integrins, colorectal cancer, polymorphisms,single nucleotide polymorphisms, 1373

Survival, minichromosome maintenance proteins, MCMs,cyclin D3, CCND3, Hodgkin lymphoma, 3585


4792

Survival, neutrophil-lymphocyte ratio, non-small cell lungcancer, 2995

Survival, non-small cell lung cancer, TIMP1, mRNA, DFI,blood plasma, 4031

Survival, polymorphism, XRCC1, Arg399Gln, Arg194Trp,GSTP1 Ile104Val, GSTT1, GSTM1, gastric cancer, 705

Survival, prognosis, left colon, right colon, sigmoid, coloncancer, gender, 2347

Survival, prostaglandin E2 receptor, renal cell carcinoma,pathological features, immunohistochemistry, 597

Survival, quality control, brain tumor, pediatric neuro-oncology, 661

Survival, κ-actin, hepatocellular carcinoma, postoperativeprognosis, 2037

Surviving fraction, human lung cancer cell lines, doublingtime, radiobiology model, clonogenic assay, 1125

SVCAM-1, breast cancer, chemotherapy, dose-dense,sICAM-1, 2617

Swedish-type smokeless tobacco, cigarette smoking, Snus,ethanol, human normal cells, cell death, endothelial cells,fibroblasts, 1527

Synchronous, colorectal cancer, liver metastases, lungmetastases, metachronous, 1049

Synergism, cisplatin, CTR1, bortezomib, drug combination,proteasomal degradation, drug uptake, drug resistance, 2757

Synergism, drug resistance, drug combination, quercetin,thymoquinone, cisplatin, oxaliplatin, 3789

Synergism, ovarian cancer, cisplatin, curcumin, EGCG,drug combination, 1131

Synergism, oxaliplatin, phytochemicals, ovarian cancer celllines, cytotoxicity, 4283

T lymphocytes, nucleotide, insoluble protein, dendritic cell,immunotherapy, 881

T(10;17) translocation, endometrial stromal sarcoma,neuroectodermal, 2367

T(3;3)(q21;q26), Inv(3)(q21q26), breakpoint distribution,chromosomal abnormalities, fluorescent in situhybridization, 3441

T0070907, PPARγ, breast cancer, PPARG, migration,invasion, 813

T47D cells, genistein, breast cancer, p90RSK, cellproliferation, 209

Taiwanese, cyclin D1, CCND1, polymorphism, lung cancer,smoking, 3601

T-ALL, HB-EGF, CRM197, doxorubicin, 2483Tamoxifen, aromatase inhibitors, anti-estrogens, breast

cancer, steroid sulfatase, anastrozole, postmenopausalwomen, 1367

Tamoxifen, breast cancer, anastrozole, radiotherapy,ipsilateral breast tumor recurrence, 367

Tamoxifen-resistance, insulin-like growth factor-1, IGF-1,oestrogen resistance, breast cancer recurrence, oestrogenreceptor-alpha, EGFR, 23

Target, KRAP, KRAS, cancer, obesity, diabetes, review, 2413Targeted therapy, NSCLC, methylation, MLPA, gene

methylation, TKIs, smoking, EGFR mutation, 4647Targeted therapy, ovarian cancer, HB-EGF, CRM197, 2461γδ T-Cells, antigen presentation, cytotoxic T-cells, 2419T-cell infiltration, SDF1β, RCC, grade, 2797Tegafur, S-1, 5-fluorouracil, phase I, FBAL, FT, reversible


Telomerase activity, sodium meta-arsenite, cancer cells,stem cells, telomere length, 4315

Telomerase, indole, prostate cancer, diethylstilbestrol, cellviability, 3733

Telomere length, sodium meta-arsenite, cancer cells, stemcells, telomerase activity, 4315

TEM8, triple negative breast cancer, breast cancer,immunohistochemistry, lymph node metastasis, 3417

Temozolomide, anaplastic ependymoma, multifocalrecurrence, 1023

Temozolomide, anaplastic gliomas, long-termadministration, 3873

Temozolomide, diffuse intrinsic pontine glioma,chemotherapy, rofecoxib, bevacizumab, inflammatoryprocesses, 2265

Temozolomide, glioma, EGFR, cell cycle, 3253Temozolomide, glioma, PTEN, cell cycle, ionizing

radiation, radiosensitivity, 1653Temozolomide, ionizing radiation, immunogenicity, cell

death, Hsp70, 3727Temozolomide, metastastic melanoma, melanoma, brain

metastases, whole-brain radiation, 4537Temozolomide, mKate2, mCherry, glioblastoma model,

intracranial, live imaging, 2161Temsirolimus, chromophobe renal cell carcinoma, mTOR,

sorafenib, interferon, 331TENIS syndrome, thyroid neoplasms, thyroglobulin, iodine

radioisotopes, 21092, 1, 3, 4-Tetrahydroisoquinolins, QSAR, tumor-specificity

index, semi-empirical molecular-orbital method, artificialneural network, 4231

Tetramethylnaphthalene, HTLV-1, ATL, inhibitor, cellcycle, 2241

TFPI2, methylation, gastric cancer, 3835TGF-α, silibinin, CD44, EGFR, EGF, MMP-9, breast

cancer metastasis, 3767TGF-β, cytoskeleton, paxillin, phosphatase, PP-1, 3159TGF-β, epithelial to mesenchymal transition, lung cancer,

potassium channels, Eag1, 1265Therapy efficacy, circulating tumor cells, metastatic breast

cancer, chemotherapy, 979Therapy personalization, breast cancer, primary culture,

chemotherapeutics, oncogramme, individualized tumourresponse testing, 139


4793

Therapy response, hepatocellular carcinoma, 1H MRI,apparent diffusion coefficient, extracellular space,benzamide riboside, angiography, motion effect, 2045

Thermal cancer therapy, hyperthermia, hepatic stellatecells, fibrosis, HCC, HepG2, 1583

Thermal cancer therapy, hyperthermia, hepatic stellatecells, fibrosis, HCC, transwell, co-culture, 3713

Thermal neutron irradiation, boron tracedrug, BODIPY,curcuminoid, neutron dynamic therapy, dynamic drug,BNCT, 2477

Thiazide diuretic, prostate cancer, PSA, statins, NSAID,1735

6-Thioguanine, GLI2, PTHrP, osteolysis, breast cancer,2705

Thioredoxin, non-small cell lung cancer, TXNDC5, proteindisulphide isomerase, 1577

Thioredoxin, selenoprotein, colon cancer, glutathione,antioxidant enzyme expression, 2693

Thioridazine, multidrug-resistant cancer cells, MDR mouseT-lymphoma cells, ABCB1 transporter, P-glycoprotein,phenothiazines, apoptosis, 4201

Third-line treatment, non-small cell lung cancer, erlotinib,gefitinib, review, 649

Thoracic malignancy, carboplatin, cisplatin,hypersensitivity, antineoplastic, immunoglobulin E, 4525

Thrombin, colon cancer, vascular endothelial growth factor,vascular endothelial growth factor receptor-2,coagulation factor, angiogenesis, 843

Thrombosis, germ cell tumour, cisplatin, hypercoagulation,vascular toxicity, von Willebrand factor, 4501

Thromoboembolism, breast cancer, chemotherapy,outcome, 2383

Thymic carcinoma, chemotherapy, ADOC, refractory, S-1, 299Thymidine kinase, adenovirus, prodrug activation, HNSCC,

ganciclovir, apoptosis, 3851Thymidine kinase1, 5’(3’)-deoxyribonucleotidase,

fluorothymidine, proliferation, lung cancer, colon cancer,2135

Thymidine phosphorylase, paclitaxel, doxifluridine, gastriccancer, chemotherapy, 287

Thymidylate synthase, 5-FU resistance, cyclooxygenase-2,etodolac, 2893

Thymidylate synthase, ERCC1, adenosine triphosphate,drug screening assay, colorectal neoplasm, 3843

Thymidylate synthase, gastric cancer, cetuximab, S-1, 3691Thymidylate synthase, HGF, c-Met, NK4, CT26, 5-

fluorouracil, Akt, Erk1/2, 2217Thymidylate synthase, lung adenocarcinoma, 5-

fluorouracil, dihydropyrimidine dehydrogenase,chemosensitivity, 4665

Thymidylate synthase, oral squamous cell carcinoma,dihydropyrimidine dehydrogenase, lymph nodemetastasis, KAI1/CD82, 3521

Thymoquinone, drug resistance, drug combination,synergism, quercetin, cisplatin, oxaliplatin, 3789

Thymus vulgaris L. (thyme), oral cavity squamous cellcarcinoma OCSCC, head and neck squamous cellcarcinoma HNSCC, natural product, pharmacogenomics,81

Thyroglobulin, thyroid neoplasms, iodine radioisotopes,TENIS syndrome, 2109

Thyroid cancer, biomarker, diagnosis, sensitivity,specificity, metastasis, immunohistochemistry, 3433

Thyroid hormones, proliferation, PI3K, MAPK, 89Thyroid malignant neoplasma, sialic fibronectin, lymph

node metastasis, MoAb Jt-95, 1395Thyroid neoplasms, thyroglobulin, iodine radioisotopes,

TENIS syndrome, 2109Tight junction regulation, HAVcR-1, tight junction,

endothelial cells, 467Tight junction, HAVcR-1, endothelial cells, tight junction

regulation, 467Time to castration resistance, castrate-resistant prostate

cancer, predictors of survival, chemotherapy, advancedprostate cancer, 1475

TIMP, ADAM, MMP, solid cancer nest, invasive front,colorectal cancer, 1567

TIMP1, non-small cell lung cancer, mRNA, DFI, survival,blood plasma, 4031

TIP60, quantitative real-time PCR, gastric cancer, 77Tissue engineering, high hydrostatic pressure, bone,

revitalization, 1235Tissue microarray, breast cancer, DAPK, 3633Tissue microarray, cortactin, breast cancer, 293Tissue microarray, cytokeratin 4, fascin, biomarker,

squamous cell carcinoma, esophagus, 945Tissue microarrays, non-small cell lung cancer, cancer stem

cell antigens, biomarkers, prognosis, CD133, CD117,BCRP1, 4491

Tissue sections, renal cell carcinoma, chromophobe renalcell carcinoma, renal oncocytoma, fluorescence in situhybridization, isolated nuclei, 3137

TKIs, NSCLC, methylation, MLPA, targeted therapy, genemethylation, smoking, EGFR mutation, 4647

T-lymphoblastoid leukemia, arsenic trioxide, arsenic acid,organic arsenicals, daunorubicin resistance, apoptosis,4169

TMPRSS2:ERG, prostate cancer, microRNA, Fusion gene,403

TNF-alpha, hepatoma, proteomics, 2-DE, LC-MS/MS,apoptosis, 2059

TNF-α, resveratrol, glioma, invasion, urokinaseplasminogen activator, 4223

TNM classification, child’s classification, hepatocellularcarcinoma, liver cirrhosis, MELD-score, nonhepaticcancer, survival probability, 2931


4794

Tobacco smoking, EGFR, mutation, methylation, lungadenocarcinoma, FHIT, RASSF1A, RUNX3, 1211

Tobacco-caused cancer, cigarette smoking, race, 3891Tomotherapy, anal cancer, chemoradiation, image-guided

radiotherapy, 4393Tongue carcinoma, matrix metalloproteinases, gelatinase,

green fluorescent protein, xenograft, peptide, 3659Tongue, oral carcinogenesis, immunohistochemistry, beta-

catenin, mice, 2805Tonsillar cancer, base of tongue cancer, oropharyngeal

cancer, head and neck cancer, HPV, revie, 1515Toombak, oral squamous cell carcinomas, genes, apoptosis,

cell cycle regulation, intermediate filament proteins,Sudan, 3345

Topotecan, cisplatin, small cell lung cancer, 3449Total estrogen blockade, high-dose chemotherapy,

leuprorelin, anastrazole, premenopausal breast cancer,VEGF, 671

Total testosterone (TT), prolactin (PRL), luteinizinghormone (LH), free testosterone (FT), prostate-specificantigen (PSA), prostate cancer, 3913

Total testosterone, luteinizing hormone, LH, TT, freetestosterone, FT, prostate-specific antigen, PSA, prostatecancer, 1071

Toxicity, colorectal cancer, adjuvant chemotherapy,MTHFR C677T, MTR A2756G, survival, 3057

Toxicity, epigenetic modifiers, kidney, ROS, p66shc,mitochondria, 3267

Toxicity, LPS, endotoxin, oral administration, absorption,lipopolysaccharide, review, 2431

Toxicity, serum 25(OH)D, vitamin D, chemoprevention,607

TP53, mutations, polymorphisms, FHIT, chronicesophagitis, esophageal carcinoma, 1685

TP53, ovarian cancer, gene mutations, BRCA 1/2, PI3K,AKT, BRAF, KRAS, review, 2661

TPS, uveal melanoma, metastasis, liver function tests,tumor markers, OPN, S-100β, MIA, 351

TPS, uveal melanoma, metastasis, tumor markers, OPN, S-100β, MIA, 345

TRAIL, apoptosis, liver metastases, invasion front, FAS,colorectal cancer, 1215

TRAIL, histone deacetylase inhibitor, LBH589, coloncancer, apoptosis, 3385

TRAIL, small cell lung cancer, paclitaxel, chemotherapy,3193

Transarterial chemoembolization, hepatocellular carcinoma,miriplatin, 2983

Transarterial chemoembolization, liver directed therapy,metastatic colon cancer, irinotecan, DEBIRI, DC Bead,4581

Transarterial chemoembolization, lymph node metastasis,hepatocellular carcinoma, resection, 3991

Transcriptional response, neuroblastoma, radiotherapy,neem leaf extract, apoptosis, 161

Transitional carcinoma, bladder cancer, lymphovascularinvasion, upper tract transitional carcinoma, prognosticrole, review, 3503

Translational research, EGFR, Ki-67, squamous cellcarcinoma, head and neck cancer, 665

Transrectal ultrasonography, prostate cancer, contrast-enhanced ultrasonography, 1421

Transwell, hyperthermia, thermal cancer therapy, hepaticstellate cells, fibrosis, HCC, co-culture, 3713

Trastuzumab, breast cancer, neoadjuvant chemotherapy,pCR, 3041

Trastuzumab, HER2-positive, S-1, metastatic breast cancer,3035

Treatment, panitumumab, metastatic colorectal cancer,bevacizumab, 1033

Treatment-free interval, ovarian cancer, consolidationchemotherapy, recurrent, salvage chemotherapy,paclitaxel, cisplatin, irinotecan, 4613

Trihaloacetylazulenes, QSAR, cytotoxicity, semiempiricalmolecular-orbital method, 515

Triphala, prostate cancer, cytotoxicity, gallic acid,Ayurvedic medicine, 3739

Triple negative breast cancer, TEM8, breast cancer,immunohistochemistry, lymph node metastasis, 3417

Triple negative, breast cancer, biomarker, 2389Triple-negative, metastatic breast cancer, capecitabine,

HER2-negative, prognostic factors, 1079Triplet combination chemotherapy, paclitaxel, cisplatin, S-1, advanced gastric cancer, feasibility study, 3085Triptolide, medicinal compounds, proteasome inhibitors,

apoptosis, cancer therapy, 1TS, colorectal cancer, pulmonary metastases, OPRT,

ERCC1, BRCA1, MVD, adjuvant chemotherapy, 2763

TS-1, two-dimensional gel electrophoresis, LC-MS/MS,pancreatic cancer, proteomics, 2103

TT, luteinizing hormone, LH, total testosterone, freetestosterone, FT, prostate-specific antigen, PSA, prostatecancer, 1071

Tubulin alpha-6 chain, HCV-HCC, proteomics, 2-DE, MS,3331

Tumor cell proliferation, quinazoliniminium salts, Ki-67expression, macromolecule syntheses, DNA interactionand fragmentation, multiple mitotic figures, nuclei,micronuclei, 2083

Tumor growth, MT477, NRF2, AURKA, 1181Tumor location, colon cancer, microsatellite instability, age,

early onset, 967Tumor markers, colorectal cancer, biological activity,

angiogenetic factors, metalloproteinases, adhesionmolecules, 373


4795

Tumor markers, growth factors, breast cancer, CA 15-3,CEA, IGF1, EGF, HGF, 4653

Tumor markers, renal failure, mesothelioma, N-ERC/mesothelin, osteopontin, 1427

Tumor markers, uveal melanoma, metastasis, liver functiontests, OPN, S-100β, MIA, TPS, 351

Tumor markers, uveal melanoma, metastasis, OPN, S-100β,MIA, TPS, 345

Tumor models, immunotherapy, immunomodulation,natural killer cells, Parapoxvirus ovis, Orf virus, 4185

Tumor progression, hyperdiploid multiple myeloma,cytogenetics, 1599

Tumor progression, portal vein embolisation, liverhypertrophy, serum markers, 339

Tumor residual, ovarian cancer relapse, secondarycytoreductive surgery, predictive factor, complete tumorresection, 2583

Tumor response, rectal cancer, hyperthermo-chemo-radiation therapy, HCRT, distal margins, 3963

Tumor stage, soluble leptin receptor, colorectal cancer,3381

Tumor suppressor gene, FUS1, sarcoma, RT-PCR,immunohistochemistry, growth inhibition, 11

Tumor suppressors, cell cycle arrest, DNA N-methyltransferase, ERK, 2723

Tumor volume, magnetic resonance imaging, micro-computed tomography, optical reflectance imaging,molecular imaging, GFP, RFP, 2907

Tumor, angiogenesis, cancer, CD105, endoglin, review,2283

Tumor, cyclooxygenase, COX-2, breast cancer,prostaglandin, carcinogenesis, 4359

Tumor-associated proteins, neoadjuvant therapy, responseprediction, squamous-cell esophageal cancer, 1769

Tumorigenesis, CD133, colon cancer, azomymethane,dextran sodium sulphate, 4273

Tumor-infiltrating lymphocytes, memory T- cell, CD44,melanoma, 4099

Tumor-specificity index, 1, 2, 3, 4-tetrahydroisoquinolins,QSAR, semi-empirical molecular-orbital method,artificial neural network, 4231

Tumour markers, breast cancer liver metastases, liversurgery, prognostic factors, differental diagnosis, benignliver lesions, 1447

Tumour markers, cervical cancer, artesunate, artenimol,clinical symptoms, 4417

Tumour markers, monoTotal, lung cancer, cytokeratins,3107

Tumour regression, GLUT-1, rectal cancer, chemotherapy,radiotherapy, prognosis, 311

Tumour, microvesicles, chemokine, monocyte, 1329TURBT, bladder cancer, radiochemotherapy, radiation

therapy, 985

Two-dimensional gel electrophoresis, LC-MS/MS,pancreatic cancer, TS-1, proteomics, 2103

TXNDC5, non-small cell lung cancer, thioredoxin, proteindisulphide isomerase, 1577

Type C, bening breast disease, personality, hopelessness,cancer risk, 4019

Type C, personality, commitment, cancer risk, 4013Type I collagen, MMP-13, bone metastasis, integrin,

MAPK, 1307Tyrosine kinase inhibitor, sunitinib, metastatic renal cell

carcinoma, sequential treatment regimen, mTORinhibitor, 3507

Tyrosine kinase inhibitor, VEGFR2, drug resistance,angiogenesis, endothelial cells, HUVEC, 2787

Tyrosine kinase, hepatocellular carcinoma, liver resection,multidrug resistance, ABC proteins, 3883

Ubiquitin–proteasome system, extracellular proteasome,breast cancer, 2197

UC-associated colorectal cancer, leukocytapheresis,ulcerative colitis, 2547

Ulcerative colitis, colorectal cancer, surveillance, 2499Ulcerative colitis, leukocytapheresis, UC-associated

colorectal cancer, 2547Ulcerative colitis, polymorphism, DNA methylation, CD14,

p22PHOX, MBL, 933Ultrasound, breast cancer, screening, mammography,

automated 3D imaging, 2569Ultrasound, mono-l-aspartyl chlorin e6, antitumor effect,

sonodynamic therapy, sarcoma 180, colon 26, 501Uncontrolled ascites, hepatocellular carcinoma,

perioperative factors, hepatectomy, prognosis, 4545U-PA, oncostatin M, interleukin-6, VEGF, prostate cancer,

3273Upper tract transitional carcinoma, bladder cancer,

transitional carcinoma, lymphovascular invasion,prognostic role, review, 3503

Upper tract urothelial cancer, CCND1 1722, cyclin D1,polymorphism, 1043

Upper urinary tract urothelial carcinoma, maspin, activin A,androgen receptor, prognosis, 1713

Urachal cancer, recurrence, gemcitabine, cisplatin,chemotherapy, 2335

Uridine phosphorylase, hybrid steroidal alkylators, in silicomolecular docking, in vitro assay, mitrogen mustards,pancreatic cancer cells, 831

Urokinase plasminogen activator, resveratrol, glioma,invasion, TNF-α, 4223

Urothelial carcinoma, hOGG1, XPD, polymorphism, 3939Urothelial lesion, BBN, gemcitabine, sirolimus, mice, 1637Uterine cervical cancer, FDG-PET, lymph node, MRI,

3865Uterobrush, cytology, endometrial brush, endometrial

cancer, endometrial pathology, screening test, 3469


4796

UVB, normal human keratinocytes, 18β-glycyrrhetinicacid, glabridin, ROS, 2209

Uveal melanoma, metastasis, liver function tests, tumormarkers, OPN, S-100β, MIA, TPS, 351

Uveal melanoma, metastasis, tumor markers, OPN, S-100β,MIA, TPS, 345

V600E, BRAF mutation, KRAS, EGFR, ERBB2 mutation,lung cancer, adenocarcinoma, squamous cell carcinoma,SSCP, 4619

Vaccine, DC, whole tumor cell, IFN-γ, ELISPOT, 3995Vaccine, Her-2/neu, peptide, B-cell epitope, antitumor

effect, 3361Valproic acid, apoptosis, celecoxib, cytotoxicity,

neuroblastoma, 2231Valspodar, isolated lung perfusion, sarcoma lung metastases,

p-gp modulation, doxorubicin, cyclosporine, 2121Vascular endothelial growth factor (VEGF), cysteine-

histidine-rich protein (PINCH), colorectal carcinoma,epithelial mesenchymal transition (EMT), FAS, 4127

Vascular endothelial growth factor receptor-2, colon cancer,thrombin, vascular endothelial growth factor,coagulation factor, angiogenesis, 843

Vascular endothelial growth factor receptors, paclitaxel,bevacizumab, breast cancer, 3007

Vascular endothelial growth factor, alternative splicing,angiogenesis, autologous stem cell transplantation, chickchorioallantoic membrane assay, high-dosechemotherapy, placental growth factor, VEGFR1, 3115

Vascular endothelial growth factor, angiogenic factors,basic fibroblast growth factor, endostatin, cervical cancer,2645

Vascular endothelial growth factor, colon cancer, thrombin,vascular endothelial growth factor receptor-2,coagulation factor, angiogenesis, 843

Vascular endothelial growth factor, VEGF, gene expression,anti-VEGF therapy, bevacizumab, epithelial ovariancancer, 731

Vascular toxicity, germ cell tumour, cisplatin, thrombosis,hypercoagulation, von Willebrand factor, 4501

Vascular tube formation, angiogenic factor, cervical cancer,antiangiogenic therapy, 2609

Vascularisation, athymic mice, low-grade liposarcoma, softtissue sarcoma, xenograft, 4061

Vascularity, CEUS, HCC, dysplastic nodule,characterization, cirrhosis, 3977

VEGF, angiogenic factors, cervical cancer, angiogenin,endoglin, 2589

VEGF, bevacizumab, safety, pediatrics, 3953VEGF, mTOR, HIF-1α, angiogenesis, oral cancer, 4429VEGF, oncostatin M, interleukin-6, u-PA, prostate cancer,

3273VEGF, polymorphism, colorectal cancer, MMP2, HIF1A,

SNP, 575

VEGF, sunitinib, antitumor, antimetastasis, VEGFR,phosphorylation, mammary cancer, 1225

VEGF, total estrogen blockade, high-dose chemotherapy,leuprorelin, anastrazole, premenopausal breast cancer,671

VEGF, vascular endothelial growth factor, gene expression,anti-VEGF therapy, bevacizumab, epithelial ovariancancer, 731

VEGF-C, breast cancer, lymphatic microvessel density,molecular classification, VEGFR-3, 1757

VEGF-C, lymphangiogenesis, lymphovascular invasion,liver metastases, colorectal cancer, 4605

VEGFR, sunitinib, antitumor, antimetastasis, VEGF,phosphorylation, mammary cancer, 1225

VEGFR1, alternative splicing, angiogenesis, autologousstem cell transplantation, chick chorioallantoicmembrane assay, high-dose chemotherapy, placentalgrowth factor, vascular endothelial growth factor, 3115

VEGFR2, tyrosine kinase inhibitor, drug resistance,angiogenesis, endothelial cells, HUVEC, 2787

VEGFR-3, breast cancer, lymphatic microvessel density,molecular classification, VEGF-C, 1757

Vessel identification, angiogenesis, breast cancer, imageanalysis, CD34, MVD, 4053

Vimentin, EMT, E-cadherin, gamma catenin, fibronectin,lung adenocarcinoma, 4451

Vimentin, quantitative methylation-specific PCR,hepatocellular carcinoma, 1289

Vincristine, drug delivery, cancer, liposome, folate receptor,drug targeting, 1521

Vincristine, glioma, oligodendroglioma, 1p19q, 1p, PAV,ACNU, procarbazine, chemotherapy, 4475

Vincristine, medulloblastoma, lomustine, apoptosis,chemotherapy, 1721

Vinorelbine, chemotherapy, carboplatin, paclitaxel, non-small cell lung cancer, 317

Vinorelbine, histoculture drug response assay, non-smallcell lung cancer, class III β-tubulin, predictive marker,999

Viral hepatitis, hepatocellular carcinoma, non-cirrhoticlivers, 1055

Virotherapy, pancreatic cancer, chemoresistance,gemcitabine, PDAC, GFP, 1279

Vitamin D analog, prostate cancer, ZK191784, MMP-2,MMP-9, adhesion molecules, 4091

Vitamin D, 25-hydroxyvitamin D, breast neoplasms,case–control studies, epidemiology, meta-analysis,prevention, 2939

Vitamin D, colorectal cancer, breast cancer, prostate cancer,lung cancer, 3619

Vitamin D, serum 25(OH)D, toxicity, chemoprevention,607

Voluntary running, metastasis, cytokines, mice, 3337


4797

Von Willebrand factor, germ cell tumour, cisplatin,thrombosis, hypercoagulation, vascular toxicity, 4501

W-APC, cyclooxygenase, COX-2, right colon, left colon,colon cancer, 2191

Western blotting, estrogen receptor, breast cancer cell lines,flow cytometry, RT-PCR, 521

Whole tumor cell, DC, vaccine, IFN-γ, ELISPOT, 3995Whole-brain radiation, metastastic melanoma, melanoma,

brain metastases, temozolomide, 4537Wilms’ tumor 1 (WT1), myeloid dendritic cell, cancer

vaccine, immunotherapy, 2447WISP-1, esophageal cancer, CCN family, WISP-1v, 991WISP-1v, esophageal cancer, CCN family, WISP-1, 991Wnt pathway, colorectal cancer, immunohistochemistry,

LGR5, stem cell marker, 263Wnt pathway, multiple myeloma, signal transduction,

myeloma, myeloma therapy, review, 725Wnt, leukemia, notch, hedgehog, γ-secretase inhibitor, 893WT1 peptide vaccine, immunotherapy, ovarian cancer,

2441WU, human polyomavirus, BK virus, JC virus,

hemotopoetic stem cell transplantation, cerebrospinalfluid, KI, 3489

XELIRI, bevacizumab, FOLFIRI, colorectal cancer,efficacy, safety, 1777

Xenograft model, (+)-spongistatin 1, anticancer, naturalproduct, mitosis, 2773

Xenograft model, 3-Indole, cell cycle arrest, ATM, ATR,SMAD3, lung cancer cells, 203

Xenograft, athymic mice, low-grade liposarcoma, softtissue sarcoma, vascularisation, 4061

Xenograft, breast cancer, ADAMTS1, amphiregulin,immunotherapy, 3839

Xenograft, heparan sulfate, proteoglycans, HepG2 cells,immunotherapy, liver cancer, 4067

Xenograft, hepatitis C virus, liver tumour, sarcomatoidtumour, cell line, culture, spectral karyotyping, 129

Xenograft, matrix metalloproteinases, gelatinase, tonguecarcinoma, green fluorescent protein, peptide, 3659

Xenografts, ischemia, immunohistochemistry, phospho-proteins, pre-analytical variables, biopsy, 2073

Xenografts, radioimmunotherapy, HNSCC, SCID mice,radio-labeled monoclonal antibody, Cytokeratin 8, 3315

XhoI restriction site, EBV polymorphism, BamHI W1/I1,EBV-associated gastric cancer, Latin America, 3607

XPD, hOGG1, polymorphism, urothelial carcinoma, 3939X-ray repair cross-complementing group 1, XRCC1,

polymorphism, DNA repair, skin cancer, meta-analysis,3945

XRCC1, genetic polymorphisms, cancer susceptibility,DNA-repair genes, metabolizing genes, CYP1A1,CYP1E1, 1359

XRCC1, polymorphism, Arg399Gln, Arg194Trp, GSTP1Ile104Val, GSTT1, GSTM1, gastric cancer, survival, 705

XRCC1, polymorphism, Helicobacter pylori, gastricatrophy, intestinal metaplasia, GSTP1, GSTT1, GSTM1,1459

XRCC1, X-ray repair cross-complementing group 1,polymorphism, DNA repair, skin cancer, meta-analysis,3945

YB-1, non-Hodgkin’s lymphoma, prognosis, immuno-histochemistry, 2963

YT, myeloma, CD86, interleukin-2, cytotoxicity, 475Zanthoxylum ailanthoides Sieb and Zucc., human colon

adenocarcinoma cell, colo 205 cells, caspases, apoptosis,flavone, 1667

Zeranol, ACI rat serum, breast cancer, mitogenic activity,481

Zeranol, cell proliferation, protein disulfide isomerase,mammary tumorigenesis, 1659

Zinc, clioquinol, cyclin D1, miR-302C, MCF-7 cells, 2739ZK191784, prostate cancer, vitamin D analog, MMP-2,

MMP-9, adhesion molecules, 4091


4798


4799

Abbas A, 4637Abbruzzese JL, 1417Abdel-Nabi H, 411Abdulkarim B, 3559Abdullah A, 2017Abe F, 2915, 4339Abe T, 3463, 3535Abo T, 4545Abou-Elkacem L, 2907Aboussekhra A, 1721Abraham I, 1407Absenger G, 1373Abujamra AL, 2723Abuzenadah A, 97, 2975,

4179Acha-Sagredo A, 677Ackermann H, 665Acquati P, 1881Adachi M, 2893Adamo V, 1315Addo J, 591Adler S, 3733Adoubi I, 4417Advani PP, 335Agatsuma T, 299Agharahimi M, 3739Agostini A, 3047Aguirregaviria JI, 677Aguirre-Urizar JM, 677Ahmad A, 1105Ahn SH, 4641Aieta M, 1359Akada JK, 3331Akagi Y, 2517, 2541, 2547Akaike M, 325Akashi H, 763Akaza H, 2065Akazawa K, 1483Akeda K, 4163Akiba S, 3607Akiyoshi K, 1653Aklilu M, 255Akrivos T, 3469Aksoy-Sagirli P, 2225Aktas B, 3623Alamanis C, 1475Al-Ayadhi B, 521Al-Bader M, 521Al-Benna S, 4061

Alberg AJ, 3891Albisinni S, 1812Albo G, 1880Alcaraz JE, 2939Al-Eisawi Z, 2757Alessandro M, 1876Alexander A, 3559Alexander J, 785Alexiadou A, 3469Alexopoulou A, 1467Alfaro R, 1599Al-Ghamdi K, 4179Al-Hindi H, 1721Ali S, 209Aliberti C, 4581Al-Kofide A, 1721Al-Maghrabi J, 97, 4179Almhanna K, 4387Al-Muhayawi S, 4179Al-Qahtani M, 97, 2975,

4179Al-Quran SZ, 3417Al-Saad S, 1603Al-Shail E, 1721Al-Shibli K, 1603Altherr K, 2797Al-Thobaiti F, 2975Al-Thubaity F, 97Amano S, 3839Amant F, 2367Amaral L, 3285, 4201Amatulli M, 2149Ambrosio MR, 1865Amellal N, 2271Amend B, 3783Amendola F, 4575Amérigo J, 3019Amirkhan RH, 4135Amoroso D, 1061An W-W, 1647Anai H, 3909Anastasiou I, 1475Andergassen U, 2749Andersen S, 1603Andersen SN, 861Anderson KM, 487Ando M, 3449Andratschke M, 3315Andratschke N, 561

Andre T, 2271Angelopoulou MK, 3585Angiero F, 719, 4485Anichini C, 3973Anlasik T, 2197Anthoine G, 281Anthony B, 2813Antonacopoulou AG, 1677Antonelli A, 1922, 1924Antonia SJ, 3193Antoniolli SZ, 3913Aoki M, 3991Aoki S, 1685Aoki T, 633Aoki Y, 1437, 3527Aomatsu K, 2787Aomatsu N, 3369Aoyama H, 2241Aoyama M, 3353Aoyama T, 1297Apostolaki A, 3093Aragona F, 4445Arai M, 4169Arany I, 3267Arao T, 2787, 4561Aravantinos G, 3007Aravindan N, 161Aravindan S, 161Arbab AS, 3673Arcoria D, 4553Ardavanis A, 1033, 3093Arena V, 4273Ariad S, 913Ariga T, 3527Ariizumi T, 11Arima N, 2241, 4251Arisawa T, 705, 933, 1459Arkins AM, 2073Armakolas A, 4259Armakolas N, 4259Armentano R, 555Arnes M, 2319Arnold D, 1961Arnolds J, 3151Arnoldt J, 2012Arrias-Herrera V, 849Arthur G, 3809Arthur JR, 2693Asai K, 3353

Asaka S, 2989Asanuma K, 4163Asao T, 2847, 3963Ashton J, 255Astner ST, 3935Ata M, 2975Atasoylu O, 2773Ater J, 2265Aubard Y, 3865Auge JM, 3107Aung W, 1549Avgerinou G, 2373Avruch L, 3921Awasthi V, 161Ayabe T, 2995Azmi AS, 1105Azzarok A, 1961Azzoni P, 2209Baak JPA, 443Baba E, 3995Baba H, 991, 2983Baba M, 2241Babayeva SN, 2693Babsky AM, 2045Bachmann K, 1962Bacigalupo B, 1061Badisa RB, 3739Badisa VLD, 2017Bae SB, 3385Bafaloukos D, 3007Baggerly LL, 607Baghi M, 665Bahram F, 1527Baj-Krzyworzeka M, 1329Bakker J, 4043Baldazzi V, 1870Baldoli E, 3401Balkin ER, 3143Ballaré A, 1885Ballester M, 4469Bally MB, 2161Balogh S, 3051Bamias A, 1475Bandapalli OR, 1215Bando Y, 2389Bansal N, 2045Banys M, 4423Barak V, 345, 351, 1962Baran J, 1329

Authors Index(Figures refer to page numbers)

Barboro P, 1828Bardin C, 2813Barekati Z, 2623, 4267Barinoff J, 2609, 2645, 2651Barla G, 1033Barlett B, 3747Barnett CM, 973Barsotti C, 3483Barth S, 2907Barth TFE, 2343, 4599Bartnitzke S, 753Baruch R, 351Bas M, 3151Basinko A, 3441Ba-Ssalamah A, 2379Bassi R, 2149Basso SMM, 693, 3879,

3969Basso U, 693Bastian S, 3181Bates V, 2661Bau D-T, 221, 227, 745,

1043, 2395, 3511, 3601,3629, 4301

Baxi S, 249Beale P, 1131, 2757, 3789,

4283Bechter K, 2343Bechter O, 4407, 4439Beckers S, 53Bedke J, 3783Beer TM, 973Beldì D, 1909Belge G, 753Bellardita L, 1826Bellastella G, 1847Bellavita R, 1912, 1913Bellyei S, 1769Benali-Furet N, 427Benassi L, 2209Benbrook DM, 2739Bendell JC, 255Benea G, 4581Benecchi L, 1860, 1911,

1912, 1914Benedicenti S, 719Benesova L, 4647Benharoch D, 913Bennett S, 2045Beppu T, 2983Berger G, 147, 153Bergerat J-P, 1765Berghmans T, 281

Bergmann C, 3151Bergmeier S, 871, 1345Bergner A, 849Bergqvist M, 1125Beris P, 3585Berkkan H, 2225Berkowitz JA, 427Bernacki R, 411Bernardo G, 3927Bernreuther C, 591Bernués M, 1599Berremila S-A, 585Bersani S, 3137Bertazzoni G, 2209Bertelli E, 1922Bertini R, 1840Bertucci F, 1079Besalduch J, 1599Bessette B, 139Betz M, 4393Bhattacharya A, 387Bhayani MK, 2893Bianchino G, 1359Bieglmayer C, 3615Biesterfeld S, 53, 2797Bilal A, 1510Billecke L, 1963Birner P, 4605Bischofs E, 3219Bittman R, 3809Blankenstein Th, 1963Blau CA, 1189Blau T, 561Blobe GC, 255Blohmer J-U, 2575, 2589,

2645Bobek V, 1535, 3125Bobos M, 3007Boc M, 1777Body G, 1783Boix M, 4191Bojic M, 2379Bolikal S, 421Bölling T, 3903Bollito E, 1947Bolotin A, 913Boltetsou E, 3585Bonanno A, 3069Bondor C, 2637Bonetta A, 1849, 1850, 1863,

1942Borel Rinkes IHM, 1379,

4507

Borges KS, 1337Borja-Cacho D, 1181Borrelli D, 1903Bortolato B, 1894, 1895Bortolus R, 1941Bouche O, 2271Boulware D, 2191Boumendjel A, 3213Bournakis E, 1475Bouteille C, 585Boutonnat J, 3213Bouvet M, 3125, 3665Bovo C, 1007, 3441Bowen KA, 1153Bradley C, 1417Brady PC, 243Braicu EI, 2583, 2597, 2603,

2629, 2637Braissant O, 2121Branca G, 3069Brand K, 1215Brandau S, 3151Brattström D, 1125Braun S, 2657Brausi M, 1817, 1819, 1834Bravaccini S, 1864Breidenbach M, 4039Brekken RA, 843Bremmer F, 1497Bremnes RM, 1603Brenner H, 1501Brenner W, 2797Brion N, 331, 3507Brochez L, 3697Brodin O, 1125Brodt P, 3219Bruckner T, 3219Bruha F, 4647Bruha J, 1447, 4031Bruland ØS, 4053Brunelli M, 3137Brunello A, 693Brunet B, 3559Brunetti E, 89Bruni E, 2209Bruno P, 4207Brunocilla E, 271, 3503Bryan BA, 3645Büchler MW, 3883Buclin T, 2121Budde U, 4501Bufo P, 4211Bugis A, 2975

Buhmeida A, 97, 2975Buhr HJ, 147, 153Bukac D, 1964Bukholm IR, 861Bullerdiek J, 753, 1541Büntzel J, 1964, 1965Buonocore G, 3973Buonocore V, 1399Burger CW, 4043Burgkart R, 1235Burke WM, 243Busetto GM, 1399, 1845Busund L-T, 1603Byrne GJ, 2383Byun H-S, 3809Byun SJ, 4641Cabanillas F, 1417Cai FF, 4267Cai J, 3897Cakmakoglu B, 2225Calì S, 4553Calisti G, 3977, 4575Camacho J, 1265Camerini A, 1061Cammarota F, 1863Camoutsis C, 831Camozzi V, 3969Candeloro G, 671Cangiarella J, 4401Cao W, 39Caparrotti P, 1898Capellini C, 1061Caraglia M, 1836Cardinali M, 1889Cardoso SV, 2805Caredda E, 4273Carlberg C, 1491Carlotti Jr CG, 1337Carlson D, 249Carlsson G, 3057Carmignani L, 1837Carpenter MJ, 3891Carrasquer CA, 3247Carson DA, 725Caruso B, 1071, 3913Caruso MG, 555, 3381Caruso ML, 555Caruso R, 3069Casati S, 3401Castellano A, 3953Casto BC, 3279Catanzaro MA, 1827Catlin T, 3193


4800


4801

Cattoretti G, 4485Cavina M, 681Cayre YE, 427Ceausu R, 1757Cerna M, 4653Chabot S, 4083Chacko J, 421Chacon P, 3607Chadalapaka G, 3799Chammas R, 2805Champelovier P, 3213Chan C, 2757, 3789Chandra KL, 2083Chang CA, 3407Chang C-H, 221, 745Chang C-T, 1667Chang EL, 2265Chang K-W, 2037Chang L-L, 1043Chang S-J, 2203, 2821Chang W-S, 221, 2395, 3511,

3601, 3629Chanvorachote P, 193Characiejus D, 639, 699Chatelut E, 359Chaudhary A, 97, 2975, 4179Chauhan SC, 897Chekerov R, 2603, 2657,

2669, 2679Chen C-T, 3407Chen C-Y, 3475Chen F, 3165Chen H, 3423Chen H-W, 129Chen Jung-Chou, 2821Chen Jyh-Cheng, 3407Chen P-J, 4007Chen R, 4537Chen T-C, 129, 2037Chen TC, 1497Chen WJ, 4267Chen X, 243Chen Y, 2231Chen Y-J, 1713Chen Y-R, 4239Chen Y-Y, 1691Cheng A-L, 4007Cheng C-L, 3497Cheng H-N, 221Cheng L, 3137Cheng Y-W, 3475Cheong H-J, 3385Chereau E, 4469

Chi A, 4393Chiang J-H, 2821Chiang P-H, 3407Chiara F, 1911Chiara GB, 3879Chiba I, 2351Chikaishi Y, 4451, 4631Chikamoto A, 2983Chilosi M, 3137Chiou H-Y, 3939Chiou S-H, 3407Chiou S-M, 2203Chirinos JL, 3607Chiu C-F, 3629Chiu S-J, 3407Chiu SS, 907Chiumento C, 1857Cho CH, 2675Cho DH, 4329Cho GJ, 4223Cho H, 33Cho M-H, 1249Cho YB, 3843Choe J-H, 3767Choi C-M, 3457Choi DR, 3457Choi Han Seok, 3301Choi Hyeong Sim, 3301Choi I, 3301Choi J, 4223Choi K-C, 1249, 2853Choi SH, 3843Choi WS, 4223Choi YK, 3301Chon CY, 4641Chong K, 23Chou A, 2037Chou M-C, 3475Chou S-E, 3633Chou S-T, 1667Chow H-HS, 2781Choy E, 1115Chrisofos M, 1475Christodoulou C, 3007Chu C-C, 3601Chueh F-S, 2203Chun F, 1965Chun H-K, 3843Chun YH, 4641Chundong G, 1141Chung HJ, 3843Chung H-K, 1667Chung J-G, 1667, 1691,

2203, 2821Chung R, 421Chunhacha P, 193Cibei E, 1061Cimpean AM, 1757Cindolo L, 1935, 1937, 1938Ciolino HP, 2699Ciortea R, 2637Cisternino A, 1833, 1856,

1859Cittadini A, 1359, 4273Cividini R, 1943Clark JS, 3267Classe J-M, 1783Clemenson A, 585Clouqueur E, 3047Cocco C, 1071, 3913Cochetti G, 1936Coenegrachts L, 2367Cohen D, 4393Cohen L, 2141Colaço A, 1637Collan Y, 97Collettini F, 2597Collins S, 1627Colombo R, 1852Comoe KC, 4417Comunale L, 1071, 3913Conrad GR, 2109Constantinides C, 1475Conti G, 1952Coombes RC, 1367Cooperwood J, 2017Copeland EM, 3417Coppola C, 2291Coppola D, 2191, 2957Corbella F, 3727Cordes T, 1495Cormio L, 1931, 1934Cornalba G, 3927Cornuau M, 1783Cortesi E, 4219Cortez A, 4469Corvalan AH, 3607Cosio S, 3483Costin N, 2637Coutant C, 4469Cova G, 1869Covas DT, 2173Cozza R, 3953Crandon S, 961Crepin M, 1321Cricca A, 1947

Cristofani R, 3483Cruz O, 953Cseh J, 3051Cseke L, 1769Cstoth I, 281Cufino V, 4273Cui H, 39, 411Cui L, 1279Cui QC, 1Cunningham AR, 3247Cunningham SL, 3247Curran JN, 3891Curri V, 3213Cushman S, 255Cusi V, 953Cusimano MD, 2283Czejka M, 3573D’Angelo L, 4211Dahle J, 2113Dahlmann B, 2197Dai L-J, 3705Dai Z, 2699Daigeler A, 4061Dailey Jr OD, 3165Dalezis P, 831Dalgleish AG, 3747Dalianis T, 939, 1515, 3489Dallara S, 4581Dallol A, 2975Dang D, 1205Danilevičiūtė V, 639Danilin S, 2705Daraï E, 4469Date H, 4619Datler P, 2379Daubine F, 4141De Berardinis E, 1399, 1843,

1844De Braekeleer E, 3441De Braekeleer M, 1007, 3441De Bruijn MT, 1379, 4507De Cnodder T, 4417De Cobelli O, 1894De Faria PR, 2805De Geest S, 1407De Gramont A, 2271De Grève J, 1407, 1753, 4457De Ioris MA, 3953De Laurentis C, 3953De Manzoni G, 3543De Marinis F, 649De Nunzio C, 1811, 1812,

1813

De Pasquale MD, 3953De Rosa A, 4211De Sanctis V, 3555De Sio L, 3953De Stefano G, 2291, 3977,

4575De Vogelaere K, 3579De Vries A, 4407De Witte O, 4457Debald M, 1966Debiec-Rychter M, 2367Debski R, 1453Decloedt J, 2367Decoster L, 1753Decosterd LA, 2121Deeb D, 3673Deevi D, 2149Deguchi T, 3983Deichert U, 753Del Carmen Villa Cadenas

M, 53Delahunt B, 3137Deliveliotis C, 1475Dell’Atti L, 1811Delle Cave A, 1851Delmonte A, 3927Delord J-P, 359Delpeuch A, 1765Delvaux G, 3579Demars LC, 3337Dempke WCM, 1966Den Otter W, 639, 699Denecke T, 2597Dertimas V, 3469Derwinger K, 2347, 3057Desbordes C, 421Desideri G, 671Desitter I, 427Desper J, 2083Dessanti P, 1061DeStefanis P, 1820, 1825,

1833, 1839Deutsch I, 243Devetzi M, 3093DeVito N, 4537Dhakal HP, 4053Di Bartolo RM, 3973Di Cesare P, 3927Di Domenico M, 4211Di Lallo A, 1864Di Liberto R, 3727Di Maggio EM, 4553Di Sarno A, 2291, 3977,

4575Di Silverio F, 1399, 1843,

1929Di YP, 2877Dian D, 451Díaz-Delgado M, 3019Dick Jr EJ, 2187Dieckmann K-P, 4501Diedrich K, 4359Diehl P, 1235Dienemann H, 4491Dimitrakopoulos F-ID, 1677Dimopoulos AM, 3007Dimopoulos MA, 1475Dimozi A, 4291Ding H, 1521Ding S, 3607Ding W-Q, 2739Ding Y-H, 4007Dionisi F, 1874Diorio C, 4369Dirix L, 1407Distel RJ, 427Ditsch N, 451Dittmer C, 4359Dlaska M, 4439Dobrovolskienė N, 699Dohi S, 2441, 2447Doi K, 2453, 2535Doki Y, 507Domanska G, 2629Dong R, 3229Donizy P, 711, 2963Donnem T, 1603Dono M, 1061Dorff TB, 3897Doroshow JH, 961Dorr RT, 2781Dosaka-Akita H, 263Dou QP, 1Doudican NA, 3259Douet-Guilbert N, 1007,

3441Dowell JE, 4135Dowsett M, 1367Drews N, 209Driever PH, 661Du Four S, 4457Du P, 3205Duan Z, 1115Duchamp E, 3213Duck L, 1407Ducreux M, 2271

Duda V, 4039Dudek AZ, 1181, 3945Dudhgaonkar S, 379Dulchavsky SA, 3673Dumas I, 4369Durán MA, 1599Duranti E, 4207Duret A, 359Dürr S, 1966Dutour A, 2813Dziegiel P, 2833, 3027Dziewanowska ZE, 2303Ebara T, 2847Eberle J, 807Eberle N, 1541Ebert AD, 2657Ebi M, 3353Eble JN, 3137Eckardt A, 665Eckardt AM, 2313Eckert K, 1169Eckhardt SG, 1093Edamatsu T, 2733Efferth T, 81, 185, 4417Efstathiou E, 1475Efstratiou I, 3007Egami T, 1279Egashira A, 3073Egawa Y, 2499Egawa-Takata T, 4513Eggeman H, 2617Eggen T, 2319Eguchi K, 3449Eichbaum C, 3219Eichbaum MHR, 3219Eichhorn T, 81, 185Eichler C, 4039Eidukevičius R, 699Eijkemans MJ, 4043Eisterer W, 4407, 4439Eizuru Y, 3607Elder DJE, 1577Elgersma OE, 4043El-Kum N, 1721Eller J, 1431Elling D, 2617Elliott RL, 2899El-Maghrabi J, 2975Elsing C, 459Elstner E, 2713Ember I, 3051, 3267Endo I, 1049, 1055Endo M, 3775, 4075, 4519

Endo N, 11Endo T, 725Endoh M, 171, 1211Engel JB, 1967Enomoto T, 4513, 4613Enrici RM, 3555Erasmus E, 825Erol E, 2679Errico A, 1901, 1903Escobar HM, 1541Escudero JM, 1968Eskelinen M, 739, 1065,

1801, 3101, 4013, 4019Esposito F, 4211Esposito V, 2291Essa S, 1498Esterni B, 1079Estévez J, 4191Etienne M-C, 359Ettlinger D, 3573Eucker J, 2713Evers BM, 1153Ewell L, 4393Extra J-M, 1079Faber TJE, 1968Fabrini MG, 3483Facoetti A, 3727Fadlalla K, 233Faiss S, 1969Fakih M, 335, 975, 4637Falandry C, 359Faller DV, 2723Fan W, 777Fandella A, 1858, 1859Fanti G, 3879Fanucchi A, 3483Farella N, 2291, 3977, 4575Farkas R, 1769Fassina A, 693Faussner F, 1969Fazio A, 2283Fedele F, 3069Fedeli F, 1061Fehm T, 979, 4025, 4423Fehr Y, 1970Feldman D, 1493Fellin G, 1815Feng E, 481Feng W, 443Feng Y, 3595Feola A, 4211Ferda J, 339Fermeaux V, 139, 3865


4802


4803

Fernando NH, 255Fernando S, 3417Ferraù F, 4553Ferrera G, 1930Ferro M, 1916, 1918, 1926Ferro P, 1061Fersching D, 1970Festuccia C, 1821, 1822Feyen O, 1971Fichtl J, 339Fiebig H-H, 4185Fiegl M, 2949Filiotou A, 1467Finek J, 1447, 3619Finek J, 1971Fink D, 2161Finn OJ, 3151Fiorentini G, 4581Fiorentino A, 1857Fiorino C, 1931Flamiatos JF, 973Flessas I, 2373Fletcher BS, 3417Focan C, 1407Fogelman DR, 1417Folkerd EJ, 1367Fontana A, 1906Ford CHJ, 521Ford ME, 3891Forest F, 585Forget F, 1407Forman LW, 2723Formenti SC, 4401Fotiou S, 3469Fotopoulou C, 2583, 2603,

2629, 2675Fountzilas G, 3007Fourie E, 825Fraccon AP, 3543Franceschini MC, 1061Francescutti V, 3429Francis I, 521Franklin MJ, 3945Frati L, 4219Freibauer C, 3615French CB, 607Frenkel S, 345, 351Freydanck MK, 1972Freyer G, 359Freyschlag CF, 1023, 3873Frezza G, 1878Fridrik MA, 4439Friebe A, 4185

Friedrich M, 4359Friedrich RE, 1972, 1973,

1974, 1975Friese K, 451, 2749Fryer RA, 3747Fuchsova R, 1976, 3107,

3619, 4653Fuerst F, 1373Fujibayashi M, 2989Fujieda A, 2733Fujii H, 2999Fujii Makoto, 4657Fujii Masashi, 1019, 2339Fujii S, 1055Fujii T, 3963Fujimoto T, 2413, 2453, 2535Fujioka K, 1653, 3253Fujioka M, 2733Fujisaki M, 3983Fujishima T, 1501Fujita Hayato, 1279Fujita Hiroshi, 705, 933Fujita J, 113Fujita M, 4513, 4613Fujita Yoshihiko, 2787, 4561Fujita Yoshimasa, 1741, 2297Fujitani K, 3085Fujiwara H, 67, 495, 2217Fujiwara M, 1643Fujiyama S, 2983Fukada J, 3079Fukai T, 501Fukami T, 2461, 2483Fukazawa T, 1197Fukuda K, 3079Fukunaga M, 2129Fukusato T, 3691, 4147Fukushima Takeo, 2527Fukushima Toshihiro, 1741,

2297Fulford AD, 2073Fulton D, 3559Fumaki T, 2553Funada T, 2339Funakoshi Y, 4665Furák J, 1431Fürst S, 1976Furukawa A, 3361Furukawa Takako, 1549Furukawa Tatsuhiko, 4251Furuta K, 2787Furutani A, 67Fury MG, 249

Fusch G, 2629Futami K, 2499Futawatari N, 2361Fuyuhiro Y, 3369Gadducci A, 3483Gakis G, 2053Galán P, 1599Galle PR, 2797Galleggiante V, 1893Galosi A, 1938Galustian C, 3747Gansukh T, 711Gao X, 3673Gari M, 97, 2975, 4179Garibaldi E, 1899Garland CF, 607, 2939Garrett-Mayer E, 3891Garritsen HSP, 4267Gasbarrini A, 4273Gast S-M, 725Gautam SC, 3673Gazzaniga P, 4219Gebauer B, 2597Geers C, 3579Geinitz H, 1735Geleff S, 4605Gellermann J, 2675Gelli MC, 681Gellrich N-C, 2313Genazzani AR, 3483Genet D, 3865Geng F, 3229Gentile V, 1399George B, 2045Georgoulias V, 807Gerestein CG, 4043Gerger A, 1373Gerhardt TE, 4111Germano IM, 959Geromichalos GD, 831Geromichalou E, 831Ghimenton C, 1071, 3913Ghosh S, 3559Giannetti A, 2209Gianni W, 4219Giarnieri E, 4207Giatromanolaki A, 1745Giberti C, 1913, 1915Gibson Wood W, 1667Giffen C, 945Gilabert M, 1079Gildehaus FJ, 3315Gil-Ibáñez B, 2583

Gill R, 2161Giorgio A, 2291, 3977, 4575Giorgio V, 2291, 3977, 4575Giovagnoli MR, 4207Giraud G, 3489Giraud S, 139Giri U, 33Giudice S, 2209Giuffrè G, 1315Giuffreda P, 3401Giulianelli R, 1814, 1815,

1835, 1836, 1837, 1881Glehr M, 1373Gnekow A, 661Gobbo S, 3137Gochman E, 1607Gockel I, 2797Goishi K, 4155Goldnau C, 3623Golzio M, 4083Gomes MV, 1337Gon Y, 2129Gonçalves A, 1079González-Cámpora R, 3019González-Rodilla I, 4191Goodman CB, 3739Gopas J, 913Gordanpour A, 403Gordian E, 3757Gorham ED, 2939Gossmann A, 4039Gotanda Y, 2517, 2541Goto T, 77, 777, 1289, 1293,

2249, 2889, 3377, 3835Gotsis AD, 1677Gottschling S, 4491Grabarska A, 565Gradilone A, 4219Graf C, 2797Grant WB, 1502Gray T, 4135Greco C, 3483Greco G, 3927Green JA, 2661Green S, 959Greil R, 4439Greiner J, 2343Gremse F, 2907Greve J, 3151Grieco V, 1359Grimm C, 2259Grivas AA, 831Gröber U, 1976

Grobmyer SR, 3417Grondin JM, 2073Groth S, 1977Grünberger B, 4439Grünberger T, 4605Grünhage F, 1505Gudlaugsson E, 443Guéganic N, 1007, 3441Guerra V, 3381Guerrouahen BS, 427Guinan P, 487Gundling F, 2931Gunning AC, 4507Günthner-Biller M, 1977Gunturu KS, 4397Guo AM, 3673Gustafsson B, 3489, 2347Guth A, 4401Gutierrez ME, 961Gutwein LG, 3417Gwin J, 209Györffy B, 711Ha CS, 33Ha YJ, 4329Haanpää ML, 3493, 4413Haapasalo HK, 4413Häberle L, 985Habu S, 3361Hachiman M, 4251Hack R, 2949Haddad R, 2173Haese A, 1978Haffty BG, 2327Hagiwara Y, 1427Hagström J, 3659Hah Y-S, 4315Halim H, 193Halon A, 711, 2963Hamada S, 1011Hamada T, 4251Hamasaki K, 4545Hamasaki T, 2241Hambek M, 665Hambruegge C, 3903Hamburger AW, 3129Hamm B, 2597Hamour O, 4179Han J, 3767Han K-H, 4641Hanagiri T, 277, 619, 4631Handzlik J, 3285Hang L-W, 3601Hanke St, 1979

Haque S, 249Harada H, 4519Harada Y, 2889Haragâş D, 2637Haraoka K, 2983Harashima H, 2065Harbeck N, 4039Hare R, 3429Hariri N, 1215Harnack U, 475, 1169, 4195Harrison GM, 467Hartkopf AD, 979Hartlapp J, 3903Hase K, 1567Hasegawa A, 3665Hasegawa H, 3085Hasegawa M, 3909Hasegawa T, 2915, 3369,

4339Hasegawa Y, 2893Hashiguchi Y, 1567Hashimoto K, 3073, 4481Hashimoto S, 999, 2129Hashimoto Y, 2241Hassan NM, 1197, 1307Hata K, 731Hata T, 731Hatae M, 3063Hatooka S, 3535Hatziolou E, 2373Hauser J, 4061Haussler MR, 1492Havelund BM, 1559Hawes D, 3897Hayashi E, 1259Hayashi K, 2927, 3665Hayashi M, 543Hayashi N, 991Hayashi T, 597Hayes M, 4135Hayward R, 2023Hazama S, 4569Head JF, 2899Heaney RP, 607Hector J, 2669Hedman M, 1125Heesom KJ, 1577Hefler L, 2259Heidecke H, 2589, 2609,

2645Heigener D, 1979Heikkilä P, 3659Heinze G, 2259

Heinzer H, 1979Hejna M, 2379Helm J, 2957Helmke BM, 753Helson L, 907Henderson-Jackson EB, 2957Hendler K, 345, 351Hendruschk S, 3181Henne-Bruns D, 4599Hennenlotter J, 3783Henry H, 2121Hepp P, 1979Herberger B, 4605Herbstreit C, 2657Herman TS, 161Hermann TW, 2303Hernando-Rodriguez M, 677Herpel E, 4491Herrmann T, 459Herry A, 1007Herth FJF, 4491Herzog TJ, 243Hetzel MR, 1577Heubner M, 2197, 3623Heusner T, 2645Hewicker-Trautwein M, 1541Hewitt SM, 945Hibi K, 77, 777, 1289, 1293,

2249, 2889, 3377, 3835Hidaka S, 4545Hidalgo H, 3607Hideghéty K, 1431Hietaharju AJ, 4413Higaki T, 3991Higashi D, 2499Higashiyama S, 4155Hikita E, 4169Hikita S, 2461, 2553Hilbe W, 2949Hino O, 1427Hinrichs J, 1379Hirahara N, 2733Hirai Y, 999Hirakawa K, 3369Hirakawa M, 1437, 3527Hirakawa T, 3369Hirano T, 3839, 4169Hirao M, 3085Hirashima M, 2467Hirashima T, 4525Hirata I, 705, 933, 1459Hirata Y, 3353Hirooka S, 3827

Hirose K, 3839Hirose Y, 1741Hiroshige S, 4481Hirota K, 2489Hirota M, 1011Hirsch J-M, 3345Hitora T, 549Ho C-Y, 3511Ho M-R, 4239Ho P-C, 789Ho T-C, 1173Ho WJ, 3237Hochrath K, 1505, 1506Hoellen F, 4359Hoffman RM, 387, 1535,

2907, 3125, 3665Hoffmann K, 3883Hoffmann O, 2197, 3623Hoffmann TK, 3151Hofmann G, 1373Holdenrieder S, 1980Holick MF, 1491, 1504Hollidt J-M, 1980Holm PS, 2963Holmberg AR, 4141Holubec Jr L, 373, 1447,

3107, 3619, 4031Holubec L, 1981Holzer TR, 2073Honda J, 2389Honda K-I, 1271Honda T, 2493Hong DS, 3385Hong JY, 421Hönig A, 1982Honoki K, 543Hoogwater FJH, 4507Hoopmann M, 4039Hori H, 2477, 2489, 2561Horiguchi J, 3041Horiuchi S, 2553Hornicek FJ, 1115Horvath OP, 1769Hoshiai H, 731, 3063Hoshina A, 1471Hoshino S, 633Hosomi Y, 3449Hotchkiss S, 2971Hotta K, 2915Hotta T, 11Hou JC-T, 929Hsia T-C, 1691, 3601Hsiao K-H, 1043


4804


4805

Hsieh S-C, 4301Hsieh Y-H, 4301Hsu C-F, 227, 2395Hsu C-H, 4007Hsu N-Y, 3475Hu N, 945Hua C-H, 227, 2395Huang Chao-Cheng, 293,

3633Huang Chien-Chung, 4007Huang C-L, 4619Huang C-Y, 293, 3633Huang Guangwu, 797Huang Guohui, 3165Huang K-C, 2773Huang M, 2045Huang S, 1321Huang S-M, 203Huang T-H, 3407Huang X, 771Huang Y, 3433Huang Y-T, 1691Huber K, 3273Huber RM, 849Hudacsko A, 2637Huebner CA, 459Hung C-F, 3497Hunter TB, 3193Huq F, 1131, 2757, 3789,

4283Hurwitz HI, 255Husøy T, 785Huszár A, 3051Hüttenberger D, 1982Huylebrouck M, 4457Hwang K-A, 2853Hydock DS, 2023Iacovelli R, 4219Iavazzo C, 3469Ibaragi S, 1307Iberer F, 1583, 3713Ibrahim SO, 3345Icard P, 797Ichikawa D, 67, 495, 2217Ichikawa Y, 1049Ichinose Y, 3449Ieni A, 1315Iida H, 1297Iino T, 4163Iizuka N, 3331Ijichi K, 2893Ikeda K, 1653, 3253Ikeda M, 507

Ikeda T, 501Ikoma H, 495Ikonomidou C, 565, 3181Imada T, 325Imai K, 3361Imai M, 2511Imamura CK, 4561Imamura Y, 991Improta G, 1359Inaba N, 1653, 3253Inaba S, 3995Inagaki D, 325Inagaki Y, 535Inagawa H, 2431, 2437,

2467, 2493Inaji H, 367Inamine M, 1437, 3527Inghirami G, 4401Inomata M, 4519Inoue A, 2999Inoue K, 3827Inoue M, 2441, 2447, 2999,

4665Inoue S, 2999Inoue T, 2527Inoue Y, 1653, 3253Iori F, 1933Iraha S, 3527Isaka K, 3063Isbir T, 2225Ise N, 4155Ishaq R, 2575Ishibashi K, 77, 777, 1289,

1293, 2249, 3377Ishibashi Y, 2499Ishibe T, 1297Ishida K, 1011Ishiguro S, 3463Ishihara M, 4231Ishihara M, 515Ishikawa D, 3361Ishikawa H, 287, 4625Ishikawa M, 4619Ishikawa S, 991Ishikawa T, 2483, 2553Ishiko O, 1271Ishinaga Y, 1427Ishioka C, 3719Ishitobi M, 367Ishitsuka K, 2483Ishizawa S, 3253Ishizuka T, 705, 933, 1459Ismaeel F, 2675

Isohata N, 2989Isowa S, 1307Ito H, 1011Ito R, 3361Ito S, 3463Ito T, 3035Ito Y, 3463Itoh M, 781, 893Iwabuchi Y, 3719Iwadate Y, 4475Iwagami S, 991Iwaki H, 1297Iwanami T, 1141, 4277Iwao H, 1741, 2297Iwasaki A, 2535Iwase S, 1483, 3567Iwase Y, 501Iwashita A, 2499Iwata M, 705, 1459Iwatsuki M, 991Iwazaki S, 287, 4625Izawa S, 2999Izumi K, 2389Izumi M, 287, 4625Izumi N, 2255Jaakkola PM, 311Jackson LN, 1153Jacobs JJL, 639, 699Jacobsen MB, 861Jacquemier J, 1079Jagota A, 2657Jahnke K, 317Jakob A, 825Jakobsen A, 1559Jalouli J, 3345Jalouli MM, 3345Jamnig H, 2949Jang S, 4393Jankevičius F, 699Jankowska R, 2833Jänne PA, 427Janni W, 2749Jansen FH, 4417Jansen N, 4417Janssen E, 443Janzen E, 3873Japink D, 1983Jaramillo S, 3019Jarkowski III A, 3429Jasinski P, 1181Javle M, 1417Jaworska-Posadzy A, 1453Jayaram HN, 2045

Jedinak A, 379Jenkner A, 3953Jensen BT, 2023Jensen K, 4491Jeon B-G, 4315Jeon C-H, 1161Jeon YJ, 4329Jeong JY, 4223Jeschke S, 2589Jeschke U, 451, 1983Jess P, 613Jethon A, 2833, 3027Jeung E-B, 1249, 2853Ji B-C, 1691Ji L, 11Jia F, 3143Jiang J, 687Jiang L, 2327Jiang M, 1321Jiang WG, 303, 467, 1703,

3205, 4115Jiang X-P, 2899Jin D, 3859Jin J, 2877Joh T, 763, 3353Johannsmeyer KD, 2657Johannson V, 3315Johnen H, 475Johnson CS, 1497Johnson M, 3559Johnson RW, 2705Jones G, 1493Jones GL, 2095Jonker DJ, 3921Joone GK, 825Joosens E, 1407Joraku A, 2065Joseph S, 3799Joshi G, 3851Ju S, 2045Juchems M, 4599Jueckstock J, 2749Juncos LA, 3267Jung A, 849Jung H-K, 575Jung JM, 575Jung S-A, 575Jutooru I, 3799Juzeniene A, 1502Kadomura T, 3983Kadowaki T, 2467Kage M, 2541Kageyama S, 1297

Kahán Z, 1431Kahkonen B, 2877Kahlert C, 1215Kai L, 3323Kaiga T, 1019, 2339Kaino S, 2103Kaira K, 2763Kaira K, 3775, 4075Kaiser I, 459Kaiserman I, 345, 351Kajita Y, 1297Kajiwara Y, 1567Kakeji Y, 3073Kakinohana Y, 3527Kakinuma S, 287, 4625Kalamanathan S, 2661Kalanxhi E, 2113Kalas W, 2869Kalden M, 2675Kaley K, 2971Kalickman I, 345, 351Kalinoglou N, 3469Kalofonos HP, 1677Kalogeris K, 1745Kalso E, 3493Kamano T, 705Kamatani T, 2841Kambara K, 881Kamei R, 4569Kametani Y, 3361Kamigaki S, 3035Kaminuma T, 2847Kamiura S, 3063, 4513Kamiya T, 3353Kamiya Y, 705, 1459Kamoshita N, 4625Kan S, 4569Kanai Y, 3775, 4075Kanakura Y, 113Kanamori N, 1019, 2339Kanazawa A, 325Kanda S, 597Kane CJ, 2939Kaneda H, 2787Kanematsu S, 3517Kanemitsu Y, 3463Kanetake H, 597, 2335Kang C-C, 129Kang E-J, 4315Kang H-Y, 1713Kang M, 961Kang M-J, 575Kang N-H, 2853

Kang Seokmin, 4223Kang SS, 4223Kang Sumin, 113Kanintronkul Y, 921Kanitakis J, 807, 2373Kanno A, 1011Kano J, 529Kanwar J, 1Kanz L, 4025Kao H-W, 4239Kapapa T, 4599Kaparelou M, 4259Karagiannis A, 1033Karameris A, 3093Karapanagiotou EM, 649Karashima R, 991Karihtala P, 1411Kashima S, 2173Kashiwagi S, 3369Kasimir-Bauer S, 2197, 3623Kasuya G, 3527Katada N, 2361Katano I, 3361Katano M, 2419, 2505, 3995Kataoka H, 763, 3353Katayose Y, 1011Kates RE, 4039Kato Ayako, 2915Kato Ayu, 3983Kato Takeshi, 4657Kato Tomoyuki, 3463Kato Toshihide, 3963Kato Yukihiro, 3369Kato Yutaro, 3983Katsambas A, 2373Katsifis A, 2883Katsube T, 2989Kaufmann Y, 215Kaun C, 3273Kauppila S, 1411Kautiainen H, 3493Kautio A-L, 3493, 4413Kawabata H, 1741Kawaguchi O, 3079Kawaguchi T, 1483Kawaguchi Y, 2999Kawaguchi-Ihara N, 781Kawahara A, 2517, 2541Kawai K, 2065Kawamura N, 3063Kawasaki G, 3521, 4429Kawase I, 4525Kawase M, 4231

Kawashima H, 11Kawate S, 287, 4625Kaytan-Saglam E, 2225Kazlauskaitė N, 639Ke H-L, 221, 1043Keese M, 2693Keilholz U, 317Kellermann U, 4195Kelley MR, 379Kelling K, 4359Kellogg Parsons J, 2939Kellokumpu-Lehtinen P-L,

4413Kelly KW, 249Kendler D, 4407Kenmotsu H, 3775, 4075,

4519Kenney B, 4397Keohavong P, 2877Ketonen L, 2265Khaddage A, 585Khafaga Y, 1721Khamaisie H, 177Khan M, 2699Khan R, 4393Khushalani N, 3429Kichikawa K, 3909Kieć-Kononowicz K, 3285Kiełbus M, 565Kiessling F, 2907Kigawa G, 77, 777, 1289,

1293, 2249, 2889, 3377,3835

Kijima K, 2889Kikuchi M, 3041Kikuchi R, 4619Kikuchi S, 2361Kilgore MW, 813Kim BJ, 4111Kim BS, 4329Kim C-K, 3385Kim DY, 4641Kim Han Jo, 3385Kim HC, 3843Kim Hee Jin, 4329Kim HN, 4347Kim Ho Jin, 4307Kim Hyun Joon, 4223Kim Hyun Jung, 3385Kim JC, 4329Kim J-H, 3767Kim JS, 3767Kim JW, 3237

Kim KH, 3385Kim N, 4223Kim S, 3767Kim S-E, 575Kim Seung U, 1249, 2853Kim Seung Up, 4641Kim SH, 3385Kim S-J, 3385Kim S-W, 3457Kim SY, 4329Kim T-H, 575Kim Y, 725Kim Y-B, 1249Kim Y-J, 4307Kim YS, 4329Kimmig R, 2197, 3623Kimura Hideharu, 4561Kimura Hiroaki, 3665Kimura M, 1653, 3253Kimura Tadashi, 4513, 4613Kimura Toshihiro, 4513,

4613Kinchington E, 2877Kinoshita I, 263Kinoshita S, 1395Kinugasa T, 2517, 2541,

2547Kioi M, 2893Kirschenhofer A, 1984Kirwan CC, 2383Kishimoto H, 3665Kisi T, 4339Kisiel W, 843Kiss A, 3573Kiss I, 3051Kiss R, 953Kitagawa Y, 3079Kitajima M, 3983Kitamura K, 1483, 3567Kitamura Y, 1289, 2249,

2889, 3377Kittaka A, 1500Kiura K, 3449Kiyota A, 2505Kiyota H, 4561Kizir A, 2225Kjellevold K, 443Klapdor R, 1984, 1985, 1986Klatka J, 565Klein A, 3733Klein MA, 3683Kleinschmidt S, 1541Kleiveland CR, 861


4806


4807

Klement RJ, 1987Klimberg VS, 215Kmiya Y, 933Knobloch TJ, 2683Knolle P, 4185Knuth A, 3115Knutsen HK, 785Ko S-G, 3301Ko Y-C, 1691Kobayashi E, 4613Kobayashi H, 1027Kobayashi I, 4625Kobayashi J, 287, 4625Kobayashi Masashi, 4525,

4619Kobayashi Mitsinobu, 287Kobierzycki C, 3027Kobunai T, 3691, 4147Kochi M, 1019, 2339Kodama S, 1307Kodera Y, 1643Koessner C, 3573Koestenbauer S, 1583, 3713Kofune H, 4251Kohama H, 2065Kohchi C, 2431, 2467Kohler C, 2623, 4267Kohyama K, 123Koike M, 1643Koizumi F, 2787Koizumi M, 2477Koizumi T, 299Kojima M, 3983Kokuba Y, 495Kokudo N, 535Kolb HC, 1987Kolodziej B, 1453Kolostova K, 1535, 3125Komatsu H, 501Komatsu S, 495Komatsu Y, 299Komiyama S, 495Komoike Y, 367Komori K, 3463Kondo C, 3535Kondo F, 2915Kondo H, 2461, 2763, 3775,

4075Kondo K, 4657Kondo N, 2477Kondo S, 2841Kondo Y, 4525Kong B, 3229

Kong X, 2327Königsrainer A, 4407Konishi T, 535Kono K, 2999Kono R, 549Konrad K, 1583, 3713Kontopidou F, 1467Kontos M, 831Kooi GS, 4043Kopeckova M, 4647Kopetz S, 1417Kopij M, 2869Kopp H-G, 4025Koriyama C, 3607Korkeila EA, 311, 4529Korkolopoulou P, 3585Korlach S, 2589, 2609, 2617,

2645, 2651Kormunda S, 1447Kornmann M, 4599Kortmann R-D, 661Koryllou A, 4291Koskas M, 3047Koskinas J, 1467Koskinen MJ, 4413Kotake T, 2255Kothan S, 4067Koto M, 33Kotoula V, 3007Kottorou A, 1677Koukourakis MI, 1745Kourea HP, 3007Koutras A, 3007Koutsilieris M, 4259Kovacs K, 2283Koya N, 2505Koyama A, 4561Koyama H, 367Koyanagi M, 2453, 2535Koyano T, 287Kozako T, 4251Kozawa E, 123Kraemer B, 4423Kramm CM, 661Kranenburg O, 1379, 4507Krasagakis K, 807Kratzik C, 3615Krause FS, 985Krause R, 1502Krauss K, 4025Krawczyk N, 4423Kresty LA, 2683Kreuzberg B, 339

Krippl P, 1373Krishnamoorthy S, 4397Krockenberger M, 1987Krohn V, 59Kronenberger C, 2657Kruck S, 2053Krueger T, 2121Krüger C, 1508Krüger-Krasagakis S, 807Krukemeyer MG, 3903Krūmiņa G, 1421Ku BM, 4223Kuang Y, 427Kubicka M, 1453Kubo K, 299Kubodera N, 1500Kubota E, 105, 3353Kubota K, 3983Kubota T, 67, 2217Kučera R, 3619Kucera R, 4031, 4653Kudaka W, 1437, 3527Kudo C, 3719Kudo K, 2787Kudo S, 3449Kudo T, 2255Kuehs U, 3783Kuemmel S, 2669Kuemmerle A, 2121Kuge T, 1647Kuhara H, 4525Kuhn C, 451Kujawa K, 3027Kulda V, 4031Kuliczkowski K, 2963Kulikowski GN, 1093Kumamoto T, 1055Kumar A, 897Kumar BM, 4315Kumar D, 1795Kummar S, 961Kümmel S, 2569, 2575,

2589, 2609, 2617, 2645,2651

Kunami N, 2483Kunisaki C, 325, 1055Kupisz K, 565Kuramitsu Y, 1259, 2059,

2103, 3331Kurashige J, 991Kurihara Y, 2841Kurio N, 1197, 1307Kuriu Y, 495

Kuroda J, 3983Kuroda Y, 1483, 3567Kurokawa T, 3991Kurokawa Y, 3085Kuroki H, 3995Kuroki Masahide, 2453,

2425, 2461, 2483, 2499,2527, 2535, 2553

Kuroki Motomu, 2425Kushida T, 1241Kusumoto T, 4481Kusuzaki K, 4163Kuttesch J, 2265Kuwada E, 881Kuwano H, 3963Kuwata T, 4631Kvols LK, 2957Kwack D-O, 4315Kwon A-H, 3517, 3827Kydlicek T, 4653Kyo S, 2441, 2447Kyoda S, 1395Kyrgias G, 1745Kyrtopoulos SA, 4291Kyrtsonis M-C, 3585La Sala GB, 681Laatio L, 1411Labombardi V, 959Lacetera V, 1917, 1925Lackland DT, 3891Lackner J, 3615Lacola V, 3913Lacquaniti S, 1848Lage H, 711, 2963Lahouassa R, 1509Lai HC, 4111Lai L-J, 1173Lai M-W, 2037Lai SY, 2893Lai T-Y, 2821Laino L, 4211Lambaudie E, 3047Lambert J, 3697Lamerz R, 1988Lan C, 4135Lan J, 797Lanciotti M, 1880Landas S, 929Landt S, 2569, 2575, 2589,

2609, 2617, 2645, 2651Lane H-Y, 3511Lang H, 825Lang JC, 2683

Lang S, 3151, 3315Langle F, 4605Langsenlehner T, 1373Langsenlehner U, 1373Lanzi F, 1920Lasano S, 4347Lasaponara F, 1829Latinwo LM, 2017Lautrette C, 139Lavoue V, 4469Laytragoon-Lewin N, 1527Le Bot R, 4141Le Bris M-J, 1007, 3441Le Mercier M, 4457Lea MA, 421Leber B, 1583, 3713Lederle W, 2907Lee C-C, 2037Lee Dae Ho, 3457Lee Dong Hoon, 4223Lee EY, 1153Lee H, 3475Lee HJ, 2135Lee H-S, 1161Lee H-Z, 3601, 4301Lee JE, 3767Lee J-H, 2179Lee J-S, 3457Lee K-D, 1161Lee KT, 3385Lee KY, 4307Lee LJ, 771, 1619Lee N, 3385Lee RJ, 771, 1521, 1619Lee S-C, 3385Lee SH, 4307Lee SJ, 2135Lee U, 105Lee WY, 3843Lee Y-H, 4007Lee Y-J, 3407Lee YK, 4223Lee Y-M, 4315Leers MPG, 1988Lefranc F, 953Lehner J, 1989Lehnerdt G, 3151Lehrer S, 959Lekka C, 3469Leminen A, 3493Lemke J, 4599Lemound J, 2313Lenner P, 4267

Leobon S, 3865Leong J, 481. 1659Lerch T, 1989Leszinski G, 1989Levenson AS, 3323Leveque D, 1765Leveque J, 1783, 4469Levidou G, 3585Levy M, 373Lewin F, 1527Lewis MR, 3143Li B, 1495Li C, 2029Li D, 529Li F-J, 3511, 3629Li G, 11Li H, 2149Li Jie, 3229Li Jin, 1703Li Junan, 2683Li L, 3229, 3423Li M, 3595Li P-K, 2029Li QQ, 3423, 3433Li W, 3945Li W-T, 3407Li Xiaodong, 687Li Xiaoyuan, 2327Li Y, 1105Liang H, 3433Liang K-H, 2037Liao S-K, 129Liao Z, 2141Lichtenegger W, 2583, 2589,

2645, 2651, 2679Lien C-Y, 2023Liguori G, 1873Limmer A, 4185Lin C, 3859Lin C-C, 745, 2395, 3629Lin Chih-Hsueh, 3511, 3601Lin Chun-Hsuan, 3475Lin H, 3433Lin H-H, 221, 1043Lin HQ, 2883Lin H-Y, 2821Lin J, 2029Lin S-H, 481, 1659Lin T-W, 4239Lin W-C, 4239Lin YC, 481, 1659Lin Y-H, 3633Lin Z-Z, 4007

Linares V, 3607Lincet H, 797Lindebjerg J, 1559Lindhorst D, 2313Linhardt RJ, 4067Lipson BL, 249Lisi D, 1399Liska V, 339, 1447, 1990,

4031Littlefield BA, 2773Liu A, 2029Liu C-J, 3601Liu C-T, 3939Liu D, 2265Liu F-T, 2805Liu H, 2713Liu J, 2773Liu J-Y, 481, 1659Liu L-C, 3511Liu M, 3859Liu SV, 3897Liu Xianzhe, 1115Liu Xiaoping, 2877Liu Xiyong, 3475Liu Y, 3673Liu Yan, 2029Liu Y-F, 3629Liu Ying, 1521Liu Y-W, 3633Liu YY, 1443Liu Y-Y, 293Ljungman P, 939Lledo G, 359, 2271Lloyd RV, 2283Lo Monte AI, 1930Lo Muzio L, 4211Lo Rizzo C, 3973Lo W-C, 221, 3601Lo Y-H, 789Loew JE, 2723Löfdahl H, 2187Löffler N, 2931Lohr F, 1023, 3873Lohri C, 3115Longerich T, 3883Longini M, 3973Longo F, 1845, 4219Lopes C, 1637Lopes N, 1494Lopez A, 2191Lopez E, 3401Lord R, 2661Lorenz J, 3289

Lorusso D, 3381Lorusso F, 1932Lotrecchiano G, 1851Loum E, 139Loyola AM, 2805Lu C-C, 2821Lu D, 725Lu H, 3705Lu K-T, 203Lu L, 1Lu Y, 797Lucarelli G, 1896Lucianò R, 3069Luckett M, 1577Lucot JP, 3047Luddy KA, 3193Lüdecke G, 1991Luebbers CW, 3315Luethy A, 3115Lüftner D, 317, 2617Lui E, 907Luisetto G, 3969Luiten RM, 3697Luk F, 1147Lukas P, 4407Luksch H, 565, 3181Lumachi F, 693, 2923, 3879,

3969Lunglmayr G, 3615Luo G, 3595Luo W, 2303Luo Z, 3433Luton D, 3047Lv S, 4457Lyer St, 1991Lyn-Cook BD, 3171Lyu P-C, 4239Ma C, 481, 1659Ma T, 2327Mabuchi M, 763Maccagnano C, 1854Macchione N, 1839Macdonald K, 1407Macera CA, 2939Machado HR, 1337Macher-Göppinger S, 1215Machida T, 2453, 2535Maciejczyk A, 711Mack B, 3315Mack C, 4423Madelenat P, 3047Madroszyk A, 1079Maeda H, 4665


4808


4809

Maeda Kazuhiko, 2553Maeda Kazunari, 4569Maeda M, 1427Maeda N, 4569Maeda Y, 4569Maehara Y, 3073Maekawa T, 2499Maeng G-H, 4315Maffezzini M, 1948Mafune K-I, 535Maggioni M, 1824Magnani T, 1946Magnoni C, 2209Mahajan A, 2265Mahajna J, 177, 1607Maher DM, 897Mahlstedt J, 1503Mahner S, 1992Maier JAM, 3401Maindrault-Goebel F, 2271Maines F, 1905Maitra A, 907Majeed M, 907Makimura C, 4561Makino T, 1241Makishima M, 3839Makita F, 287, 4625Makuuchi H, 3361Malafa M, 2191, 4387Malaponte E, 4553Malik R, 3921Malizia M, 1919Malki A, 871, 1345Malo N, 2303Manabe S, 2483Mancini R, 4207Mandai H, 1307Mandato VD, 681Mandic R, 59Mangel L, 1769Mangialardo C, 89Mangolini A, 1816Manimala NJ, 3193Mankin H, 1115Manoel-Caetano F, 1685Manome Y, 1395, 1653, 3253Mansel RE, 1703Maráz A, 1431Marchesi P, 2923Marchioro G, 1907Marek E, 3051Marenghi C, 1944Maresch J, 2379

Margari C, 1033Marichalar-Mendia X, 677Marin B, 3865Mariniello A, 2291Marino F, 693, 3879Marino L, 1872, 1873, 1905Marino R, 1948Mariotta S, 4207Markowski DN, 753Marnerides A, 3585Márquez M, 4141Marschke KB, 2303Marsh J, 2773Martano M, 4211Martignoni G, 3137Martin G, 1877Martin TA, 467Martinesi M, 4091Marton S, 1769Martorana G, 271, 1949,

3503Maruyama N, 705Maruyama T, 2999Marzahn J, 565, 3181Masaki Y, 1741, 2297Masamune A, 1011Mascaux C, 281Masieri L, 1879Masin D, 2161Mason MD, 467Mastorakos G, 3469Mastronuzzi A, 3953Masuda M, 325Masuda N, 3449Masuda T, 2983Materna V, 2963Matheisen N, 1992Matkowski R, 711Matschke J, 591Matsubara T, 4163Matsui K, 3449Matsui T, 2499Matsumine A, 4163Matsumoto G, 105Matsumoto Kazuko, 2787,

4561Matsumoto Kotaro, 3995Matsumoto Kunio, 1279,

2217Matsumura Akihide, 4665Matsumura Atsushi, 2217Matsuno Y, 263Matsuo K, 1049

Matsuo T, 2335, 4465Matsuoka H, 4561Matsuoka J, 3369Matsushita K, 4251Matsutani T, 4475Matsuzaki S, 4613Matsuzaki T, 3369Mattheis S, 3151Maubon A, 3865Maurer BJ, 961Maurer G, 3273Mauricas M, 639, 699Mavropoulou S, 1745May MT, 1577Mayer F, 4025Mayr D, 451Mayrbaurl B, 4439Mayrhauser U, 1583, 3713Mazur G, 2963Mazza M, 1902Mazzeo F, 1407Mazzini G, 3727Mazzio E, 3739Mazzotta M, 4211McCollum CN, 2383McDowell G, 2383McLennan G, 2045Meert A-P, 281Meglasson MD, 2303Meister M, 4491Mekada E, 2553Melchiorre F, 3927Melegari S, 1896, 1897Mendelson DS, 625Menen RS, 3125Meng Z, 2141Merdad A, 97, 2975Merger M, 2271Meriaty H, 2883Merkel AR, 2705Merrouche Y, 359Mesbah H, 1783Meschenmoser K, 725Meszarosova A, 4647Metaxari M, 807Meyer A-S, 3219Michienzi S, 89Michiura T, 3827Michotte A, 4457Micke O, 1993, 1994, 1995Midasch O, 1507Miele L, 1105Migliorini F, 1071, 3913

Mihara Y, 1019, 2339Mihu CM, 2637Mihu D, 2637Mikalsen LTG, 4053Miki M, 1741, 2297Milano G, 359Milas L, 2141Miliaras D, 3007Milioudis N, 1745Milk N, 913Miller CP, 1189Miller WH, 3143Millington DJ, 3739Mills M, 4393Mimori K, 507Mimura K, 2999Min B-S, 2179Minarik M, 4647Minato N, 1027Mininno M, 3213Minniti G, 3555Miotto D, 2923Mirchandani D, 4401Mirka H, 339Misawa K, 3463Mischo A, 3115Misciagna G, 555Mishima H, 4657Misiti S, 89Mitsudo K, 2893Mittelmeier W, 1235Miyagui J, 3607Miyaki A, 2989Miyako H, 3361Miyamoto K-I, 4339Miyamoto S, 2461, 2483,

2553Miyashita A, 495Miyashita K, 1427Miyata K, 2553Miyata Y, 597, 2335, 4465Miyazaki J, 2065Miyazaki T, 1019Miyazawa M, 2989Miyoshi Y, 4613Mizokami A, 2927Mizoshita T, 3353Mizota A, 3535Mizue Y, 2511Mizukami H, 777, 1289,

2889Mizuki M, 113Mizumoto K, 1279

Mizumura K, 2129Mizuno A, 3521, 4429Mizushima T, 507Moan J, 1502Mochizuki H, 1567Moerman P, 2367Moertel S, 665Mohr SB, 2939Mohri K, 4231Mok I, 1417Mokbel K, 23, 4115Molina R, 1995Molina V, 1996Molkentine D, 2141Molls M, 3935Molnár J, 1431, 3285, 4201Moltrasio F, 4485Mombelli G, 1924Momose Y, 501Monaco C, 1071, 3913Monaco F, 1868Monaco F, 3555Moniri MR, 3705Montagna B, 3927Montanari M, 1860Monteil J, 3865Moon DH, 2135Moon IH, 575Moran MS, 2327Mordelt K, 2651Morel F, 1007, 3441Morelli MP, 1093Moreno CS, 403Moreno DA, 1337Mori M, 507Mori Y, 3353Moriggi G, 89Moriguchi M, 3991Morikawa T, 1395Morimoto A, 4613Morimoto J, 1225Morimoto M, 2389Morinaga S, 325Morini D, 2209Morioka T, 2351Morisaki T, 2419, 2505, 3995Morishita N, 4525Morishita Y, 529Morita A, 763Morita H, 3963Morita M, 3073Morita S, 3035Moriya T, 2389

Morse MA, 255Mössner J, 3289Motohashi N, 515Motomura K, 367Motoo Y, 2297Motoyama T, 171, 1211Motta R, 2923Mousa SA, 411Mouzaki A, 1677Mucciardi G, 1941Muecke R, 1996Muermans K, 1407Muggia F, 4401Mukensnabl P, 4647Mukudai Y, 2841Muley T, 4491Mulherkar R, 3851Muller C, 3115Müller CSL, 1509Mundy CW, 2073Mundy GR, 2705Muñoz A, 1492Muñoz A-B, 4191Murakami H, 2763, 3775,

4075, 4519Murakami K, 2103, 3353Murata S, 2893Murawa D, 711Murayama M, 2989Murayama S, 1437, 2351,

3527Murayama Y, 495, 2217Murgo AJ, 961Muro K, 3535Murohashi I, 781Murotani K, 2547Murtha A, 3559Musa MA, 2017Muszczynska-Bernhard B,

2833Muto Y, 4481Muzzio PC, 4581Myojo S, 2447Mytar B, 1329Nagai T, 2787Nagai Y, 991, 1437, 3527Nagamatsu I, 2505Naganaboina VK, 2083Nagano Y, 1049, 1055Nagao T, 2389Nagaoka R, 3041Nagarkatti M, 4099Nagarkatti P, 4099

Nagasaka M, 705, 933, 1459Nagata N, 4657Nagata T, 495Nagata Y, 4631Nagayasu T, 4545Nagumo T, 2841Nagumo Y, 1483, 3567Nair V, 2699Naito K, 999Naito T, 3775, 4075, 4519Najajreh Y, 177Nakagami K, 287, 4625Nakagawa Kazuhiko, 4561Nakagawa Kazuo, 4075Nakagawa Makoto, 1141,

4631Nakagawa Misako, 2389Nakagawa Yoshihito, 705,

1459Nakagawa Yoshinori, 2489Nakahara S, 367Nakai H, 731Nakajima A, 1741, 2297Nakajima H, 2297Nakajima T, 2763, 3775,

4075Nakajima Y, 3909Nakamura K, 1259, 2059,

2103, 3331Nakamura M, 705, 933Nakamura Masakatsu, 1459Nakamura Mitsunari, 3995Nakamura O, 549Nakamura S, 287Nakamura Takahiro, 2217Nakamura Takashi, 1297,

2065Nakamura Takuji, 1741, 2297Nakamura Tomoki, 4163Nakamura Toshikazu, 2217Nakamura Y, 4519Nakanishi M, 495Nakanishi T, 3063Nakano T, 2847, 3963Nakao A, 1643Nakashima M, 4251Nakashima Y, 3073Nakata E, 2477, 2489Nakata K, 2437Nakata M, 535Nakaya A, 2065Nakaya K, 1647Nakayama G, 1643

Nakayama T, 3035Nakazawa H, 1027Nam RK, 403Nam SJ, 3767Nam SO, 2553Nambara D, 4155Namiki M, 2927Nanashima A, 4545Nano R, 3727Naomoto Y, 1197Nara N, 781, 893Narayanan B, 4347Narayanan NK, 4347Naritaka Y, 2989Narsanska A, 339, 3619,

4653Naruse T, 4429Nasir A, 2073, 2191Nasir NA, 2957Nassiri F, 2283Nassos P, 1745Natarajan M, 161Necozione S, 671Negro-Vilar A, 2303Nehme E, 4637Nehoda H, 4407Nemoto H, 77, 777, 1289,

1293, 2249 2889 3377,3835

Nemoto M, 2361Neri F, 1910, 1908Nesi G, 1789, 2187, 4091Nesland JM, 4053Nessa MU, 3789Neubauer A, 2343Neuhaus P, 2583Newbold RF, 4115Newton-Bishop JA, 1498Neyns B, 3579, 4457Nezos A, 4259Ng S-C, 2303Nguyen MP, 2705Nguyen NP, 4393Nicol F, 2693Nicolazzo C, 4219Nicolle E, 3213Nieder C, 561, 1735, 3935Niho S, 3449Nijkamp MW, 4507Nilsson R, 2187Nilsson S, 4141Nimzyk R, 753Nishi H, 501


4810


4811

Nishi K, 501Nishi R, 2863Nishida H, 2927Nishiguchi H, 999Nishijo K, 1297Nishimaki T, 2351, 3527Nishio K, 2787, 4561Nishio M, 495Nishiofuku H, 3909Nishiyama H, 2065Nitori N, 3983Nitsios I, 2373Nixon AB, 255Noda S, 3369Nogata H, 2999Noguchi K, 881Noguchi M, 529Noguchi S, 3035Nojiri K, 1049, 1055Nolte I, 1541Nomoto K, 2773Nomura M, 1653, 3535Nong J, 3705Nonogaki S, 2805Norberto L, 693Norca J, 1783Norton R, 1499Norum J, 1735Nose K, 2255Notarnicola M, 555, 3381Noto A, 4207Nowak M, 725Nowak-Markwitz E, 711Nucciotti R, 1829Nyberg P, 3659O’Hanlon D, 1627O’Sullivan GC, 1627Obayashi Y, 4339Oberhoff C, 3623Obrist P, 4439Ochiai K, 3063Ochiai T, 495, 2217Ock S-A, 4315Ocsovszki I, 3285Ocvirk J, 1777Odagiri H, 1483, 3567Odawara H, 3041Odawara T, 2483Oderda M, 1830, 1870Odin E, 3057Oehr P, 2013Oertl A, 1997Öfner D, 4407

Ogata T, 633Ogawa Kazuhiko, 1437,

2351, 3527Ogawa Kenji, 2989Ogawa Tetsushi, 287Ogawa Tetsuya, 2893Ogino K, 3361Ogino T, 2505Ogose A, 11Ohashi N, 1643Ohba K, 597, 2335, 4465Ohde Y, 2763, 4075Ohga T, 3073Ohi H, 763Ohira M, 3369Ohkura K, 2561Ohlinger R, 4039Ohmichi M, 3063Ohmura T, 2527Ohnishi T, 2389Ohno S, 2441, 2447Ohno Y, 2441Ohori H, 3719Ohta M, 4665Ohta T, 2447Ohta Yasuyuki, 2447Ohta Yukinobu, 4513Ohtsuka T, 1279Ohuchida K, 1279Oh-Uchida Y, 2983Ohya T, 287, 4625Oikonomopoulos G, 649Oizumi H, 171, 1211Oka M, 3331, 4569Oka S, 4277, 4631Okabe K, 543, 2983Okabe T, 4625Okada Akihiro, 3983Okada Alan, 2511Okada F, 1259Okada H, 2511Okada N, 2511Okaichi K, 2255Okamoto K, 67, 495, 2217Okamoto M, 2241Okamoto N, 4525Okamoto T, 1395Okamoto Y, 3353Okamura H, 67Okamura S, 67Okamura Y, 999Okazawa M, 4513Oki E, 3073

Okita K, 3331Okubo K, 4619Okubo M, 705, 933, 1459Okudaira K, 501Okuhashi Y, 781, 893Okui T, 1197Okulicz K, 3151Okumura M, 4665Okumura T, 2763, 4075Okuno Y, 2553Okuyama Y, 4657Oliveira PA, 1637Ollonen P, 739, 1065, 1801,

3101, 4013, 4019Olsen DR, 4053Omi K, 4155Omi Y, 105Onaka K, 2477Onda K, 4169Onimaru M, 1279Onishi H, 2419, 2505, 3995Onishi T, 1471Onitsuka T, 855, 1141, 2995Onizuka S, 2489Ono A, 4519Ono F, 2511Ono K, 2477Onodera K, 501Ørbo A, 2319Ordonez P, 3607Oremek GM, 1997Origuchi N, 3983Oriuchi N, 3775, 4075Orlow SJ, 3259Orrego A, 2187Orsós Z, 3051Ortega A, 421Osada S, 4589Osaka Y, 633Oshima T, 325, 2915Oskay-Özcelik G, 2583, 2679Osti MF, 3555Ota F, 999Ota M, 1049Ota T, 2453, 2535Otsuji E, 67, 495, 2217Otsuka Masatomo, 4561Otsuka Masayasu, 113Otsuki Y, 1225Ott OJ, 985Ottria R, 3401Ou Y-C, 3497Oura S, 999

Ouyang H, 1321Ovarian Cancer (EKZE

Berlin), 2583Owston M, 2187Oyama T, 1141, 3041, 3079Paesmans M, 281Paganin-Gioanni A, 4083Pagano M, 4401Palakurthi S, 897Palazzo A, 4219Palermo S, 1823Pálföldi R, 1431Pall G, 2949Palloni T, 1882Palma PVB, 2173Palmeri R, 3069Palmieri C, 1367Palmieri F, 1823, 1834Palminteri E, 1832Palomino LF, 1637Pan E, 4537Pan Z-M, 3423Panaia R, 1923Panayiotidis P, 3585Panebianco V, 1399, 4553Pang H, 255Pangalis GA, 3585Pannone G, 4211Panoussi A, 3469Pantel K, 1997Panteleakou Z, 4259Panteliadou M, 1745Paoli G, 3973Paolini A, 3727Papadaki H, 1677Papadimitriou C, 3007Papadopoulou A, 1745Papageorgiou A, 831Papageorgiou M-V, 1467Papagerakis S, 4211Papakostas P, 3007Papaleo A, 1920Papandreou CN, 3007Papanikolaou G, 2603Papazisis KT, 3007Papp A, 1769Pappagallo GL, 1872Pappi V, 3585Parisi A, 4553Park B-W, 4315Park HS, 3385Park JB, 4307Park JS, 4111

Park JY, 4641Park SK, 3385Parolini C, 3137Parziani S, 1890Pasi F, 3727Pasini F, 3543Passariello R, 1399Pastore AL, 1837Pašukonienė V, 639, 699Patani N, 4115Patel S, 3559Patrinou-Georgoula M, 4291Patsouris E, 3585Patta A, 975Pattanapanyasat K, 921Paule B, 331, 3507Pavlik R, 451Pawade J, 1577Paz K, 2149Pazdiora P, 3619, 4653Pázsit E, 3051Pe’er J, 345, 351Pecen L, 373, 1447, 3619,

4031, 4653Pecher G, 4195Pecher G, 475, 1169Pectasides D, 1467, 3007Pehl C, 2931Pellucchi F, 1852, 1853Pelofy S, 4083Penate-Medina O, 3659Peng H-Y, 1667Penney R, 2971Pentheroudakis G, 3007Peoc’h M, 585Pepe P, 4445Perchellet EM, 2083Perchellet J-PH, 2083Perdonà S, 1918Pereira MA, 3279Perez J, 2813Perillo L, 4211Pernetti R, 271, 1849, 3503Perrine SP, 2723Perugia G, 1856Pesek M, 3619, 4031, 4647Pessin-Minsley MS, 959Pesta M, 1447, 3107, 4031Petracca A, 4219Petraki K, 3007Petralia G, 1842Petrongari MG, 1928Petrozziello A, 1071, 3913

Pettersen I, 2319Pfab G, 2749Pfister DG, 249Pflüger H, 3273Philippou A, 4259Phillips L, 1577Phillips PG, 411Pi GE, 395Pi Z, 1321Piazze J, 671Picozzi S, 1934Pierantoni GM, 4211Pietsch T, 661Pietzner K, 2603, 2669,

2675, 2679Pike JW, 1491Pinney E, 3125Pinski J, 3897Pinterova D, 1535Piotrowska A, 2833, 3027Pircher A, 2949Pirillo D, 681Pirrelli M, 555Pissimissis N, 4259Pitts TM, 1093Pizzirusso G, 1838Pizzocaro G, 1940Pletsa V, 4291Plinkert PK, 81, 185Pluschnig U, 2379Plyta S, 3469Pneumaticos SG, 4259Podhorska-Okolow M, 2833,

3027Poellinger A, 2597Poggi G, 3927Pogorzala M, 1453Pohlen U, 147, 153Polberg K, 565Polo Padillo J, 3019Polterauer S, 2259Pommeri F, 4581Pontoriero A, 1888Porcaro AB, 1071, 3913Poree P, 1783Portugaller RH, 1583Possinger K, 2713Post S, 2693Potenberg J, 2657Poulain L, 797Pozsgai E, 1769Pradier C, 1783Pramanik D, 907

Prati V, 1871Prazakova M, 3107, 3619,

4031Prewett M, 2149Prezas P, 3093Prezioso D, 1846Pries R, 3819Priftakis P, 3489Procopio G, 1831Proietti F, 3973Pschowski R, 2629Pudelko M, 711Puget G, 1599Puistola U, 1411Pula B, 2833, 3027Pultrone CV, 1884Punt CJA, 1379Purohit A, 1367Pylväs M, 1411Pyrhönen S, 311, 4529Qamar S, 3247Qin K, 3705Qiu D, 2773Qu X, 3229Quaretti P, 3927Quartier E, 4457Quay E, 3259Queiroz RG, 1337Quon H, 3559Raats DAE, 1379Racchiusa S, 3069Rack B, 2749Radpour R, 2623Rafinska-Kurylo B, 1453Rahal P, 1685Rahdon R, 1443Raica M, 1757Raimondi C, 4219Rajah TT, 209Rajendran S, 1627Rajput A, 387Raju U, 33, 2141Rak J, 2869Ramachandran K, 3757Ramos DM, 1205Ramos J, 4397Ramqvist T, 1515, 3489Rana M, 2313Rancati T, 1927Ranjan AP, 907Rank A, 1998Ranta T-M, 3659Rapak A, 2869

Rashid G, 3733Raspollini MR, 1921Rau K-M, 1713Ravage-Mass L, 625Ravo V, 1866Rayat S, 2083Razis E, 3007Rea S, 671Rebersek M, 1777Rebischung C, 359Recchia COC, 671Recchia F, 671Reddavide R, 555Reed MJ, 1367Rega G, 3273Regierer A-C, 2713Reichrath J, 1498Reifenberger G, 725Reinke P, 2629Reinthaller A, 2259Renaudie J, 3865Renner C, 3115Renner W, 1373Renninger M, 3783Repana D, 3007Restrepo-Angulo I, 1265Reszka R, 147Reunanen J, 3659Reuter C, 2609, 2645Rey-Barja N, 677Reynolds CP, 961Rezai M, 2569, 2575Reznick AZ, 1607Rho G-J, 4315Ribatti D, 1757Riccardi A, 3927Ricci A, 4207Richter E, 1998Richter R, 2583, 2657, 2679Riebe C, 3819Riesterer O, 33Rigal C, 2813Ring A, 4061Ríos-Moreno MJ, 3019Ris H-B, 2121Risatti CA, 2773Roa W, 3559Rob L, 1765Rocca BJ, 1866Rocchini L, 1853Rocco B, 1883, 1884Rochel N, 1492Rödel C, 985

4812



4813

Rodrigues ES, 2173Rodriguez-Tojo MJ, 677Roh GS, 4223Roh SA, 4329Rokutanda N, 3041Rolinski B, 1999Romano M, 1071, 3913Romeo A, 1877Romeo K, 2517, 2541, 2547Romeo P, 4553Roncella S, 1061Roppongi T, 287Roscigno M, 1840, 1841,

1842Rosell J, 1599Rosen LS, 625Rosenzweig KE, 959Roses DF, 4401Rossi T, 2209Rothmund R, 979, 4423Rotondo F, 2283Rousseau R, 2813Roux S, 3865Rouzier R, 4469Rozen WM, 1443Ruan P, 1321Ruat S, 3047Rubenstein M, 487Rubilotta E, 3913Rubin J, 3489Rubio CA, 1789, 2187Ruchirawat S, 921Ruegg C, 3115Ruge F, 3205Rullo R, 4211Russ G, 4439Russell Jr LH, 3739Russo D, 1915Rustum YM, 387Ruthardt M, 177Rutigliano M, 1892Rutkowski S, 661Rutqvist LE, 1527Ryoo S, 2179Ryozawa S, 2103Rys J, 3027Rytting M, 2265Ryu J, 4223Ryu Y, 2517, 2541, 2547Rzeski W, 565Saarto T, 3493, 4413Sadahiro M, 1211Sadones J, 4457

Saeki H, 3073Saeki N, 4475Safe SH, 3799Safranek J, 3107, 4031Safyan RA, 4401Saga T, 1549Sagara Y, 2335, 4465Sager G, 2319Saif MW, 625, 649, 1039,

2971, 4397Saikawa Y, 3079Saini SS, 3683Saito Hidetsugu, 1653, 3253Saito Hiroko, 2915, 4339Saito J-I, 3963Saito K, 625Saito M, 77, 777, 1289, 1293,

2249, 2889, 3377, 3835Saito Y, 1653, 3361Sajjad M, 411Sakagami H, 515, 1241, 4231Sakaguchi H, 3909Sakai Hideki, 597, 2335,

4465Sakai Hiroshi, 3449Sakai K, 2787Sakai T, 1741, 2297Sakaida I, 2103, 3331Sakakura C, 495Sakamoto A, 1395Sakamoto I, 287, 4625Sakamoto J, 3035, 4657Sakashita S, 529Sakata M, 2889Sakuma S, 763Sakuraba K, 77, 777, 1289,

1293, 2249, 2899, 3377Sakuraba M, 1427Sakurai K, 3839Sakurai Y, 2477Sakuramoto S, 2361Salama S, 4179Salehin D, 1494Salmon I, 4457Salo T, 3659Samadder P, 3809Samakoglu S, 2149Samaras P, 3115Samonigg H, 1373Samuel T, 233Samulitis BK, 2781Samura H, 3527San Martin ID, 387

Sanada Y, 77, 1289, 1293,2249, 3377, 3835

Sánchez-León M, 3019Sánchez-Torres C, 1265Sand L, 3345Sanders AJ, 303Sanders JM, 2303Sanguedolce F, 4211Sano O, 2983Sano T, 3463Sanseverino R, 1908, 1909,

1911, 1940Sant’Ana JM, 2805Santi R, 4091Santo M, 4525Santoro A, 4211Santos L, 1637Sanui A, 2553Sapkota D, 3345Saraswati S, 1999Saris PEJ, 3659Sarkar FH, 1105Sarkar S, 2723Sartori Chr, 2000Sasa M, 2389Sasada S, 4525Sasaki A, 1197, 1307Sasaki Kanji, 549Sasaki Kazunari, 2527Sasaki Kenji, 3839Sasaki S, 3361Sasaki Takeshi, 1471Sasaki Tomikazu, 4111Sasazuki T, 2453, 2535Sato Atsuko, 3719Sato Ayako, 3041Sato M, 2129Sato T, 325, 529, 2297Sato Y, 287, 2847, 4625Satoh K, 1011Satoi S, 3827Satonaka H, 4163Sauer R, 985Sauter G, 2000Sava T, 1071, 3913Sawada D, 1501Sawada T, 3369Sawaki T, 1741, 2297Scaldaferri F, 4273Scardigno M, 3069Scattoni V, 1861, 1862Schade AE, 2073Schaffran A, 4061

Schallier D, 1753Scharf JP, 2657Schatzl G, 3615Schauwecker J, 1235Scheckenbach K, 3151Schefe J-H, 2713Schefold JC, 2629Scheithauer BW, 2283Schemmer P, 3883Schepp W, 2931Schiavina R, 1949, 1950,

1951Schill S, 561Schilling1 G, 1963Schimanski CC, 2797Schindlbeck C, 2749Schirmacher P, 1215Schlenker T, 459Schlomm T, 2001Schmid P, 2589, 2617Schmidt SC, 2603Schmidt T, 2931Schmidtler F, 2931Schmidt-Wolf IGH, 725Schmieder K, 1023, 3873Schmitt B, 3315Schmitt M, 1235, 2343Schmitt S, 1Schmittel A, 317Schmitz I, 4061Schmuck RB, 2675Schnabel PA, 4491Schnakenberg E, 2001Schnapauff D, 2597Schnegelsberg B, 1589Schneider CM, 2023Schneider J, 4191Schneider T, 2001Scholz C, 451, 2713Schönknecht CE, 3935Schoppmann A, 4605Schoppmann SF, 2379, 4605Schork NJ, 2303Schramm M, 53Schröder T, 4141Schroeder JK, 2669Schroeder KN, 3819Schueller J, 3573Schuler P, 3151Schuller DE, 2683Schulten H-J, 4179Schulz C-O, 2713Schumacher U, 1589


4814

Schwab JH, 1115Schwarzlose-Schwarck S,

2713Schwidde I, 2609, 2651Sciarra A, 1399Scognamiglio U, 2291, 3977,

4575Scopa C, 1677Scorilas A, 3093Scozzi D, 4207Scrideli CA, 1337Sculier J-P, 281Seffert P, 585Segala D, 3137Sehouli J, 1387, 2569, 2575,

2583, 2589, 2597, 2603,2609, 2629, 2645, 2651,2657, 2669, 2675, 2679

Seidl H, 2931Seiz M, 1023, 3873Sekimoto M, 507Sekine F, 2733Selle F, 4469Senda Y, 3463Seo HS, 3301Seo J, 2179Sergeev IN, 1494Serkova NJ, 1093Serra A, 3953Serretta V, 1817, 1818Sertel S, 81, 185Seshadri M, 387Sesterhenn AM, 3959Seth A, 403Seto Y, 535Seuter S, 1504Sgambato A, 1359, 4273Shao Y-Y, 4007Shapiro O, 929Sharif EA, 1507Sharma A, 23Sheen-Chen S-M, 293, 3633Sheline CT, 3395Shen C-H, 3939Shen K-H, 3939Shen R, 249Shen Y, 687Shen Y-J, 129Sherman C, 403Shi Y, 3595Shiba A, 529Shiba S, 2999

Shibaguchi H, 2425, 2527Shibata H, 3719Shibata M-A, 1225Shibata T, 705, 933, 1459,

2361Shibo L, 3883Shibuya M, 3449Shichinohe T, 263Shigematsu N, 3079Shigematsu Y, 4631Shim K-N, 575Shimada H, 1049Shimakawa T, 2989Shimazaki H, 1567Shimizu T, 2995Shimizu Y, 263, 3463Shimo T, 1197, 1307Shimoji H, 2351Shimokawa H, 1141, 4277,

4631Shimosegawa T, 1011Shimura T, 3353Shin YC, 3301Shindo Y, 4569Shinmura K, 2889Shinoda M, 3535Shinohara M, 633Shinohara S, 4631Shinohara Y, 2561Shinozaki N, 4475Shintani S, 2841Shintani Y, 4665Shinto E, 1567Shinwari Z, 1721Shiomi K, 1427Shiomi S, 1427Shioya M, 3963Shiozaki A, 67, 495Shiozawa M, 325Shipp C, 2095Shirahata A, 77, 777, 1289,

1293, 2249, 2889, 3377,3835

Shirai T, 2927Shiraishi M, 3527Shirasawa S, 2413, 2453,

2535Shiratsuchi I, 2517, 2541,

2547Shirota K, 2553Shirouzu K, 2517, 2541,

2547

Shitara K, 3535Sho M, 3909Shou J-Z, 945Shukuya T, 3775, 4075, 4519Siegfried JM, 2877Siegling A, 4185Sierko E, 843Sifringer M, 565Sigmundsdottir H, 1500Signore A, 719Silva AE, 1685Silva SR, 1153Silveira APF, 1685Silvestri GA, 3891Simak R, 3273Simoni A, 4091Sinclair A, 2017Singal R, 3757Singh H, 961Singh NP, 4111Singh-Ranger G, 1795Sinha P, 2109Sion-Vardy N, 913Siracusano S, 1875Sivridis E, 1745Sixt SU, 2197Skaane P, 2575Skaland I, 443Skalicky T, 339, 1447Skelton IV WP, 395Slewa A, 443Sliva D, 379Smerdely M, 3559Smith III AB, 2773Smith JA, 907Smolczyk DR, 3873Snoeren N, 4507So T, 4631Sogawa C, 1549Sohail M, 1577Sohn C, 3219Søiland H, 443Söletormos G, 613Solomayer E-F, 4423Soma G-I, 2431, 2437, 2441,

2467Somasundaram K, 3851Sommer H, 2749Somura H, 1653Song K, 3229Song W, 39Sonkoly E, 3151

Sonobe M, 4619Sonoda H, 3073Sonoyama T, 495Sørby LA, 861Søreide K, 967Sørensen FB, 1559Sorenson M, 209Sorsa T, 3659Sottotetti F, 3927Southard RC, 813Spaczynski M, 711Spagnoletti G, 1885, 1886,

1887, 1926Spechtenhauser B, 4407Speeckaert M, 3697Speeckaert R, 3697Spengler G, 3285, 4201Sperga M, 1421Sperry JB, 2773Spilotros M, 1892Spindler K-LG, 1559Spisakova M, 3107Spitz J, 2002Spratlin JL, 1093Springer C, 3783Sreevalsan S, 3799Srivastava D, 3851Sroka T, 4393Stadlbauer V, 1583, 3713Staebler A, 4025Stambuk H, 249Stamschror J, 209Stanczyk FZ, 1367Stanimirovic A, 403Stanway SJ, 1367Stathopoulos EN, 807Staufner C, 3181Stefanatou G, 3469Stein A, 2002Steinau H-U, 4061Steinborn A, 3219Steiner R, 3115Steinhagen PR, 1387Steinmeyer A, 4091Steinstraesser L, 4061Stelkens-Gebhardt R, 2569,

2575Stella MG, 3927Stenner F, 3115Stenvold H, 1603Stenzl A, 2053, 3783Stepulak A, 565, 3181


4815

Sterenczak KA, 1541Sterlacci W, 2949Sterling JA, 2705Stewart D, 3921Stieber P, 2003, 2004Stiegler P, 1583, 3713Stigliano A, 89Stigliano E, 4273Stio M, 4091Stöblen F, 2569, 2575, 2589,

2617, 2645, 2651Stokes C, 1506Stopfer P, 2271Story MD, 33Stöver T, 665Strakova M, 3619, 4653Strassen I, 2931Strazdiņa A, 1421Street CA, 3645Stricker I, 4061Strimpakos AS, 2971Strosberg J, 2957, 4387Struss WJ, 4501Strutt D, 2161Strzadala L, 2869Sturgeon C, 2004Styczynski J, 1453Su C-H, 3511Subramanian A, 23Suchi K, 67Sudo A, 4163Sueoka N, 3517Suetsugu A, 3125Sueyoshi S, 3909Sugar L, 403Sugiura H, 123Sugiyama H, 2441, 2447Suh C, 3457Sumi T, 1271Sun M-T, 1713Sun X, 243Sun XF, 4127Sun X-Y, 3705Sun Y, 3859Sundström J, 311, 4529Suñol M, 953Sunose Y, 287, 4625Suojanen J, 3659Surarit R, 921Surowiak P, 711, 2963Sussan S, 177Sutnar A, 339, 1447Suto T, 3963

Suwanborirux K, 193Suzuki H, 4525Suzuki K, 1427Suzuki S, 4251Svacina S, 373Svasti J, 921Svendsen C, 785Svobodova S, 373, 3107,

3619, 4653Swarts JC, 825Swiderek E, 2869Syrigos KN, 649, 2971Syrjänen K, 97, 311, 2975,

4529Syro LV, 2283Szántó E, 1431Szatanek R, 1329Szczuraszek K, 2963Szewczyk M, 2005Szigeti A, 1769Szkandera J, 1373Taba K, 2103Tabata Y, 105Tabe Y, 3963Tada T, 2511Tadaki T, 881Tae N, 2179Taflin H, 3057Tagliaferri B, 3927Taguchi O, 123Taguchi T, 3035Tahara T, 705, 933, 1459Tai D-I, 129Taiyoh H, 2217Takagi Y, 633Takahari D, 3535Takahashi H, 2335Takahashi H, 4465Takahashi K, 1427Takahashi M, 2389Takahashi N, 2129Takahashi S, 763Takahashi Takao, 4589Takahashi Takeo, 2847Takahashi Toshiaki, 2763,

3775, 4075, 4519Takahashi Tsunehiro, 3079Takahashi Tsuyoshi, 4619Takahashi Y, 2461Takai C, 2389Takaishi H, 3079Takakura M, 2441Takamatsu R, 2351

Takano F, 2447Takano J, 3607Takaoka M, 1197Takashima M, 3331Takashima T, 3035Takashima Y, 2535, 2453Takata D, 3041Takayama T, 1019, 2339,

3991Takayama Y, 1019Takeda Kayoko, 263Takeda Kazuhisa, 1055Takeda Kazuyoshi, 501Takeda Koji, 3449Takeda M, 4561Takemasa I, 507Takemoto H, 4657Takenaka M, 4631Takeshita H, 4545Takeuchi A, 2927Takeuchi Hideya, 4481Takeuchi Hiroya, 3079Takeuchi M, 4339Takeuchi R, 2489Takeyama H, 1395Takeyoshi I, 287, 3041, 4625Takikita M, 945Tal M, 177Talieri M, 3093Tamaki W, 2351Tamamoto T, 3909Tamandl D, 4605Tamegai H, 1019, 2339Tamesa T, 3331Tamiya M, 4525Tamura D, 2787Tamura G, 171, 1211Tamura K, 2483Tamura S, 325Tanabe K, 1027Tanahashi Y, 287, 4625Tanaka F, 855, 1141, 4277,

4451, 4631Tanaka H, 2505Tanaka Kanji, 3517Tanaka Katsuaki, 325Tanaka Kuniya, 1049, 1055Tanaka Kyoko, 4561Tanaka Mamoru, 763, 3353Tanaka Masao, 1279, 1741,

2297Tanaka N, 3063Tanaka S, 4169

Tanaka Toshihiro, 3909Tanaka Tsuneo, 2733Tanaka Yoko, 2453, 2535Tanaka Yoshihiro, 4589Tanaka Yoshihisa, 1225Tanaka Yoshimasa, 1027Tang B-J, 3423Tang N-Y, 1691Tang R-P, 293, 3633Tang W, 535Tangney M, 1627Tangoku A, 2389Tanida S, 3353Tanioka A, 1647Tanzawa Y, 2927Taran F-A, 2617Tarpin C, 1079Tavaré JM, 1577Tavernarakis N, 807Taylor PR, 945Teerenstra S, 1379Teissie J, 4083Televantou D, 3007Temme A, 3181Tempfer C, 2259Tendyke K, 2773Teng L, 1521Tentler JJ, 1093Terada H, 2489Terai K, 1181Teramoto S, 1483Terao K, 2511Terkola R, 3573Testoni N, 1943Teugels E, 4457Thaler J, 4439Thall P, 2265Thallinger CMR, 2379Thasana N, 921Theobald M, 2797Theos A, 4259Thiel E, 317Thielemans K, 3579Thiem U, 1507Thill M, 1495, 2609, 2617,

2645, 4359Thomas A, 4039Thomas M, 4491Thomé C, 1023, 3873Thorpe PE, 843Thorsteinsson M, 613Thrum S, 3289Thüroff JW, 2797


4816

Thurzó L, 1431Thymara I, 3585Tian YF, 4127Tilkorn D, 4061Tilli M, 4581Timotheadou E, 3007Tiscione D, 1890, 1891, 1939Tisnek N, 2113Tiszlavicz L, 1431Tjin EPM, 3697Toda T, 3331Todo M, 67Todorova VK, 215Toguchida J, 1297Tohda S, 781, 893Tohnai I, 2893Toita T, 1437, 3527Tokiniwa H, 3041Tokuda Y, 3361Tokuno K, 4569Tol J, 1379Tominaga H, 4657Tominaga T, 4545Tomita K, 3665Tomita M, 2995Tomiyasu S, 2983Tomizawa N, 287, 4625Tomomura A, 1241Tomomura M, 1241Tone LG, 1337Toniolo P, 4267Tonra JR, 2149Tooker P, 2303Topolcan O, 339, 373, 1447,

3107, 3619, 4031, 4653Topolèan O, 2005Topuz E, 2225Torelli T, 1826Torigoe S, 2893Tortorella S, 4211Tosca AD, 807Toscano V, 89Tosco L, 1936Totaro A, 1936Touloupidis S, 1745Tousseyn T, 2367Townsend Jr CM, 1153Toyama M, 2241Toyoda H, 4169Toyokawa H, 3827Tozuka K, 3041Trafalis DT, 831Traficante A, 1359

Tramacere F, 1889Trellakis S, 3151Trémezaygues L, 1509Treska V, 339, 1447, 3619,

4031, 4653Treskova I, 339, 3619, 4653Treves C, 4091Trigo-Sánchez I, 3019Trump DL, 1496Tsai C-H, 3633Tsai C-W, 221, 227, 745,

1043, 2395, 3511, 3629Tsai M-H, 227, 2395, 3629Tsai R-Y, 221Tsai S-J, 4301Tsai Y-H, 2231Tscheliessnigg K, 1583, 3713Tschulakow A, 4417Tseng C-J, 4301Tseng H-C, 4239Tseng S-H, 2231Tsigris C, 831Tsopra O, 3585Tsou Y-A, 227, 745, 2395,

3629Tsubaki K, 1647Tsubota Y, 3517Tsuchida A, 633Tsuchiya H, 2927, 3665Tsuda B, 3361Tsujii M, 4163Tsujinaka T, 3085Tsujino I, 2129Tsujioka H, 2461, 2553Tsujiuchi T, 543Tsukamoto H, 2841Tsukiyama I, 2915, 4339Tsunoda T, 2453, 2535Tsuru H, 2425Tsurutani J, 4561Tsutsumi S, 3963Tsuya A, 4519Tübel J, 2006Tubiana-Mathieu N, 3865Tuccari G, 1315Tuebel J, 1235Tuettenberg J, 1023, 3873Tujii R, 763Tumor Bank Ovarian Cancer

Network (TOC), 2583Tung M-C, 3939Tuohimaa P, 1503Turesson I, 1527

Turner T, 233Turowski SG, 387Turski L, 565Tutino V, 3381Tzovaras AA, 1033Uchida K, 1395Uckermann O, 565, 3181Ueda M, 1049, 1055Ueda T, 2461, 2553, 2863Ueda Y, 4513, 4613Uejima D, 1297Uemura M, 507Uemura N, 3463Uemura T, 4163Uemura Y, 3517Ueno H, 1567Uesawa Y, 4231Ueyama J, 2915Ueyama Y, 1259Uhmann A, 1499Ulrich U, 2657Ulsperger E, 2949Um J-Y, 3301Umebayashi M, 2505Umeda M, 3521, 4429Umehara H, 1741, 2297Umehara S, 67Umemura S-I, 501, 2527Umezu H, 11Unno J, 1011Unno M, 1011Uozumi K, 4251Ura T, 3535Uramoto H, 277, 619, 855,

1141, 4277, 4451, 4631Urban N, 1189Urtasun R, 3559Uto Y, 2477, 2489Utsumi H, 4169Vala H, 1637Valdagni R, 1945Valente MG, 4485Valentiner U, 1589Valentini AM, 555Valeriani M, 3555Vallés A, 1599Van De Winkel N, 3579Van Den Broek M, 3115Van Der Burg MEL, 4043Van Geel N, 3697Van Gele M, 3697Van Hillegersberg R, 4507Van Houdt WJ, 4507

Van Lierde M-A, 1407Van Moorselaar RJ, 699Van Pijkeren JP, 1627Van Rensburg CEJ, 825Vanderlinden K, 3579Vangara KK, 897Varin E, 797Varkaris A, 1475Vasconcelos-Nóbrega C,

1637Vassilakopoulos TP, 3585Vasta F, 4553Vats T, 2265Vavallo A, 1898Vavassori A, 1900, 1901Veeraraghavan J, 161Veith J, 411Veratti E, 2209Vereczkei A, 1769Verga Falzacappa C, 89Vermaelen K, 3697Verna V, 4191Verreault M, 2161Verzoni E, 1831Vesely DL, 395Vetvicka V, 47Vetvickova J, 47Viens P, 1079Vieth R, 1496Vilen S-T, 3659Villani D, 1855Villani L, 3927Vincent EE, 1577Vinh-Hung V, 4393Virgolini I, 4407Visconti C, 1867Visconti D, 1847Vishwanatha JK, 907Vitale FV, 4553Viveiros M, 3285, 4201Vo RP, 4393Vock J, 4393Voest EE, 4507Vogel RI, 1181Vogel U, 3783Vogel W, 4025Volk H-D, 4185Volmer DA, 1508Volpe A, 1903, 1904Von Eisenhart-Rothe R, 1235Von Haehling S, 2629Von Helden R. 1508Vongchan P, 4067


4817

Vorgias G, 3469Voss A, 459Vrzalova J, 339, 1447, 2006,

3107, 3619, 4031, 4653Vycital O, 1447, 4031Wada N, 3079Wada T, 2733Wagenblast J, 665Wagner P, 979Wagner W, 3903Wakabayashi H, 515Wakabayashi N, 543Wakata K, 4545Wakatsuki A, 4339Walker F, 3047Wallis NK, 813Wallwiener D, 979, 4423Walsh JE, 3159Walsh WR, 1147Walter B, 985Wang Chaoyu, 945Wang Chunrui, 3859Wang CY, 929Wang H, 3171Wang H-C, 3511Wang Li, 2141Wang Lilin, 427Wang N, 3219Wang Q, 3423Wang Q-H, 945Wang S-C, 789Wang Shusheng, 4111Wang S-M, 3423Wang Su, 2149Wang Xi, 3165Wang Xinmei, 1619Wang Y-C, 203Wang Y-H, 3939Wang Yu, 303Wang Yufeng, 2059, 3331Wang YY, 4127Wang Z, 1105Ward R, 1367Warm M, 4039Warnock GL, 3705Warth A, 4491Wasa J, 123Watanabe J, 3607Watanabe Kazushi, 4339Watanabe Koshiro, 3449Watanabe Masahiko, 2361Watanabe Masayuki, 991Watanabe Megumu, 1019,

2339Watanabe Michiko, 1395Watanabe Mitsuaki, 2999Watanabe S-I, 597, 4465Watanabe T, 3691, 4147Watanabe Y, 3063Watanabe Y, 3991Watanabe Y, 4569Watanabe Y, 731Waters AM, 2083Watson A, 233Watson K, 2095Weber O, 4185Wechsler J, 427Wefstaedt P, 1541Weghorst CM, 2683Węglarczyk K, 1329Wehler TC, 2797Wehling M, 2589Wei J, 3595Weiss C, 985, 3873Weiss G, 2007Weiss HL, 1153Weiss TW, 3273Weissenbacher T, 451Wells J, 3921Wen S, 1475Weng W-H, 129Wenger RH, 3115Wenz F, 3873Werner JA, 59, 3959Werynska B, 2833West HC, 2109Wettergren Y, 3057White Y, 2241, 4251Whiteside TL, 3151Wide K, 3489Wiedmann M, 3289Wiegand S, 59, 3959Wiest I, 2007Wilgenhof S, 3579Wilkinson N, 3429Winayanuwattikun P, 921Wingard DL, 2939Winterhalter M, 2197Witte L, 2149Wittwer Chr, 2008Wohlschlaeger J, 2197Wojnar A, 3027Wojta J, 3273Wojtukiewicz MZ, 843Wolf P, 2931Wolff B, 661

Wolff JE, 661 2265Wolff RA, 1417Wöll E, 4407, 4439Wollenberg B, 3315, 3819Womastek I, 3615Won J-H, 3385Wong NS, 255Woo S, 2265Wood KB, 1115Worayuthakarn R, 921Word BR, 3171Wright JD, 243Wrobel T, 2963Wu BM, 3237Wu C, 687Wu C-I, 3511Wu C-Y, 221Wu F, 2249, 3377Wu H-C, 221, 745Wu J-Y, 3475Wu K-C, 2203Wu RS-C, 2203Wu S-H, 1691Wu W-J, 1043Wu Y, 771, 1619Wullich B, 985Wust P, 2597Wutti-In Y, 4067Wysocki M, 1453Xiao Z, 3883Xie K, 3433Xie Y, 4135Xiong S, 3897Xu B, 687Xu H, 535Xu N, 687, 3595Xu Q, 2773Xu S, 1521Xu X, 2343Xu Y, 11Xue W, 771Yabana T, 1471Yagi J, 1027Yagublu V, 2693Yajima R, 3963Yalcin M, 411Yamada H, 705, 933Yamada K, 123Yamada S-I, 3521Yamada T, 4625Yamada Takanobu, 325Yamada Tatsuya, 287Yamaguchi Kazuya, 4589

Yamaguchi Kentaro, 2989Yamaguchi S, 3963Yamaki S, 3827Yamakoshi H, 3719Yamamoto C, 3567Yamamoto D, 1483, 3517,

3567Yamamoto H, 507Yamamoto I, 2493Yamamoto Naoto, 325Yamamoto Nobuyuki, 2763,

3775, 4075, 4519Yamamoto Norio, 3665Yamamoto S, 2489Yamamoto Tetsuji, 549Yamamoto Tomohisa, 3827Yamamura S, 2983Yamanaka T, 2983, 4561Yamasaki A, 2419Yamasaki LHT, 1685Yamashita H, 705, 933, 1459Yamashita K, 2361Yamashita Y, 2477Yamauchi K, 3665Yamauchi T, 2863Yamazaki S, 3991Yan H, 2121Yan J, 4135Yan L, 3337Yanagawa N, 171, 1211Yanagimoto H, 3827Yanagita M, 427Yanamoto S, 3521, 4429Yang C, 1115Yang C-K, 3497Yang DC, 2899Yang H-C, 3423Yang J-H, 3767Yang Jia-Lin, 1147Yang Jiun-Long, 1691Yang J-S, 1667, 1691, 2203,

2821Yang P, 2141Yang Q, 2327, 3229Yang S-T, 1667, 2821Yang Yeongae, 4223Yang Yong, 3205Yang Z-J, 3423Yano I, 2065Yano S, 763Yarom N, 3921Yashiro M, 3369Yasuda A, 2841


4818

Yasui T, 1271, 1279Yatabe Y, 3535Yazbeck C, 3047Ye L, 1703, 3205Ye LI, 303Ye W, 1659Ye W-P, 481Yeatman TJ, 2957Yeh C, 2037Yeh C-T, 2037Yeh R-D, 2821Yeh S-D, 3939Yeh T-S, 2037Yehualaeshet T, 233Yellepeddi VK, 897Yen Y, 3475Yi B-R, 2853Yi P, 1321Yi SY, 575Yin J, 2877Ying T-H, 4301Yokomizo K, 77, 777, 2889Yokota T, 3535Yokoyama T, 4613Yokoyama Y, 3331Yoneda M, 67Yonei A, 2995Yonemura J, 705, 933, 1459Yoo H, 4307Yoo K, 575Yoon J, 3385Yoon SN, 4329Yoshida D, 2847Yoshida H, 1271, 3517Yoshida H, 3567Yoshida Kanako, 2103Yoshida Kazuhiro, 4589Yoshida N, 2339

Yoshida T, 2517, 2541, 2547Yoshida Y, 2453, 2535Yoshidome K, 3035Yoshihara K, 325Yoshikawa Y, 4481Yoshiki T, 1297Yoshimasu T, 999Yoshimi N, 2351Yoshimitsu M, 4251Yoshimura K, 4569Yoshinari D, 4625Yoshino K, 4513, 4613Yoshino S, 4569Yoshioka D, 705, 933, 1459Yoshitomi I, 3521Yoshiwara E, 3607Yoshizato T, 2553Yoshizawa A, 4619Yoshizawa S, 2527Yotsumoto F, 2461, 2483,

2553Young MR, 3159Yousef GM, 2283Yu B, 771, 1619Yu C-C, 2821Yu C-S, 1691, 2203, 2821Yu H, 2739Yu JQ, 1131, 2757, 3789,

4283Yu M, 4537Yu Yan, 1147Yu Yang, 3595Yu Yinhua, 443Yuan B, 4169Yuan Z, 303Yui R, 3827Yumita N, 501Yun SH, 3843

Yung B, 1521Yunos NM, 1131, 4283Zabernigg A, 4439Zacherl J, 2379Zago MA, 2173Zagouri F, 2373Zahm J, 4025Zanella S, 693, 3969Zang C, 2713Zapala MA, 2303Zaytseva YY, 813, 1153Zebisch M, 2008Zeidler R, 3315Zeillinger R, 2259Zeindl-Eberhart E, 849Zeleniuch-Jacquotte A, 4401Zelger B, 2949Zembala M, 1329Zergebel C, 625Zerini D, 1869Zervou M, 807Zhan S, 3433Zhang B, 4267Zhang C, 1Zhang Haijun, 3945Zhang Haitian, 797Zhang Hui, 443Zhang Jinkun, 2303Zhang JJ, 4267Zhang Jun, 3595Zhang LJ, 4127Zhang N, 3125Zhang P, 3229Zhang R, 39Zhang S, 3259Zhang T, 3859Zhang W, 3423Zhang Xiaodong, 797

Zhang Xiulian, 1259, 2059,2103

Zhang Y, 3129Zhang Zhaoxia, 2683Zhang Zhen, 2141Zhang ZY, 4127Zhao C, 1Zhao Han, 1321Zhao Huajun, 789Zhao M, 1279Zhao ZR, 4127Zheng J, 2739Zheng JI, 39Zheng L, 3595Zheng X, 687Zhi X, 1271Zhong S, 481, 1659Zhong XY, 2623, 4267Zhong Yin, 4099Zhong Yuhua, 3433Zhou H, 3129Zhou J, 4099Zhu J, 771, 1521Zhu Z-P, 3739Zimmermann AP, 3959Zimmermann T, 2797Zimnoch L, 843Zittermann A 1503Zografos G, 2373Zorzetto M, 3927Zuegel U, 4091Zugor V, 2009, 2010, 2011Zupa A, 1359Zustin J, 591Zweifel M, 3115Zwirner M, 2011Zwolak P, 1181


4819

Errata

Volume 30, No. 9, page 3817: The Authors’ names should read:

GRAZIA ARTIOLI1, SIMONE MOCELLIN2, LUCIA BORGATO1, ALESSANDRO CAPPETTA1

FERNANDO BOZZA3, GIORGIO ZAVAGNO2, STEFANIA ZOVATO1,ALBERTO MARCHET2 and DAVIDE PASTORELLI1

Volume 30, No. 7, page 3015: The name of the last Author should read:

ANDREW C. WOTHERSPOON

Volume 31, No. 5, page 1857: The Authors’ names of Abstract No 90 should read:

Costanza Chiumento, Alba Fiorentino, Anna Maria Mileo, Rocchina Caivano, Mariella Cozzolino, Piernicola Pedicini and Vincenzo Fusco

Volume 30, No. 5, page 1727: The name of the second Author should read:

MANUEL TODOROVIC2

Volume 31, No. 6, page 2303: The affiliation of the first Author, Dr. Wen Luo, should read:

1Biomarker Discovery Service, Ligand Pharmaceuticals, San Diego, CA, U.S.A.;

Volume 31, No. 7, page 2553: The name of the third Author should read:

TATSUYA FUKAMI1

Volume 31, No. 9, page 2940, right column:Lines 18-27 should read:

following cut-off points: 0-13.6 ng/ml; 13.7-20.9 ng/ml; 21.0-25.8ng/ml; 25.9-32.9 ng/ml and ≥33 ng/ml. Odds ratios were thencalculated for the association between each quintile of serum25(OH)D and risk of breast cancer (39). Since raw cell frequencieswere used from each study, the odds ratios calculated for thedose–response analysis were unadjusted for potential confounders.The medians of the quintiles were: 10, 16, 23, 31 and 38 ng/ml. Thelowest quintile was used as the reference group. Confidenceintervals were calculated using the method of Woolf, as for theForest plots (36, 37).

Volume 31, No. 9, page 2975: The name of the third Author should read:

JUDAH AL-MAGHRABI3


4820

Volume 31, No. 9, page 3007, right column, lines 3, 5; andpage 3008, Patients and Methods: lines 31, 34:

The dose of bevacizumab should be 10 or 15 mg/kg (instead of μg/kg).

Volume 30 (2010), No. 6, page 1999, right column, line 27 should read:

identified a peptide of 22 amino acids, named GA3, which

Volume 30 (2010), No. 6, page 2000, Materials and Methods: first line should read:

Reagents. GA3 (WTIIQRREDGSVDFQRTWKEYK) was synthesized


4821

Instructions to AuthorsGeneral Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinicalcancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papersapplying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstractsand Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetingsrelated to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related tocancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from finalacceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are notunder consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR willbe subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the rightto improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warranteedue diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscriptto the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of allpublished parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or publishedelsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editorsmay invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentationclear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, conciseEnglish. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), includingabstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess pagecharges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, nameof the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental”study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may notetheir individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according tothe following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materialsand Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively.Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articlesshould not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submittedas photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering shouldbe clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be providedwherever possible, and not photographic copies. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If anew abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of “Index Medicus” and must be numberedconsecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significancefor cancer research. Anticancer Res 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In:Receptors for Reproductive Hormones (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.


4822

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC–IUB", "Bergey’s Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), andMIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC)(http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations arepreferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by CurrentControlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the uniquenumber, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example:ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX representsthe unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to BiomedicalJournals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org).Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specificguidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences shouldfollow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhereto the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects,effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approvedby the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervisionof a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of humanfoetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways tosubmit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)2. You can send your article via e-mail to [email protected]. Please remember to always indicate the name of the journal you wish to

submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mailattachments.

3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) togetherwith three hard copies to the following address:John G. DelinassiosInternational Institute of Anticancer Research (IIAR)Editorial Office of ANTICANCER RESEARCH, IN VIVO, CANCER GENOMICS and PROTEOMICS.1st km Kapandritiou-Kalamou RoadP.O. Box 22, GR-19014 Kapandriti, AttikiGREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections ofgalley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and OpenAccess may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into otherlanguages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic,mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.


4823

Publication Data: ANTICANCER RESEARCH (AR) ispublished monthly. Each annual volume contains twelve issuesand index.

Copyright: Once a manuscript has been published in AR,which is a copyrighted publication, the legal ownership of allpublished parts of the paper passes from the Author to theJournal.

ANTICANCER RESEARCH is available in print (ISSN:0250-7005) and online (ISSN: 1791-7530) through StanfordUniversity’s HighWire Press with access to full text/PDFarticles from all previous volumes since January 1st, 2004. Foronline/print subscription rates, please visit the IIAR websites:www.iiar-anticancer.org; www.ar.iiarjournals.org

Annual Subscription Rates 2012: Institutional subscriptiononline: Euro 1,650.00. Institutional subscription print: Euro1,670.00. Institutional subscription online & print: Euro1,700.00. Personal subscription online: Euro 780.00. Personalsubscription print: Euro 800.00. Personal subscription online& print: Euro 830.00. Prices include rapid delivery andinsurance. Previous volumes of Anticancer Research (Vol. 1-31, 1981-2011) are available at 50% discount on the aboverates.

Subscription Orders: Orders can be placed at agencies,bookstores, or directly with the publisher. Cheques should bemade payable to J.G. Delinassios, Executive Publisher ofAnticancer Research, Athens, Greece and should be sent to theEditorial Office.

Correspondence: (subscription orders, reprint orders, changeof address, disposition of submitted manuscripts, advertisingrates requests, and general editorial matters) should be directedto Dr. J.G. Delinassios, Executive Publisher and ManagingEditor, Editorial Office.

Advertising: Correspondence and rate requests should beaddressed to the Editorial Office.

Book Reviews: Recently published books and journals shouldbe sent to the Editorial Office. Reviews will be published within2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed inall bibliographic services, including Current Contents (LifeSciences), Science Citation Index, Index Medicus, BiologicalAbstracts, PubMed, Chemical Abstracts, Excerpta Medica,University of Sheffield Biomedical Information Service, CurrentClinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database,EMBASE, Compendex, GEOBASE, EMBiology, ElsevierBIOBASE, FLUIDEX, World Textiles, Scopus, Progress inPalliative Care, Cambridge Scientific Abstracts, Cancergram(International Cancer Research Data Bank), MEDLINE, ReferenceUpdate - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar,BRS), CABS, Immunology Abstracts, Telegen Abstracts, GeneticsAbstracts, Nutrition Research Newsletter, Dairy Science Abstracts,Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase,CAB Abstracts/Global Health Databases, Investigational DrugsDatabase, VINITI Abstracts Journal, Leeds Medical Information,PubsHub, Sociedad Iberoamericana de Informaciόn Cientifica(SIIC) Databases.

Authorization to photocopy items for internal or personal use, or theinternal or personal clients, is granted by ANTICANCERRESEARCH, provided that the base fee of $2.00 per copy, plus 0.40per page is paid directly to Copyright Clearance Center, 27 CongressStreet, Salem, MA 01970, USA. For those organizations that havebeen granted a photocopy license by CCC, a separate system ofpayment has been arranged. The fee code for users of theTransactional Reporting Service is 0250-7005/2010 $2.00 +0.40.

The Editors and Publishers of the journal ANTICANCERRESEARCH accept no responsibility for the opinions expressedby the contributors or for the content of the advertisementsappearing herein.

Editorial OfficeInternational Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.Box 22, Attiki 19014, GreeceTel and Fax: +30-22950-53389

PHOTOCOMPOSITION BY IIARPRINTED BY ENTYPO, GREECEPRINTED ON ACID-FREE PAPER

Editorial StaffManaging Editor and Executive Publisher: J.G. DELINASSIOS, Athens, GreeceAssistant Managing Editor: S. AZOUDIS

Production Editor: E. ILIADIS, Athens, Greece

Editorial OfficeInternational Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.Box 22, Attiki 19014, GreeceTel and Fax: +30-22950-53389

Please visit the IIAR websites: www.iiar-anticancer.org; www.iiarjournals.org

e-mails: Editor: [email protected]; Journals: [email protected]; IIAR: [email protected]

4673.full.pdf - Anticancer Research

Documents